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Preface to ”Metabolically Healthy Obesity”
This book, compiled from a Special Issue of the journal Nutrients, demonstrates the wide spectrum
of current research efforts underway internationally which aim to advance our understanding of the
role of biological, genetic, dietary and lifestyle factors as determinants of metabolically healthy obese
(MHO) phenotypes. Included are 15 articles, with contributions from South Africa, Canada, China,
Colombia, Lebanon as well as several countries of the European Union. Comprising original research
articles based on observational and intervention studies in humans and animal models, narrative
reviews and a systematic review and meta-analysis these contributions describe the current state of
the art and illustrate the breadth of cutting edge research underway in this field.
The evidence suggests that MHO is a transient phenotype. While transitions between phenotypes
over time may account for disparities in both their reported prevalence and risk of developing
cardiometabolic disease or mortality, characterisation of the factors which distinguish those who
progress to or maintain MHO from those who transition from MHO to metabolically unhealthy
obesity is important as it may uncover potential intervention targets. Both Zheng et al., and
Muoz-Garach et al., examine MHO stability, the former in the context of investigating the impact
of weight change, whereas in the latter paper they analyze responsiveness to traditional lifestyle
recommendations and bariatric surgery.
The use of biomarkers to improve our understanding of the biological mechanisms underpinning
MHO is highlighted. Allam-Ndoul et al. employ a metabolomics approach to investigate differences
in plasma metabolomic profiles between normal weight and overweight/obese individuals, with or
without metabolic syndrome (MetS). Bermdez-Cardona and colleagues determine fatty acid profiles
in obese youth with and without MetS. The role of gut microbiota as a determinant of MHO and how
dietary medium chain triglycerides can ameliorate metabolic health via their capacity to improve
both the intestinal ecosystem and permeability is discussed by Rial et al. Pujia et al., investigate
whether a difference in fasting fat utilization exists between overweight/obese individuals with a
favorable cardiovascular risk profile and those with MetS and Type 2 diabetes (T2DM). Two studies
focus on blood pressure. Yang et al., explore associations between BMI and mortality in hypertensive
adults. Zhang and colleagues investigate fasting ghrelin concentrations during a high-salt diet among
non-obese and normotensive subjects. Nguyen and co-workers focus on MHO in combination with
human immunodeficiency virus (HIV). In a sample of HIV infected people recruited across primary
care facilities in South Africa they assess the distribution of body size phenotypes in people with
HIV infection overall and according to antiretroviral therapy, diagnosed duration of the infection and
CD4 count.
Animal studies may be particularly useful in mechanistic research. Zubira and colleagues
examine the balance of hypertrophic/hyperplastic adipose tissue expansion and the metabolic
profile in a high glucocorticoids mouse model. Using a mouse model of diet-induced obesity,
Soni et al., examine the effect of high fat diet supplemented with marine fatty acids (eicosapentaenoic
acid and docosahexaenoic acid) on skeletal muscle function.
Limited and inconsistent data regards the impact of dietary interventions in human MHO
exist. In a systematic review and meta-analysis Stelmach-Mardas et al., assess the effect of dietary
intervention on changes in metabolic health profiles of MHO subjects. Matta et al., examine the
socio-demographic correlates of MHO and investigate the independent effect of dietary patterns.
Scant data regards genetic predisposition to MHO is available. Gajewska et al., investigate whether
vii
certain genetic backgrounds (selected functional single nucleotide polymorphisms in LEP, LEPR and
ADIPOQ) are associated with changes in serum levels of their corresponding adipocytokines and
weight loss in prepubertal obese children undergoing lifestyle intervention. In further analysis of
the role of adipocytokines Savino et al., investigate correlations between mother and infant BMI,
their serum leptin values and breast milk leptin concentration in early infancy. This is important as
increasing evidence suggests that early life exposure to a range of environmental factors, including
nutrition for example, plays a critical role in defining offspring health, both in childhood and in later
life. According to the Developmental Origins of Health and Disease (DOHaD) hypothesis, transient
environmental exposures during critical periods of development (such as the pre-conceptional,
fetal and early infant phases of life) can alter normal physiology and have a persistent impact
on metabolism and gene expression thereby influencing offspring phenotype and disease risk in
later life.
The contributions presented here illustrate that a great body of research regarding obesity-
associated metabolic health phenotypes has been performed to date. However it is clear that much
remains to be done. These contributions also serve to identify gaps and new avenues which warrant
further investigation, particularly with respect to life course epidemiology based on the DOHaD
hypothesis and whether risk stratification of obese individuals based on their metabolic health
status may offer new opportunities for more personalised approaches in diagnosis, intervention
and treatment.
Finally I would like to acknowledge the excellent work of the authors and reviewers, their time
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Abstract: The mechanisms underlying the change in phenotype from metabolically healthy to
metabolically unhealthy obesity are still unclear. The aim of this study is to investigate whether a
difference in fasting fat utilization exists between overweight/obese individuals with a favorable
cardiovascular risk profile and those with Metabolic Syndrome and Type 2 diabetes. Furthermore,
we sought to explore whether there is an association between fasting fat utilization and insulin
resistance. In this cross-sectional study, 172 overweight/obese individuals underwent a nutritional
assessment. Those with fasting glucose ě126 mg/dL or antidiabetic treatment were considered to be
diabetics. If at least three of the NCEP criteria were present, they had Metabolic Syndrome, while
those with less criteria were considered to be healthy overweight/obese. An indirect calorimetry was
performed to estimate Respiratory Quotient, an index of nutrient utilization. A lower Respiratory
Quotient (i.e., higher fat utilization) was found in healthy overweight/obese individuals than in
those with Metabolic Syndrome and Type 2 diabetes (0.85 ˘ 0.05; 0.87 ˘ 0.06; 0.88 ˘ 0.05 respectively,
p = 0.04). The univariate and multivariable analysis showed a positive association between the
Respiratory Quotient and HOMA-IR (slope in statistic (B) = 0.004; β = 0.42; p = 0.005; 95% Confidence
interval = 0.001–0.006). In this study, we find, for the first time, that the fasting Respiratory
Quotient is significantly lower (fat utilization is higher) in individuals who are metabolically healthy
overweight/obese than in those with metabolically unhealthy obesity. In addition, we demonstrated
the association between fat utilization and HOMA-IR, an insulin resistance index.
Keywords: obesity; nutrition assessment; fat utilization; Metabolic Syndrome; metabolically
unhealthy Obesity; diabetes
1. Introduction
Epidemiological research established that overweight and obese individuals do not always show
high rates of cardiovascular diseases (CVD) and mortality [1,2]. Those without dyslipidemia, insulin
resistance, and hypertension are characterized by a low risk, despite the presence of an elevated
body mass index (BMI) [3]. However, this phenotype seems to be a transient state [4,5] since a high
risk of developing Type 2 diabetes mellitus (T2DM) has been demonstrated in those who maintain
an unhealthy lifestyle over time [5]. The mechanism underlying the switch in phenotype from
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the metabolically healthy status to T2DM is still unclear. Obesity, inflammation, and worsening of
insulin resistance are recognized as important risk factor in the pathogenesis of diabetes [6,7] but
other mechanisms could play a role. A high fat (HF) diet results in an increase in β-oxidation [8].
However, other investigations demonstrated a reduction in β-oxidation [9–16]. These studies are not
conflicting because the mechanisms described above could be sequential (first it increases and then, it
decreases), leading to the switch from a metabolically healthy but overweight/obesity status to T2DM.
In this regard, it is well known that nutrient utilization can be assessed with Indirect Calorimetry
by measuring the ratio between carbon dioxide production and oxygen consumption (Respiratory
Quotient (RQ)) [17]. Some investigations have demonstrated that subjects who tend to burn less fat
have an increased RQ value [18,19]. High RQ is associated with a high rate of subsequent weight
gain [20]. Recently, a high post-absorptive RQ was associated with hypertension [21] and increased
Carotid Intima-Media Thickness (CIMT), a well-known predictor of cardiovascular events [22,23]
in individuals with obesity [24]. Furthermore, fasting RQ is higher in individuals with obesity and
hypertriglyceridemia [25] and in overweight/obese individuals with cardiac remodelling than in
those who are just obese [26]. In this study, we sought to investigate whether a difference in RQ (and
thus, in fat utilization) exists between overweight/obese individuals with a favorable cardiovascular
risk profile and those with Metabolic Syndrome (MS) and T2DM, and whether RQ is associated with
insulin resistance. This investigation could be useful to hypothesize the mechanisms underlying the
progression from a metabolically healthy but overweight/obese phenotype towards metabolically
unhealthy obesity and T2DM, and probably to distinguish subjects who will be at a high risk for T2DM
and cardiovascular diseases.
2. Methods
In this cross-sectional study, the population consisted of white overweight/obese subjects who
were undergoing health-screening tests at our outpatient nutrition clinic. All the participants were
over 45 years old with a BMI of more than 24.9. Participants underwent a medical interview and the
nutritional assessment to verify if there had been any changes in their food habits or if they followed
a special diet or used any dietary supplements in the three months prior to our tests. We enrolled
consecutively only those who had not performed these actions. All enrolled individuals had the same
diet, determined by nutritional intake assessment, i.e., a solid-food diet that supplied 50%–55% of the
calories as carbohydrate, 18%–20% as protein, and no more than 30% as fat.
All patients included in the study were not suffering from any diseases (like chronic obstructive
pulmonary disease, thyroid dysfunction, cancer, congestive heart failure, myocardial infarction,
stroke) and did not take any drug (anti-obesity medications, psychotropic drugs and chronotropic
agents)which could affect respiratory gas exchange or had debilitating diseases known to affect blood
pressure or plasma glucose or lipid concentrations (like stage 2–5 chronic kidney disease and end stage
liver failure) as determined by medical history, a physical examination, and laboratory tests.
Furthermore, we assessed the presence of the known classical cardiovascular (CV) risk factors,
MS presence and anthropometric characteristics. The following criteria were used to define the
distinct CV risk factors: diabetes: fasting blood glucose ě126 mg/dL or antidiabetic treatment;
hyperlipidemia: total cholesterol >200 mg/dL and/or triglycerides >200 mg/dL or lipid lowering
drugs use; hypertension: systolic blood pressure ě130 mmHg and/or diastolic blood pressure
ě85 mmHg or antihypertensive treatment; overweight: 25 kg/m2 ď BMI < 30 kg/m2; obesity: body
mass index (BMI) ě30 kg/m2; smoking: a current smoker who has smoked more than 100 cigarettes in
their lifetime and smokes cigarettes every day or some days [27,28].
The selection criteria for MS individuals were based on the National Cholesterol Education
Program’s (NCEP) Adult Treatment Panel III report (ATP III). Individuals with 0–2 cardiometabolic
abnormalities were identified as having a metabolically healthy but overweight/obese phenotype,
while those with at least three or more abnormalies were identified as having MS [29]. Furthermore,
all participants underwent the instrumental evaluation of the carotid intima-media thickness (CIMT).
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Therefore, in this study we enrolled 172 overweight/obese subjects, categorized into the following
three groups: healthy overweight/obese (with maximum two NCEP abnormalities and without
T2DM); MS (with three or more NCEP abnormality and without T2DM) and T2DM (only those with
fasting glucose ě126 mg/dL or antidiabetic treatment). Written informed consent was obtained. The
protocol was approved by local ethic committee at the University Hospital (projects codes 2013-1/CE).
The investigation conforms to the principles outlined in the Declaration of Helsinki.
2.1. Blood Pressure Measurement
The measurement of the systemic blood pressure (systolic blood pressure (SBP) and diastolic
blood pressure (DBP)) of both arms was obtained by an auscultatory blood pressure technique with
aneroid sphygmomanometer. Clinic BP was obtained in supine patients, after 5 min of quiet rest.
A minimum of three BP readings were taken using an appropriate BP cuff size (the inflatable part of
the BP cuff covered about 80 percent of the circumference of upper arm) as previously described [30].
2.2. Biochemical Evaluation
Venous blood was collected after fasting overnight into vacutainer tubes (Becton & Dickinson,
Plymouth, UK) and centrifuged within 4 h. Serum glucose, total cholesterol, high density
lipoprotein (HDL)-cholesterol, and triglycerides were measured with enzymatic colorimetric test.
Low-density lipoprotein (LDL) cholesterol level was calculated by the Friedewald formula: total
cholesterol—HDL cholesterol—(triglycerides/5). Plasma insulin concentration was determined by
radioimmunoassay. We calculated Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
by the following formula:
HOMA-IR “ Fasting blood glucose pmg{dLq ˆ insulin pU{mLq{405
Quality control was assessed daily for all determinations.
2.3. Anthropometric Measurements
All tests were performed after a 12 h overnight fast. Body weight was measured with a calibrated
scale with the subjects lightly dressed, subtracting the weight of clothes. Height was measured with a
wall-mounted stadiometer (TANITA, Middlesex, UK). BMI was calculated with the following formula:
weight (kg)/height (m)2. Waist circumferences and hip circumferences (WC and HC) were measured
with a nonstretchable tape over the unclothed abdomen at the narrowest point between costal margin
and iliac crest at the level of the widest diameter around the buttocks, respectively [31]. Bioelectrical
impedance analysis (BIA) (BIA-101, Akernsrl, Florence, Italy) was performed to estimate the percentage
of Total Body Water (TBW), Fat Mass (FM), Muscle Mass (MM), total Fat-Free Mass (FFM) [32].
2.4. Dietary Intake Assessment
The participant’s nutritional intake was calculated using nutritional software MetaDieta 3.0.1
(Metedasrl, San Benedetto del Tronto, Italy). Dietary intake data comprised a 24-h recall and a
seven-day diet record. The 24-h recall was collected via an interview by a dietitian who used images
associated with a comprehensive food list in the program. All participants were also given a food diary,
measuring sheet with life-size images of a spoon, cup and bottle sizes for food diaries. The INRAN
(National Institute of Food Research) 2000 and IEO (European Institute of Oncology) 2008 database
serves as the source of food composition information in the program. The data was entered by
dietitians into the program. All foods are assigned a unique code which allows categorization of foods
into food groups. The resulting database was exported into SPSS (IBM Corporation, New York, NY,
USA) for analysis.
3
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2.5. RQ Assessment—Indirect Calorimetry
RQ and the Resting Energy Expenditure (REE) were measured by Indirect Calorimetry using
the open circuit technique (Viasys Healthcare, Hoechberg, Germany). All tests were performed after
fasting overnigh, between hours of 7 a.m. and 8:30 a.m. after 48 h abstention from exercise, in a
sedentary position. The participant rested quietly for 30 min in an isolated room at a controlled
temperature (21–24 ˝C). Respiratory gas exchange was measured within a canopy circuit for at least
30 min, until steady state was achieved. The calorimeter quantifies the volume of O2 inspired and
CO2 expired by the subject. Resting Energy Expenditure is calculated by the Weir formula. RQ was
calculated as CO2 production/O2 consumption. Criteria for a valid measurement was at least 15 min
of steady state, with less than 10% fluctuation in minute ventilation and oxygen consumption and less
than 5% fluctuation in RQ [26,33].
2.6. Carotid Arteries Assessment
The participants underwent B-mode ultrasonography of the extracranial carotid arteries by use of
a high-resolution ultrasound instrument (Toshiba Medical Systems Corporation, model TUS-A500,
1385, Shimoishigami, Otawara-Shi, Tochigi, Japan). We used a 5- to 12-MHz linear array multifrequency
transducer. All the examinations were performed by the same ultrasonographer blinded to clinical
information with patients in the supine position. ECG leads were attached to the ultrasound recorder
for on-line continuous heart rate monitoring. The right and left common (CCA) and internal carotid
arteries (including bifurcations) were evaluated with the head of the subjects turned away from the
sonographer and the neck extended with mild rotation. The IMT, defined as the distance between
intimal-luminal interface and medial—adventitial interface, was measured as previously described [24].
In posterior approach and with the sound beam set perpendicular to the arterial surface, 1 cm from the
bifurcation, three longitudinal measurements of IMT were completed on the right and left common
carotid arteries far-wall, at sites free of any discrete plaques. The mean of the three right and left
longitudinal measurements was then calculated. Then, we calculated and used for statistical analysis
the mean CIMT between right and left CCA. The coefficient variation of the methods was 3.3%.
3. Statistical Analysis
Data is reported as mean ˘ SD. Thirty subjects for each group are required to detect a significant
difference of RQ greater than 2% (21–26) with 80% power on a two-sided level of significance of 0.05.
A chi-square test was performed to analyze the prevalence of the cardiovascular risk factors and
medications. ANOVA was performed to compare the means between groups with a Fisher’s LSD test
as a post-hoc analysis. REE and RQ values were eventually adjusted according to the difference in
FFM between groups or if RQ and REE correlated with FFM.
The Pearson’s correlation was used to identify the variables correlated with RQ given that the
continuous variables were normally distributed. We analyzed the correlation with the following
variables: REE, FFM, age, BMI, WC, glucose, LDL, HDL, triglycerides, PAS, PAD, HOMA-IR. Stepwise
multivariable linear regression analysis was used to test the association between RQ and the variables
selected among those correlated with RQ in the univariate analysis, with p < 0.1. When we tested
the association with HOMA-IR and cardiometabolic risk factors, glucose was excluded since it was
considered as part of HOMA-IR. Significant differences were assumed to be present at p < 0.05
(two-tailed). All comparisons were performed using SPSS 20.0 for Windows (IBM Corporation,
New York, NY, USA).
4. Results
Among the participants, we enrolled 80, 58, and 34 individuals who were overweight/obese, with
MS and Type 2 Diabetes, respectively. Since we did not find any difference of RQ between gender and
between individuals taking medications or not (data not shown) we presented the data altogether.
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The demographic and anthropometric characteristics, the prevalence of cardiovascular risk factors,
and medications use of the population are indicated in Table 1. Healthy overweight/obese had a
lower RQ than those with MS and Type 2 diabetes (p = 0.04; ANOVA, Table 2). In particular, healthy
overweight/obese had a lower RQ than MS (p = 0.04; post-hoc analysis) and a lower RQ than T2DM
(p = 0.03; post-hoc analysis; Table 2), respectively. FFM did not differ between groups (p = 0.92).
Furthermore, RQ and FFM (as absolute value) did not correlate (r = 0.11 and p = 0.27). As expected,
CIMT were significantly higher in T2DM than in MS (p = 0.03; post-hoc analysis) and the healthy
overweight/obese (p = 0.02; post-hoc analysis).
Table 3 shows the factors significantly associated with RQ in the univariate analysis, which were
the following: HOMA-IR, glucose, triglycerides, SBP. In the multivariable analysis, RQ remained still
associated with HOMA-IR, while triglycerides and SBP were not associated (Table 4).
5. Discussion
In this investigation, we find that fasting RQ, an index of nutrient utilization assessed by indirect
calorimetry, is significantly lower in individuals with metabolically healthy overweight/obesity than
in those with MS and T2DM. This suggests that individuals who are healthy overweight/obese
are still able, to some extent, to utilize fat in the fasting state while fat utilization is significantly
reduced in individuals with unhealthy obesity (Table 2). These results could help to hypothesize
that new factors are involved in the pathogenesis of T2DM and potential new therapeutic goals
exist. Furthermore, in this population, we demonstrated the association between RQ and HOMA-IR,
which is widely utilized as an insulin resistance index (Table 4). This result could have important
implications in predicting diabetes, which must be confirmed by longitudinal studies. The mechanisms
underlying the switch in phenotype from healthy overweight/obese to T2DM are still unknown and
our study was not designed to investigate these mechanisms. However, our study may be useful in
generating intriguing hypotheses. Whether [34,35] or not [36–39] increase in fatty acid β-oxidation
leads to insulin resistance is still a subject of debate. There is evidence that obesity-associated glucose
intolerance might develop from an overload of fatty acid in muscle mitochondria [40]. It has been
demonstrated that the excessive availability of fatty acids may exert an insulin-desensitizing action
in muscle mitochondria [8]. Furthermore, it has been demonstrated that a HF diet and/or obesity
can increase the expression of several β-oxidative enzymes [41] and reduce RQ [8]. It is interesting
that these events precede the onset of insulin resistance [8]. Our findings are in line with these
studies since we find that individuals who are metabolically healthy overweight/obese have, to some
extent, a greater ability to burn fat (lower RQ) in comparison to those with MS and T2DM. However,
it has also been demonstrated that an unhealthy lifestyle, including HF feeding and the absence of
physical activity, favors incomplete β-oxidation caused by the mismatch between β-oxidation and
tricarboxylic acid cycle activity, contributing to mitochondrial damage [41,42]. Incomplete fatty acid
oxidation also facilitates the production of reactive oxygen species (ROS) which can cause damage
to mitochondrial enzymes [42]. Furthermore, the production of ROS represents a common pathway
in the cascade of events that finally results in β-cell failure [43]. Consequently, as confirmed by other
investigations, both glucose-tolerance and fat oxidation are decreased [9–11,44–46]. Together these
studies lead us to hypothesize that a reduction in fatty acid oxidation is achieved over time, probably
in the context of an unhealthy lifestyle. The significant difference of RQ (of fasting fat utilization)
between metabolically healthy but overweight/obese phenotype, with MS and T2DM individuals may
confirm this mechanism.
5
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Table 4. Multivariate linear regression analysis—factors associated with respiratory quotient.
Dependent Variable RQ B SE β t p
95% C.I.
Lower Limit Upper Limit
HOMA-IR 0.004 0.001 0.42 2.98 0.005 0.001 0.006
Triglycerides 0.001 0.001 0.20 1.37 0.17 ´0.002 0.002
SBP 0.001 0.001 0.05 0.34 0.73 ´0.001 0.001
Legend: RQ, respiratory quotients; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; SBP,
systolic blood pressure.
Furthermore, it is well recognized that despite the substantial research efforts in the last
10–15 years, many individuals unavoidably progress to T2DM [47] thus, longitudinal studies are
needed to clarify the eventual role of RQ in predicting the risk of diabetes. Additional studies are also
needed to find appropriate intervention (dietetic, pharmacological) to maintain the healthy phenotype
by increasing fat oxidation [48].
In this study, some strengths and weaknesses must be pointed out. For some researchers,
it is important to consider HOMA-IR to define metabolically healthy obese individuals [49]. However,
at present there is a lack of consensus on this definition [50–52]. According to previous investigations,
we used the NCEP ATP III criteria to define individual who were “metabolically healthy” [53,54],
taking the CVD risk into account [55]. Our study was limited by cross-sectional design, thus,
it is impossible to infer causality. Nevertheless, cross-sectional studies indicate associations that
may exist and are therefore useful in generating hypotheses for future research. In addition, in
our study the statistical analysis is robust and adequate. Our results were not purely random as
established by previous investigations [9–16,20–26] and were confirmed by multiple statistical analyses.
The investigation was carried out on representative samples of the population which originates from a
Mediterranean context, potentially increasing knowledge on this issue from a geographical perspective.
Finally, our results are in line with those of other authors who demonstrated the association between
metabolic inflexibility, which is independently associated with fasting RQ, and insulin resistance [56].
However, to our knowledge, this is the first time that a difference in fasting RQ has been found between
individuals who are metabolically healthy but overweight/obese who have MS and T2DM.
6. Conclusions
We find that fasting fat utilization is significantly lower in individuals who are metabolically
healthy overweight/obese than in those who are metabolically unhealthy. These results can help to
hypothesize the factors involved in the pathogenesis of T2DM.
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Abstract: The study evaluated the profile of circulating fatty acids (FA) in obese youth with and
without metabolic syndrome (MetS) to determine its association with nutritional status, lifestyle
and metabolic variables. A cross-sectional study was conducted in 96 young people, divided into
three groups: obese with MetS (OBMS), obese (OB) and appropriate weight (AW). FA profiles were
quantified by gas chromatography; waist circumference (WC), fat folds, lipid profile, high-sensitivity
C-reactive protein, glucose, insulin, the homeostasis model assessment (HOMA index), food intake
and physical activity (PA) were assessed. The OBMS group had significantly greater total free
fatty acids (FFAs), palmitic-16:0 in triglyceride (TG), palmitoleic-16:1n-7 in TG and phospholipid
(PL); in the OB group, these FAs were higher than in the AW group. Dihomo-gamma-linolenic
(DHGL-20:3n-6) was higher in the OBMS than the AW in PL and FFAs. Linoleic-18:2n-6 in TG and
PL had the lowest proportion in the OBMS group. WC, PA, total FFA, linoleic-18:2n-6 in TG and
DHGL-20:3n-6 in FFAs explained 62% of the HOMA value. The OB group presented some higher
proportions of FA and biochemical values than the AW group. The OBMS had proportions of some
FA in the TG, PL and FFA fractions that correlated with disturbances of MetS.
Keywords: obesity; metabolic syndrome; fatty acids; serum; youth
1. Introduction
Obesity is a pandemic that affects 34.3% of the adult population, generating an increase in
the prevalence of chronic diseases [1]. Obesity is also present in youth; in 2013, the prevalence of
overweight reached 22.6% in girls and 23.9% in boys in industrialized countries [2]. In Latin America,
it is estimated that there are between 16.5 and 22.1 million obese adolescents, with a prevalence of
overweight of 17% in Colombia, 20% in Brazil, and 35% in Mexico and Chile [3].
Obesity, mainly abdominal, induces metabolic disturbances, such as insulin resistance (IR),
glucose intolerance, decreased high-density lipoproteins (HDL-C), elevated triglycerides (TG) and
increased blood pressure, which together make up Metabolic Syndrome (MetS) [4].
In states of chronic excess energy, both subcutaneous and visceral adipocytes undergo hypertrophy
and saturation of their storage capacity, along with infiltration and activation of macrophages; these
events result in an increased release of fatty acids (FAs) and pro-inflammatory substances, such as
tumor necrosis factor (TNF)α and interleukin (IL)-6, which generates tissue dysfunction and metabolic
damage [5,6].
The release of pro-inflammatory substances and free FAs (FFAs) could be the connection between
central obesity and metabolic disturbances. Once released into the portal circulation, FAs invade
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organs, such as the liver, where the excessive deposit of triglycerides affects lipoprotein synthesis
and may induce simple steatosis or fatty liver (FL), which may be complicated by liver inflammation
(non-alcoholic steatohepatitis, NASH), alterations that induce the development of non-alcoholic
fatty liver disease (NAFLD), which is widely considered to be the liver expression of metabolic
syndrome [7,8]. The FFAs also affect the pancreas where they impair insulin production (lipotoxicity);
in addition, they simultaneously generate IR in muscle and adipose tissue through the activation of
pathways such as protein kinase C (PKCθ) [6,9].
The FA profile can be modulated with food, as some FAs, such as linoleic-18:2n-6 and
αlinolenic-18:3n-3, are not synthesized by humans and reflect dietary intake. Thus, circulating FA
levels and cell membrane compositions depend on this intake. In serum, the FA profile specifically
reflects the intake of the last two to six weeks, and tissue FAs represent the dietary patterns of months
or years [10]. Blood levels of FAs, such as palmitoleic-16:1n-7 and DHGL-20:3n-6, are less dependent
on intake and could reflect endogenous metabolism (lipogenesis) [11,12].
Research in adults has demonstrated the relationship between an altered FA profile, obesity, IR
and MetS [13,14]. This profile is characterized by high percentages of saturated fatty acids (SFAs), such
as palmitic-16:0 and stearic-18:0, and monounsaturated FAs (MUFAs), such as palmitoleic-16:1n-7,
and decreased percentages of polyunsaturated fatty acids (PUFAs), including arachidonic acid
(ARA-20:4n-6) and docosahexaenoic acid (DHA-22:6n-3) [14,15].
In obese individuals, a decrease in PUFAs may be due to a deficit in the synthesis and elongation
of essential FAs, caused by metabolic disturbances arising from obesity, such as hyperinsulinemia; a
high SFA intake and a low PUFA intake, especially omega-3 [16]. However, the FA profile in adults is
affected by intervening variables, such as atheromatous disease, advanced metabolic disorders and
long-term exposure to unfavorable lifestyle factors (i.e., a sedentary lifestyle, overeating, and alcohol
and tobacco consumption) [17].
In youth, describing the circulating FA profile could contribute to a better understanding of the
obesity-IR-MetS relationship, given that confounding factors are less involved in metabolic analyses
at early ages. However, the results in youth are also conflicting, possibly because fractions from
which circulating FAs are recovered are different and not comparable among studies. Some obtain FA
from cholesterol esters (CE) and others from phospholipids (PL), fractions in which FAs are mainly
recovered from HDL-C and low-density lipoprotein (LDL-C), respectively, which are influenced by
consumption [18]. Other studies recover FAs from TG, which is the fraction of highest proportion
in circulation and mainly reflects endogenous synthesis of FAs produced from energetic nutrients
(carbohydrates and fats) that travel in very-low-density lipoproteins (VLDL) [19]. Finally, others report
FFAs released from adipose tissue and carried by albumin, which could be an indirect marker of the
FA composition of adipose tissue in states of obesity if recovered after a 10- to 12-h fast [18,20]. Given
the differences between fractions and modulations of the FA profile by diet, comparisons of results
and the establishment of a consensus on FA profiles are complex. Therefore, the objective of this study
is to evaluate the profile of circulating FAs in obese youth with and without MetS between 10 and
18 years old and to determine its association with nutritional status, lifestyle and components of MetS.
2. Materials and Methods
Study design: A cross-sectional study was developed that included 96 youth, boys and girls, 10 to
18 years old, selected from a previous population study [21].
The sample size necessary to form three groups was defined with the software Primer®,
considering an alpha error of 0.05, a power of 85% and an expected minimum difference between the
case and control groups in the concentrations of different FAs according to reports from other studies:
Palmitic-16:0 in CE [22] and FFAs [23]; Palmitoleic-16:1n-7 in PL, CE and TG [22,24]; Stearic-18:0 in
PL [22] and FFAs [23]; and DHGL-20:3n-6 in PL [24,25] and CE [22], which indicated a number of
32 youth per group.
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The groups were formed as follows: (1) obese with MetS (OBMS): body mass index
(BMI) >98 percentile [26] and diagnosis of MetS; (2) obese (OB): BMI >98 percentile and without
MetS; and (3) appropriate weight (AW): BMI between the 15–85 percentile and none of the
components of MetS. Groups were matched one to one by age, gender, pubertal maturation and
socioeconomic stratum.
MetS was diagnosed when the affected youth had three or more of the following criteria:
TG ě110 mg/dL, HDL-C ď40 mg/dL, fasting blood glucose ě100 mg/dL, blood pressure
ě90 percentile and waist circumference (WC) ě90 percentile [27].
Youth who consumed drugs for metabolic disturbances of MetS or nutritional supplements, who
had diabetes mellitus (DM) II, who were elite athletes or who were pregnant or lactating were excluded
from the study.
Anthropometric evaluation: weight and height were measured; BMI was calculated (kg/m2)
and was classified according to the 2007 World Health Organization (WHO) standard [26]; fat fold
measurements were taken at the triceps and subscapular areas, % of body fat was calculated and
classified according to Lohman [28]; and WC was taken and classified according to Fernández [29].
Measurements were performed with equipment and techniques for international use [28].
Food consumption: The 24-h recall was distributed on different weekdays. A second recall was
consequently distributed among a random subsample constituted by 20% of the study population (19
adolescents) to calculate intra-individual variation [30,31]. The Evaluation Program of Dietary Intake
(EVINDI-v4) was used [32]. The nutrient report was processed using the PC version of the Software
for Intake Distribution Estimation (SIDE) program, Iowa State University, version 1.0, June 2004.
Physical activity (PA): The 3-day Physical Activity Recall (3DPAR) method was applied [33].
Metabolic equivalent (METs) values of each activity were obtained from the Compendium of Physical
Activities of the American College of Sports Medicine [34]. The PA of 3–6 METs was classified as
moderate to vigorous intensity (MVPA), and vigorous PA (VPA) was classified as >6 METs [35].
Time dedicated to watching television and playing video games: The reported times were
converted into hours/day and were classified into two categories: less than three hours and three or
more hours per day [36].
Clinical and biochemical tests: Pubertal maturation was evaluated and classified by self-report
according to Tanner’s methodology [37,38].
Blood pressure was taken with a mercury sphygmomanometer (Riester®) and was classified
according to Fourth Task Force methodology [39].
An antecubital venous blood sample was taken following a 10- to 12-h fast, and serum was
obtained and stored at ´80 ˝C. Total cholesterol (TC), HDL-C, LDL-C and TG were determined by
spectrophotometry in an RA-50 photocolorimeter (Bayer, series 71663, Dublin, Ireland) using specific
enzymatic colorimetric kits (BioSystems Reagents and Instruments, Barcelona, Spain). Blood glucose
and insulin were determined by micro-particle enzyme immunoassay (MEIA) [40]. IR was estimated
by the mathematical model of the HOMA (Homeostasis Model Assessment) index using the HOMA
Calculator Version 2.2.2 software, copyrighted by the Diabetes Trials Unit of the University of Oxford.
IR was defined as a HOMA ě3.1, based on three criteria: 3.1 was the HOMA in the 95 percentile in the
population under study [21], 3.1 was the cutoff point established by others authors [41,42]. hsCRP was
determined by immunoturbidimetry and was classified as low cardiovascular risk <1 mg/L, average
risk 1-3 mg/L and high risk >3 mg/L [43].
Profile of circulating FFAs: Lipid extraction from serum was performed according to the Folch
method [44]. For separation of CE, TG and PL fractions, the methodology by solid-phase extraction
(SPE) of Agren J [45] and Kaluzny M [46] was used. To the dry extract of each fraction, hexane and
boron trifluoride (BF3) in 20% methanol were added, and the mixture was heated between 80 ˝C
and 90 ˝C for one hour. [47]. Chromatographic analysis was performed in an Agilent 6890N gas
chromatograph with a flame ionization detector (FID), TR-CN100 column, 60 m ˆ 0.25 mm ˆ 0.2 μm
ID, oven temperature program beginning at 90 ˝C ˆ 7 min, increased at a rate of 5 ˝C/min to 240 ˝C for
14
Nutrients 2016, 8, 54
15 min, detector temperature of 300 ˝C, and He carrier gas at a flow of 1.1 mL/min. FA identification
was performed by comparisons of retention times with the standard FAME Mix of 37 components
(Supelco, Bellefonte, PA). The results are presented as relative amounts of each FA.
Total concentrations of SFA, MUFA and PUFA were calculated from the sum of each FA from
14 to 22 carbons of each family, in each fraction. The product/precursor ratios were calculated as an
indirect indicator of the activity of the desaturase enzymes. These ratios were as follows: stearoyl CoA
desaturase = Palmitoleic-16:1n-7/Palmitic-16:0 and Oleic-18:1n-9/Stearic-18:0, delta-5 desaturase =
ARA-20:4n-6/DHGL-20:3n-6 and delta-6 desaturase = DHGL-20:3n-6/Linoleic-18:2n-6, as previously
reported [10,13,48].
Ethical management: The investigation was classified as having a minimum risk according to the
Colombian Ministry of Health, Resolution 008439, Article 11 of October 1993. The study was approved
by the University of Antioquia Bioethics Committee. Informed consent was signed by the youth and
their parents and included the Helsinki declaration.
Statistical analysis: Normality was established with the Shapiro-Wilk test. The difference among
groups was performed by analysis of variance (ANOVA) or Kruskall-Wallis. For comparisons
between two groups, Scheffe or Mann-Whitney U tests were performed. Qualitative variables were
expressed with frequencies; quantitative variables, with means and standard deviations or medians
and interquartile ranges. For associations of qualitative variables Chi2 and Odds Ratium were used,
while Pearson R or Spearman Rho were used for quantitative variables. A stepwise multiple linear
regression model was applied to explain the HOMA (dependent variable in logarithmic units) with WC,
average METs, linoleic-18:2n-6 in TG, DHGL-20:3n-6 in FFAs and total FFAs as independent variables;
the model was adjusted by food intake variables: daily intake of calories, simple carbohydrates,
saturated fat, monounsaturated fat and polyunsaturated fat. R2 and ANOVA determined the fit of the
model, and fulfillment of assumptions (Durbin Watson, normality of residuals, inflation factor of the
variance and independence) was checked. Finally, the β values of the crude and the adjusted model
were transformed with antilogarithm to express in units of the dependent variable: HOMA, in Table 5.
A p < 0.05 was considered significant. Statistical analysis was performed using the program Statistical
Package for the Social Sciences (SPSS®) V 21.0.
3. Results
Matched variables between groups did not show significant differences (Table 1).
Table 1. Matched characteristics of the study groups.
OBMS n = 32 OB n = 32 AW n = 32 p *,†
Age (Me, IQR) 13.9 (4.8) 14.2 (4.1) 14.0 (4.2) 0.93 *
Gender (%)
Boys 56.3 56.3 56.3
1.00 †Girls 43.8 43.8 43.8
Pubertal Maturation (%)
Prepubescent 12.5 12.5 12.5
0.99 †Pubescent 25.0 21.9 25.0
Post-pubescent 62.5 65.6 62.5
Socioeconomic Stratum
(%)
Low 53.1 53.1 50.0
0.84 †Medium 37.5 31.3 38.5
High 9.4 15.6 11.5
OBMS: obesity with metabolic syndrome; OB: obesity; AW: Appropriate weight; Me: medians; IQR: interquartile
ranges; * Kruskal Wallis; † Pearson Chi squared.
Both obese groups showed similar behaviors for fat percentage and inflammation. The risk of
mild chronic inflammation (high-sensitivity C-reactive protein (hsCRP > 1 mg/dL)) in obese youth
was 2.6 times greater than in the appropriate weight (AW) group (odds ratio 2.6; confidence interval
1.27–5.54; p = 0.001), only this risk was significant; hsCRP correlated with fat percentage (r = 0.51
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p = 0.001). The obese with MetS (OBMS) group had higher BMI, WC, blood glucose, insulin, HOMA
and TG and lower HDL-C compared to the other two groups (p = 0.001). A total of 97.3% of the OBMS
group simultaneously had high TG and low HDL-C, according to the criteria used in the diagnosis
of MetS in this study. Of the OBMS, 53.1% simultaneously had high WC and HOMA; both variables
were correlated (Rho = 0.71; p < 0.001) (Table 2).
Table 2. Anthropometric, biochemical, food intake and physical activity variables of the study groups 1.
OBMS n = 32 OB n = 32 AW n = 32 p *,†
Anthropometric
BMI kg/m2 31.1 ˘ 5.0 a, 2 27.1 ˘ 2.9 b 20.2 ˘ 2.3 c <0.001 *
Waist circumference cm 91.2 ˘ 10.9 a 80.5 ˘ 5.6 b 67.6 ˘ 5.4 c <0.001 *
Subscapular fold mm 29.9 ˘ 10.9 a 25.5 ˘ 8.1 a 11.5 ˘ 3.5 b <0.001 *
Triceps fold mm 25.2 ˘ 6.7 a 23.6 ˘ 6.2 a 12.9 ˘ 4.1 b <0.001 *
% fat 38.1 (18.7) a 34.7 (15.8) a 22.2 (14.2) b <0.001 †
Biochemical
Blood glucose mg/dL 90.3 ˘ 8.2 a 83.7 ˘ 7.5 b 83.3 ˘ 6.9 b <0.001 *
Insulin mU/L 25.7 (12.4) a 11.5 (7.8) b 7.1(4.1) c <0.001 †
HOMA 3.2 (1.7) a 1.5 (1.0) b 0.9(0.5) c <0.001 †
Cholesterol (mg/dL) 192.6 ˘ 50.3 a 172.3 ˘ 34.5 162.1 ˘ 27.9b <0.001 *
Triglycerides (mg/dL) 162 (94) a 92 (37) b 71 (32) c <0.001 †
HDL-C (mg/dL) 38 (6) a 45 (15) b 54 (15) c <0.001 †
LDL-C (mg/dL) 99 (61) a 88 (37) a 79 (31) b <0.001 †
hsCRP (mg/dL) 1.7 (2.9) a 0.9 (2.5) a 0.4 (0.7) b <0.001 †
Nutrient consumption/day
Kilocalories 2238 (436) a 2007 (264) a 2442 (229) b <0.001 †
Total fat (g) 79.5 (14.6) a 70.3 (12.5) b 96.9 (44.0) c <0.001 †
Saturated fat (g) 31.3 (9.2) 28.5 (8.3) a 36.4 (20.1) b 0.015 †
Monounsaturated fat (g) 26.7 (5.1) a 25.5 (3.5) a 30.0 (1.7) b <0.001 †
Polyunsaturated fat (g) 16.3 (1.6) a 15.4 (1.5) b 15.7 (1.8) c 0.004 †
Total carbohydrates (g) 294 (50) a 276 (57) a 329 (36) b <0.001 †
Complex carbohydrates
(g) 232 (58)
a 222 (51) a 263 (28) b <0.001 †
Fiber (g) 14 ˘ 2 a 14 ˘ 3 a 16 ˘ 1 b 0.001 *
Physical activity
METs/day 61.5 (15.4) 61.1 (10.0) 62.8 (14.7) 0.88 †
MVPA Blocks 1.3 (3.60) 1.3 (2.3) 1.0 (2.5) 0.317 †
VPA Blocks 0.1 (1.0) 0.3 (1.0) 0.0 (1.3) 0.991 †
Hours of TV/day 3.6 ˘ 1.7 3.8 ˘ 2.7 3.3 ˘ 3.1 0.57 *
OBMS: obesity with metabolic syndrome; OB: obesity; AW: Appropriate weight; BMI: Body Mass Index;
HOMA: Homeostasis Model Assessment; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein;
hsCRP: high-sensitivity C-reactive protein; MET: Metabolic equivalent; MVPA: moderate to vigorous physical
activity; VPA: vigorous physical activity; 1 Averages ˘ standard deviations and medians (interquartile ranges);
2 Different letters between lines show significant differences between groups; * ANOVA with Scheffé or †
Kruskal-Wallis with Mann–Whitney U post-test.
In the TG fraction, the OBMS group has a significantly higher proportion of SFAs compared to the
other groups (p = 0.001); additionally, the OB group had a higher proportion of SFAs compared to the
AW (p = 0.028). Total MUFAs was significantly greater in the OBMS group compared to the AW group
(p = 0.003). The proportion of palmitoleic-16:1n-9 for OBMS and OB was higher than AW (p = 0.009). Of
the total PUFAs represented in this case by linoleic-18:2n-6, the OBMS group had the lowest proportion
among the three groups (p = 0.001), followed by the OB group, with the highest being AW (p = 0.042)
(Table 3). In this fraction, palmitic-16:0 correlated directly with the HOMA (Rho = 0.55 p = 0.001) and
serum TG (Rho = 0.66 p = 0.001) and inversely with HDL-C (Rho = ´0.52 p = 0.001). Linoleic-18:2n-6
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was correlated inversely with the HOMA (Rho = ´0.56 p = 0.001) and serum TG (Rho = ´0.70 p = 0.001)
and directly with HDL-C (Rho = 0.49 p = 0.001) (Table S1).
Table 3. Major fatty acids in lipid fractions of youth according to the study groups 1.
Triglycerides
FA (% Total FA)
OBMS OB AW
p *,†n = 32 n = 32 n = 32
SFA sum 38.3 (7.1) a, 2 34.6 (8.9) b 30.8 (7.6) c <0.001 †
Palmitic-16:0 29.7 ˘ 4.0 a 26.4 ˘ 3.7 b 23.6 ˘ 3.3 c <0.001 *
Stearic-18:0 6.2 (3.8) 7.4 (4.1) 7.2 (3.8) 0.42 †
MUFA sum 36.1 ˘ 5.2 a 33.5 ˘ 5.0 31.7 ˘ 5.0 b 0.003 *
Palmitoleic-16:1n-7 3 4.5 (2.0) a 4.1 (1.4) a 3.0 (1.6) b 0.009 †
Oleic-18:1n-9 32.1 ˘ 4.3 30.7 ˘ 3.9 30.1 ˘ 4.3 0.14 *
PUFA sum - - - -
Linoleic-18:2n-6 25.6 ˘ 5.8 a 32.2 ˘ 6.3 b 36.4 ˘ 7.5 c <0.001 †
Phospholipids
SFA sum 52.8 (11.3) a 54.1 (11.3) 56.4 (5.9) b 0.017 †
Palmitic-16:0 30.6 ˘ 3.4 a 31.7 ˘ 3.0 33.2 ˘ 3.0 b 0.006 *
Stearic-18:0 19.8 (4.9) 20.1 (6.0) 21.2 (2.1) 0.34 †
Behenic-22:0 0.5 (0.2) a 0.6 (0.2) b,c 0.8 (0.2) b,c 0.015 †
MUFA sum 17.5 (7.3) a 15.1 (8.3) b,c 13.8 (3.5) b,c <0.001 †
Palmitoleic-16:1n-7 4 0.9 (0.4) a 0.8 (0.2) b 0.5 (0.2) c <0.001 †
Oleic-18:1n-9 16.7 (7.3) a 14.1 (8.1) b,c 13.5 (3.4) b,c <0.001 †
PUFA sum 30.0 (4.8) 31.1 (3.8) 29.9 (4.1) 0.74 †
Linoleic-18:2n-6 18.0 ˘ 2.2 a 19.2 ˘ 2.6 a 21.0 ˘ 2.8 b <0.001 *
DHGL-20:3n-6 2.8 ˘ 0.7 a 2.5 ˘ 0.4 2.1 ˘ 0.5 b <0.001 *
Eicosatrienoic-20:3n-3 5 8.2 ˘ 2.2 7.7 ˘ 2.0 5.6 ˘ 2.7 0.063 *
Arachidonic-20:4n6 5.0 (1.2) 5.3 (1.5) 4.8 (2.3) 0.77 *
Cholesterol Esters
SFA sum 35.7 (15.5) 35.1 (16.0) 35.7 (13.2) 0.92 †
Palmitic-16:0 33.2 ˘ 7.7 31.0 ˘ 7.1 31.2 ˘ 5.2 0.35 *
Stearic-18:0 6 10.4 (12.1) 11.3 (7.0) 12.3 (9.3) 0.96 †
MUFA sum - - - -
Oleic-18:1n-9 28.4 (4.1) 26.3 (8.2) 26.2 (5.7) 0.44 †
PUFA sum - - - -
Linoleic-18:2n-6 35.9 ˘ 9.5 34.5 ˘ 10.7 35.2 ˘ 10.4 0.84 *
Free Fatty Acids
SFA sum 44.7 (4.1) 46.1 (6.4) 43.2 (6.7) 0.59 †
Myristic-14:0 1.1 (0.2) 1.4 (0.1) 1.1 (0.5) 0.47 *
Palmitic-16:0 30.0 (2.4) 30.0 (3.7) 30.8 (4.5) 0.93 †
Stearic-18:0 14.4 (2.2) 15.4 (2.7) 14.5 (3.4) 0.45 †
MUFA sum 20.9 (4.1) 19.1 (4.6) 19.1 (5.6) 0.22 †
Palmitoleic-16:1n-7 7 1.7 (0.7) 1.7 (0.5) 1.5 (0.6) 0.46 †
Oleic-18:1n-9 19.3 (4.0) 17.9 (3.3) 18.4 (3.4) 0.31 †
PUFA sum 33.5 (3.4) 34.0 (4.1) 34.4 (4.9) 0.68 †
Linoleic-18:2n-6 21.7 (3.3) 22.6 (3.3) 24.5 (5.3) 0.14 †
DHGL-20:3n-6 3.0 ˘ 0.6 a 2.8 ˘ 0.6 2.4 ˘ 2.5 b <0.001 *
Arachidonic-20:4n6 6.6 (1.1) 6.5 (3.1) 5.8 (2.0) 0.25 †
DHA-22:6n-3 1.9 ˘ 0.4 1.9 ˘ 0.5 1.8 ˘ 0.5 0.51 *
Total FFA (mg/dL) 199.5 (40.0) a 100.8 (24.1) b 98.8 (29.9) b 0.014 †
OBMS: obesity with metabolic syndrome; OB: obesity; AW: Appropriate weight; SFA: saturated fatty
acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; FFA: free fatty acid; DHGL:
Dihomo-gamma-linolenic; DHA: docosahexaenoic acid; * ANOVA; † Kruskal-Wallis test; 1 Data expressed
as Averages˘standard deviations or medians (interquartile ranges); 2 Different letters between lines show
significant differences between groups, according to the Scheffé post-test for parametric variables or the
Mann–Whitney U test for nonparametric variables; 3 OBMS n = 28, OB n = 20, AW n = 16; 4 OBMS n = 28
OB n = 25, AW n = 8; 5 OBMS n = 15, OB n = 13, AW n = 6; 6 OBMS n = 15, OB n = 13, AW n = 6; 7 OBMS n = 27,
OB n = 19; AW n = 8.
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In the PL fraction, total SFAs were present in significantly lower amounts in the OBMS group
compared to the AW group. The OBMS group had higher total MUFAs compared to the other two
groups (p = 0.001), with no difference between the OB and AW groups (p = 0.05). In particular,
palmitoleic-16:1n-7 was higher in OBMS compared to the other two groups (p = 0.001), and time was
higher in OB than AW (p = 0.004). With respect to linoleic-18:2n-6, a significantly lower proportion was
found in the OBMS and the OB group compared to the AW group (p = 0.001, p = 0.021, respectively).
DHGL-20:3n-6 had a significantly higher proportion in the OBMS group compared to the AW group
(p = 0.001), with no differences between OB and AW (p = 0.079) (Table 3). In the PL fraction,
palmitoleic-16:1n-7 was directly associated with serum TG (Rho = 0.54 p = 0.001) and inversely
associated with HDL-C (Rho = ´0.43 p = 0.001). DHGL-20:3n-6 correlated directly with the HOMA
(Rho = 0.36 p = 0.000) and serum TG (Rho = 0.33 p = 0.001), while linoleic-18:2n-6 correlated inversely
with the HOMA (Rho = ´0.31 p = 0.002) and serum TG (Rho = ´0.29 p = 0.004) and directly with HDL-C
(Rho = 0.30 p = 0.003) (Table S1).
In the FFA fraction, total circulating FFAs were significantly greater in the OBMS group, with
double the concentration compared to the other groups (p = 0.014). The OB group had the same
concentration of total FFAs as the AW group (Table 3). Among PUFAs, DHGL-20:3n-6 was significantly
higher in the OBMS group than in the AW group (p = 0.001); with no differences between OB and
AW. The DHGL-20:3n-6/linoleic-18:2n-6 ratio was significantly greater in the OBMS and OB groups
compared to the AW group (p = 0.001) (Table 4). DHGL-20:3n-6 correlated directly with the HOMA
(Rho = 0.36 p = 0.001) and TG (Rho = 0.33 p = 0.001) (Table S1).
Table 4. Ratios of fatty acids in lipid fractions of youth according to the study groups 1.
Ratio of Fatty Acids
OBSM OB AW
p *,†n = 32 n = 32 n = 32
Triglycerides
16:1/16:0 3 0.1 (0.1) a, 2 0.1 (0.2) 0.1 (0.1) b 0.005 †
18:1/18:0 5.1 ˘ 1.9 4.4 ˘ 1.9 4.4 ˘ 1.8 0.30 †
Phospholipids
16:1n-7/16:0 4 0.03 (0.01) a 0.02 (0.01) b 0.01 (0.01) c <0.001 †
18:1n-9/18:0 0.8 (0.7) a 0.7 (0.7) 0.6 (0.2) b <0.001 †
20:3n-6/18:2n-6 0.2 (0.1) a 0.1 (0.0) b 0.1 (0.0) c <0.001 †
20:4n6/20:3n6 1.9 (0.7) 2.0 (1.2) 2.3 (1.4) 0,059 †
Cholesterol Esters
18:1n-9/18:0 5 2.3 (2.6) 2.4 (1.7) 2.1 (1.6) 0.94 *
Free Fatty Acids
16:1/16:0 6 0.5 (0.0) 0.6 (0.0) 0.5 (0.0) 0.57 †
18:1n-9/18:0 1.3 (0.4) 1.2 (0.4) 1.3 (0.4) 0.47 †
20:3n-6/18:2n-6 0.1 ˘ 0.0 a 0.1 ˘ 0.0 a 0.1 ˘ 0.0 b <0.001 *
20:4n6/20:3n6 2.2 (0.8) 2.3 (0.8) 2.5 (1.5) 0.22 †
OBMS: obesity with metabolic syndrome; OB: obesity; AW: Appropriate weight; * ANOVA; † Kruskal-Wallis
test; 1 Data expressed as Averages˘standard deviations, medians (interquartile ranges); 2 Different letters
between lines show significant differences between groups, according to the Scheffé post-test for parametric
variables or the Mann–Whitney U test for nonparametric variables; 3 OBMS n = 28, OB n = 20, AW n = 16;
4 OBMS n = 28, OB n = 25, AW n = 18; 5 OBMS n = 15, OB n = 13, AW n = 6; 6 OBMS n = 27, OB n = 19, AW n = 8.
A descriptive multivariate analysis of the HOMA revealed that WC increased the average HOMA
by 1.025, total FFAs increased average HOMA by 1.004, and each unit of DHGL-20:3n-6 in FFAs
increased the average HOMA by 1.258, while physical activity (METs) and linoleic-18:2n-6 in TG
decreased average HOMA by ´1.018 and ´1.016, respectively. The independent variables explained
62% of the behavior of the HOMA. All relationships observed were significant and remained the same
after making adjustments for food consumption variables (Table 5).
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Table 5. Multiple linear regression model with explanatory variables of the HOMA index.
Variables β * β † IC † p † IFV †
Waist circumference 1.025 1.025 0.008; 0.015 0.000 1.543
Average METs/d ´1.018 ´1.018 ´0.012; ´0.003 0.001 1.278
Linoleic-18:2n-6 in TG ´1.016 ´1.016 ´0.013; ´0.001 0.024 1.606
DHGL-20:3n-6 in FFA 1.276 1.258 0.028; 0.172 0.007 1.767
Total FFA in mg/dL 1.004 1.004 0.000; 0.003 0.028 1.379
HOMA: The Homeostatic model assessment.* Raw model: R2: 0.637, ANOVA: p = 0.0001, Normality: p = 0.200,
Colinearity: Inflation factor of the variance (IFV) <5, Durbin Watson: 0.930. Values expressed in HOMA units.
† Adjusted for total calories, saturated fat, monounsaturated fat, polyunsaturated fat and simple carbohydrates.
Values expressed in HOMA units. Adjusted model: R2: 0.620, ANOVA: 0.0001, Normality: p = 0.050, Colinearity:
IFV < 5, Durbin Watson: 0.987.
4. Discussion
This study detected proportions of some FA for youth with OBMS in the TG, PL and FFA fractions
that correlated with disturbances of MetS.
In OBMS the TG fraction showed significantly higher concentrations of total SFAs and MUFAs,
but a lower concentration of PUFAs. This pattern could be due to accelerated hepatic lipogenesis
that results in the incorporation of FAs, such as palmitic-16:0, palmitoleic-16:1n-7 and oleic-18:1n-9 in
VLDL, with a simultaneous decrease in the amount of linoleic-18:2n-6 [19].
This study, consistent with that detected previously by others, found high proportions of MUFAs
in the OBMS and OB groups [23,24,49]. Palmitoleic-16:1n-7 was directly and significantly associated
with serum TG. The palmitoleic-16:1n-7/palmitic-16:0 and oleic-18:1n-9/stearic-18:0 ratios that could
indirectly indicate enzyme activity of delta-9 desaturase were higher in the OBMS group, consistent
with other studies [10–12,24] where they have been associated with obesity [10], IR and MetS [12]. The
increase in the activity levels of desaturase enzymes in obesity could be related to hyperinsulinemia
arising from excess states, as insulin is a potent activator and regulator of delta-6 and delta-9
desaturases [50].
This study found low proportions of PUFAs in the OBMS group. The concentrations of
linoleic-18:2n-6 in both the TG and PL fractions were correlated directly with HDL-C and inversely
with serum TG and the HOMA. These inverse relationships could be explained because reduced
availability of PUFAs in cell membranes has been associated with lower fluidity and changes in insulin
sensitivity [51].
DHGL-20:3n-6, a product of desaturation and elongation of linoleic-18:2n-6, appears at
significantly higher percentages in the PL and FFA fractions in the OBMS group than in the AW
group; consistent with this finding, the DHGL-20:3n-6/linoleic-18:n-6 ratio was higher in the OBMS
group in both fractions, with similar results as those reported by Okada [11]. DHGL-20:3n-6 in
the PL and FFA fractions correlated positively and significantly with WC, HOMA and TG, which
agrees with other studies that conclude that this FA is associated with greater IR, cardiovascular
risk [10,22,24,25] and inflammation [22]. In adults, Kurotani et al. also associated this FA
and the DHGL-20:3n-6/linoleic-18:2n-6 ratio with early markers of IR and DM, such as high
levels of C peptide [52]. DHGL-20:3n-6 is a precursor of thromboxanes and series 1 prostanoids
(anti-inflammatory) via cyclooxygenase; its increase in these young people, without a simultaneous
increase in ARA-20:4n-6, could indicate a compensatory mechanism associated with increased activity
of delta-6 desaturase, which would enhance the anti-inflammatory activity helping to maintain the
balance between pro- and anti-inflammatory substances [53].
The main finding in the FFA fraction was that the OBMS group had double the circulating total
FFAs of other groups. This finding has been reported by other authors [54,55], in addition to its positive
correlations with WC, insulin, HOMA [55], CT and serum TG [54]. The increase in total FFAs suggests
that in those who present central obesity, adipocytes increase FA release due to saturation of the storage
capacity and stress to the endoplasmic reticulum of visceral adipocytes. This effect diminishes the
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anti-lipolytic signal of insulin, perpetuating the release of FAs from visceral adipose tissue, which,
once in circulation, are lipotoxic and are associated with the development of lipid alterations, IR and
MetS [6,55,56].
Given the aforementioned associations, it was investigated whether FAs could explain the link
between visceral obesity and insulin resistance in these youth using a multiple linear regression model.
It was found that 62% of the HOMA was explained by the increases in total FFAs, DHGL-20:3n-6 in
FFA and WC, in addition to decreases in linoleic-18:2n-6 in TG and the average METs/d.
The OB group presented proportions similar to those of the AW group in DHGL-20:4n-6 and
in the total amount of circulating FFAs, variables – which in the OBMS group – has been associated
with metabolic alterations, especially with IR. However, the OB group, compared to the AW group,
presented a greater proportion of SFAs and MUFAs, a lower proportion of PUFAs in the TG fraction,
higher values of WC, HOMA and TG and lower proportions of HDL-C, which is consistent with
increased lipogenesis and confirms that obesity itself is a disorder that leads to future metabolic
abnormalities and probably to NAFLD, if weight gain continues; consequently, the OB youth group
should not be considered metabolically healthy. In these obese youth, therapeutic measures necessary
to avoid or diminish MetS and NAFLD should be considered, especially in stimulating weight
reduction with an increase in physical activity and the adoption of healthy eating habits, among
others, as well as encouraging a greater consumption of polyunsaturated fat, a source of Omega 3 FA;
if necessary, prescribe the consumption of lipid-lowering agents [57].
Like Waresnjo, this study found no association between circulating FAs and the PA level [12];
however, PA was incorporated as an explanatory variable of the HOMA in the multiple regression
model, indicating that certain FAs in the profile and environmental factors influence its value.
In this study, the AW group consumed more calories and fats than the obese groups, results
that have been reported by other authors [58,59]; these findings may be due to underestimations in
evaluations of self-reported consumption, especially in obese individuals, or, when excess weight is
evident, obese individuals decrease food intake. Therefore, current consumption cannot be correlated
with nutritional status.
We did not detect a consumption pattern that could explain the differences in the FA profiles
among the groups. Qualitative analysis of diets allowed us to establish that these youth did not
consume significant omega-3 food sources, such as fish or seed oils, which could explain to some
degree the low proportions of these FAs in the different fractions. In any event, to eliminate the effect
of consumption on the descriptive model of the HOMA index, an adjustment was made for these
variables, and the model was not modified.
This study has some limitations: the 24-h recall does not allow establishing individual associations
with biochemical variables because of intra-individual variations in food intake; estimation of
desaturase enzymes was performed using an indirect method due to technical difficulties involving
their measurement in vivo. The diagnostic criteria for NAFLD in youth were not evaluated,
which prevents establishing some degree of association with the profile of the fatty acids of the
different fractions.
Finally, it is expected that there will be further research involving more complex lipids, such as
waxes and eicosanoids, and methodological designs that establish causal relationships between the FA
profile and metabolic disturbances that make up MetS, especially in children and youths.
5. Conclusions
This study detected proportions of some FA for youth with OBMS in the TG, PL and FFA fractions
that correlated with disturbances of MetS, principally IR. High concentrations of total FFAs, high
proportions of palmitic-16:0 in TG, high palmitoleic-16:1n-7 and low linoleic-18:2n-6 in TG and PL,
and high DHGL-20:2n-6 in PL and FFAs could all be early markers of IR in youths. The findings
further suggest that the connection between FA profiles and metabolic disturbances is associated more
with high WC than BMI. The OB group presented greater proportions of SFA and MUFA and lower
20
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proportions of PUFA, as well as some higher biochemical values than those youth with AW, suggesting
the possibility of developing future metabolic abnormalities if weight gain continues.
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Abstract: Obesity and associated metabolic complications, such as non-alcoholic fatty liver disease
(NAFLD) and type 2 diabetes (T2D), are in constant increase around the world. While most obese
patients show several metabolic and biometric abnormalities and comorbidities, a subgroup of
patients representing 3% to 57% of obese adults, depending on the diagnosis criteria, remains
metabolically healthy. Among many other factors, the gut microbiota is now identified as a
determining factor in the pathogenesis of metabolically unhealthy obese (MUHO) individuals and
in obesity-related diseases such as endotoxemia, intestinal and systemic inflammation, as well as
insulin resistance. Interestingly, recent studies suggest that an optimal healthy-like gut microbiota
structure may contribute to the metabolically healthy obese (MHO) phenotype. Here, we describe
how dietary medium chain triglycerides (MCT), previously found to promote lipid catabolism,
energy expenditure and weight loss, can ameliorate metabolic health via their capacity to improve
both intestinal ecosystem and permeability. MCT-enriched diets could therefore be used to manage
metabolic diseases through modification of gut microbiota.
Keywords: obesity; metabolically unhealthy obese; metabolically healthy obese; metabolic
syndrome; non-alcoholic fatty liver disease; gut microbiota; Bacteroidetes; Firmicutes; endotoxemia;
lipopolysaccharide; medium chain triglycerides; medium chain fatty acids
1. Introduction
Obesity has become an international public health problem with 2.1 billion people worldwide
being overweight (body mass index (BMI) ě 25.0) and more than half a billion among them being obese
(BMI ě 30.0) [1,2]. Obesity is now described as a pandemic with increased prevalence in both adult
and child populations. Since the 1980s, the combined prevalence of obesity and overweight increased
by 28% in adults and 47% in children [1,2]. Obesity is a multifactorial affection with broad etiology,
and multiple comorbidities. Most of these comorbidities are thought to be the result of aberrant
body fat distribution leading to the metabolic syndrome [3–5]. This pathology is associated with an
elevated waist circumference, a progressive state of non-alcoholic fatty liver disease (NAFLD) [3,4],
insulin resistance, type 2 diabetes (T2D), some types of cancers (especially in women), hypertension,
cardiovascular diseases, reproductive abnormalities, dyslipidemias, psychological affections [6], and
a severely reduced life expectancy [3,7,8]. Obesity is also considered a risk factor for several other
diseases such as chronic respiratory diseases [9] and arthritis [3].
Some contributing factors for obesity progression are: unfavorable genetic determinants [10],
lack of physical activity [11], socio-economic status [1], circadian cycle disturbance [12], sleep
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deprivation [13], hormonal dysregulation [14], persistent organic pollutants [15] and alteration of the
gut microbiota [16,17]. However, the most powerful inducer of obesity and its associated adverse
metabolic effects remains, by far, inappropriate food intake [18]. The modern prevalence of obesity
and metabolic syndrome is likely due to the rise in consumption of energy-dense food, containing
high amounts of fat and carbohydrates [18], especially in Western countries. In these countries, fats
typically account for 33% to 42% of dietary energy intake, with a rich proportion of long chain saturated
fat [18]. When the energy intake exceeds both the caloric needs of the body and its glycogen storage
capacity, dietary carbohydrates and fats are first converted and stored as triglycerides (TG) in white
adipose tissue (WAT) and, later on, in other tissues such as the liver [19,20]. Sustained and abusive
accumulation of lipids in the liver induces NAFLD (highly concurrent with obesity) which may result
in lipotoxicity, steatohepatitis, hepatocyte cell death, fibrosis and eventually liver cirrhosis as well as
hepatocarcinoma [21].
We aim here to overview the underlying causes of obesity and its associated metabolic
abnormalities while paying special attention to a unique subset of the obese population: the
metabolically healthy but obese (MHO) individuals. We will highlight the potential involvement of
the gut microbiome as one of several contributors to the MHO status. We will finally introduce the
idea of a medium chain triglycerides (MCT)-based dietary intervention with the aim of improving the
metabolic state of metabolically unhealthy obese (MUHO) patients, either through modification of
their intestinal health or by directly influencing lipid metabolism.
2. Etiology of Obesity and Associated Metabolic Complications
The current paradigm posits that fat accumulation leading to obesity results from an imbalance
between energy intake and energy expenditure. Post-World War II food processing and marketing
practices (quickly available energy-dense foods) and reductions in physical activity are the two main
factors often blamed for the contemporary prevalence of obesity. As such, most treatment options
involve creation of a negative energy balance, achieved by consuming fewer calories than energy
expended. Alternatively, pharmacological and surgical therapies also exist [22]. Nevertheless, complex
interactions among heredity [23], epigenetic imprinting [24], lifestyle, feeding behavior [25], as well
as environmental [26] and physiologic inflammatory factors [27,28] also contribute to the etiology
of obesity.
2.1. Comorbidities Related to Obesity
Most obese individuals fall into the MUHO category and are at increased risk for several
diseases. They suffer from a severely reduced life expectancy: a 5.8 years average decrease for
men and 7 years for women [29]. The visceral adipose tissue (typically abundant in obese individuals)
secretes pro-inflammatory cytokines [27,28] that are, in part, responsible for obesity-associated
pathogenesis [27,28]. The resulting metabolic syndrome defines a group of metabolic risk factors linked
to health problems associated with overweight and obesity such as elevated visceral adiposity, larger
waist circumference (>102 cm in men and >88 cm in women), hyper-triglyceridemia (>150 mg/dL) [5],
reduced HDL (high density lipoprotein) cholesterol levels (<40 mg/dL in men and <50 mg/dL in
women), elevated blood pressure (systolic > 130 mmHg and/or diastolic > 85 mmHg) and high fasting
glucose levels [30]. A patient with at least three of these risk factors is currently diagnosed with the
metabolic syndrome.
High levels of glycemia, associated with insulin resistance, are a hallmark of prediabetes and
T2D, common diseases occurring in obese individuals suffering from the metabolic syndrome [5].
According to the most recent criteria, prediabetes is defined by a fasting glucose ranging between 100
and 125 mg/dL or between 140 and 199 mg/dL 2 h post-prandium, while these two values often exceed
126 mg/dL and 200 mg/dL in T2D, respectively [5]. In addition, the latest medical updates indicate
that 50%–90% of patients with TD2 have a BMI > 25.0 (the overweight threshold) while those with a
BMI > 35 have a 20-fold higher risk of developing T2D than healthy lean patients [31].
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Risk of cardiovascular diseases, including atherosclerosis, coronary artery disease, stroke and
pulmonary embolism, is higher in obese patients [32]. Obesity is also associated with a large
spectrum of liver abnormalities including NAFLD [33]. Several additional comorbid disease risks are
associated with obesity such as cholelithias, pancreatic failure sleep apnea, gynecological abnormalities,
osteoarthritis, psychiatric illness as well as some types of cancer (breast, endometrial, prostate and
colon) [22].
2.2. Metabolically Healthy but Obese Individuals (MHO)
There is a large body of evidence suggesting that not all obese individuals develop such important
metabolic complications [34]. A unique subtype of obese individuals has been identified as MHO [35].
Despite excessive levels of body fat mass, MHO patients present higher levels of insulin sensitivity, a
normal circulating lipid profile, no pronounced hepatic steatosis nor associated inflammatory state, no
hypertension, and a lower visceral, muscle and hepatic fat content compared to MUHO subjects [36].
Since there is no standard definition for the identification of the MHO phenotype, the true prevalence
of MHO individuals in the obese population is currently unclear. Depending on the method and the
cut-off point used for certain metabolic risk factors, the prevalence of MHO subjects may range from
approximately 3% to 57% of obese adults [37,38].
The favorable metabolic profile of MHO individuals has been associated with a lower risk of
developing T2D or cardiovascular disease (CVD), and having a lower mortality risk compared to
MUHO individuals [39]. There is also evidence refuting the notion that MHO subjects are totally
protected from metabolic diseases [40]. The fundamental mechanisms underlying the different
metabolic profiles of MHO and MUHO individuals remain poorly understood [41]. However, Berezina
et al. showed that among patients with abdominal obesity, MHO phenotype was associated with a
G45G Adiponectin genotype, while the T45T genotype for Adiponectin increased metabolic disorders
risks [42]. This observation is all the more interesting since Adiponectin is a potent modulator of insulin
sensitivity [43]. Also, in the latter decade, a consensus has emerged, which make the gut microbial
population (also called the gut microbiota) a key determinant in the host metabolic profile [17,44]. The
gut microbiota should therefore be taken into consideration in dietary and clinical approaches, for
both MUHO and MHO treatments.
3. The Gut Microbiota: A Determining Factor for Metabolic State
3.1. Gut Microbiota Dysbiosis in Obesity
Current estimations indicate that the human intestine is colonized by a large population of above
100 trillion microbial cells organized in several taxa and constituting the gut microbiota [45]. The total
biomass of the gut microbiota exceeds 1kg and is mainly concentrated in the large intestine, where
about 1012 bacteria per gram of colonic tissue are found [46]. Such an important quantity of “foreign”
cells implies a tightly regulated acceptance by the immune system of the host [46]. The gut microbiota
plays a symbiotic role, ensuring several metabolic functions essential to the host. It is involved in
the degradation of polysaccharides and oligosaccharides into simple metabolites such as short chain
fatty acids (SCFA). These SCFA were recently found to promote intestinal impermeability [47] as well
as hepatic sugar and lipid anabolism [48–50]. The gut microbiota is also an indispensable source of
essential vitamins B and K [51]. Gut microbiota composition and diversity are subjected to important
variations between individuals but also within the same individual under the influence of several
physiologic and environmental factors such as antibiotic consumption, lifestyle and diet [52].
The alteration of gut microbiota is closely linked to tissue inflammation and to a broad range of
metabolic abnormalities, including obesity and insulin resistance [52,53]. First observations suggested
a link between the gut microbiota and the metabolic state of the host [54,55]. Several studies have since
confirmed a direct implication of gut microbiota in obesity progression [17].
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Backhed and colleagues first demonstrated that germ-free mice were protected against high
fat and high sugar diet-induced obesity, via enhanced expression of hepatic and muscular Pgc-1α
(a PPAR coactivator) and activation of lipid catabolism via AMPK activity [56]. Subsequently,
Cani and collaborators established a close link between gut microbiota-induced “metabolic
endotoxemia” and obesity-related insulin resistance in mice. They established the paradigm of
gut microbiota-mediated metabolic endotoxemia inducing chronic low-grade of inflammation in the
host. In obese mice, a dramatic change in caecum-resident bacteria characterized by a decrease in low
lipopolysaccharide (LPS)-expressing bacterial taxa (such as Bifidobacteria) and concomitant elevation in
high LPS-expressing taxa (gram-negative bacteria) was observed. This lead to increased concentration
of circulating pro-inflammatory LPS [55]. A prolonged high fat diet was also reported to induce
physiologic high-grade inflammation, weight gain and T2D progression by an LPS-dependent gut
microbiota-associated endotoxemia mechanism in mice [56]. In addition, it was shown that genetically
obese ob/ob mice display a lower endotoxemia and caecal LPS content following the inactivation of
CD14, a cell receptor involved in inflammation [55,57]. Concomitantly, in a randomly recruited human
male cohort, a link has been observed between circulating LPS and food intake [58].
In mice fed a high-fat diet, and in genetically obese ob/ob mice, suppression of gut microbiota via
administration of a broad range of antibiotics resulted in a significant decrease of LPS caecal content.
Consequently, fat accumulation and body weight were diminished, endotoxemia and inflammation
at both systemic- and tissue-specific levels were blunted, and insulin sensitivity was improved [57].
Intriguingly, administration of antibiotics to livestock trough water and food is typically used to
promote cattle and swine growth and weight-gain [59,60]. The mechanisms underlying this opposite
effect are not known yet support a link between enteric bacteria and host metabolism, suggesting
variable responses between animal species [59,61,62].
A dysbiosis induced by obesogenic factors adversely enhances intestinal permeability by
modulating the expression of epithelial junction genes zo-1 and occludin [63,64]. An optimal gut
microbiota helps maintain intestinal barrier impermeability via the production of SCFA, which
serve as metabolic precursors for colonocytes in normal physiologic hypoxia conditions [47–49].
Colonocytes require the catabolism of SCFA to potentiate the Hypoxia-inducible factor 1-dependent
expression of key genes involved in biosynthesis [47–49]. This may explain why, in metabolic diseases
such as obesity, an inappropriate microbiota adversely impacts intestinal permeability, leading to
infiltration of bacterial LPS from gut lumen into intestinal epithelia, bloodstream and tissue (such as
the liver) contributing to metabolic endotoxemia [47–49,65]. In fact, administration of antibacterial
agents targeting caecal aerobic and anaerobic bacteria with high efficiency (namely norfloxacin and
ampicillin) to mice fed a high-fat diet and ob/ob mice significantly enhanced their global glucose
tolerance, decreased their fasting glycaemia and circulating LPS levels, and improved the secretion
of Adiponectin [66], known for its positive effects on insulin sensitivity [43]. The current model
of obesity-associated endotoxemia posits that gut-derived LPS and free fatty acids activate M1
macrophages which, together with other immune cells, create a hepatic and physiologic inflammatory
process sustaining the above-mentioned obesity-related comorbidities [67].
Gut microbiota is now considered as a key factor of metabolic health [44,64]. The relative
abundance of some bacterial phyla within the gut microbiota are associated with specific metabolic
states, and subjected to the influence of diets [54]. In fact, quantitative identification of bacteria using
the 16S ribosomal RNA gene showed that obesity is associated to a notable decrease in the relative
abundance of Bacteroidetes vs. Firmicutes (from a proportion of 40:60 in lean patients or non-obese mice
down to a proportion of 20:80) [54,68,69]. Interestingly, this ratio is similarly decreased in ob/ob mice,
in mice subjected to obesogenic and diabetogenic diets, as well as in obese human subjects [68,70,71].
Moreover, within these two superkingdoms, bacterial subpopulations are themselves submitted
to specific changes reflecting metabolic health, diet and antiobesity medical interventions such as
bariatric surgery-induced weight loss [72–74]. These changes are diverse and still not well established
(see Delzenne and Cani for a detailed review [69]).
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While these observations established a definitive link between gut microbiota disturbance and
metabolic diseases progression, it is still unclear which one of the two events induces the other. This
question was addressed by several microbiota transplantation experiments [44,75]. The transplantation
of fecal microbiota from obese mice and obese patients into germ-free lean mice transformed the
lean mice into obese mice, while the germ-free mice receiving microbiota from lean mice did not
show any metabolic symptoms related to obesity or insulin resistance [54,75–77]. These findings
revealed a microbiota-mediated transmissible effect of diets and metabolic status, demonstrating that
gut microbiota is not simply a collateral unit modulated by metabolic diseases but an active and
potent modulator of metabolism. The gut microbiota may therefore play a role in the determination of
metabolic status.
3.2. Correlation of MHO Metabolic Status with Gut Microbiota Profile
To date, very few animal studies described a clear role for gut microbiota in the establishment of
the MHO phenotype. Serino et al. showed that different cohorts of mice issued from the same C57BL6
genetic background became either diabetic or resistant to diabetes and metabolic disorders despite
being fed the same obesogenic high-fat diet. Compared to diabetic mice, resistant mice showed higher
insulin sensitivity, lower inflammation, improved intestinal impermeability (in the ileum, caecum and
colon) and lower adipogenesis [78]. Moreover, the metabolic profile of resistant mice was similar to
the metabolic profile observed in mice fed a high fat diet supplemented with gluco-oligosaccharidic
fibers. Oligosaccharidic fibers are commonly used to prevent high fat diet-induced endotoxemia,
dysbiosis and obesity [79]. Interestingly, the resistant mice harbored a distinctive gut microbiota.
The gut microbiota of the diabetic mice, in comparison with resistant mice, was characterized by a
20% decrease in the abundance of Firmicutes to the benefit of Bacteriodetes, mainly resulting from a
dramatic decrease of the lachnospiraceae bacterial family. Within the Bacteroidetes phylum, the family
of S24-7 bacteria was specifically increased (3-fold). In addition, compared to the diabetic mice,
the microbiota of resistant mice presented an important decrease of the helicobacter genus, while
actinobacteria remained stable [78]. The authors suggested that the gut microbiota could represent
a “signature of the metabolic phenotype independent of differences in host genetic background
and diets”. This suggestion is consistent with the results of a recent study performed in the brown
bear (Ursus arctos) [80]. The bear is a mammal well known to accumulate very large amounts of
adipose fat during the summer; developing hyperlipidemia while remaining metabolically healthy
and resistant to atherosclerosis [81]. Sommer and colleagues showed that, during summer, bears
harbored a different gut microbiota composition than during winter. Summer microbiota was enriched
in Firmicutes, Actinobacteria and, in a lower proportion, enriched in proteobacteria while being depleted
in Bacteroidetes [80]. Moreover, the abundance of several other bacterial families was also seasonally
modulated. Interestingly, the transplantation of summer or winter microbiota from bear intestines
to germ-free mice revealed a microbiota-dependent transmissible seasonal metabolic status as mice
receiving summer microbiota showed a significant elevation of adiposity and body weight gain but a
better glucose tolerance and a lower circulating TG level, suggesting an improved cardiometabolic
state [80].
Completely ignored previously, the fungal subdivision of the gut microbiota (or “mycobiota”)
has recently been revealed as a determinant of human metabolic state. As for bacteria, its specific
composition seems to distinguish MHO from MUHO [82]. For example, Rodriguez and collaborators
showed that obese patients with relative abundance of Eurotiomycetes > 1% in their gut, showed
improved fasting insulinemia, insulin resistance index and circulating LDL-cholesterol levels [82].
There is a definite correlation between MHO status and intestinal flora. Gut microbiota
remodelling could therefore be considered as a strategy to ameliorate metabolic health. Hence, we
believe that a switch from MUHO into MHO metabolic state may be possible following gut microbiota
remodelling, and that dietary interventions (such as those using prebiotic or bioactive nutrients) may
help in this process.
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4. MHO and MUHO: From Classical Dietary Interventions to a MCT-Based One?
Obese individuals have a lower success rate of maintaining weight loss after one year compared to
non-obese individuals [83]. This high risk of weight regain may lead to a pattern of weight cycling [83],
and this may be associated with metabolic complications as well as CVD and mortality [84,85].
In addition, significant weight loss can increase the levels of persistent organic pollutants (POPs) in the
bloodstream [86,87] and may offset the beneficial effects of weight loss. In support of this idea, a recent
study showed that obese subjects with the highest POP blood levels after weight loss suffered from a
delay in the improvement of lipid and liver toxicity markers [88]. Therefore, health professionals may
want to favor a metabolically healthy state instead of focusing on weight loss.
4.1. Weight Management in MHO Subjects
Several studies have examined the effect of lifestyle interventions, including diet and/or exercise
training in MHO individuals. These have led to contradictory findings. Some have shown that,
compared to MUHO, the metabolic profile of MHO individuals after weight loss did not improve
following weight loss [89–91] while other studies have reported an improvement of several metabolic
risk factors [92–95]. For example, a 9-month intensive lifestyle intervention program that consisted of
Mediterranean diet nutritional counselling and high intensity interval training was associated with
a reduction of metabolic risk factors (e.g., blood pressure, fasting glucose level) [94]. Furthermore,
weight loss following laparoscopic adjustable gastric banding in MHO patients was associated with an
improvement of insulin sensitivity levels after 6 months [96]. However, a significant decrease in insulin
sensitivity was observed after weight loss in a different cohort of MHO individuals [97,98]. Finally,
MHO women may lose less weight than MUHO subjects after 3 months on a low fat diet [99]. Based
on the current evidence, it appears difficult to prescribe an optimal lifestyle intervention program to
both MUHO and MHO individuals.
4.2. The Metabolic Protective Potential of Medium Chain Triglycerides (MCTs)
4.2.1. MCTs as Bioactive Lipids
One angle of attack against metabolic diseases is the modification of the quality of dietary
lipids. Such a nutritional strategy may be based on the consumption of “bioactive lipids”, such
as mono-unsaturated or poly-unsaturated lipids, phytosterols, and free or esterified medium chain
lipids [100,101]. We will emphasize our review on the metabolic benefits of medium chain free fatty
acids (MCFA) and medium chain triglycerides (MCT).
Dietary medium chain fatty acids (MCFA) range between 6 and 10 carbon-chain lengths, including
hexanoate (C6:0), octanoate (C8:0) and decanoate (C10:0). Large amounts of MCFA are found, in
the form of MCT, in coconut and palm kernel oils where they account for more than 50% of total
lipids [102,103]. They are also found in smaller amounts in bovine milk, where they can reach 14%–15%
of the total lipid mass depending on cow breeds, types of pasture and seasonal conditions [104]. MCT
differ from long chain triglycerides (LCT) by several physicochemical characteristics such as their
smaller molecular size. MCT are hydrolyzed both faster and more extensively during digestion. Most
of the remaining non-hydrolyzed MCT are readily absorbed by intestinal cells [103]. In addition,
MCFA show greater solubility in aqueous media while remaining capable of passive, non-rate-limiting
diffusion across cell membranes as a result of their relative short chains [100–103,105,106]. MCFA show
a low affinity for anabolic enzymes (such as diglyceride acyltransferase) therefore undergoing minimal
re-esterification, a process necessary for de novo synthesis of TG. Once absorbed during digestion,
most of MCFA and MCT are transported through the portal system directly to the liver with minimal
mobilization of chylomicrons while long chain fatty acids (LCFA) are packed in chylomicrons prior
to their shipment to the periphery mainly via the lymphatic system [100–103,105]. Finally, in the
liver, MCFA are preferentially metabolized to generate energy [107]. In fact, MCFA are known to
enter cells passively before crossing mitochondria membranes, independently of the availability of the
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rate-limiting carnitine palmitoyltransferase 1 (CPT-1) transport system, to fuel the β-oxidation and
ATP-generating pathways [105,106], induce thermogenesis and reduce de novo lipogenesis [108].
Because of these properties, MCT have been used for decades to overcome many metabolic
and digestive abnormalities such as pancreatic insufficiency, fat malabsorption, impaired lymphatic
chylomicron transport, severe hyperchylomicronemia, and total parenteral nutrition. MCTs are also
used in preterm infant formulas [106].
4.2.2. MCT-Supplemented Diets Prevent Obesity
(i) MCT and MCFA Exert Antilipogenic Effects
Using chick embryo hepatocytes, we have previously demonstrated, that free non-esterified
hexanoate and octanoate significantly decrease insulin and T3 (triiodothyronine)-induced fatty acid
synthase (FAS) expression and activity [108]. Activity of FAS, a key enzyme of de novo lipogenesis, is
positively regulated in the post-prandial state by several hormones (such as insulin, ghrelin and T3)
and nutrients (dietary lipid and carbohydrate derivatives) [109,110], and is an important contributor
to obesity and NAFLD [20,111]. We and others have demonstrated that MCFA inhibit binding of
transactivating receptors on the T3 response elements of FAS and Acetyl-CoA carboxylase (ACC)
promoters [108,112–114]. Using LO2 hepatocytes, Wang and collaborators showed that the induction
of cellular steatosis by LCT (esterified oleate and palmitate) is reversed by addition of either octanoate
or decanoate. MCFA treatment shifts cells from global lipid anabolism to lipid catabolism and
downregulates main de novo lipogenesis-activating transcription factors (Liver-X-receptor alpha and
Sterol regulatory element binding protein-1), the lipogenic enzymes (ACC and FAS) and enzymes
involved in fatty acid-uptake (Cluster of differentiation-36 and Lipoprotein lipase) [115].
(ii) The Cardiometabolic Protective Effects of Dietary MCT
The propensity of MCFA to be catabolized rather than esterified, highlights their metabolically
beneficial potential. Several years ago, it was shown in rats that replacement of dietary LCT
by octanoate-based MCT led to a significant attenuation of alcoholic steatosis associated with a
decrease in de novo TG synthesis an adiposity, as well as elevated lipid oxidation [116]. Therefore,
MCT-supplemented diets constitute a promising tool against adipogenic and steatogenic diseases.
Feeding healthy rats with MCT-containing diets vs. diets containing LCT greatly decreases fat
deposition without affecting whole-body protein content and assimilation [117]. Consumption
of MCT is safe in regards to toxicological considerations and has been sanctioned by the FDA
(Food and Drug Administration) for over 20 years [106,118]. Interestingly, dietary MCT promote
post-prandial energy production. A single dose of MCT ranging between 5 and 50 g or a weeklong
diet containing 40% MCT-fat systematically leads to elevated post-prandial oxygen consumption
and thermogenesis, increased total lipid oxidation, higher energy expenditure and diminished
energy storage in comparison with LCT administered under identical conditions [101,119–123].
Importantly, the propensity of MCT/MCFA to be degraded by oxidation is also observed in obese
individuals [120,124].
Long-term replacement of LCT with TG composed of esterified MCFA and LCFA induces a
measurable body fat loss without any impact on energy intake and global metabolism [101,125,126].
These specific TG, produced from the transesterification of MCT and LCT (S-MLCT) are interesting
compounds because of their higher smoking temperature making them more appropriate for
cooking purposes than simple mixtures of MCT and LCT. S-MLCT display a “L-M-L”-type structure
(TG with LCFA in sn-1 position, MCFA in sn-2 and LCFA in sn-3), are preferable substrates for
pancreatic enzymes and are therefore highly digestible [101,125,126]. Feeding healthy young volunteers
for 3 months with either S-MLCT or LCT-enriched liquid formulas (1040 kJ/day) led to a bodyweight
increase from the baseline in both groups [127]. Interestingly, diets supplemented with S-MLCT
induced a lower increase in body fat mass compared to the LCT supplemented diets (+10% for
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S-MLCT vs. +30% for LCT) [127]. The general metabolic profiles between the two groups were not
different, with the exception of glycemia (S-MLCT = 924 vs. LCT = 853 mg/100 mL) [127]. A clear
link was concurrently established between the propensity of MCT to increase thermogenesis and their
previously reported capacity to reduce diet-induced adiposity and body weight-gain [107,128]. Wistar
rats submitted to a single oral gavage of 1 g MCT or LCT showed significant elevation in oxygen
consumption concomitantly with elevated thermogenesis (1.5 kcal/6 h for MCT vs. 0.8 kcal/6 h for
LCT) [107]. Another study showed that feeding rats with a diet containing 10% MCT during 6 weeks
diminished body fat mass by decreasing subcutaneous and intra-abdominal adiposity compared
to a diet containing 10% LCT, suggesting that dietary-MCT lowered body fat mass by inducing
thermogenesis [107]. Interestingly, MCT also lower caloric intake, compared to LCT, by improving
satiety [129,130]. Octanoate, which constitutes most of the MCT used in dietary interventions,
was suggested to be the main co-substrate of the Ghrelin O-acetyltransferase enzyme, involved
in the activation of the powerful orexigenic peptide hormone Ghrelin [131–133]. However, an acute
diminution of food intake induced by the consumption of MCT oil is associated with an elevation
of Leptin, a hormone with a well-known anti-orexigenic effect [129]. These unsolved discrepancies
between different studies highlights the necessity to better understand the molecular effects of MCT
and their physiologic implications [132].
Consistent observations related to anti-obesity effects of MCT were generated through animal and
human clinical studies. Daily consumption (for 12 weeks at breakfast) of bread supplemented with
14 g S-MLCT (produced by a transesterification of MCT and LCT) led, in comparison with control LCT,
to a mild but significant decrease in body weight, and a decrease in subcutaneous and visceral adiposity
as well as in total cholesterol level. However, the other metabolic and anthropometric parameters did
not significantly vary [134]. The impact of MCT consumption on body-weight is noticeably variable
depending on studies and diet protocol designs. Women on a one-month diet where 30% of total
energy was supplied by MCT displayed improved fat oxidation and energy expenditure compared
to women on LCT-containing meals, and showed a tendency towards decreasing body weight [135].
Interestingly, studies suggested that the catabolic effects induced by the dietary MCT may depend
on BMI. In humans, MCT consumption for 4 weeks induced energy expenditure, fat oxidation and
body weight loss inversely proportional to BMI [136]. A recent observation has been also made on the
impact of MCFA diets on cardiac functions [137]. Compared to LCFA, a 2-week administration of a 38%
fat diet containing mostly MCFA positively altered plasma lipids and potentially improved cardiac
function as well as insulinemia in adult type 2 diabetics. However, this diet did not significantly impact
cardiac TG load or cardiac steatosis [137].
Nevertheless, the consumption of MCT is systematically associated with higher energy
expenditure compared to LCT. Solid evidences support the feasibility of using MCT preparations for
nutritional trials against obesity, considering their sources, their flexible use and their safety. Compared
to soybean oil (providing high amounts of LCT), coconut oil, which is the most easily obtained source of
MCT, improves (in synergy with exercise) the cardiometabolic and anthropometric profiles (including
waist circumference) of women presenting unhealthy abdominal obesity [138]. However, coconut
oil contains other compounds such as antioxidant polyphenols also known to improve metabolic
profile by lowering LDL and VLDL while increasing HDL [138,139]. St-Onge and collaborators
demonstrated that consumption of a combination of MCT, phytosterols and omega-3-enriched flaxseed
oil for 1 month compared to olive oil or beef tallow-based diets, led to improvement in plasma lipid
profile in both healthy and overweight women as well as in MHO men [140,141]. In addition, MCT oils
can be incorporated into a weight loss program without any adverse effects on metabolic health [142].
Table 1 summarizes the main studies that have revealed the antiobesity potential of MCT.
Consistent with these observations, a recent meta-analysis of randomized controlled trials,
combining a broad spectrum of publication resources, showed that MCT administered for 3 weeks
or more reduced body weight (´0.51 kg average), waist circumference (´1.46 cm average), hip
circumference (´0.79 cm average), total body fat, total subcutaneous fat and visceral fat in comparison
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with LCT and despite high heterogeneity [143]. Such observations strongly support the relevance of
using MCT to modulate body weight and metabolic profile in MUHO patients.
Table 1. Antiobesity effects of MCT and MCFA.
Model Main Reported Effects for MCT or MCFA References
Hepatocyte
Downregulated expression of genes involved in
DNL and fatty acid uptake; promoted lipid
catabolism; reduced steatosis; prevented
deleterious lipid accumulation
[108,113,115]
Rat Lowered TG accumulation in the liver; reducedalcoholic steatosis [116]
Rat
Decreased body weight gain and body fat mass;
lowered fat accumulation and visceral adiposity;
did not affect protein assimilation
nor metabolism
[107,117]
Rat Resulted in a higher induction of oxygenconsumption and thermogenesis [107]
Human
Significantly increased postprandial oxygen
consumption, energy expenditure, and fat
oxidation, in a MCT dose-dependent manner and
at a greater extend for lower BMIs
[119–122,135,136,142,144]
Human
Decreased global adiposity, body fat, and
whole-body subcutaneous adipose tissue loss,
waist circumference; significantly lowered rate of
variation of body fat percentage
[127,130,134]
Human Did not improve global adiposity [135]
Human
Did not elevate postprandial circulating TG; did
not modulate glucose response, insulinemia and
circulating TG levels; lowered LDL/HDL ratio,
total and HDL-cholesterol; improved
cardiometabolic profile
[129,134,136,138,141]
Human Promoted rise in leptin and peptide YY [129]
MCT: medium chain triglyceride; MCFA: medium chain fatty acid; DNL: de novo lipogenesis; TG: triglyceride;
BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; Peptide YY: peptide
tyrosine tyrosine.
4.2.3. MCT-Supplemented Diets Improve Gut Microbiota and Intestinal Health
MCT are known for their antimicrobial properties. MCT, as well as their constituent MCFA, when
provided by maternal milk (along with endogenous long chain unsaturated monoglycerides), exerted
antimicrobial effects on the gastro-intestinal tract of suckling neonates and contributed to reduce
pathogen transmission [145–147]. Moreover, MCT and MCFA were also shown to reduce proliferation
of certain species of Malassezia, an infectious fungus widespread in hospitals [148].
Kono and collaborators demonstrated that MCT could prevent LPS-mediated endotoxemia. Rats
were fed MCT or corn oil (a source of LCT) by daily gavage for 1 week, prior to an intravenously
acute dose of endotoxic LPS. Interestingly, while LPS injection led to mortality in corn oil-fed animals,
this mortality was prevented in MCT-fed rats [149]. Furthermore, in contrast with the corn oil/LPS
group, the MCT/LPS group showed a lower liver injury and inflammation as revealed by a significant
decrease in CD14 and tumor necrosis factor alpha (TNF-α) expression in Kupffer cells. In parallel
with this, while the corn oil/LPS combination induced a significant increase of intestinal permeability
compared to corn oil without LPS, the MCT/LPS combination was associated with a significant
improvement of intestinal permeability [149]. In addition, MCT gavage prevented intestinal atrophy
(a current problem occurring during parenteral nutrition) and massively reduced (10-fold) the bacterial
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fecal content [149]. This study showed that MCT administration prevented CD14-activation dependent
endotoxemia mediated by LPS, a model consensually associated to obesity and metabolic syndrome.
Most studies on juvenile models use piglets because of their similarities with humans during
intestinal development [150–153]. MCT supplements can be used as alternatives to antibiotics
against certain types of porcine colitis [152,154,155]. MCT-fed piglets had a better gastro-intestinal
health, with improved intestinal apoptotic index and mucosal turnover, and lowered intraepithelial
lymphocyte infiltration (reflecting reduced local inflammation and diminished immune response)
compared to controls [152,153]. Furthermore, piglets fed with MCT supplements display a marked
modulation of microbial gastric and intestinal populations [152,153,156]. This contributed to a
decrease in intestinal inflammation and to an improvement of gut health and integrity [157] with
a direct impact on the gut bacteria from Gram-positive (low LPS) and Gram-negative (high LPS)
subdivisions [156]. Another study showed that dietary organic acids (OA) and MCFA changed
the gut microbiota of weaning piglets [151]. MCFA were shown to reduce the pH of the digesta
because of diminished bacterial acid production. OA and MCFA altered the population distribution
of Bacteroidetes/Porphyromonas/Prevotella phyla and Clostridia/Streptococcus genus in a tissue specific
manner (stomach, jejunum, ileum and colon). MCFA specifically modulated the bacterial populations
in specific regions such as jejunum and colon by promoting the growth of Escherichia/Hafnia/Shigella
bacteria and Clostridia genus [151]. Combining SCFA and MCFA may constitute a potent tool
for the management of optimal gut microbiota. This combination as well as other sources of
MCT including coconuts oils, functional mixed oils, or purified MCT oils may be therefore useful
for remodelling MUHO gut microbiota and improving metabolically unhealthy obesity. Table 2
summarizes these advances.
Table 2. Antimicrobial and gut-managing effects of MCT.
Model Main Reported Effects References
Malassezia Supressed growth of M. sympodialis and M. furfur [148]
Rats
Prevented acute LPS administration-induced
mortality, liver injury, liver inflammation, gut




Significantly blunted TNBS-induced colitis;
improved both colonic MPO activity and
colonocytes-expressed inflammatory markers
[155]
Rats Improved gut integrity; modulated immuneresponse to LPS; improved intestinal secretion of IgA [158]
Piglets
Lowered intestinal pH, in synergy with OA;
modulated several gut microbial taxa, potentially
preventing postweaning diarrhea
[151]
M. sympodialis: Malassezia sympodialis; M. furfur: Malassezia furfur; LPS: lipopolysaccharide; TNBS:
2,4,6-trinitrobenzene sulphonic acid; MPO: myeloperoxidase.
5. Synthesis and Conclusions
This review aimed to highlight several aspects underlying the condition of obese subjects, which
can be either metabolically unhealthy obese (MUHO) or metabolically healthy obese (MHO). While a
panel of criteria serves to define the MUHO state, those defining metabolically healthy obesity remain
the subject of current discussions. We underline the necessity of better defining the potential role of gut
microbiota in the establishment of MUHO or MHO states. Moreover, we believe that gut microbiota
structure may not only serve as a biomarker of those metabolic states, but can also be subjected to
a diet-induced remodelling, modifying in turn the metabolic status of patients (MUHO vs. MHO
or lean state). Dietary MCT, taken alone or with other supplements (such as prebiotics, probiotics,
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organic acids, etc.) could be used as anti-obesity interventions, in regards to their capacity to prevent
intestinal permeability/endotoxemia by remodeling gut microbiota, and to prevent unhealthy storage
by improving the lipid catabolism/anabolism balance. Figure 1 illustrates this concept.
Figure 1. Crosstalk between gut, liver and peripheral metabolic tissues under 4 metabolic states.
Under condition of healthy leanness (A) an optimal relative abundance of LPS-expressing vs.
non-expressing bacteria contribute to gut impermeability, low intestinal and hepatic inflammation,
and non-obesogenic/steatogenic nutrient supply. Under MUHO conditions (B), an elevation in the
relative abundance of LPS-expressing bacteria (Gram-negative) induces LPS infiltration and leads to
altered intestinal barrier integrity, local inflammation, liver injury and endotoxemia. At the same time,
a high fat and carbohydrate supply contributes to adiposity, hepatic steatosis and peripheral insulin
resistance. In MHO subjects (C), despite an adiposity sustained by a rich diet, a balanced gut microbiota
would contribute to maintain intestinal and systemic metabolic health, prevent endotoxemia, and
lower hepatic injury and peripheral insulin resistance. Our hypothetical model (D) suggests that
diet MCT supplementation for MUHO subjects may facilitate a shift towards an MHO-like profile by
improving lipid catabolism and lowering adiposity in part, but also by remodelling the gut microbiota
into a metabolically beneficial structure. SCFA: short chain fatty acids; FA-U: Fatty acid uptake; AT:
adipose tissue; DNL: de novo lipogenesis; SM: skeletal muscle; MUHO: metabolically unhealthy obese
(or obesity); IR: Insulin resistance; β-ox: beta-oxidation; MHO: metabolically healthy obese (or obesity);
MCT: medium chain triglycerides; MCFA: medium chain fatty acids; LPS: lipopolysaccharides; VLDL:
very low density lipoproteins.
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Abstract: Overweight/obesity is a chronic disease that carries an increased risk of hypertension,
diabetes mellitus, and premature death. Several epidemiological studies have demonstrated a clear
relationship between salt intake and obesity, but the pathophysiologic mechanisms remain unknown.
We hypothesized that ghrelin, which regulates appetite, food intake, and fat deposition, becomes
elevated when one consumes a high-salt diet, contributing to the progression of obesity. We, therefore,
investigated fasting ghrelin concentrations during a high-salt diet. Thirty-eight non-obese and
normotensive subjects (aged 25 to 50 years) were selected from a rural community in Northern China.
They were sequentially maintained on a normal diet for three days at baseline, a low-salt diet for seven
days (3 g/day, NaCl), then a high-salt diet for seven days (18 g/day). The concentration of plasma
ghrelin was measured using an immunoenzyme method (ELISA). High-salt intake significantly
increased fasting ghrelin levels, which were higher during the high-salt diet (320.7 ˘ 30.6 pg/mL)
than during the low-salt diet (172.9 ˘ 8.9 pg/mL). The comparison of ghrelin levels between the
different salt diets was statistically-significantly different (p < 0.01). A positive correlation between
24-h urinary sodium excretion and fasting ghrelin levels was demonstrated. Our data indicate that a
high-salt diet elevates fasting ghrelin in healthy human subjects, which may be a novel underlying
mechanism of obesity.
Keywords: ghrelin; high salt; obesity; diet intervention
1. Introduction
Obesity has serious health consequences and is, therefore, a public health concern worldwide,
according to the World Health Organization. By 2014 obesity was more than double what it had
been in 1980. Of the 1.9 billion overweight adults in 2014, 600 million were classified as obese.
Obesity at one time was a problem only in wealthy countries, but today it is common in low- and
middle-income countries as well, particularly in the cities [1]. Health dangers caused by obesity
include cardiovascular disease, the leading cause of death worldwide in 2012, diabetes mellitus,
osteoarthritis, other degenerative joint diseases, and some forms of cancer, in particular endometrial,
breast, and colon cancer. Increasing evidence shows that in both humans and experimental animals,
obesity, like hypertension, is related to high salt consumption [2–11]. The belief that elevated sodium
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intake is a cause of obesity appears to have its origins in the idea that salt intake may increase the
desire to eat certain types of foods and beverages, thus contributing to weight gain [2,3,8]. However,
the pathophysiologic mechanisms remain unresolved.
Ghrelin is a 28-amino-acid peptide with an N-octanoyl alteration at serine-3, produced mainly
in the stomach, which has been identified as the endogenous ligand of the growth hormone (GH)
secretagogue receptor (GHS-R) [12]. Ghrelin has various physiological functions, such as stimulating
the release of growth hormone and of appetite, as well as fat accumulation. Administration of
exogenous ghrelin reportedly enhances appetite and increases food intake through the activation of
hypothalamic neuropeptide Y/agouti-related peptide neurons, expressing GHS-R type 1a. In addition,
ghrelin controls glucose homeostasis by regulating insulin secretion and sensitivity in pancreatic
beta cells. Elimination of ghrelin in obese diabetic ob/ob mice increases basal insulin concentrations,
enhances glucose-stimulated insulin secretion, and improves peripheral insulin sensitivity [12–15].
Data are still scarce in the literature with regard to the link between salt intake and ghrelin.
We hypothesized that ghrelin contributes to the progression of obesity during high-salt loading. In the
present study, which included non-obese and normotensive subjects, we investigated whether salt
intake influences fasting ghrelin levels.
2. Materials and Methods
2.1. Subjects
From a total of 50 screened, normotensive subjects with similar dietary customs from a rural
community in Northern China, 38 were enrolled in this study, and 12 were excluded because
of hypertension or obesity. A brief medical questionnaire was administered. Subjects with a
previous history of hypertension, obesity, liver, or renal disease or with diabetes mellitus were
excluded. Hypertension was defined as mean systolic blood pressure ě140 mmHg and/or mean
diastolic blood pressure ě90 mmHg. Obesity was defined as BMI ě 28 kg/m2. All subjects were
non-smokers. The institutional ethics committee of Xi’an Jiaotong University Medical School (Code:
XJTU1AF2013LSL-056) approved the study protocol, and each subject gave written informed consent.
All of the procedures were performed in accordance with institutional guidelines.
2.2. Protocol
The protocol consisted of a series of investigations, including a three-day baseline period in which
a clinical history and physical examination (height, weight, and blood pressure (BP)) were obtained
and subjects consumed a normal-salt diet, followed by seven days of a low-salt diet (51.3 mmol or 3 g
of NaCl per day), then 7 days of a high-salt diet (307.7 mmol or 18 g of NaCl per day) [16]. During the
baseline investigational period, each subject was given detailed dietary instructions to avoid table salt,
cooking salt, high-sodium foods, and food rich in nitrite/nitrate for the subsequent 14 days. All meals
were prepared in research kitchens and consumed onsite. Dietary total energy intake was supplied
according to their baseline energy intake assessed by a brief food frequency questionnaire. Food
consumption of study participants was carefully recorded at each meal by study staff members.
2.3. Biochemical Analyses
Blood glucose was measured using the glucose oxidase method. Serum lipids (total cholesterol,
triglycerides, HDL-C) were measured. Blood samples for measurement of fasting plasma ghrelin
concentrations were drawn with EDTA-aprotinin tubes and immediately placed on ice. All tubes were
centrifuged at 4 ˝C for collection of plasma and stored at ´80 ˝C until the time of analysis. Ghrelin
was determined using a validated sandwich ELISA using a ghrelin-specific antibody (Wuhan USCN
Science and Technology Co., Ltd., Wuhan, China). Five plasma samples were used to evaluate intra-
and interassay coefficients of variation, which, for ghrelin, ranged from 2.1%–4.3% (mean, 3.2) to
6.4%–9.2% (mean, 7.8), respectively.
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2.4. 24-h Urinary Sodium and Potassium Determination
Twenty-four-hour urine samples were collected at baseline and on day seven of each intervention
period. Twenty-four hour urine collection was obtained with the first voided urine upon waking
on the day of collection being discarded and participants then collecting all voided urine up to, and
including, the first void the following morning. Participants were instructed to keep collected samples
inside cooler bags provided and stored in a cool, dark place until completion when a research assistant
was contacted to collect the sample. The times at the beginning and the end of urine collection were
recorded. The samples were kept frozen at ´40 ˝C until analysis. Urinary concentrations of sodium
were determined using ion-selective electrodes (Hitachi, Ltd., Tokyo, Japan). The 24-h urinary excretion
of sodium and potassium was calculated by multiplying the concentration of sodium and potassium,
respectively, by the 24-h total urine volume.
2.5. Statistical Analysis
The data are shown as mean ˘ SD. Differences between biochemical markers obtained at low-
and high-salt intakes were calculated by analysis of variance with the repeated measures design.
Age, sex, and body mass index (BMI) were adjusted using multivariable analysis. All calculations
were performed with SPSS for Windows 16.0 software (SPSS, Inc., Chicago, IL, USA). Probability was
assessed using a two-tailed p value of < 0.05 to describe statistical significance.
3. Result
3.1. Profiles of Study Subjects
All enrolled subjects completed this interventional study. Their average age was 50.9 ˘ 1.3 years
and systolic BP and diastolic BP were 110.7 ˘ 2.2 and 72.6 ˘ 1.3 mmHg, respectively (Table 1).
The 24-h urinary sodium excretion averaged 173.8 mmol/day (median: 131.5), which approximates an
intake of 8 g of salt/day. Daily urinary potassium excretion averaged 48 ˘ 0.9 mmol/day (median:
44 mmol/day).
Table 1. Baseline demographic and clinical characteristics.
Parameter Values
Mean age (year) 50.6 ˘ 2.1
Sex (male/female) 21/17
BMI (kg/m2) 22.8 ˘ 0.4
Systolic BP (mmHg) 110.6 ˘ 5.8
Diastolic BP (mmHg) 72.1 ˘ 2.7
Glucose, mmol/L 3.91 ˘ 0.11
Total cholesterol, mmol/L 4.18 ˘ 0.14
Triglycerides, mmol/L 1.32 ˘ 0.11
LDL-cholesterol, mmol/L 2.35 ˘ 0.11
HDL-cholesterol, mmol/L 1.21 ˘ 0.04
3.2. Effects of Salt Intake on BP and 24-h Urinary Sodium Excretion
Table 2 shows BP responses to the low-salt and high-salt dietary interventions. BP significantly
increased with the change from the low-salt to high-salt intervention (p < 0.05). The 24-h sodium
excretions in the urine were calculated at the end of the intervention period to ensure compliance
with the study protocol. As shown in Table 2, urinary sodium excretion significantly decreased with
the change from baseline to the low-salt diet, but increased with the change from the low-salt to
the high-salt diet (all p < 0.05). These results confirmed the subjects’ compliance with the dietary
intervention protocol.
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Table 2. BP Levels (mmHg) and 24-h Urinary Sodium (mmol/day) at Baseline and During
Dietary Interventions.
SBP DBP 24 h Urinary Na+ (mmol/Day)
Baseline 110.6 ˘ 5.8 72.1 ˘ 2.7 175.8 ˘ 11.1
Low-salt diet 108.7 ˘ 2.8 73.5 ˘ 2.0 98.8 ˘ 9.3
High-salt diet 116.4 ˘ 5.8 * 77.3 ˘ 4.2 * 268 ˘ 10.2 *
* p < 0.05 versus low-salt diet.
3.3. The Effect of High-Salt Intake on Fasting Ghrelin Levels
As shown in Figure 1, the statistical difference was slight in the fasting ghrelin levels between
the baseline and the low-salt dietary intervention (192.4 ˘ 12.6 pg/mL vs. 172.9 ˘ 8.9 pg/mL,
p = 0.037). Moreover, high-salt intake clearly enhanced plasma ghrelin levels (320.7 ˘ 30.6 pg/mL vs.
172.9 ˘ 8.9 pg/mL, p < 0.01). Further analyses (Figure 2) showed that the fasting ghrelin concentration
correlated with the 24-h urinary sodium excretion during among baseline, low-salt, and high-salt
dietary intervention periods (r = 0.637, p < 0.001).
Figure 1. The effect of low-salt and high-salt intake on fasting ghrelin in all subjects.
Figure 2. The correlation between plasma ghrelin levels and 24 h urinary sodium excretions in all
subjects on baseline, a low-salt diet and on a high-salt diet.
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4. Discussion
The initial finding of the present study is that high-salt intake is associated with fasting ghrelin
elevation in non-obese and normotensive subjects. In addition, a positive correlation between 24-h
urinary sodium excretion and fasting ghrelin levels was demonstrated in these Chinese subjects.
The well-established role of ghrelin as an important regulator of appetite and fat accumulation
may be attributed to the pathogenesis of obesity. Chronic ghrelin administration increases body weight
via diverse, concerted actions on food intake, energy expenditure, and fuel utilization [17–23]. On the
contrary, congenital ablation of the ghrelin or ghrelin-receptor gene causes resistance to diet-induced
obesity [24–26], and pharmacologic ghrelin blockade reduces food intake and body weight [21,27–30].
There may be a relationship between the genomic variation in the ghrelin gene and obesity [21–33].
In particular, the Leu72Met polymorphism in ghrelin was found to be associated with the early onset
of obesity [31]. Ghrelin is produced primarily in the stomach, circulates in the blood, and serves
as a peripheral signal, informing the arcuate nucleus of the central nervous system (via the vagus
nerve) to stimulate hunger. Moreover, ghrelin also could be involved glucose metabolism through
suppressing insulin secretion, which insulin plays a crucial role in obesity. It has been well documented
that systemic administration of ghrelin or endogenous ghrelin could restrict glucose-induced insulin
release and deteriorate glucose tolerance in vivo and in vivo [34–36], which leads to insulin resistance,
indirectly take part in obesity. Therefore, ghrelin may possibly be a useful target against obesity.
Ghrelin may be the key to revealing the mechanisms of salt-induced obesity. Several
epidemiological studies have demonstrated a clear relationship between salt intake and obesity [2,6,7],
and interventional studies also show that a high-salt diet might induce subcutaneous and visceral
adipose tissue [4,11]. A hypothesis has been proposed to explain the relationship between sodium
intake and obesity: salty foods might be considered addictive substances that stimulate opioid receptors
in the brain and the pleasure center, so that the consumption of salty foods every day produces an
addiction to these foods, producing an increase in food consumption (tolerance to opiates), increased
caloric intake, overweight, sedentary lifestyle, obesity, and related diseases [37,38]. In our study,
we found that the high-salt diet elevated fasting ghrelin. Recently, Cai et al. reported that ghrelin is
co-expressed with ENaC subunits in taste-receptor cells in fungiform papillae on the tongue and that
Ghrelin/GHS-R/mice possess a significantly reduced salty taste sensitivity compared to wild-type
mice [39]. Therefore, we conclude the salt-induced ghrelin increase may be a novel mechanism of
obesity via informing the arcuate nucleus of the central nervous system to stimulate hunger.
Our study has several important strengths. First of all, the subjects were recruited from a rural
community and were similar with respect to lifestyle and environmental risk factors, including diet
and physical activity. Thus, confounding due to these exposures should be minimized. Moreover,
participants with body mass index (BMI) more than 28 kg/m2 was excluded, and adjustment
for BMI was conducted; therefore, confounding effects of BMI probably had no influence on salt
intake and ghrelin. Participation in the dietary interventions was high, and compliance with the
study interventions, as assessed by urinary excretion of sodium during each intervention period,
was excellent.
The present study has some limitations that should be addressed. Because all of the subjects were
recruited from the Chinese population, whether or not our observation could be generalized to other
racial populations is unknown. Further studies are required to validate our findings in a larger and
more diverse sample and to elucidate the mechanisms by which salt loading affects plasma ghrelin.
Meanwhile, insulin resistance could be involved in salt-induced obesity, and further studies will be
needed to reveal the relationship between ghrelin and insulin during high-salt diet.
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5. Conclusions
In conclusion, our human intervention study found that salt loading could increase circulating
ghrelin production in normotensive Asian subjects. Our findings indicate that the elevation of ghrelin
might be the underlying mechanism of salt-induced obesity, which sheds some new light on prevention
and a possible therapeutic target for obesity in the future.
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Abstract: Underlying mechanisms associated with the development of abnormal metabolic
phenotypes among obese individuals are not yet clear. Our aim is to investigate differences in plasma
metabolomics profiles between normal weight (NW) and overweight/obese (Ov/Ob) individuals,
with or without metabolic syndrome (MetS). Mass spectrometry-based metabolite profiling was
used to compare metabolite levels between each group. Three main principal components factors
explaining a maximum of variance were retained. Factor 1’s (long chain glycerophospholipids)
metabolite profile score was higher among Ov/Ob with MetS than among Ov/Ob and NW
participants without MetS. This factor was positively correlated to plasma total cholesterol (total-C)
and triglyceride levels in the three groups, to high density lipoprotein -cholesterol (HDL-C) among
participants without MetS. Factor 2 (amino acids and short to long chain acylcarnitine) was positively
correlated to HDL-C and negatively correlated with insulin levels among NW participants. Factor 3’s
(medium chain acylcarnitines) metabolite profile scores were higher among NW participants than
among Ov/Ob with or without MetS. Factor 3 was negatively associated with glucose levels
among the Ov/Ob with MetS. Factor 1 seems to be associated with a deteriorated metabolic profile
that corresponds to obesity, whereas Factors 2 and 3 seem to be rather associated with a healthy
metabolic profile.
Keywords: metabolic syndrome; obesity; metabolites
1. Introduction
Metabolic syndrome (MetS) is defined as the association of obesity, insulin resistance (IR),
hypertension and dyslipidemia [1]. MetS predisposes an individual to several metabolic diseases
such as type 2 diabetes and cardiovascular diseases (CVD) [2]. Obesity is mainly considered to be
responsible for the rising prevalence of MetS [2], associated with higher plasma triglyceride (TG) levels,
lower high density lipoprotein-cholesterol (HDL-C) levels, hyperglycemia and increased CVD risk [1].
The prevalence of obesity has been increasing dramatically worldwide over the past three decades [3].
Obesity results from a complex interaction between predisposing genetic factors and changes in
environmental factors such as diet. It is recommended that obesity be the primary target of intervention
for MetS [4]. Nevertheless, it is important to point out the fact that 10%–30% of obese individuals are
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insulin sensitive and have normal plasma lipid profile and blood pressure, thus being considered as
obese but metabolically healthy [5–7].
Metabolites are intermediate products of different metabolic pathways. Their levels can be
modulated by genetic factors, environmental factors or gene–environment interactions. In recent
years, advanced laboratory techniques, such as metabolomics have been developed. It has allowed the
investigation of a large number of metabolites in human biological fluids or tissues [8]. Metabolomics is
a powerful tool which provides the possibility to study metabolite differences between several groups
at any given time and thus allows capturing the dynamic physiological conditions corresponding to
disease outcomes or metabolic alterations.
Several studies used metabolomics to investigate metabolite profiles associated with obesity.
For instance, Lee et al. observed a shift in metabolite composition in obese individuals compared
to normal-weight individuals [9]. In a study examining the influence of fat free mass on metabolite
profile, Jourdan et al. showed that the serum metabolite composition was strongly associated with
obesity stages [10]. Therefore, investigation of serum metabolite concentrations provides an ideal way
to uncover the underlying mechanisms associated with the development of abnormal metabolic status
in obese individuals. We hypothesize that metabolite profiles differ between lean and obese subjects
with or without MetS. The aim of the present study was to apply comprehensive metabolic profiling
tools to gain broader understanding of metabolic differences between lean and obese subjects with or
without MetS.
2. Materials and Methods
2.1. Subjects
Two hundred subjects aged between 18 and 55 years were randomly selected from the INFOGENE
study [11]. The recruitment took place between May 2004 and March 2007 in the Quebec City
metropolitan area. The final study sample consisted of 664 individuals. Participants were recruited
using advertisements in local newspapers and radio stations, in addition to electronic group messages
sent to university and hospital employees. During their visit at the clinical investigation unit,
participants completed a questionnaire on socio-demographic characteristics and lifestyle habits.
All participants signed a written consent to participate in this study that has been approved by the
ethics committee of Laval University.
2.2. Anthropometric Measurements
A trained research assistant measured height, weight, waist (WC) and hip circumferences. Systolic
(SBP) and diastolic (DBP) blood pressure were measured after a 5 min rest while participants were lying
on their backs, with arms and legs uncrossed. Fat and lean masses were assessed using a bioelectrical
impedance meter (101-RJL Systems, Detroit, MI, USA). Body mass index (BMI) was calculated by
dividing weight in kilograms by height in meters squared. The obesity status of the participants was
assessed using BMI and the body fat mass percentage. Subjects were classified in the overweight and
obese (Ov/Ob) group if they had a BMI ě 25 kg/m2. Body fat ě25% of total body fat mass in men and
ě30% in women were considered to classify an individual as being obese [12].
2.3. Biochemical Parameters
Fasting blood samples were obtained from an antecubital vein into vacutainer tubes containing
Ethylenediaminetetraacetic acid (EDTA) after a 12 h overnight fast. Total cholesterol (total-C) and TG
levels were determined from plasma and lipoprotein fractions using the Olympus AU400e system
(Plympus America Inc., Melville, NY, USA). A precipitation of low-density lipoprotein cholesterol
(LDL-C) fraction in the infranatant with heparin-manganese chloride [13] was used to obtain the
HDL-C fraction. LDL-C concentrations were estimated using the Friedewald’s equation [14,15].
Radioimmunoassay with polyethylene glycol separation was used to measure fasting insulin [16].
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Fasting glucose concentrations were enzymatically measured [17]. Homeostasis model assessment of
insulin resistance (HOMA-IR) was obtained using: (fasting glucose ˆ fasting insulin)/22.5 [18].
2.4. Metabolite Profiling
To assess the metabolite profiling, the Absolute ID p180 Kit (Biocrates Life Sciences AG,
Innsbruck, Australia) for mass spectrometry was used. The quantification of 95 metabolites
was done for 200 participants. Metabolites were composed of 67 Glycerophospholipids (GPs),
12 Acylcarnitines (ACs), 10 Sphingolipids (SGs) and 6 amino acids (AA). For GPs, ACs and SGs
x:y notation was used, x denotes the number of carbons in the side chain and y the number
of double bonds. The lipids were subdivided into different classes: 28 Phosphatidylcholines
diacyl (PCaa); 36 Phosphatidylcholines acyl-alkyl (PCae); 3 LysoPhosphatidylcholines acyl (LysoPC);
4 Hydroxyshingomyelins; and 6 Shingomyelins (SM). GPs are differentiated with respect to the
presence of ester (a) and ether (e) bonds in the glycerol moiety. Two letters indicate that the first and
second positions of glycerol unit are bound to a fatty acid residue, while a single letter (a or e) indicates
a bond with only one fatty acid residue. The concentration of all metabolites was reported in μM.
Metabolites for which more than half of the values were below the limit of detection and or with
standard out of range were excluded.
2.5. Statistical Analyses
Transformations were applied to the variables that were not normally distributed. Logarithmic
transformations were performed for fasting insulin, total-C and HDL-C, and an inverse transformation
for TG and fasting glucose. All analyses were conducted on age- and sex-adjusted data; analysis of
variance was used to underline the differences in metabolic characteristics between obese/overweight
with or without MetS and normal-weight participants with or without MetS. Individuals with MetS
had at least 3 of the following five criteria: waist circumference (WC) >88 cm for women and 102 cm
for men, fasting plasma triglycerides (TG) ě1.7 mmol/L, high-density lipoprotein cholesterol (HDL-C)
levels ď1.03 mmol/L for men and 1.29 mmol/L for women, glucose levels ě 5.6 mmol/L and resting
blood pressure ě130/85 mmHg.
The significance level of all analyses was set at p ď 0.05. Differences between groups were
assessed using the least square means. Principal component analysis (PCA) was used to reduce the
large number of correlated metabolites into clusters of fewer uncorrelated factors. Factors derived
from PCA that had eigenvalues greater than or equal to 1 were identified and considered for further
analyses. Metabolites with a factor loading ě0.50 or ´0.50 were reported as composing a given
PCA-derived factor. Then, scoring coefficients were used to calculate baseline metabolite factor scores
for each individual. These scores corresponded to the sum of metabolic signature groups multiplied
by their respective factor loading. These scores represented the degree of each participant’s metabolic
signature conforming to each factor. To detect association between factors and MetS criteria, Pearson
correlations were used. All statistical analyses were performed using SAS statistical software version
9.2 (SAS Institute, Inc., Cary, NC, USA).
3. Results
3.1. Descriptive Characteristics
Descriptive characteristics of study participants are presented in Table 1. Groups were defined
according to BMI and MetS status. Ov/Ob individuals with or without MetS were older than normal
weight (NW) subjects. Among obese individuals, subjects with MetS were older than those without
MetS. As expected, WC and fat mass increased progressively with the deterioration of metabolic
state (i.e., obesity and MetS status). The same trend was observed for fasting insulin levels and
SBP. The Ov/Ob subjects with the MetS had a more deteriorated plasma lipid profile including
increased plasma TG levels and decreased plasma HDL-C levels compared to Ov/Ob without MetS
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or NW individuals. There was no significant difference between groups for plasma LDL-C levels.
NW individuals had lower HOMA-IR index values than Ov/Ob with or without MetS.
Table 1. Baseline characteristics.
MetS´ MetS+
p-Value
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
Age (years) 35.7 ˘ 10.4 2 28.9 ˘ 7.4 1 37.9 ˘ 10.0 3 <0.0001
BMI (kg/m2) 31.4 ˘ 4.2 2 22.2 ˘ 1.8 1 34.3 ˘ 4.9 3 <0.0001
Waist circumference (cm) a 97.8 ˘ 10.8 2 74.7 ˘ 5.7 1 109.0 ˘ 11.9 3 <0.0001
Fat mass (kg) 31.3 ˘ 9.0 2 14.5 ˘ 4.3 1 36.5 ˘ 10.5 3 <0.0001
Lean mass (kg) 57.5 ˘ 11.1 2 48.9 ˘ 8.9 1 65.3 ˘ 12.1 3 <0.0001
Systolic blood pressure (mmHg) 119.9 ˘ 9.0 2 115.9 ˘ 9.8 1 130.1 ˘ 10.6 3 <0.0001
Diastolic blood pressure (mmHg) 77.7 ˘ 7.7 1 74.0 ˘ 9.9 1 83.5 ˘ 9.5 2 <0.0001
Fasting glucose (mmol/L) 5.4 ˘ 0.5 2 5.8 ˘ 1.3 1 6.1 ˘ 1.1 3 0.002
Fasting insulin (pmol/L) 86.1 ˘ 56.3 2 48.7 ˘ 17.1 1 133.1 ˘ 72.3 3 <0.0001
HOMA-IR 2.98 ˘ 1.77 2 1.84 ˘ 0.94 1 5.33 ˘ 3.70 3 <0.0001
Total-C (mmol/L) 4.57 ˘ 1.00 2 4.13 ˘ 0.67 1 4.84 ˘ 1.14 2 0.02
LDL-C (mmol/L) 2.81 ˘ 0.91 2.52 ˘ 0.70 2.99 ˘ 1.23 0.29
HDL-C (mmol/L) 1.32 ˘ 0.30 2 1.60 ˘ 0.45 1 0.99 ˘ 0.24 3 <0.0001
TG (mmol/L) 1.15 ˘ 0.56 2 0.77 ˘ 0.31 1 2.16 ˘ 1.21 3 <0.0001
Values are means ˘ SD. a p values are adjusted for age, sex and BMI. p values in bold were considered
significantly different. 1,2,3 Represents the differences between groups using generalized linear models (GLM).
Abbreviations: Ov/Ob, overweight/obese; NW, Normal weight; MetS+, with the metabolic syndrome; MetS´,
without the metabolic syndrome.
3.2. Serum Metabolite Score
Using PCA, we retained three main factors that explained a maximum of variance in the data
(Figure 1). Factor 1 was composed of 81 metabolites, including long chain PCaa and PCae, and few
medium to long chain SGs. Factor 2 was composed of short and long chain ACs and several AA (C0,
C16, C18, C3, C4, glutamic acid, isoleucine, leucine, methionine, phenylalanine, tyrosine and valine),
whereas factor 3 was composed of few medium chain ACs (C12, C14:1-OH, C14:2, C18:2). Lists of
metabolites composing each factor are available in Tables S1–S3.
Figure 1. Metabolites patterns of the INFOGENE study. Metabolites with absolute factor loadings ě0.5
or ´0.5 were regarded as significant contributors to the pattern. The blue line represents factor 1, the
purple factor 2 and the orange factor 3.
In Table 2, factor scores are presented according to BMI and MetS status (Table 2A), and according
to bioelectrical impedance analysis (BIA) measurement and MetS status (Table 2B). In fact, since
body composition is difficult to predict based on a single indicator such as BMI, we also classified
the subjects as being obese or not according to their percentage of body fat mass assessed by BIA.
Briefly, when the BMI status was used, factor 1 score was higher among Ov/Ob participants with
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MetS (0.36 ˘ 1.01) than among Ov/Ob participants without MetS (0.01 ˘ 1.01) or NW participants
(´0.31 ˘ 0.84). Factor 2 score was higher among NW subjects (0.14 ˘ 1.03) than among Ov/Ob
subjects with (´0.22 ˘ 0.73) or without (´0.05 ˘ 1.04) MetS. NW subjects had higher factor 3 scores
(0.34 ˘ 0.95) than Ov/Ob subjects with (´0.36 ˘ 0.95) or without MetS (´0.01 ˘ 0.99). When the fat
percentage was used, factor 1 score was higher among Ov/Ob participants with MetS (0.30 ˘ 0.16)
than among Ov/Ob participants without MetS (0.03 ˘ 0.11) or NW participants (´0.35 ˘ 0.14). Factor
2 score was higher among NW subjects (0.29 ˘ 0.14) than among Ov/Ob subjects with (0.03 ˘ 0.17) or
without (´0.08 ˘ 0.12) MetS. However, associations with factor 3 were lost. The association of obesity,
metabolic syndrome and metabolite profile remained similar in the present study sample even though
BMI or BIA measurements are used to define obesity. Thus, for the rest of the study, the obesity will be
defined using BMI criteria.
Table 2A. Metabolite factor scores (obesity classification of subjects according to BMI criteria).
MetS´ MetS+
p-Value
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
Factor 1 0.01 ˘ 1.01 2 ´0.31 ˘ 0.84 3 0.36 ˘ 1.01 1 0.003
Factor 2 ´0.05 ˘ 1.04 2 0.14 ˘ 1.03 3 ´0.22 ˘ 0.73 1 0.02
Factor 3 ´0.01 ˘ 0.99 2 0.34 ˘ 0.95 3 ´0.36 ˘ 0.95 1 0.03
Table 2B. Metabolite factor scores (obesity classification of subjects according to BIA criteria).
MetS´ MetS+
p-Value
Ob (n = 84) NW (n = 65) Ob (n = 36)
Factor 1 0.03 ˘ 0.11 3 ´0.35 ˘ 0.14 2 0.30 ˘ 0.16 1 0.005
Factor 2 ´0.20 ˘ 0.11 1 0.29 ˘ 0.14 2 ´0.17 ˘ 0.16 1 0.03
Factor 3 ´0.08 ˘ 0.12 1 0.12 ˘ 0.15 1 0.03 ˘ 0.17 1 0.59
3.3. Relation between Cardiometabolic Risk Factors and PCA Factors
Table 3 shows that factor 1 was positively correlated with total-C and TG levels in all three groups.
HDL-C was also positively correlated with factor 1 but only in subjects without MetS (Ov/Ob: r = 0.27;
p = 0.01 and NW: r = 0.26; p = 0.04) while LDL-C was correlated with factor 1 only in Ov/Ob people
with MetS (r = 0.31; p = 0.04). In Table 4, we observe that factor 2 was negatively correlated to WC
among Ov/Ob with MetS (r = ´0.36; p = 0.02). Factor 2 was also associated with HDL-C (r = 0.34;
p = 0.008) and insulin levels (r = ´0.25; p = 0.05) in NW individuals without MetS. In addition, factor 2
was associated with LDL-C (r = 0.30; p = 0.007) and total-C (r = 0.34; p = 0.002) among Ov/Ob subjects
without MetS. Finally, Table 5 shows that factor 3 is negatively associated with glucose among Ov/Ob
with MetS (r = ´0.30; p = 0.05) and with insulin (r = ´0.27; p = 0.02) and HOMA-IR (r = ´0.24; p = 0.03)
among Ov/Ob without MetS.
Table 3. Correlations between cardiometabolic risk factors and factor 1.
MetS´ MetS+
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
WC r 0.14 0.23 0.01
p 0.23 0.07 0.95
Total-C r 0.32 0.38 0.63
p 0.003 0.003 <0.0001
TG r 0.61 0.45 0.44
p <0.0001 0.0002 0.003
HDL-C r 0.27 0.26 0.19
p 0.01 0.04 0.22
56
Nutrients 2016, 8, 324
Table 3. Cont.
MetS´ MetS+
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
LDL-C r 0.11 0.22 0.31
p 0.33 0.09 0.04
Glucose r ´0.03 0.03 0.16
p 0.81 0.81 0.32
Insulin r 0.12 ´0.05 ´0.03
p 0.39 0.69 0.86
SBP r 0.03 ´0.07 0.23
p 0.81 0.64 0.19
DBP r ´0.1 ´0.04 0.16
p 0.39 0.74 0.29
HOMA-IR r 0.08 ´0.03 0.002
p 0.47 0.82 0.91
Pearson correlation coefficients (r) and associated p values are provided. Abbreviations: Ov/Ob,
overweight/obese; NW, Normal weight; MetS+, with the metabolic syndrome; MetS´, without the
metabolic syndrome.
Table 4. Correlations between cardiometabolic risk factors and factor 2.
MetS´ MetS+
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
WC r ´0.10 0.09 ´0.36
p 0.35 0.47 0.02
Total-C r 0.34 0.18 0.17
p 0.002 0.17 0.28
TG r 0.01 ´0.09 0.05
p 0.91 0.46 0.75
HDL-C r 0.09 0.34 0.12
p 0.42 0.008 0.53
LDL-C r 0.30 ´0.02 0.16
p 0.007 0.91 0.31
Glucose r ´0.02 0.002 0.14
p 0.83 0.99 0.36
Insulin r 0.08 ´0.25 0.15
p 0.49 0.05 0.32
SBP r 0.05 ´0.04 0.09
p 0.67 0.79 0.58
DBP r 0.09 0.08 0.06
p 0.44 0.56 0.71
HOMA-IR r 0.07 ´0.14 0.16
p 0.54 0.30 0.30
Pearson correlation coefficients (r) and associated p values are provided. Abbreviations: Ov/Ob,
overweight/obese; NW, Normal weight; MetS+, with the metabolic syndrome; MetS´, without the
metabolic syndrome.
Table 5. Correlations between cardiometabolic risk factors and factor 3.
MetS´ MetS+
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
WC r ´0.07 0.02 0.17
p 0.55 0.89 0.28
Total-C r ´0.06 0.14 0.13
p 0.62 0.29 0.41
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Table 5. Cont.
MetS´ MetS+
Ov/Ob (n = 83) NW (n = 65) Ov/Ob (n = 46)
TG r ´0.16 0.04 ´0.22
p 0.16 0.75 0.15
HDL-C r 0.16 0.22 0.14
p 0.16 0.09 0.36
LDL-C r ´0.08 0.01 0.11
p 0.46 0.93 0.48
Glucose r 0.0009 ´0.10 ´0.32
p 0.99 0.42 0.05
Insulin r ´0.27 ´0.21 ´0.1
p 0.02 0.09 0.52
SBP r 0.07 0.06 ´0.06
p 0.51 0.67 0.71
DBP r ´0.04 0.01 0.25
p 0.71 0.92 0.11
HOMA-IR r ´0.24 ´0.23 ´0.17
p 0.03 0.08 0.26
Pearson correlation coefficients (r) and associated p values are provided. Abbreviations: Ov/Ob,
overweight/obese; NW, Normal weight; MetS+, with the metabolic syndrome; MetS´, without the
metabolic syndrome.
4. Discussion
Abdominal obesity is a feature of MetS. The risk of developing metabolic disorders is proportional
to the degree of obesity [19]. However, all obese individuals do not have MetS [4,20]. Mechanisms
explaining the development of MetS are poorly understood and must be intensely investigated since
their understanding may favor the design of prevention and therapeutic strategies. Metabolites
are the intermediate products of different metabolic pathways. In the present study, employing
metabolomics, we investigated differences in plasma composition between lean and Ov/Ob people,
with or without MetS.
Obesity is defined as an excess of body fat. Unfortunately, body fat is tricky to measure. Several
methods can be used to determine whether a human being is obese or not [21]. Depending on the
method used, the definition of obesity can be surprisingly different. In the present study, obesity status
was assessed using BMI and fat mass quantification by BIA. Metabolite score remained similar when
either BMI or percent body fat were used. Thus, the rest of the analyses were done using BMI criteria
to classify study subjects as being obese or not.
Using PCAs, we identified three metabolite clusters: factor 1, 2 and 3. Factor 1 is composed of long
chain phosphatidylcholines and SMs. It regroups metabolites that seem to be linked with MetS but
also with obesity itself. In fact, factor 1 score was higher and positive among Ov/Ob participants with
and without MetS and negative among NW people. PCaa and SMs composing factor 1 are involved
in lipid metabolism and are important for lipid transport. Their concentrations have been related
to fat accumulation in liver of obese subjects [22], possibly explaining higher plasma levels of these
metabolites in this population. In a study realised by Eisingerand et al., an increase of total PCs and SMs
was observed in mice fed a high fat diet in comparison with mice fed with a standard chow diet [23].
Plasmalogens (PLs) are a subclass of GPs characterized by the presence of a vinyl-ether bond and
an ester bond at the sn-1 and sn-2 positions, respectively, of the glycerol backbone [24]. They have
several cell functions; in fact, they act as reservoirs for second messengers or as structural attributes in
the plasma membrane. They are also anti-oxidants preventing lipoprotein peroxidation; the hydrogen
atoms adjacent to the vinyl-ether bond have relatively low disassociation energies and are preferentially
oxidized over diacyl GP when exposed to various free radicals and singlet oxygen. PLs are consumed
in this reaction. This was proposed to spare the oxidation of polyunsaturated fatty acids and
58
Nutrients 2016, 8, 324
other vulnerable membrane lipids, suggesting a role for PLs as sacrificial oxidants [25]. Sinder
and collaborators showed that the oxidative products of PLs are unable to further propagate lipid
peroxidation; thus PLs may terminate lipid oxidation. In the present study, a global reduction of
PL concentrations was seen among Ov/Ob subjects (Table S1) in line with increased oxidative state
observed in obesity [26]. To investigate environmental factors related to obesity, Pietilainen et al. led
a study in monozygotic twins discordant for obesity. A change in the general metabolites serum
composition was seen between obese and non-obese twins [27]. A decrease of ether phospholipids was
observed among obese twins compared to lean twins [27,28]. Jordan et al. also reported a diminution
of PCae with an increase of subject’s fat mass. Studies among children have shown a decrease of PCae
between lean and obese children [9,29]. As far as PCaa are concerned, Oberbach et al. showed an
increase of several PCaa including C32:0, C32:1 and C40:5 levels among obese as compared to lean
individuals [30,31], a trend that was also observed for PCaa C32:1 and C40:5 in the present study.
Globally, our current study adds to others arguing that development of obesity comes along with a
global decrease of PCae and with an increase of several PCaa by demonstrating that these changes are
more important in the group of subjects with MetS.
Factor 2 is composed of AA including branch chained AA (BCAAs) (isoleucine, leucine and
valine) and few ACs. BCAAs are essential AA that must be supplied by the diet [32]. BCAAs play
a variety of physiological roles. They are regulatory molecules that have several cellular functions.
They are nutrient signals that regulate protein synthesis, degradation and insulin secretion [33–35].
Although BCAAs are essential to the human body, studies have shown a dysregulation of their plasma
concentrations with diseases [15]. For instance, in obese and insulin resistant subjects, an increase of
BCAA levels is often observed when compared to lean individuals [30,36,37]. Factor 2 was comprised
of a few ACs including free and odd short-chain ACs (C3 and C5). These two ACs are by-products of
BCAA catabolism, thus their presence may be related to the degradation of BCAAs.
Factor 2 and factor 3 scores are higher among NW than among Ov/Ob individuals. It seems that
the clusters of metabolites belonging to factors 2 and 3 are more tightly linked to a healthy metabolic
state than factor 1. Several authors reported that increased plasma BCAA and AC levels were linked
to several metabolic diseases [32,38]. In the present study, factor 2 and 3 scores were higher among
NW subjects with a more favorable metabolic state. Factor 2 and 3 metabolite scores were lower
among Ov/Ob participants with MetS and intermediate for Ov/Ob without MetS. This suggests a
relation between metabolites composing these factors, MetS and obesity status. In the present study,
an increase of the BCAA levels can be seen from NW participants to Ov/Ob ones, this increase being
more important among Ov/Ob subjects with MetS. The same situation was observed for short chain
ACs such as C0, C3 and C5.
Correlations between factor 1 and cardiometabolic risk factors were investigated. A positive
correlation of factor 1 with plasma total-C and TG levels was observed in each group. This suggests
that the association between factor 1, total-C and TG is independent of the metabolic state of study
participants. A positive correlation was also seen between factor 1 and LDL-C levels but only among
Ov/Ob participants with MetS. LDL-C is an established risk factor for CVDs but is not included as
one of the five components of the MetS [39]. In literature, evidence regarding the association between
LDL-C levels and MetS is not abundant, thus the contribution of LDL-C levels to the altered plasma
lipid profile in MetS is unclear. HDL-C levels are known to be negatively associated with a deteriorated
metabolic health. Here, we observed a positive association between factor 1 and HDL-C levels but
only in groups without MetS irrespective of their obesity status. Factor 1 discriminates participants
according to their MetS status rather than on obesity status. Factor 1 is mostly composed of GPs and
SGs. Since these lipids are present in membranes and are involved in lipoprotein metabolism and
transport, the association between blood lipids and these metabolites was expected. In a study led
by Graessen et al., bariatric surgery was associated with an improvement of the plasma lipid profile.
In fact, they reported an improvement of the LDL-C levels along with a decrease of PC concentrations
in obese subjects with MetS [15,40].
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Factor 2 is composed of AA including BCAAs and few ACs. BCAAs have several physiological
functions [41,42]. However, despite these beneficial effects on metabolic health, studies have shown
that increased levels of circulating BCAAs were associated with poor metabolic health. In the present
study, factor 2 was positively correlated with HDL-C and negatively correlated with insulin levels
among NW participants without MetS. A negative correlation was also noted between WC and factor
2 but only among Ov/Ob with MetS. These results are concordant with what was observed with the
metabolite scores; in fact, NW participants had higher metabolite scores and lower concentrations
of BCAAs and short chain ACs. The association of factor 2 with a better health profile seems to be
positively linked to HDL-C and negatively to insulin levels. Factor 3 is composed of medium ACs
and is negatively correlated with glucose levels among Ov/Ob subjects with MetS and also negatively
correlated to insulin levels and HOMA-IR among Ov/Ob individuals without MetS. In a study led by
our group, a cluster of metabolites composed of medium to long chain ACs was negatively associated
to a Western dietary pattern [43]. These results strengthen the hypothesis that the medium to long
chain AC parts of factor 3 are positively associated with metabolic health.
5. Conclusions
Using metabolomic profiling, we identified a handful of relevant metabolites distinguishing
obesity and MetS. For instance, long chain PCaa, PCae and medium chain SMs composing factor 1
were distributed differently between Ov/Ob and the other groups. They seem to be rather associated
with a deteriorated metabolic profile. In contrast, factors 2 and 3 are associated with a healthy metabolic
profile. So far, mechanisms explaining the shift of metabolite levels from normal to abnormal metabolic
phenotypes are not clear. More validation studies are needed to better understand the underlying
mechanisms triggering the dysregulation of metabolic traits in obesity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/6/324/s1,
Table S1: Factor 1 metabolites composition categorized by obesity and MetS status, Table S2: Factor 2 metabolites
composition categorized by obesity and MetS status, Table S3: Factor 3 metabolites composition categorized by
obesity and MetS status.
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Abstract: In obese individuals, weight loss might be affected by variants of the adipokine-encoding
genes. We verified whether selected functional single nucleotide polymorphisms in LEP, LEPR
and ADIPOQ are associated with changes in serum levels of the respective adipokines and weight
loss in 100 prepubertal obese (SDS-BMI > 2) Caucasian children undergoing lifestyle intervention.
Frequencies of the -2548G > A LEP, Q223R LEPR, K656N LEPR, -11377C > G and -11426A > G ADIPOQ
polymorphisms were analyzed by restriction fragment length polymorphism. Serum adipokine and
soluble leptin receptor (sOB-R) concentrations were measured using the ELISA method. Among the
analyzed polymorphisms, only LEPR polymorphisms were associated with changes of SDS-BMI or
sOB-R concentrations in children after therapy. Carriers of the wild-type K665N and at least one
minor Q223R allele had the greatest likelihood of losing weight (OR = 5.09, p = 0.006), an increase in
sOB-R (ptrend = 0.022) and decrease in SDS-BMI correlated with the decrease of fat mass (p < 0.001).
In contrast, carrying of the wild-type Q223R and at least one minor K665N allele were associated
with a decrease in sOB-R concentrations and a decrease in SDS-BMI correlated with a decrease in
fat-free mass (p = 0.002). We suggest that the combination of different LEPR variants, not a single
variant, might determine predisposition to weight loss in the prepubertal period.
Keywords: leptin receptor; polymorphisms; weight loss; adipokines; prepubertal period
1. Introduction
It is widely recognized that the response to lifestyle interventions, such as changes in dietary habits
and physical activity, can be heterogeneous and largely genetically determined [1]. Functional variants
of genes involved in appetite regulation, energy metabolism and fat storage are considered candidates
to confer susceptibility to weight loss, and their identification may be helpful in the prevention of
future health problems.
Among several genetic variants investigated in relation to the effectiveness of weight loss
therapy in obese subjects are Q223R (or Gln223Arg, rs1137101) and K656N (or Lys656Asn, rs8129183)
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polymorphisms in the leptin receptor gene (LEPR) [2–4]. Leptin receptor, which is a member of the
cytokine receptor family, has several isoforms of different locations and functions [5]. For example, the
weight-regulating effects of leptin are mediated by binding to and activation of the specific receptor
(long isoform, OB-RL) in the brain, while a soluble form of this receptor (one of its short isoforms,
sOB-R) modulates leptin levels by binding free leptin in the circulation and preventing the hormone
from degradation and clearance [6].
The Q223R A > G (A668G) and K656N G > C (G1968C) polymorphisms in LEPR result in
nonconservative changes: glutamine to arginine at codon 223 and lysine to asparagine at codon 656,
respectively [7,8]. These amino acid substitutions result in changes of the electric charge from neutral
to positive for Q223ÑR and from positive to neutral for K656ÑN and, therefore, are likely to have
functional consequences resulting in changed leptin signaling and, in the broader perspective, an
affected response to energy restriction [7]. However, there are only a few studies that have evaluated
the impact of these polymorphisms on changes in metabolic parameters during weight loss.
The diverse response of leptin levels and body mass changes depending on polymorphic variants
of LEP and LEPR has been investigated mainly in obese adults [2,3,9–13]. There are also studies
suggesting a gene-gene interaction between the LEP and LEPR variants in a genetic susceptibility
to the development of obesity [14]. A cumulative effect of LEPR polymorphisms with other obesity
susceptibility loci, including variants in the adiponectin locus (ADIPOQ), on weight loss was also
observed in Spanish obese adolescents after a multidisciplinary intervention [15]. Case-control studies
on the association between polymorphisms in genes encoding adipokines with childhood obesity
have been conducted [16–20], but to our knowledge, there is no data concerning the influence of these
polymorphisms on weight loss and adipokine concentrations after multidisciplinary intervention.
Therefore, the aim of our study was to investigate the effect of selected functional single nucleotide
polymorphisms (SNPs) in LEPR, LEP, and ADIPOQ loci on metabolic response and weight loss after a
3-month lifestyle intervention in prepubertal obese children.
2. Methods
2.1. Subjects
One hundred obese prepubertal Caucasian children aged 5–10 years were recruited between
2010 and 2012 from a group of consecutive patients seeking dietary counseling in the Department of
Nutrition at the Institute of Mother and Child in Warsaw. Obesity was classified as standard deviation
score-body mass index (SDS-BMI) >2. Exclusion criteria were: (a) presence of endocrine disorders or
genetic syndromes, including syndromic obesity; (b) other chronic medical conditions; (c) intake of
medications that could affect growth, pubertal development, nutritional or dietary status. Pubertal
stage was determined according to the Tanner scale and subjects who showed pubertal development
were excluded. Written informed consent was obtained from the parents of all the examined children.
The study was performed in accordance with the Helsinki Declaration for Human Research and the
study protocol was approved (No. 25/2006) by the Ethics Committee of the Institute of Mother and
Child in Warsaw, Poland.
2.2. Dietary Intervention
To evaluate changes in clinical, anthropometric and biochemical parameters in response to lifestyle
changes, the obese prepubertal patients underwent a 3-month intervention program consisting of
dietary and physical activity modifications and behavioral therapy, including individual psychological
care for the child and his/her family. The dietary guidelines, recommending a low-energy diet based
on a balanced distribution of carbohydrates, proteins and lipids, for children and their parents, were
described in a previous study [21]. The recommended daily energy intake was 1200–1400 kcal/day.
The diet was composed of 20% protein, 30% fat and of 50% carbohydrates. Patients had 3–5 meals every
day. Study participants did not receive vitamins or mineral supplements. Patients received instructions
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concerning physical activity, details of which were also previously described [22]. Children were
advised to reduce sedentary activities, including watching television and playing computer games
to less than two hours a day. Two weeks before the visit in the Department of Nutrition, study
participants completed a 10–14 days food diary using a standard questionnaire. Next, randomly
selected 3-day records: two consecutive weekdays and one weekend day, before (visit T0) and after
3 months of therapy (visit T3) were analyzed. The subjects and their parents were asked to record
the type and amount of food and beverages consumed for the selected days. We evaluated the
average daily energy intake and the percentage of energy intake from protein, fat and carbohydrates
in the children’s diets. Average daily food rations and their nutritional value were calculated using
nutritional analysis software (Dietetyk®, National Food and Nutrition Institute, version 2.0, Warsaw,
Poland) [23]. The age- and sex-specific dietary reference intake (DRI) percentage was calculated using
reference values of daily energy intake for children and adolescents according to Jarosz et al. [24].
2.3. Anthropometric Parameters
Physical examinations, including body height and weight measurements, were performed before
(visit T0) and after 3 months of therapy (visit T3). Body height was measured using a standing
stadiometer and recorded with a precision of 1 mm. Body weight was assessed unclothed, to the
nearest 0.1 kg, with a calibrated balance scale. BMI was calculated as body weight divided by
height squared (kg/m2). The BMI of each individual was converted to a standard SDS-BMI for the
child’s age and sex using Polish reference tables [25]. The data of this reference population were
derived from a study concerning the physical development of Warsaw children and adolescents
aged 1–18 years, which was conducted in the years 1996–1999 by the Department of Development
of Children and Adolescents at the Institute of Mother and Child. Skinfolds were measured with a
Holtain skinfold caliper (Holtain Ltd., Wales, UK). Fat mass percentage was calculated according to
Lohman’s formula [26].
2.4. Biochemical Measurements
Biochemical parameters were determined twice: before (visit T0) and after 3 months of therapy
(visit T3). Venous blood samples were collected between 8:00 and 10:00 a.m. after an overnight
fast, and centrifuged at 1000ˆ g for 10 min at 4 ˝C. Serum specimens were stored at ´70 ˝C prior
to assay. Commercially available ELISA kits (DRG Diagnostics, Marburg, Germany) were used to
determine leptin and sOB-R concentrations. Inter-assay variations (CV%) were 5.3% and 3.3% for
total leptin and sOB-R, respectively. Serum levels of total adiponectin and high molecular weight
(HMW) adiponectin were determined using ELISA kit (ALPCO Diagnostics, Salem, NH, USA).
Adiponectin multimers were selectively measured after sample pretreatment with two proteases
that specifically digested the trimeric forms or both the hexameric and trimeric forms. In this assay,
total adiponectin and HMW adiponectin levels were determined directly. Inter-assay variations were
5.0% and 5.7% for total adiponectin and HMW adiponectin, respectively. Glucose, total cholesterol,
LDL and HDL-cholesterol and triglycerides were measured by standard methods (Roche Diagnostics,
Basel, Switzerland). To reduce interassay variance, samples obtained before and after therapy were
analyzed in one assay.
2.5. DNA Isolation and Genetic Analysis
DNA was isolated from 4 mL of venous blood samples by a salting-out procedure [27]. Genotyping
of the -2548G > A LEP (rs7799039), Q223R (A668G, rs1137101) and K656N (G1968C, rs8129183) LEPR,
as well as -11377C > G (rs266729) and -11426A > G (rs16861194) ADIPOQ polymorphisms was
performed by PCR amplification followed by digestion with an appropriate restriction enzyme [20].
The obtained restriction fragments were visualized on 2%–3% agarose gels. For quality control of
genetic testing: (i) amplification blank controls consisting of only amplification reagents without DNA
were performed during each PCR reaction; (ii) randomly selected DNA samples were analyzed by
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sequencing; (iii) control samples with genotypes identified by sequencing were included into each
PCR-RFLP reaction.
2.6. Statistical Analysis
The results are presented as means ˘ standard deviation (SD) for normally distributed data
or medians and interquartile range (25th–75th percentiles) for non-normally distributed variables.
The Kolmogorov-Smirnov test and graphical inspections of data were used to evaluate the distribution
for normality.
Due to the fact that an increase in height between visit T0 and T3 could be partially responsible for
a decrease in SDS-BMI in that time period, weight loss during intervention was defined as SDS-BMI
change (Δ) ď ´0.5. Differences in anthropometric characteristics and biochemical parameters between
children who lost weight and those who have not were assessed using the Student t test for normally
distributed data and the nonparametric Mann-Whitney test for non-normally distributed data. Paired
Student t test or nonparametric Wilcoxon test were used to compare the parameters mentioned above
before and after intervention in the whole group and in subgroups of children who lost weight and
those that did not.
The Hardy-Weinberg equilibrium analysis was performed using a chi-square test with one degree
of freedom. Additive, dominant, recessive and allelic models were tested for every polymorphism
for associations with weight loss. Under each model, the odds ratios (ORs) with their 95% confidence
intervals (CI) were calculated, and the chi-square test, Fisher exact test and Cochran-Armitage test
for trend were used, as appropriate. The procedure described by Benjamini and Hochberg was used
to correct p-values for multiple testing [28]. Linkage disequilibrium (LD) was analyzed using the
pairwise LD measure D’, and haplotype blocks were constructed from population genotype data
using Haploview software [29], with the default algorithm for generating haplotype blocks based on
methods established by Gabriel et al. [30]. A D’ value of 1 indicates complete LD between the two
markers; a D’ value greater than 0.8—strong LD; 0.2–0.8—incomplete LD; whereas a D’ of less than
0.2—negligible LD. Multiple logistic regression analysis was conducted to assess the combined impact
of two LEPR polymorphisms on weight loss during therapy.
Changes in SDS-BMI, body composition and biochemical parameters were expressed as delta
variables, calculated by subtracting values at baseline (T0) from values measured after 3 months
of therapy (T3). Differences in anthropometric characteristics and biochemical parameters between
different genotypes were assessed using the Student t test for normally distributed data and the
nonparametric Mann-Whitney test for non-normally distributed data. To study associations of the
combined genotypes of the LEPR polymorphisms Q223R and K656N with changes in soluble leptin
receptor concentration, the multivariate linear regression model adjusted for age and sex was used.
Genetic variants of the studied polymorphisms were treated as a continuous variable and put in order
from the exclusive presence of at least one copy of Q223R minor allele to the exclusive presence of at
least one copy of K656N minor allele. Test for linear trend was applied.
The correlation coefficients between changes in body composition and changes in SDS-BMI due to
the intervention in children with combined genotypes of the LEPR Q223R and K656N polymorphisms
were calculated using Pearson correlation.
Statistical significance was set at 0.05. Statistical analysis was performed using SPSS v.18.0
software (SPSS Inc., Chicago, IL, USA) and StatXact-3 software, version 3.1 (Cytel Software Corporation,
Cambridge, MA, USA).
3. Results
3.1. Distribution of Polymorphisms in LEPR, LEP and ADIPOQ in Obese Children
One hundred obese children aged 4–10 years (47% male) were included in the analysis. After
3 months of therapy, mean height and SDS-height in the whole group increased (from 136 cm to
138 cm and from 0.98 to 1.29, respectively, both p < 0.001), while median weight, BMI and SDS-BMI
decreased (from 47.2 kg to 45.2 kg, 25.1 kg/m2 to 23.1 kg/m2, and 3.46 to 2.82, respectively, all p < 0.001).
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We categorized the children into two subgroups according to the level of SDS-BMI change during the
intervention: with weight loss (ΔSDS-BMI ď ´0.5, n = 71) and without weight loss (ΔSDS-BMI > ´0.5,
n = 29).
Genotype and allele frequencies of the studied polymorphisms are shown in Table 1. All analyzed
genotypes fulfilled the criteria of the Hardy-Weinberg equilibrium. Genotype frequencies of the LEPR
Q223R (A > G) polymorphism were significantly different in obese children with and without weight
loss. Analysis revealed the strongest association in the dominant genetic model when the presence of
the AG or the GG genotype was associated with more than a three-fold higher likelihood of weight
loss (OR = 3.45 (95% CI: 1.38–8.78), p = 0.007, adjusted FDR (False Discovery Rate) p = 0.035) compared
with the AA genotype. The frequency of the G allele was also higher in obese patients with weight
loss than without weight loss (52.1% vs. 32.8%; OR = 2.23 (95% CI: 1.18–4.23), p = 0.013, adjusted FDR
p = 0.065).
We found no differences between the studied groups in genotype and allele distribution for
K656N (G > C) LEPR, -2548G > A LEP, -11377C > G ADIPOQ and -11426A > G ADIPOQ SNPs.
Table 1. Distribution of LEP, LEPR, and ADIPOQ genotypes and alleles in prepubertal obese children


















LEP -2548G > A
Genotypes
GG 23 (32.4) 10 (34.5) additive – 0.767 0.767
GA 31 (43.7) 10 (34.5) dominant 1.10 (0.44, 2.74) 0.840 0.840
AA 17 (23.9) 9 (31.0) recessive 0.70 (0.27, 1.82) 0.463 0.926
Alleles
G 77 (54.2) 30 (51.7)
A 65 (45.8) 28 (48.3) allelic 0.90 (0.49, 1.67) 0.748 0.748
LEPR Q223R A > G
Genotypes
AA 15 (21.1) 14 (48.3) additive – 0.014 0.056
AG 38 (53.5) 11 (37.9) dominant 3.48 (1.38, 8.78) 0.007 0.035
GG 18 (25.4) 4 (13.8) recessive 2.12 (0.65, 6.93) 0.205 0.820
Alleles
A 68 (47.9) 39 (67.2)
G 74 (52.1) 19 (32.8) allelic 2.23 (1.18, 4.23) 0.013 0.065
LEPR K656N G > C
Genotypes
GG 58 (81.7) 19 (65.5) additive – 0.206 0.412
GC 11 (15.5) 10 (34.5) dominant 0.43 (0.16, 1.13) 0.081 0.203
CC 2 (2.8) 0 (0.0) recessive – 1.000 1.000
Alleles
G 127 (89.4) 48 (82.8)
C 15 (10.6) 10 (17.2) allelic 0.57 (0.24, 1.35) 0.195 0.488
ADIPOQ -11426A > G
Genotypes
AA 59 (83.1) 23 (79.3) additive – –
AG 12 (16.9) 6 (20.7) dominant 0.78 (0.26, 2.32) 0.655 1.092
GG 0 (0.0) 0 (0.0) recessive – –
Alleles
A 130 (91.5) 52 (89.7)
G 12 (8.5) 6 (10.3) allelic 0.80 (0.28, 2.24) 0.671 0.839
ADIPOQ -11377C > G
Genotypes
CC 31 (43.7) 12 (41.4) additive – 0.657 0.876
CG 31 (43.7) 12 (41.4) dominant 0.91 (0.38, 2.18) 0.834 1.043
GG 9 (12.6) 5 (17.2) recessive 0.70 (0.21, 2.29) 0.540 0.720
Alleles
C 93 (65.5) 36 (62.1)
G 49 (34.5) 22 (37.9) allelic 0.86 (0.46, 1.62) 0.646 1.077
FDR, false discovery rate; OR, odds ratio; BMI, body mass index; SDS, standard deviation score; SNP, single
nucleotide polymorphism; CI, confidence interval.
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3.2. Associations of Combination of Q223R and K656N LEPR Polymorphisms with Weight Loss in Obese
Children after a 3-Month Intervention
Combined genotype frequencies of the LEPR Q223R/K656N polymorphisms are shown in
Table 2. A complete LD between the two polymorphisms was observed (D’ = 1). The LEPR
genotype combinations Q223R/K656N: AG/CC, GG/GC and GG/CC were not observed. All children
homozygous for one LEPR minor allele were wild-type homozygotes for the other.
Table 2. Distribution of Q223R and K656N LEPR genotypes in prepubertal obese children.




AA 18 (18.0%) 9 (9.0%) 2 (2.0%) 29.0%
AG 37 (37.0%) 12 (12.0%) – 49.0%
GG 22 (22.0%) – – 22.0%
Total 77.0% 21.0% 2.0% 100.0%
Based on the finding that the presence of only one minor allele in LEPR Q223R was sufficient for a
higher likelihood of weight loss, we divided the children into four categories (Table 3): (1) the reference
group: wild-type homozygotes for both polymorphisms; (2) subjects with at least one minor allele in
Q223R only (genotypes AG or GG) and wild-type homozygotes for K656N; (3) wild-type homozygotes
for Q223R with at least one minor allele in K656N only (genotypes GC or CC); (4) combined
heterozygotes for both loci (Q223R AG and K656N GC). In the logistic regression model, we confirmed
that obese children with at least one minor allele in Q223R and wild-type homozygotes for K656N
had a 5-fold higher likelihood of losing weight (ΔSDS-BMI ď ´0.5) (OR = 5.09 (95% CI: 1.60–16.24),
p = 0.006) when compared with wild-type homozygotes for both loci. We did not find significant
effects of other combinations of LEPR polymorphisms on weight loss.
Table 3. Logistic regression model of the combined influence of Q223R and K656N LEPR polymorphisms










OR 95% CI p
Q223R/K656N genotypes
Wild-type/Wild-type 9 (12.7%) 9 (31%) Ref - -
AG or GG/Wild-type 49 (69.0%) 10 (34.5%) 5.09 (1.60, 16.24) 0.006
Wild-type/GC or CC 6 (8.5%) 5 (17.2%) 1.19 (0.25, 5.60) 0.828
AG/GC 7 (9.9%) 5 (17.2%) 1.53 (0.34, 6.85) 0.580
Sex
Male 35 (49.3%) 12 (41.4%) Ref - -
Female 36 (50.7%) 17 (58.6%) 0.95 (0.36, 2.51) 0.912
Age (year) – 0.85 (0.62, 1.16) 0.301
OR, odds ratio; CI, confidence interval; Ref, reference.
3.3. Body Composition, Biochemical Parameters and Energy Intake before and after Intervention
Of the 100 children enrolled in the study, the full set of biochemical and anthropometric parameters
as well as data on nutrition intake before and after intervention were available from 76 (aged 5–10 years,
42.1% male). Genotype and allele frequencies of the LEPR Q223R polymorphism in these 76 children
were similar to those observed in the whole group. As in the whole group (n = 100), it was shown that
the subjects carrying at least one minor allele in Q223R polymorphism (the AG or GG genotype) had a
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higher likelihood of weight loss (OR = 3.67 (95% CI: 1.24–10.84), p = 0.016) than wild-type homozygotes.
Moreover, the presence of the G allele (in the allelic model) was associated with a higher probability of
ΔSDS-BMI ď ´0.5 (OR = 2.23 (95% CI: 1.05–4.76), p = 0.036) when compared with A allele.
Both groups of children, who lost weight and those who did not, reduced their energy intake
during the therapy (p < 0.001) (Table 4). In addition, the proportions of protein, fat and carbohydrates
in daily energy intake and percentage of DRI were similar in both groups. Children with and without
weight loss at visit T3, at the beginning of the intervention (T0) did not differ significantly in terms
of anthropometric parameters, whereas at visit T3 the two groups had a similar height, SDS-height,
and SDS-BMI, but significantly different body weight (p = 0.037) and BMI (p = 0.013). In the obese
children with a change in SDS-BMI ď ´0.5 after the intervention, the median weight decrease was 5%
(p < 0.001), the median fat mass decrease was 15% (p < 0.001), and the mean fat-free mass decrease was
3% (p < 0.001), while children with a change in SDS-BMI > ´0.5 had similar values of these parameters
before and after therapy.
Leptin levels after a 3-month intervention were significantly reduced in both groups, but at visit
T3 this parameter was more than 2-fold lower (p < 0.001) in patients with weight loss compared with
those with a change in SDS-BMI > ´0.5 (Table 4). Soluble leptin receptor concentration increased only
in children with weight loss (p < 0.001) and after the therapy its median concentration was about 30%
higher than in those without weight loss (p < 0.001). Total adiponectin and HMW-adiponectin levels
increased (both p < 0.05), while LDL-cholesterol and triglycerides decreased (p < 0.05 and p = 0.001,
respectively) after the therapy only in children who lost weight (Table 4).
3.4. Associations of the LEPR Q223R and K656N Polymorphisms with the Level of Adipokines and Body
Composition after 3-Month Intervention
We observed significant differences in the mean decrease in SDS-BMI and percentage of fat
mass between individuals carrying different genotypes of the LEPR Q223R polymorphism (Table 5).
The carriers of at least one minor allele (AG heterozygotes and GG homozygotes) had significantly
greater mean changes of these parameters than the wild-type homozygotes (´0.97 vs. ´0.63, p = 0.01
and ´3.3% vs. ´0.8%, p = 0.003, respectively). However, therapy-induced decrease in leptin, sOB-R
level, leptin/sOB-R and leptin/adiponectin ratios were similar in the AG + GG and AA groups.
In contrast, we found significant differences in the mean, therapy-induced, decrease of sOB-R level
between individuals carrying different genotypes of the LEPR K656N polymorphism. The wild-type
homozygotes had significantly greater changes of sOB-R than carriers of at least one minor allele
(GC heterozygotes and CC homozygotes), (4.0 ng/mL vs. 0.0 ng/mL, p = 0.032), despite the fact that
therapy-induced changes in body composition were similar in the wild-type homozygotes and carriers
of the K656N minor allele (Table 5).
In the linear regression model, after adjustment for age and sex, the differences in change of
sOB-R concentrations among the four groups with different combinations of LEPR Q223R and K656N
genotypes remained significant (ptrend = 0.022) with the trend from the highest values in the carriers of
at least one minor allele in Q223R only towards lowest values in the carriers of at least one minor allele
in K656N only (Figure 1).
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Figure 1. Changes in soluble leptin receptor concentrations in obese children with different genotypes
of LEPR Q223R and K656N polymorphisms after 3 months of dietary intervention; results of linear
regression model adjusted for age and sex.
In addition, we found a positive correlation between therapy-induced change in SDS-BMI and
change in percentage of fat mass in the carriers of at least one minor allele in Q223R only as well as
in the wild-type homozygotes for both polymorphisms (both p < 0.001), while we did not observe a
significant correlation between changes in SDS-BMI and fat-free mass in these two groups (Table 6).
In contrast, in carriers of at least one minor allele in K656N only, a positive correlation between change
in SDS-BMI and change in fat-free mass was observed (p = 0.002), while no association between
change in SDS-BMI and change in percentage of fat mass was found. No correlation between change
in SDS-BMI and changes in body composition was found in the combined heterozygotes for both
LEPR polymorphisms.
Table 6. Correlations of changes in fat mass and fat-free mass with change in SDS-BMI in children with
different genotypes of Q223R and K656N LEPR polymorphisms after 3 months of dietary intervention.
Q223R/K656N Genotype
Change in Fat Mass (%) Change in Fat-Free Mass (kg)
Pearson r p Pearson r p
Wild-type/Wild-type 0.858 <0.001 0.334 0.244
AG or GG/Wild-type 0.519 <0.001 0.194 0.197
Wild-type/GC or CC 0.372 0.364 0.904 0.002
AG/GC 0.566 0.144 0.683 0.062
We found no differences in baseline levels and changes during intervention in BMI-SDS, body
composition, and adipokine concentrations between carriers of different genotypes of -2548G > A LEP,
-11377C > G ADIPOQ and -11426A > G ADIPOQ SNPs.
4. Discussion
Our study shows that both Q223R and K656N polymorphisms in the leptin receptor gene may
modulate the effect of lifestyle intervention in obese individuals during the prepubertal period, whereas
other investigated SNPs in genes encoding leptin and adiponectin were not related to a reduction in
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body mass. We also demonstrated that combinations of genotypes of the investigated polymorphisms
in LEPR may determine predisposition to therapy-induced changes in body composition and soluble
leptin receptor concentration in prepubertal children.
Based on the finding that obese subjects have higher serum levels of leptin and lower levels of
its soluble receptor, it has been suggested that human obesity is associated with leptin resistance [31].
Since both the Q223R and the K656N polymorphisms are located within the region encoding the
extracellular domain of the leptin receptor, the substitution of one amino acid by another can affect the
functional characteristics of the receptor leading to its modified signaling capacity and resulting in
various levels of leptin in circulation [1].
In our previous work, consistently with the results of other authors, we did not observe an
association between these two LEPR SNPs and obesity in children and adolescents [20,32,33]. However,
none of these studies took into account the combined effect of the Q223R and K656N variants on
susceptibility to obesity and the level of serum adipokines. Such an interaction was described by
Lu et al. [14] who found that a combination of a polymorphism in the LEP 31 flanking region with two
polymorphisms in LEPR (K109R and K656N) was associated with obesity in a Chinese population,
even though none of them individually were associated with body weight or BMI.
Lifestyle interventions, including modification of dietary habits and increased physical activity,
are recommended as an effective therapy for weight reduction as well as for an improvement of
biochemical parameters in obese children and adolescents [34]. Like other authors and in accordance
with our previous findings, after therapy-induced weight loss we observed a significant decrease in
leptin concentration with a parallel increase in soluble leptin receptor and adiponectin levels [35–37].
However, about 30% of the studied group did not have a change in body mass or body composition
despite having energy intake and percentage of DRI before and after therapy similar to the children with
weight loss. This finding implies that response to lifestyle interventions may be genetically determined.
Given the important role of leptin in the regulation of energy metabolism, we suggest that genetic
variants of LEPR may modulate physiological responses to lifestyle interventions and its influence on
health in prepubertal obese children. When analyzed separately, the Q223R and K656N polymorphisms
were related to different parameters in children after weight loss therapy: the Q223R LEPR SNP was
associated with changes in BMI and fat mass percentage, while the K656N with changes in soluble
leptin receptor serum concentrations. In contrast, we did not find any differences in serum leptin
levels in relation to the studied LEPR polymorphisms in obese children before and after intervention.
The results of previous studies on the relationship between LEPR variants and leptin concentrations
in the circulation are ambiguous. Mars et al. [10] also demonstrated no effect of the K109R, Q223R
and K656N SNPs on an acute decline in leptin levels after only 4 days of energy restriction in men.
However, Luis et al. [38] observed in Spanish adults a significant decrease in weight, fat mass as well
as leptin concentrations in wild-type homozygotes of K656N after a 3months lifestyle intervention,
whereas carriers of the minor allele had no decrease in fat mass or leptin levels after this period.
In addition, carriers of the minor K656N allele did not respond with a decrease in insulin level or
HOMA-IR after weight loss induced by a hypocaloric diet [3]. Similarly to other authors studying the
K656N polymorphism in adults, we also suggest that children with the minor allele, which is associated
with a lack of soluble leptin receptor changes after therapy, may be more resistant to multidisciplinary
intervention than wild-type homozygotes [4].
Repasy et al. [19] when analyzing the relationship between the Q223R polymorphism and
indicators of energy expenditure in obese children (aged 13 ˘ 2.7 years), also found no association
between leptin concentrations and different genotypes of this SNP. However, the wild-type
homozygotes compared with other genotypes showed a significantly lower post-absorptive and
postprandial respiratory quotient, which could indicate a lower binding capacity of leptin to the soluble
form of the receptor in plasma [19]. In our study, we also did not observe any differences in leptin
levels between the carriers of the Q223R genotypes before and after therapy in contrast with an adult
population in whom differences in leptin concentrations had been observed [39]. These differences
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could be explained by the younger age of Repasy et al.’s [19] study population and our patients,
in whom the full effect of Q223R polymorphism has not yet been developed. Nevertheless, our
study points at the association between this polymorphism and weight loss in children after lifestyle
intervention. Carriers of the Q223R wild-type variant lost significantly less weight and less fat mass
after therapy than carriers of the minor allele; therefore, we suggest that wild-type variant carriers may
be more resistant to weight loss therapy than carriers of the minor variant. Other authors observed that
in adults the wild-type variant of Q223R correlated not only with leptin concentrations but also with
higher BMI and body fat, impaired glucose metabolism and dyslipidemia, as well as lower respiratory
quotient during low-intensity exercise [40,41]. Therefore, it is suggested that this variant of LEPR
polymorphism may carry a risk of insulin resistance and liver steatosis in later life. Other genetic
variant at the LEPR locus (rs3790433) was also associated with increased risk of metabolic syndrome
and insulin resistance in adults with metabolic syndrome [12]. In addition, authors found that low
plasma level of (n-3) and high level of (n-6) polyunsaturated fatty acids exacerbated impact of this
polymorphism on the risk of hiperinsulinemia and insulin resistance. Many studies have shown that
fatty acids influence leptin expression and concentration, but the influence of genetic variations on
this is still unknown [42,43]. However, the knowledge of gene-nutrient interactions might be useful in
developing personalized dietary recommendations in obese adults as well as obese children.
To our knowledge, the combined influence of both LEPR polymorphisms on soluble leptin
receptor levels and weight loss in obese subjects has not yet been analyzed. Our results indicate that
the studied LEPR polymorphisms may have a complementary effect on the weight loss process in
obese prepubertal children during lifestyle intervention. Among different combinations of both LEPR
SNPs, we found that children with at least one minor allele in Q223R coupled with wild-type K665N
had the greatest likelihood of losing weight (5-fold), the greatest increase in soluble leptin receptor
concentrations and decrease in SDS-BMI correlated with a decrease in fat mass during intervention.
In contrast, carriers of the wild-type Q223R together with at least one minor allele in K665N, presented
no difference in likelihood of weight loss when compared with the reference genotype combination.
Moreover, only this tested combination showed a tendency towards a decrease in soluble leptin
receptor concentration and towards a decrease in SDS-BMI correlated with a decrease in fat-free
mass after therapy. It is known that a change of amino acid physico-chemical properties is one of the
mechanisms of SNPs affecting protein stability and function, as well as protein-protein interactions [44].
Amino acid substitutions in leptin receptor domain due to SNP in LEPR result in changes of the electric
charge from neutral to positive for Q223ÑR and from positive to neutral for K656ÑN [7]. In our study,
in the first combination of both LEPR SNPs, mentioned above, resulting in higher odds of weight loss,
223R and K565 were associated with positive electric charge, while in the latter combination, resulting
in the lack of the higher likelihood to lose weight, both SNP variants, Q223 and 565N, were associated
with neutral electric charge. Therefore, it seems that the consequence of a substitution of one amino
acid by another can be a change in leptin-leptin receptor interactions caused by the differences in
charge of amino acids, that may alter the efficiency of the weight loss process in children.
In some studies, functional SNPs in ADIPOQ were found to have a significant effect on human
body composition, but other reports did not confirm an association between these polymorphisms
and obesity [45,46]. In our previous study we found that the -11377C > G ADIPOQ polymorphism
may modulate the risk of childhood obesity and this polymorphism had a significant impact on the
adipokine profile in prepubertal obese children [20]. In the present study, we observed an increase in
adiponectin concentrations in obese children with weight loss, while levels of this adipokine remained
unchanged in children without weight loss. However, we did not observe any associations between
the two analyzed ADIPOQ polymorphisms and reduction in body mass in prepubertal children after
3 months of therapy. Sorensen et al. [47], when analyzing the -11377C > G ADIPOQ SNP in a panel
of obesity-related candidate genes in approximately 800 adults, suggested its minor role, if any, in
modulating weight changes induced by a moderate hypo-energetic low-fat diet. However, other
authors studying 2 SNPs in genes encoding adiponectin (-11377C > G ADIPOQ) and its receptor
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1 suggested that these polymorphisms may play a role in the responsiveness to dietary fatty acid
modification in adults with metabolic syndrome [13]. Several ADIPOQ polymorphisms were also
studied in Spanish obese adolescents, but none of them were associated with SDS-BMI and fat mass
changes after 3 months of multidisciplinary treatment [15], which is in concordance with our results.
This study has a few potential limitations. Firstly, adiposity was assessed by indirect estimations
(BMI, BMI-SDS, skinfold thickness); nevertheless, the same methods were used before and after
intervention, so analyzing differences in these parameters should obviate possible measurement errors.
Secondly, our findings were obtained from a relatively small sample of subjects, though thoroughly
characterized in terms of phenotypes. Therefore, ethnically matched studies should be performed
to confirm our results in different populations of prepubertal obese children. Thirdly, the 3-day
records provide only fragmentary information about dietary intake. However, these food records were
reported to yield the strongest agreement with actual dietary intake compared with 24-h recall and
5-day food frequency records in children [48]. Finally, the lifestyle intervention period in this study
was only 3 months and a study of a long-term intervention is needed to verify the relationship between
the polymorphisms in adipokine genes and adipokine levels in relation to clinical outcomes.
5. Conclusions
We found that out of the 5 analyzed polymorphisms, only the Q223R and K656N in the leptin
receptor gene may modulate the weight loss process after lifestyle intervention during the prepubertal
period. We also demonstrated a complementary effect of these LEPR variants on the predisposition
to weight loss, changes in body composition, and to leptin receptor concentrations in obese children.
Children with at least one minor allele in Q223R and wild-type K665N had the best likelihood of losing
weight which was associated with a decrease in fat mass and an increase in soluble leptin receptor
concentrations. We suggest that even though the contribution of a single LEPR polymorphism may
not be sufficient to influence the weight loss process, the combination of different LEPR variants might
more precisely determine a child’s predisposition to reduction of body mass in the prepubertal period.
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Abstract: The relationship between obesity and other metabolic diseases have been deeply studied.
However, there are clinical inconsistencies, exceptions to the paradigm of “more fat means more
metabolic disease”, and the subjects in this condition are referred to as metabolically healthy obese
(MHO).They have long-standing obesity and morbid obesity but can be considered healthy despite
their high degree of obesity. We describe the variable definitions of MHO, the underlying mechanisms
that can explain the existence of this phenotype caused by greater adipose tissue inflammation or
the different capacity for adipose tissue expansion and functionality apart from other unknown
mechanisms. We analyze whether these subjects improve after an intervention (traditional lifestyle
recommendations or bariatric surgery) or if they stay healthy as the years pass. MHO is common
among the obese population and constitutes a unique subset of characteristics that reduce metabolic
and cardiovascular risk factors despite the presence of excessive fat mass. The protective factors that
grant a healthier profile to individuals with MHO are being elucidated.
Keywords: metabolically healthy obesity; metabolic syndrome; adipose tissue; inflammation
1. Introduction
Obesity is a major health problem and an important risk factor for the development of diseases
such as diabetes mellitus. The mechanism by which obesity leads to the development of insulin
resistance still needs to be elucidated. There is a large body of epidemiological evidence on the
relationship between obesity and other metabolic diseases. However, there are clinical inconsistencies
that are exceptions to the paradigm of “more fat, more metabolic disease”. There are subjects with
long-standing obesity and morbid obesity who can be considered healthy despite a high degree of
obesity. This phenomenon was described 15 years ago [1], and these subjects were referred to as
metabolically healthy obese (MHO).
There is great inconsistency in the definitions of MHO, with a high degree of variability
surrounding the prevalence of this phenotype, which has been estimated to be between 10% and 34%
depending on the criteria used [2–5]. MHO appears to be more prevalent in women than in men and
its prevalence appears to decrease with age in both sexes [6]. At the same time, there are individuals
who, despite having “normal” weight, have an increased risk of disease.
Historically, the primary concern regarding obesity was the concurrent metabolic and
cardiovascular risk. In recent years, there has been increased awareness of those individuals who do
not fit into this traditional phenotype. This suggests that fat storage is not the only determinant in the
association between obesity and insulin resistance, and the term “adiposopathy” is beginning to be used.
Existing guidelines also fail to individualize the management of MHO or metabolically
unhealthy/abnormal obese (MUO) patients. This is further complicated because of a gap in the
recognition and appropriate management of those normal-weight individuals who demonstrate high
metabolic risk profiles.
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2. Definition of Metabolically Healthy Obesity
Most studies suggest the definition of MHO (body mass index (BMI) ě 30 kg/m2) to be
obesity without the presence of metabolic diseases such as type 2 diabetes (T2DM), dyslipidemia
or hypertension [1,7,8]. To date there are no accepted criteria for identifying MHO [7] individuals.
The identification of individuals with MHO is hampered by the absence of a standardized definition
of the condition. Several approaches were used to identify or define the MHO phenotype. The most
referenced are:
1. Hyperinsulinemic-euglycemic clamp [8–10].
2. The upper quartile of glucose disposal rate [10].
3. The upper quartile of an index of insulin sensitivity after an oral glucose tolerance test [11,12].
4. Less than two of the following cardiometabolic disorders (systolic blood pressure ě130 mmHg,
diastolic blood pressure ě85 mmHg, triglycerides ě1.7 mmol/L or ě150 mg/dL, fasting glucose
ě5.6 mmol/L, homeostasis model assessment of insulin resistance (HOMA-IR) ě5, ultrasensitive
C-reactive protein (CRP) ě0.1 mg/L, HDL cholesterol ď1.03 mmol/L or 40 mg/dL in men and
ď1.3 mmol/L or 50 mg/dL in women [3,13].
5. Less than three metabolic syndrome criteria [14].
6. Subjects with BMI above 30 kg/m2 and HDL cholesterol levels of at least 40 mg/dL in the absence
of T2DM and hypertension [15].
Other inflammatory markers (CRP or degree of leukocytosis) have been suggested for inclusion
in the definition of MHO [16,17].
An additional marker that is increasingly important in the context of the MHO phenotype is
liver fat content. The prevalence of non-alcoholic fatty liver disease appears to be significantly lower
in patients with MHO compared with MUO individuals [12]. According to our current knowledge,
the classification of “metabolically benign obesity” or “metabolically healthy obesity” only refers to
metabolic or cardiovascular complications and does not consider that obesity may be associated with
other non-metabolic complications such as orthopedic problems, pulmonary complications, or other
physiological conditions. Considering that the descriptions of MHO are inconsistent, the elucidation
of the factors or mechanisms underlying this protective profile is far from complete although some
works are trying to establisha standard definition of MHO [18].
3. Underlying Mechanisms That Explain the Existence of MHO
3.1. Subclinical Inflammation
Inflammation promotes insulin resistance. Greater adipose tissue inflammation is closely
associated with increased metabolic risk for T2DM, cardiovascular disease, and fatty liver disease,
whereas obese adults without adipose tissue inflammation exhibit reduced metabolic risk.
There is growing evidence to suggest that subclinical inflammation may be the underlying
mechanism that determines whether or not an individual is MHO [16]. Subclinical inflammation is
associated with insulin resistance, and CRP has emerged as one of the best predictors of vascular
inflammation, metabolic syndrome and cardiovascular disease [19]. There is a strong correlation
between circulating CRP levels and anthropometric markers and body composition, and CRP has been
proposed as a screening tool to assess the risk of the metabolic syndrome in youth [20]. In adulthood,
the MHO phenotype is associated with low levels of complement component 3, CRP, alpha necrosis
tumor factor (TNF-α), interleukin 6 (IL-6), and a low number of white blood cells, supporting the
concept of a more favorable inflammatory state compared to non-MHO subjects [21].
On the other hand, anti-inflammatory adipokines, such as adiponectin, IL-4, IL-10, IL-13, IL-1
receptor antagonist, and transforming growth factor beta are abundant within the adipose tissues of
lean individuals, whereas obese adipose tissue is dominated by the release of pro-inflammatory
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adipokines, including leptin, resistin, TNF-a, IL-6, IL-18, retinol-binding protein 4, lipocalin 2,
angiopoietin-like protein 2, CC-chemokine ligand 2, CXC-chemokine ligand 5, and nicotinamide
phosphoribosyltransferase [22].
Other systemic inflammation markers or adipose tissue inflammation markers are free fatty
acids (FFA) and the number and activation status of peripheral leukocytes. Thus obese patients with
T2DM have higher circulating levels of IL-6, FFA and glycerol and a greater absolute number of
peripheral leukocytes compared with non-diabetic obese subjects [23,24]. Similarly, our group found
that morbidly obese subjects without metabolic disease had a low degree of insulin resistance and
identical adipose tissue inflammation markers as those of non-obese subjects, with no infiltration
of macrophages and elevated values of TNF-α and IL-6 expression in visceral adipose tissue [25].
All these results suggest that MUO patients show a higher degree of both systemic and local fat
inflammation compared with MHO individuals [23].
3.2. Expansion Capacity of Adipose Tissue
Previously, to explain the transition from normal adipose tissue to that which leads to metabolic
abnormalities, studies proposed the “adipose tissue expandability hypothesis”. This postulated
that once adipocytes reached a threshold capacity for storage, they begin to promote insulin
resistance with lipotoxicity and adipokine release. This was supported by knockout studies
with PPARγ, lipodystrophy models, and alterations in adipokine secretion following saturation
of adipose tissue. Investigating this fact led to further characterization of genetic contributors to
the pathways of adipogenesis (SFRP1, Wnt, S14), apoptosis (TRAIL, TWEAK, BCL2, CASP3/7),
and angiogenesis (VEGF-A, -B,-C,-D). To improve the understanding of adipose tissue in the context
of MHO patients, Tinahones et al. looked at genes associated with both lipolysis and lipogenesis
and BMI, insulin, and HOMA-IR. They found a positive correlation in PPARγ, DGAT1, AQP7, GK,
ATGL, HSL, and perilipin and BMI, insulin, and HOMA-IR in both subcutaneous and visceral fat
tissues. Additionally, they demonstrated a negative correlation between genes—ACC1, PEPCK, ACSS2,
FABP4—and the aforementioned measures of metabolic risk.
A fairlysolid theory attributes the differences between MHO and MUHO subjects to the different
capacity for adaptation to excess energy in adipose tissue [26]. When increased fat storage is required,
fat tissue needs to increase its storage capacity and can increase the size of adipocytes or increase
their number [27]. In addition, this increase in the overall amount of fat must be accompanied by
increased vascularization [28]. In those subjects in whom adipose tissue has difficulty expanding in
the healthiest way, which is increasing cellularity, metabolic disease does appear [29]. That is what we
see in MHO who keep the proper storage capacity. But the loss of expansion capacity can even occur
in patients with normal weight, so this theory would explain the existence of metabolically unhealthy
lean subjects [30]. Furthermore, the lack of expansion capacity of adipose tissue has been linked to the
loss of its main lipogenic function, and the appearance of lipotoxic products in adipose tissue [31].
Traditionally it was thought that there was little cell turnover in adipose tissue in adulthood.
Today it is known that adipose tissue is capable of hyperplasia throughout life, and stem/progenitor
cells are responsible for this adipose tissue hyperplasia [27,32,33]. Pre-adipocytes found in the vascular
stroma are progenitor cells that differentiate into mature adipocytes through a complex program of
gene expression [33–36]. Another variable that is directly related to the total number of fat cells is cell
death, which may occur by necrosis, autophagy or apoptosis [37,38]. These studies have also alluded
to reduced adipocyte hypertrophy, fibrosis and stress as potential contributors to this presentation.
Therefore, there are four factors that are directly related to the ability for adipose tissue expansion and
functionality: (1) lipogenesis; (2) adipogenesis via the newly formed progenitor cells; (3) apoptotic and
anti-apoptotic pathways; and (4) angiogenesis.
Our group, in collaboration with other groups, has shown that metabolically healthy subjects
have higher lipogenic [39,40] and angiogenic [41,42] capacity than metabolically unhealthy patients.
Furthermore, there is also considerable evidence that adipogenesis and the functionality of
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mesenchymal cells to become new adipocytes is higher in metabolically healthy subjects because
they exhibit mesenchymal cells in the stroma of adipose tissue with a greater capacity to differentiate
both bone and fat tissue and a lower senescence [36]. This increased ability to form new adipocytes
in the MHO individuals is an observation contributed by our group which clearly shows that the
apoptosis of adipocytes increases with obesity, and this has a direct relationship with the degree of
adipose tissue inflammation [43].
Adipose tissue is a key regulator of inflammation, and inflammation is involved in the onset and
development of atherosclerosis, metabolic syndrome, and T2DM. Although the results of these initial
studies suggest that MHO is characterized by a lower inflammatory cytokine environment than MUO,
further studies are necessary to better identify the adipose tissue hormones that promote a healthy
metabolic profile in obese adults.
There are several adipose tissue compartments and they have different connections with metabolic
diseases. Visceral and intrahepatic fat has a direct association with obesity, while subcutaneous fat
is not associated with metabolic disease [44]. A plausible hypothesis is that the healthiest way to
accumulate fat is through subcutaneous fat expansion but when this capacity is decreased or lost
it must resort to other compartments and metabolic diseases occur. Could the MHO phenotype be
defined as a group of obese patients with predominantly subcutaneous fat deposits and with little or
no visceral and intrahepatic fat? These questions and more still need to be answered.
3.3. Other Possible Mechanisms
A new potential factor to explain the differences between MHO and MUO could be circulating
microRNA [45]. Insulin resistance in peripheral organs, such as the liver, can develop due to toxic
stimulus, initiating secretion of microRNAs associated with insulin resistance, which are incorporated
into muscle and fat cells, inducing insulin resistance in these tissues [46].
A study revealed that 20% of patients with a BMI above 40 kg/m2 had adiponectin levels above
the average of subjects with normal BMI, and these adiponectin levels above a certain threshold
increase the probability of being metabolically healthy, even after correcting for the confounding
effects of age, insulin and waist circumference [15]. This suggests that adiponectin plays a crucial
role in the pathogenesis of metabolic complications associated with obesity as patients with the
MHO phenotype have similar levels of adiponectin as those found in normal-weight subjects [15].
Furthermore, individuals with the MHO phenotype have a lower visceral fat, liver fat, and muscle fat
content than obese subjects without MHO or obese people with insulin resistance, suggesting that the MHO
phenotype is associated with improved ability to capture FFA in adipose tissue [12]. These differences in
body composition between MHO patients and non-MHO patients are consistent between genders [3].
Finally, lifestyle factors such as level of physical activity or cardiorespiratory condition also appear
to play a key role in distinguishing whether or not an individual is MHO. MHO subjects show higher
levels of physical activity compared to MUO individuals and have a more favourable lifestyle [14,47,48].
Likewise, occupational physical activity or leisure time physical activity also appears to be important,
since the two exercise regimens are differentially associated with obesity and insulin resistance [49].
4. Do Metabolically Healthy Obese Subjects Improve after an Intervention?
The decisive feature of MHO is the absence of visceral fat accumulation. Until definitive data
emerges linking genetic predisposition to MHO, currently recommended lifestyle modifications appear
beneficial. Thus, promoting lifestyle modifications directed at minimizing visceral fat accumulation is
a fundamental public health measure.
However, it is not completely clear if obese subjects with a MHO phenotype would benefit from
traditional lifestyle interventions, which focus on dietary therapy and/or increased physical exercise.
Few studies have analyzed the metabolic effects of lifestyle modifications with a restrictive diet and/or
exercise in MHO subjects, and their results have been contradictory [50,51]. Supporting the theory that
MHO and non-MHO individuals could require a different treatment approach, Karelisy et al. showed
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that MHO individuals reacted differently, from a metabolic viewpoint, to a six-month calorie restricted
diet compared to “at-risk” obese people despite achieving similar weight loss [52]. There are some
studies that showed combining a Mediterranean diet with moderate to high intensity aerobic training
is more effective at improving body composition [53,54]. Although the public health message for all
obese patients should continue to promote healthy lifestyle habits, the controversial results of lifestyle
interventions in MHO individuals would justify prioritizing, for cost-efficacy reasons, the intensive
interventions in metabolically abnormal obese individuals and monitoring MHO subjects for early
detection of the development of metabolic abnormalities [55].
Currently, bariatric surgery remains among the best options for patients suffering from severe
obesity, with excellent results regarding long-term weight loss and decreases in peripheral and
visceral fat depot sizes [56]. More research is needed to study the effects of different therapeutic
approaches on the metabolic profile of healthy but obese individuals. Results in this area are essential
for understanding the pathophysiology and to implement appropriate metabolically healthy obese
and healthy non-obese intervention strategies.
5. Do Metabolically Healthy Obese Subjects Stay Healthy as the Years Pass?
Debate continues concerning whether individuals with MHO are truly healthy. The literature
differs regarding the relative risk of disease among this population. MHO individuals are at decreased
risk for developing cardiovascular disease compared with MUO individuals [57]. Long-term studies
have suggested that MHO is a transient state. For example, among a group of Japanese Americans with
MHO, two-thirds developed metabolic syndrome during 10 years of observation, and the metabolic
abnormality was independently associated with visceral fat accumulation, female sex, higher fasting
plasma insulin concentration, and lower serum HDL associated cholesterol concentration [58].
Consistent with this report, among the 1051 participants in the Pizarra Study, the prevalence of
MHO decreased during 11 years of observation [59].
Individuals with MHO are not at increased risk for developing cardiovascular disease compared
to metabolically healthy normal weight [MHNW] individuals [60–63]. Studies with longer follow-up
periods (>15 years) have reported that MHO individuals were at an increased risk for major
cardiovascular disease events as compared to MHNW individuals [64,65]. Recently, analysts
conducting a systematic review of the associations between BMI and metabolic status with total
mortality and cardiovascular events reported that MHO individuals appear to be at increased risk
for cardiovascular events, as compared to MHNW individuals [66]. These researchers concluded
that obese individuals are at increased risk for adverse long-term outcomes, even in the absence of
metabolic abnormalities, compared with MHNW individuals.
A recent study evaluated the prevalence of elevated plasma high sensitivity CRP (hs-CRP)
concentrations and hepatic steatosis in MHO, MHNW, and in metabolically unhealthy normal-weight
(MUNW) individuals [67]. They observed that both elevated plasma hs-CRP concentrations and
hepatic steatosis are more prevalent among MHO and MUNW individuals than they are among
MHNW individuals. However, they are most prevalent among individuals with MHO, suggesting that
obesity in the absence of metabolic risk factors is not entirely benign but is associated with subclinical
vascular inflammation. Another recent study reported that 42% of their subjects with MHO developed
the metabolic syndrome within 10 years [68], again suggesting that MHO is not without increased health
risks. However, the identification of predictors, biological determinants, and mechanisms underlying
MHO, determining whether MHO represents a transient phenotype that is affected by aging, behavioral,
and environmental factors, and accurately calculating the true health risks associated with MHO remain
viable topics for diligent study through properly designed and conducted longitudinal studies.
The Bogalusa Heart Study examined 1098 individuals, both children (5–17 years) and adults
(24–43 years), who participated in the study between 1997 and 2002. Participants with the MHO
phenotype during childhood were more likely to maintain MHO status in adulthood. Despite the level
of obesity and fat mass continuing to increase throughout childhood and adulthood, this group of MHO
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individuals showed a generally comparable cardiometabolic profile with non-obese children and adults.
In addition, the carotid intima-media thickness did not differ in adulthood among previous MHO children
and non-obese children. These results are very important because they show that the MHO phenotype
that starts in childhood and continues into adulthood may have a very favourablecardiometabolic risk
profile [69]. Even more importantly, there is increasing evidence showing that the metabolic profile of
MHO individuals is almost indistinguishable from that of lean individuals [4,7,70].
To date it is not at all clear whether the MHO phenotype decreases morbidity and mortality
associated with obesity. MHO patients have a lower prevalence of risk factors for the development
of certain diseases. For example, the intima-media thickness as a risk marker of atherosclerosis
is significantly different between individuals with the MHO phenotype and metabolically healthy
non-obese patients [5,12,70]. However, a recent meta-analysis has evaluated eight studies comparing
mortality data from any cause or cardiovascular events in six groups of patients defined by BMI
category (n = 61,386) and metabolic comorbidities, with a 10-year follow up. Analyses revealed that
MHO individuals had an increased risk (relative risk (RR): 1.24) compared with MHNW subjects,
but this was only detected in studies of 10 or more years of follow-up. In addition, all metabolically
unhealthy subjects, regardless of their weight, had an increased risk compared with healthy lean
individuals. Curiously in metabolically unhealthy patients, the normal-weight individuals had a
higher risk (RR: 3.13), followed by overweight (RR: 2.70) and finally obese subjects (RR: 2.65) [71].
Similar results were published, indicating that both MHO and MUO individuals ultimately had a
higher risk of mortality [72].
This evidence, too, is conflicting, with the underlying question being whether MHO presentations
simply represent an early snapshot along the timeline of metabolic health. One group found that
nearly 50% of MHO patients transitioned to metabolically unhealthy phenotypes when followed
longitudinally for 10 years. Therefore, at present, it is not clear whether MHO individuals will remain
such with the passage of time, or if their cardiovascular morbidity and mortality is comparable to that
of non-obese subjects.
6. Conclusions
MHO is common among the obese population and constitutes a unique subset of characteristics
that reduce metabolic and cardiovascular risk factors despite the presence of excessive fat mass.
The protective factors that grant a healthier profile to individuals with MHO are being elucidated.
Despite the knowledge that visceral fat deposition is the seminal factor that ultimately causes
insulin resistance and the detrimental inflammatory and hormonal profile that contributes to increased
risk for cardiovascular disease, it remains unknown whether MHO has genetic predisposing factors,
and whether MHO ultimately succumbs to insulin resistance and the metabolic syndrome.
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Abstract: The distribution of body size phenotypes in people with human immunodeficiency virus
(HIV) infection has yet to be characterized. We assessed the distribution of body size phenotypes
overall, and according to antiretroviral therapy (ART), diagnosed duration of the infection and CD4
count in a sample of HIV infected people recruited across primary care facilities in the Western Cape
Province, South Africa. Adults aged ě 18 years were consecutively recruited using random sampling
procedures, and their cardio-metabolic profile were assessed during March 2014 and February 2015.
They were classified across body mass index (BMI) categories as normal-weight (BMI < 25 kg/m2),
overweight (25 ď BMI < 30 kg/m2), and obese (BMI ě 30 kg/m2), and further classified according to
their metabolic status as “metabolically healthy” vs. “metabolically abnormal” if they had less than
two vs. two or more of the following abnormalities: high blood glucose, raised blood pressure, raised
triglycerides, and low HDL-cholesterol. Their cross-classification gave the following six phenotypes:
normal-weight metabolically healthy (NWMH), normal-weight metabolically abnormal (NWMA),
overweight metabolically healthy (OvMH), overweight metabolically abnormal (OvMA), obese
metabolically healthy (OMH), and obese metabolically abnormal (OMA). Among the 748 participants
included (median age 38 years (25th–75th percentiles: 32–44)), 79% were women. The median
diagnosed duration of HIV was five years; the median CD4 count was 392 cells/mm3 and most
participants were on ART. The overall distribution of body size phenotypes was the following:
31.7% (NWMH), 11.7% (NWMA), 13.4% (OvMH), 9.5% (OvMA), 18.6% (OMH), and 15.1% (OMA).
The distribution of metabolic phenotypes across BMI levels did not differ significantly in men vs.
women (p = 0.062), in participants below vs. those at or above median diagnosed duration of HIV
infection (p = 0.897), in participants below vs. those at or above median CD4 count (p = 0.447), and by
ART regimens (p = 0.205). In this relatively young sample of HIV-infected individuals, metabolically
abnormal phenotypes are frequent across BMI categories. This highlights the importance of general
measures targeting an overall improvement in cardiometabolic risk profile across the spectrum of
BMI distribution in all adults with HIV.
Keywords: obesity phenotype; metabolic abnormalities; HIV infection
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1. Introduction
People living with HIV infection constitute a sizable proportion of the world population
and the number is increasing [1]. The advent and uptake of antiretroviral therapy (ART) has
turned HIV infection from a highly fatal infectious disease into a chronic manageable condition [2].
Consequently, the lifespan of HIV infected patients receiving ART is now close to that of the general
population [3]. This has led to a rise in chronic and age-related conditions such as cardio-metabolic
disorders in HIV-infected people [4,5], that is contributing substantially to the overall morbidity and
mortality in this population [6,7].
A major contributor to cardio-metabolic diseases is the global obesity epidemic with 52%
(1.9 millions) of the worldwide adult population being either overweight or obese in 2014 [8].
Obesity contributes to cardio-metabolic abnormalities by impairing metabolic functions that promote
dyslipidemia, insulin resistance, as well as chronic inflammation [9]. Consequently, concepts such
as “metabolically healthy” and “metabolically abnormal” have been used to characterize individuals
across the distribution of body mass index (BMI) as a function of the underlying burden of metabolic
abnormalities [10].
The changes in body fat distribution associated with HIV infection are well-described [11].
The advanced stage of untreated HIV infection is associated with changes in body fat content
and distribution, which are partially and perhaps non-optimally restored following treatment
with ART [12]. ART extends the lifespan of HIV-infected people by reducing the viral load with
a subsequent strengthening of the immune system; notably, it does not eliminate the HIV infection.
Hence, chronic inflammation persists and there is incomplete restoration of the immune system [13].
Additionally, various metabolic abnormalities are associated with HIV infection and its related
treatments [14,15]. These include dyslipidemia, insulin resistance, and abnormal blood pressure
levels, [13], which contribute to cardiovascular diseases (CVDs) and type 2 diabetes mellitus
(T2DM) [13,16].
While obesity and HIV infection have been extensively researched separately, there is a dearth of
data on the distribution of obesity phenotypes in HIV-infected people [17]. Therefore, in the current
study, we assessed the distribution of obesity phenotypes, and the effects if any, of ART and other major
distinctive characteristics of HIV infection, in a representative sample of people with HIV recruited
across primary healthcare facilities in the Western Cape Province, South Africa.
2. Materials and Methods
2.1. Study Design and Sampling Procedure
A cross-sectional survey was conducted from March 2014 to February 2015 in a random sample
of HIV-infected adults aged 18 years and older being treated at public healthcare facilities across the
Western Cape Province in South Africa. Permission to conduct the survey was obtained from Health
Research Office of the Western Cape Department of Health, and the relevant healthcare facilities.
The healthcare facilities considered for this study needed to provide ART to at least 325 HIV-infected
patients per month to ensure adequate recruitment within a reasonable period. Thus, the sample frame
comprised a total of 62 healthcare facilities with 42 across Cape Town and 20 in the surrounding rural
municipalities. Of these, 17 facilities, including four rural, were randomly selected for inclusion in this
study. At each participating healthcare facility, 15–60 patients were randomly sampled.
The study was approved by the South African Medical Research Council Ethics Committee and
conducted in accordance with the principles of the Declaration of Helsinki.
2.2. Data Collection
A team of trained clinicians, nurses, and field workers collected data by administering
questionnaires, clinical measurements, and biochemical analyses. Data were captured on electronic
case report forms, which were available on personal digital assistants (PDAs), with built-in checks
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for quality control. Data were encrypted at the point of collection and sent via mobile connection
to a dedicated server, from which it was further checked, downloaded, and stored for future use.
The interviews and the physical assessments were conducted on the day of recruitment while the
blood specimens were drawn the following day after the participant had fasted overnight.
2.2.1. Interviews
Socio-demographic data and medical history were obtained using a structured interviewer-
administered questionnaire adapted from the World Health Organization’s STEPwise approach to
Surveillance (STEPS) tool. Self-reported data included duration of being diagnosed HIV infection and
CD4 counts, whereas information on HIV treatment was obtained by capturing medications brought
to by the participants.
2.2.2. Physical Examination
Anthropometric parameters including height, weight, and waist circumference (WC) were
measured using standardized techniques. Height was measured to the nearest millimeter using
a Leicester Height Scale (Seca, Liverpool, UK) with the participant barefoot and in the upright position.
Weight was measured to the nearest gram using A&D Personal Scale (Model UC-321, Toshima-Ku,
Tokyo, Japan) with the participant in light clothes, and without shoes. WC, recorded to the nearest
millimeter, was taken at the level of umbilicus. After the participant was seated in a resting position
for at least five minutes, blood pressure (BP) was measured in mmHg on the right arm, using a digital
automatic BP monitor (Omron, M6 Comfort, Hoofddorp, The Netherland); three measurements were
taken three minutes apart.
2.2.3. Laboratory Measurements
Biochemical parameters were analyzed at an ISO 15189 accredited pathology laboratory (PathCare,
Reference Laboratory, Cape Town, South Africa) which had no access to participants’ clinical
information. All analyses were performed on venous blood samples collected after an overnight fast
of at least eight hours. Serum cholesterol and triglycerides were measured by enzymatic colorimetric
methods; ultrasensitive C-reactive protein was read; plasma glucose was measured by hexokinase
method; all implemented using a Beckman Coulter AU 500 spectrophotometer. Insulin concentrations
were measured by the Chemiluminesecence Immunoassay method while HbA1c level was determined
using high-performance liquid chromatography technique. The homeostatic model assessment of




Education level was distinguished into primary education and secondary education or above.
Smoking status was categorized as never-smoker, past-smoker (stopped smoking during the past
12 months), and current-smoker. Alcohol intake behavior was classified as non-heavy drinker
(consumed <5 standard alcoholic drinks for men and < 4 standard alcoholic drinks for women in
a row during the past 30 days), and heavy-drinker (consumed ě5 standard alcoholic drinks for men
and ě4 standard alcoholic drinks for women in a row during the past 30 days). A standard alcoholic
drink was corresponding to one can (340 mL) of beer, one glass (125 mL) wine, or one shot (25 mL) of
spirits. Duration of diagnosed HIV infection was the time since being diagnosed with HIV. ARTs were
categorized as first line ART, second line ART, and other regimens [19].
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2.3.2. Body Size Phenotype
Body mass index (BMI) was calculated as weight (kg)/height ˆ height (m2). BMI was
used to classify participants into three categories: normal weight (BMI < 25 kg/m2), overweight
(BMI ě 25 kg/m2 and BMI < 30 kg/m2) and obese (BMI ě 30 kg/m2). There is no consensus on
the definition and number of cardio-metabolic abnormalities to use when characterizing obesity
phenotypes [20]. In the current study, we considered the following four abnormalities: (1) elevated BP
determined using the average of the second and third BP measurements (systolic BP ě 130 mmHg or
diastolic BP ě 85 mmHg or known hypertension on treatment); (2) high triglycerides (ě1.69 mmol/L);
(3) low high-density lipoprotein cholesterol (HDL-C ď 1.0 mmol/L in men; ď1.3 mmol/L in women);
(4) high blood glucose (fasting plasma glucose (FPG) ě 5.6 mmol/L or known diabetes mellitus).
In secondary analysis, in a subset of participants with data available on insulin levels, we included
insulin resistance as a fifth metabolic abnormality, by classifying as insulin resistant all participants
with HOMA-IR above the data specific 90th percentile. Considering the lack of consensus on waist
circumference (or waist-to-hip ratio) threshold to define abdominal obesity in African populations,
the criteria of abdominal obesity which has been included in about 30% of studies on obesity
phenotype [20] was not included in our panel of metabolic abnormalities.
Participants were then classified for metabolic status as “metabolically healthy” if they had none
or one metabolic abnormality, and as “metabolically abnormal” if they had two or more metabolic
abnormalities. Cross-classification of participants by BMI and metabolic status led to the following
six phenotypes: (1) normal weight and metabolically healthy (NWMH); (2) normal weight and
metabolically abnormal (NWMA); (3) overweight and metabolically healthy (OvMH); (4) overweight
and metabolically abnormal (OvMA); (5) obese and metabolically healthy (OMH); and (6) obese and
metabolically abnormal (OMA).
2.4. Statistical Analysis
Participants’ characteristics are summarized as means (standard deviation, SD) and medians
(25th to 75th percentiles) for continuous variables, and as count (percentages) for categorical variables.
Comparison of baseline characteristics across BMI categories, by metabolic status, and by HIV-related
characteristics were done using chi-square tests, fisher-exact test, t-tests or Kruskal-wallis tests for
non-parametric data or Analysis of Variance test (ANOVA) where appropriate. The linear trends
across BMI categories overall and by metabolic status were examined using the Cochrane-Armitage
trend tests and Brown-Forsythe Levene procedures. The two-way interactions between BMI categories
and metabolic status (B ˆ M), and metabolic status and gender (M ˆ G) were tested using linear and
logistic regression models, by incorporating in the same model the main effects of the variables of
interest as well as their interaction term.
To assess the association between each continuous metabolic trait and BMI categories, multinomial
logistic regressions models (age and sex adjusted) were used to derive the odds ratio (OR) and 95%
confidence interval for a unit higher level of each metabolic trait in relation with overweight and
obesity risk, always using normal weight are reference category. The McFadden’s R2 [21] was then used
as a measure of the overall performance of models containing age, gender, and each metabolic trait of
interest. A two-side p-value < 0.05 indicates a statistical significance. All analyses were performed
using the R statistical software version 3.0.3 (the R Foundation for Statistical Computing Platform,
Vienna, Austria. For a z-value of 1.96 (corresponding to a 95% confidence interval), and an effective
sample size of 748 participants, our study had a margin of error of 0.05% to detect a prevalence of
normal weight metabolically abnormal phenotype of 1% in the total sample. The acceptable margin of
error is 5%, indicating that our study was well-powered for the overall and subgroup analyses.
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3. Results
3.1. Socio-Demographic Characteristics
Of the 831 participants who were interviewed and clinically assessed, 754 (91%) returned for
biochemical measurements. Blood samples from six participants were inadequate for analyses resulting
in 748 (99%) participants being included in the study. This comprised 591 women and 157 men who
had complete data on the variables of interest.
The median age (25th–75th percentiles) was 38 (32–44) years overall, 41 (35–47) years in men, and
37 (31–43) years in women (p < 0.001). As shown in Table 1, most participants (84.9%) had secondary
education or higher with a lower prevalence in men (75.8%) than in women (87.3%) (p < 0.001).
About half of the participants (54.6%) were employed with similar rates in men and women (49.7% vs.
55.9%, p = 0.162). Current smoking was more prevalent in men than in women (58.8% vs. 16.1%,
p < 0.001) but heavy alcohol consumption was similar (34.1% vs. 34.1%, p = 0.975).
Table 1. Characteristics of the HIV/AIDS patients (n (%), or median (25th–75th percentiles)).
Characteristics Overall, (n = 748) Men, (n = 157) Women, (n = 591) p
Age, year 38 (32–44) 41 (35–47) 37 (31–43) <0.001
Education level, n (%) <0.001
Primary 113/746 (15.1) 38/157 (24.2) 75/589 (12.7)
Secondary and above 633/746 (84.9) 119/157 (75.8) 514/589 (87.3)
Employed, n (%) 408/747 (54.6) 78/157 (49.7) 330/590 (55.9) 0.162
Smoking habit, n (%) <0.001
Never smoke 461/718 (64.7) 34/156 (22.2) 427/562 (76.4)
Current smoker 187/718 (25.3) 93/156 (58.8) 90/562 (16.1)
Past smoker 70/718 (13.3) 29/156 (45.3) 42/562 (9.0)
Heavy drinker, n (%) 64/187 (34.2) 22/64 (34.4) 42/123 (34.1) 0.975
HIV duration, years 5 (2–9) 4 (2–7) 5 (2.5–9) <0.001
CD4, cells/mm3 392(240–604) 272(193–448) 410(253–627) 0.001
ART treatment, n (%) 0.005
Non-ART 46/699 (6.6) 7/149 (4.7) 39/550 (7.1)
first line 426/699 (60.9) 78/149 (52.3) 348/550 (63.3)
second line 79/699 (11.3) 17/149 (11.4) 62/550 (11.3)
Others 148/699 (21.2) 47/149 (31.5) 101/550 (18.3)
Body mass index (kg/m2)
Median (P25–P75) 26.3 (22.1–32) 21.4 (19.8–22.4) 28.3 (23.8–28.9) <0.001
<25, n (%) 325 (43.4) 126 (80.3) 199 (33.7)
25.0–29.9, n (%) 171 (22.9) 21 (13.4) 150 (25.4)
ě30, n (%) 252 (33.7) 10 (6.4) 242 (40.9)
Waist circumference, cm 88 (77.5–98) 78.9 (73.9–88.3) 90 (79.5–100.8) <0.001
Systolic BP, mmHg 117 (107–129.5) 123.5 (114.5–140) 115 (105.8–127) <0.001
Diastolic BP, mmHg 82 (75–90.5) 83 (76–94) 81.5 (74.8–89.8) 0.129
Total cholesterol, mmol/L 4.3 (3.7–5.1) 4.2 (3.5–5.0) 4.4 (3.8–5.1) 0.009
HDL-cholesterol, mmol/L 1.27 (1.03–1.5) 1.2 (1.0–1.5) 1.29 (1.08–1.52) 0.010
LDL-cholesterol, mmol/L 2.5 (2.0–3.1) 2.3 (1.7–3.0) 2.5 (2.0–3.1) 0.012
Triglycerides, mmol/L 1.0 (0.74–1.34) 1.12 (0.75–1.27) 0.97 (0.74–1.28) 0.023
Fasting glucose, mmol/L 5.0 (4.6–5.4) 5.1 (4.8–5.5) 4.9 (4.6–5.4) 0.010
HOMA-IR 1.36 (0.84–2.24) 0.94 (0.53–1.64) 1.49 (0.93–2.37) <0.001
C-reactive protein, mg/L 5.6 (2.4–12) 5.0 (2.1–16.2) 5.6 (2.4–14.2) 0.728
Treated hypertension, n (%) 110 (14.7) 11 (7) 99 (16.8) 0.002
Treated diabetes, n (%) 28 (3.7) 8 (5.1) 20 (3.4) 0.432
ART, antiretroviral; BP, blood pressure; HDL, high density lipoprotein; HIV, human immunodeficiency virus;
AIDS, acquired immunodeficiency syndrome; HOMA-IR, homeostatic model assessment of insulin resistance;
LDL, low density lipoprotein.
3.2. Profile of HIV Infection
The median duration of diagnosed HIV infection was five years (25th–75th percentiles: 2–9) with
no difference by gender (p = 0.223). The median CD4 count was 392 cells/mm3 (25th–75th percentiles:
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240–604) with higher levels in women than in men (410 cells/mm3 vs. 272 cells/mm3, p = 0.002).
Most participants were receiving ART (93.4%) with the majority on first line ART (63.9%), while 11.8%
received second line ART and 17.4% were on other ART regimens. Interestingly, there were significant
differences in the distribution by gender (p = 0.005).
3.3. Profile of Cardio-Metabolic Abnormalities
The mean BMI was 26.3 kg/m2 overall with significantly lower levels in men compared with
women (21.4 kg/m2 vs. 28.3 kg/m2, p < 0.001). Overall, 43.4% of participants had normal BMI levels
while 22.9% were overweight and 33.7% obese with significant differences by gender (p < 0.001).
Women compared to men had larger WCs (90 cm vs. 79 cm, p < 0.001), higher HOMA-IR indices
(1.49 vs. 0.94, p < 0.001), and total cholesterol levels (4.4 vs. 4.2 mmol/L, p = 0.009). However, they
had lower levels of triglycerides (0.97 vs. 1.12 mmol/L, p = 0.023), fasting glucose (4.9 vs. 5.1 mmol/L,
p = 0.010) and systolic BP (115 vs. 124 mmHg, p < 0.001). Furthermore, HDL-cholesterol levels (1.29 vs.
1.2 mmol/L, p = 0.010) and prevalent treated hypertension (16.8% vs. 7.0%, p = 0.002) were higher
in women than men. Diastolic BP, hs-CRP, as well as prevalent treated diabetes were similar in both
genders (all p ě 0.129) (Table 1).
3.4. Distribution of Body Size Phenotypes
The proportion of ě2 metabolic abnormalities across normal-weight (27.1%), overweight (41.5%),
and obese (44.8%) categories increased significantly in a linear trend (p-trend = 0.001). The distribution
of body size phenotypes in the overall sample was 31.7% (NWMH), 11.7% (NWMA), 13.4% (OvMH),
9.5% (OvMA), 18.6% (OMH), and 15.1% (OMA), Figure 1.
Figure 1. Distribution of metabolic phenotypes across body mass index categories. Each vertical bar
represents the proportion of participants in the total sample with the corresponding combination of
body size (normal-weight, overweight, or obese) and metabolic phenotype (healthy or abnormal).
The accompanying proportions are shown at the tip of each bar.
In men, the majority (54.1%) were NWMH, just over a quarter (26.1%) were NWMA, while few fell
into the other categories: 6.4% (OvMH), 7% (OvMA), 0.7% (OMH), and 5.7% (OMA). In contrast, the
distribution in women was as follows: 25.7% (NWMH), 8% (NWMA), 15.2% (OvMH), 10.1% (OvMA),
23.4% (OMH), and 17.6% (OMA) (Figure 2). There was no statistically significant interaction by gender
in the distribution of body size phenotypes (p-interaction = 0.062).
The distribution of metabolic phenotypes across BMI categories was not significantly different
by longer or shorter duration of diagnosed HIV infection (median five years, p-interaction = 0.897)
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(Figure 3a), higher or lower CD4 count (median 392 cells/mm3, p-interaction = 0.447) (Figure 3b) or
across the three ART regimens (p-interaction = 0.205) (Figure 3c). The proportion of ě2 metabolic
abnormalities tended to increase significantly and linearly across BMI categories within most of the
latter subgroups except for lower CD4 count and the second line ART regimen.
Figure 2. Distribution of metabolic phenotypes across body mass index categories in men and women.
Each vertical bar represents the proportion of participants in the total gender-specific sub-sample with
the corresponding combination of body size (normal-weight, overweight, or obese) and metabolic
phenotype (healthy or abnormal). The accompanying gender-specific proportions are shown at the tip
of each bar. The p-value for the interaction by gender in the distribution are shown, together with the
p-value for le linear trend (p-trend) in the distribution of metabolic phenotypes across body mass index
categories, seperately in men and women.
Figure 3. Cont.
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Figure 3. Distribution of body size phenotypes by major HIV predictive characteristics: (a) Distribution
of metabolic phenotype across body mass index categories in participants below, and those at or
above the median of diagnosed duration of HIV infection; (b) Distribution of metabolic phenotype
across body mass index categories in participants below, and those at or above the median CD4 count;
(c) Distribution of metabolic phenotype across body mass index categories in participants on different
antiretroviral treatment regimens. For each figure panel, the p-values for the interactionb (interaction p)
in the distribution across complementary subgroups are, together with the p-value for linear trend in the
distribution of metabolic phenotype across body mass index categories within each subgroup (p-value
attached to the name of the subgroup). Each vertical bar represents the proportion of participants
in the subgroup specific sample with the corresponding combination of body size (normal-weight,
overweight, or obese) and metabolic phenotype (healthy or abnormal). The accompanying proportions
are shown at the tip of each bar.
3.5. Distribution of Metabolic Phenotypes within and Across BMI Categories
Within BMI categories, in addition to the expected differences in the levels of cardio-metabolic
risk factors, participants with metabolically abnormal phenotypes tended to be older (all p ď 0.001)
and unemployed, although differences were significant only among normal weight and overweight
(all p ď 0.002), but not among obese participants (both p ě 0.215). Furthermore, metabolically abnormal
obese participants were likely to be men (8.0% vs. 0.7%, p = 0.006) and included fewer participants on
first line ART (p = 0.009).
Age and level of education across BMI categories increased linearly overall (both p ď 0.012),
driven by a significant linear trend in metabolically healthy participants (both p ď 0.005) but not in
the metabolically abnormal (both p ě 0.396), with however no evidence of statistical interaction (both
p-interaction ě 0.065). The proportion of men who were current smokers decreased linearly overall
across increasing BMI categories (p < 0.001 for linear trend), and within both metabolic phenotype
groups (p-trend = 0.001), with no evidence of statistical interaction (both interactions p > 0.759), Table 2.
Median WC, HOMA-IR, and HDL-C levels across BMI categories increased significantly
overall (p-trend ď 0.001) and within the metabolic phenotype groups (all p-trend ď 0.024), without
evidence of statistical interaction (all p-interaction ě 0.560). Fasting glucose, triglycerides, and
prevalence of hypertension also increase across increasing BMI categories, but only on the total
cohort (p-trend ď 0.038). Interaction analyses found BMI categories and metabolic status interacted to
affect the distribution of fasting glucose (p-interaction = 0.044) whereas metabolic status interacted
with gender to influence triglycerides distributions across BMI categories (p-interaction = 0.002).
Moreover, when further analyses in the subgroup of participants with data on insulin level
(n = 711) that included insulin resistance (HOMA-IR in 90th) as a fifth metabolic abnormality.
The prevalence ě2 risk factors was found to increase slightly across BMI categories: NWMA (12.8%),
OvMA (9.3%), and OMA (16.6%), but the patterns within and across subgroups were mostly similar
(Figure 4).
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Metabolically Healthy Metabolically abnormal
Figure 4. Distribution of metabolic phenotypes across body mass index by major characteristics:
(a) Overall and in men and women; (b) in participants below, and those at or above the median of
diagnosed duration of HIV infection; (c) in participants below and those at or above the median CD4
count; (d) in participants on different antiretroviral treatment regimens. Metabollically abnormal
phenotype is based on the presence of any two of the following five abnormalities: elevated blood
pressure or known hypertension; high triglycerides; low HDL-cholesterol, high blood glucose, or
known diabetes; insulin resistance. For each figure panel, the p-values for the interaction (interaction p)
in the distribution across complementary subgroups are, together with the p-value for linear trend in the
distribution of metabolic phenotype across body mass index categories within each subgroup (p-value
attached to the name of the subgroup). Each vertical bar represents the proportion of participants
in the subgroup specific sample with the corresponding combination of body size (normal-weight,
overweight, or obese) and metabolic phenotype (healthy or abnormal). The accompanying proportions
are shown at the tip of each bar.
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3.6. Prediction of Body Mass Index Categories by the Continuous Metabolic Traits
In multinomial logistic regression models, mutually adjusted for each other and using normal
weight as a reference, male sex was associated with 81% (95% confidence interval: 68%–89%) lower
odds of overweight and 94% (89%–97%) lower odds of obesity; while each year of older age was
associated with 2% (0%–4%) higher odds of overweight and a non-significant 1% (´1% to 4%) higher
odds of obesity. The McFadden R2 for the overall performance of this basic model was 0.081. In the
presence of age and sex, all metabolic trait with the exception of systolic blood pressure (for both
overweight and obesity) and fasting plasma glucose (for overweight only) were significantly associated
with odds of overweight and obesity (Table 3). The direction of the effect with increasing metabolic
traits levels was always positive, except for HDL-cholesterol where increasing levels were associated
with decreasing odds of overweight and obesity. The highest R2 for the overall performance of resulting
models was recorded for the model containing HOMA-IR (R2 = 0.183); and ranged from 0.083 (for the
model containing systolic blood pressure) to 0.103 (for the model containing either triglycerides or
HDL-cholesterol), Table 3.
Table 3. Odds ratios (OR) and 95% confidence intervals (95% CI) from multinomial age and sex







Reference OR (95% CI) p-Value OR (95% CI) p-Value
Age, per year 1.00 1.02 (1.00–1.04) 0.093 1.01 (0.99–1.04) 0.195
0.081Sex, men 1.00 0.19 (0.11–0.32) <0.001 0.06 (0.03–0.11) <0.001
Systolic blood pressure, per mmHg 1.00 1.01 (1.00–1.02) 0.204 1.01 (1.00–1.02) 0.167 0.083
Diastolic blood pressure, per mmHg 1.00 1.02 (1.00–1.04) 0.012 1.02 (1.01–1.04) 0.005 0.087
Triglycerides, per mmol/L 1.00 2.06 (1.41–3.02) <0.001 2.70 (1.86–3.92) <0.001 0.102
HDL-Cholesterol, per mmol/L 1.00 0.40 (0.24–0.66) <0.001 0.27 (0.16–0.44) <0.001 0.102
LDL-cholesterol, per mmol/L 1.00 1.15 (0.92–1.45) <0.001 1.56 (1.26–1.93) <0.001 0.092
Fasting plasma glucose, per mmol/L 1.00 0.93 (0.79–1.10) 0.417 1.18 (1.04–1.32) 0.007 0.090
HOMA-IR 1.00 1.42 (1.19–1.70) <0.001 1.77 (1.49–2.10) <0.001 0.183
R2 is the McFadden pseudo-R2 for the overall performance of the model containing age, sex, and the metabolic
trait of interest.
4. Discussion
Although there have been rigorous reports on fat distribution and obesity in individuals with
HIV infection, to our knowledge, this is one of the first studies to document the distribution
of cardio-metabolic abnormalities in relation with body size in an HIV-infected population.
Metabolically abnormal phenotypes, defined as the presence of ě2 cardio-metabolic risk factors,
were high across all BMI categories. Even in normal weight participants, over a quarter (27.1%)
had metabolically abnormal phenotypes with this rising to 41.5% and 44.8% in the overweight and
the obese, respectively. This suggests the likely influence of multiple factors in the development of
cardio-metabolic abnormalities in this population. The high prevalence in normal weight HIV-infected
individuals suggests the possible contribution of HIV-related factors and underscores the need to
examine for cardio-metabolic abnormalities even in the absence of overweight and obesity.
In contrast, the much higher prevalence demonstrated with increasing adiposity may be
attributable to the greater role of this conventional risk factor in the development of cardio-metabolic
abnormalities in the HIV-infected population. This highlights the fine balance that needs to be
maintained between ensuring adequate nutrition and optimal weight in the HIV-infected while
simultaneously monitoring and guarding against excess weight gain. Thus, there is a need for holistic
management of these co-morbidities that may indirectly be associated with HIV infection.
The prevalence of overweight and obesity, at 13.4% and 6.4% in men and 25.4% and 40.9% in
women in this study approximated the adiposity distribution reported in South African National Health
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and Nutrition Survey (SANHANES-1) [22]. The overweight and obesity rates in the SANHANES-1
were 20.1% (95% CI: 13.7–26.4) and 11.6% (95% CI: 7.5–15.7) in men and 26.4% (95% CI: 21.7–31.0)
and 44.8% (95% CI: 38.8–50.8) in women, respectively. Similar findings have been reported in the
United States where obesity levels in HIV-infected men (19%) and women (42%) were comparable
to the general population (men: 24.7%, women: 37%) [17]. It is thus important to assess adiposity in
HIV-infected individuals and to implement appropriate management strategies for weight reduction,
similar to general populations. Notably, that the distribution of overweight and obesity in this study
mirrors that of the general population in the country is testimony of the successful implementation of
ART strategies in this community.
Although the prevalence of the metabolically abnormal phenotypes by the BMI categories
described in this study were significant at 11.7% (NWMA), 9.5% (OvMA), and 15.1% (OMA),
a substantial proportion of participants were obese but metabolically healthy (18.6%). This agrees with
the 6%–75% estimate of OMH in general populations globally and is likely because BMI is a proxy
marker of cardiovascular risk. BMI measures general fat distribution and not visceral adipose tissue
specifically, which is linked closely to insulin resistance and cardio-metabolic abnormalities. A better
proxy for visceral adipose tissue is WC and, unsurprisingly, within BMI categories, participants with
compared to without metabolic abnormalities had greater WC and elevated HOMA-IR index, a proxy
measure of insulin resistance. Similar findings have also been reported in other studies [20,23–25].
Recent studies in Caucasians that have included insulin resistance among abnormal metabolic traits,
have reported high prevalence of metabolically abnormal phenotypes both in obese and non-obese
people [26,27].
The distribution of body size phenotypes in our study is comparable with results of local studies
conducted in the general population in South Africa [24,28]. Our previous community-based study in
mixed-ancestry adults in Cape Town applying the same definition criteria found OMH and NWMA
to be present respectively 16.5% and 5% of the sample [24]. Furthermore, among normal-weight
participants (17.1% of the sample), 29.1% were classified as metabolically abnormal, while among obese
participants (53.7% of the sample), 30.8% were classified as metabolically healthy [24]. In another study
in 103 normal-weight and 122 obese premenopausal urban black South African women, Jennings and
co-workers found that 22% of the normal-weight participants were metabolically abnormal (defined
by the presence of insulin resistance), while 38% of obese women were metabolically healthy (i.e., did
not have insulin resistance) [28]. There are no recent reports available from Africa for comparison of
the metabolically abnormal phenotypes that include insulin resistance. Nevertheless, data from
a study conducted almost two decades ago in Cameroon revealed a much lower prevalence of
metabolic abnormalities with 1.4% (NWMA), 1.6% (OvMA), and 1.7% (OMA) [23]. This highlights
the epidemiological transition under way in Sub-Saharan Africa with the majority of this study’s
participants having normal weight (61%) in the year 1994, unlike more recent reports, and the
expected lower prevalence of cardio-metabolic risk factors compared with the present study [23].
Interestingly, there was no significant difference in the distribution of metabolic abnormalities across
BMI groups by duration of diagnosed HIV infection, CD4 count levels or ART regimens. There have
been diverse reports on the effects of HIV-specific factors on body fat de-arrangement, dyslipidemia,
hyperglycemia, and metabolic syndrome. However, results from a recent systematic review and
meta-analysis indicated that HIV-related characteristics had minor, if any, influence on the presence of
metabolic syndrome [29]. Nevertheless, longitudinal studies are ideally required to pronounce on the
absence or presence, if any, of a relationship between specific HIV-related factors and the development
of cardio-metabolic abnormalities by body size phenotype.
The relationship of gender, smoking status, and alcohol consumption on the distribution of
body size phenotypes remains inconclusive in studies conducted in general populations [10,30,31].
The findings of this study accorded with reports that showed little or no effect of smoking status and
alcohol use on the distribution of body size phenotypes [26]. However, a few studies showed a higher
prevalence of OMH in women than in men [26,32].
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Limitations and Strengths
The cross-sectional design of this study precludes inferences of causal associations between
the variables of interest and the development of cardio-metabolic abnormalities. The inclusion of
an HIV-uninfected and HIV-infected ART-naïve comparative groups would have strengthened our
analyses. Seeing that this was a clinic-based study limits its generalizability since it did not include
HIV-infected individuals not attending healthcare facilities. However, these limitations are inevitable
because the present project is part of a broad intervention study, which aims to explore the utilization
of HIV-care infrastructure as a gateway to detect, manage, and control non-communicable diseases
in HIV-infected populations in Africa. The relatively fewer men compared to women in the study,
characteristic of epidemiological studies in the country, might overestimate the prevalence of obesity
phenotypes. In the absence of detailed information on dietary habits/food consumption and data on
ethnicity, we could not explore possible effects of lifestyle factors and ethnicity on the distribution of
body size phenotypes among the participants. Nevertheless, differences in MHO prevalence according
to ethnicity have been reported, although this recent meta-analysis did not include any studies based
on African cohorts [33]. There are reports indicating that overall dietary intake was not associated
with healthy obesity in both Europeans and African Americans [27,34]. In addition to lifestyle and
ethnicity, data was not available on the pharmacological compounds included in the ART regimens
of the participants as well as the duration of treatment with those compounds, precluding detailed
analyses by potency of pharmacological compounds and duration of treatments.
Nonetheless, the inclusion of participants from 17 healthcare facilities, including both urban and
rural sites strengthens the representativeness in terms of the characteristics assessed. Furthermore, this
study is among the first to describe the high prevalence of metabolically abnormal phenotypes
across BMI categories in a relatively young HIV-infected population. The study findings underscore
the need for further research, particularly longitudinal studies, to understand the development of
cardio-metabolic abnormalities in the local HIV-infected population and the differential role played by
conventional risk factors as opposed to HIV-related influences.
5. Conclusions
The high prevalence of metabolically abnormal phenotypes across all BMI categories, notably
in a relatively young HIV-infected population, highlights the importance of holistic management in
HIV-infected individuals. Ideally, cardio-metabolic assessments/screenings should be done at baseline
and at regular intervals thereafter, particularly in high-risk groups. Furthermore, considering the high
prevalence of overweight and obesity in the HIV-infected, lifestyle measures for weight reduction
need to be encouraged. This is a captive audience who present regularly to healthcare facilities and
the opportunity should be used to raise greater awareness on cardiovascular disease prevention.
Such a strategy, targeting all HIV-infected patients, may contribute to a general improvement in
cardiovascular health across the spectrum of BMI distribution. If proven successful, it may possibly
have wider applicability in the general population.
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Abbreviations
The following abbreviations are used in this manuscript:
ANOVA analysis of variance
ART antiretroviral therapy
AIDS acquired immunodeficiency syndrome
BMI body mass index
B ˆ M interaction between BMI and metabolic status
BP blood pressure
CVD cardiovascular disease
DBP diastolic blood pressure
FPG fasting plasma glucose
HDL-C high density lipoprotein cholesterol
HIV human immunodeficiency virus
HOMA-IR homeostatic model assessment of insulin resistance
Hs-CRP high sensitivity-C reactive protein
LDL-C low density lipoprotein cholesterol
M ˆ G interaction between metabolic status and gender
NWMH normal-weight metabolically healthy
NWMA normal weight metabolically abnormal
OvMH overweight metabolically healthy
OvMA overweight metabolically abnormal
OMH obese metabolically healthy
OMA obese metabolically abnormal
PDA personal digital assistant
SBP systolic blood pressure
SD standard deviation
T2DM type 2 diabetes mellitus
WC waist circumference
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Abstract: Purpose: This study investigates correlations between mother and infant Body Mass Index
(BMI), their serum leptin values and breast milk leptin concentration in early infancy. Subjects
and Methods: We determined serum leptin values in 58 healthy infants and leptin values in their
mothers’ breast milk, using radioimmunoassay (RIA). Infant and maternal anthropometrics were
measured. Results: Median leptin concentration was 3.9 ng/mL (interquartile range (IQR): 2.75) in
infant serum, 4.27 ng/mL (IQR: 5.62) in maternal serum and 0.89 ng/mL (IQR: 1.32) in breast milk.
Median maternal BMI and weight were 24 kg/m2 (IQR: 4.41) and 64 kg (IQR: 15). Median infant BMI
was 15.80 kg/cm2 (IQR: 4.02), while average weight was 5.130 kg (IQR: 1.627). Infants serum leptin
values positively correlated with infants’ BMI (p = 0.001; r = 0.213) and breast milk leptin (p = 0.03;
r = 0.285). Maternal serum leptin values positively correlated with maternal BMI (p = 0.000, r = 0.449)
and breast milk leptin ones (p = 0.026; r = 0.322). Conclusion: Breast milk leptin and maternal BMI
could influence infant serum leptin values. Further studies are needed to better elucidate the role of
genetics and environment on infant leptin production and risk of obesity later in life.
Keywords: mothers; serum leptin; BMI; breast milk; infancy
1. Introduction
Leptin is a polypeptide hormone, made of 167 amino acids and discovered by Zhang et al. in 1994
thanks to studies on ob/ob gene in mice [1]. This hormone is the product of the ob gene, located on
chromosome 7q31.3. It circulates in plasma free or bound to proteins and it exerts its action through
the soluble-OB (s-OB) receptor [2]. The primary function of this hormone is to inhibit food intake and
to promote energy expenditure by regulating neuronal activity in hypothalamic arcuate nuclei: leptin,
in fact, activates anorectic Pro-opiomelanocortin/ Cocaine-and amphetamine-regulated-transcript
(POMC/CART) neurons and hinders the activity of those which stimulate food intake Neuropeptide
Y/Agouti-related protein (NPY/AgRP) [3].
There are increasing data that environmental factors in early life predict later health. The
early adiposity rebound recorded in most obese subjects suggests that factors promoting body fat
development operate in the first years of life [4]. It has been shown that higher serum leptin values
correlate with lower body mass index (BMI) in childhood and with lower predisposition to develop
metabolic disorders in adolescence and adulthood [5].
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Schuster et al. suggest that milk leptin could provide a link between maternal body composition
and infant growth and development and also plays a role in regulating infant appetite and food intake
during early infancy [6].
Increased maternal body mass index is a well-established risk factor for later infant obesity [7–9]
and prevalence of obesity women is increasing worldwide [10]. Evidence suggests that human milk
may decrease the transmission of obesity from mothers to their children, for example exerting its
effects on early growth of the infant microbiome, as recently proposed by Lemas et al. [11].
It is known that leptin is mainly produced by white adipose tissue; this is the reason why serum
leptin values directly correlate with body fat stores. During fasting or weight loss, leptin levels
decrease, while during overeating, they increase [12]. Leptin is also released by the hypothalamus,
pituitary gland, skeletal muscle, stomach, liver, placenta and mammary gland [13,14].
Leptin is found in breast milk and, interestingly, it is not only related with infants’ body fat mass,
but also with that of their mothers [15]. It is produced by mammary epithelial cells and it is associated
with fat globules. Studies conducted on mice have shown that this hormone is transferred from
maternal blood to breast milk and that it is then transferred from milk to mice puppies’ bloodstream.
Interestingly, the presence of leptin receptors has been found on gastric and intestinal epithelial cells of
both humans and rats, suggesting that leptin may play a role in the regulation of GI functions [16]. It
could be assumed that leptin taken by children with breast milk can directly pass into their bloodstream
through gut since leptin receptor isoform has been found in brush border, basolateral membrane, and
cytoplasm of enterocytes [17].
The amount of different adipokines in human breast milk is supposed to affect energy intake
of the infant. [18] It is not well determined whether only leptin plays a causal role in early life fat
deposition prevention since recently it has been reported that also sOB receptor values could have a
part in the regulation of infant energy intake and infant growth and development [19].
The aim of this study is to measure leptin in mother and infant serum and in breast milk in order
to look for correlations between mother and infant BMI, their serum leptin values and breast milk
leptin concentration in early infancy.
2. Materials and Methods
2.1. Subjects
2.1.1. Infants
We enrolled 58 AGA healthy term infants who were admitted to the Department of Pediatrics
of the University of Turin, Regina Margherita Children’s Hospital, between June 2013 and July 2015.
The infants underwent blood tests during routine outpatient examinations. The study protocol
was approved by the local Ethical Committee at Ospedale Mauriziano—Ospedale Infantile Regina
Margherita (Ethical approval code: 4698, Protocol Version 1.0., 23 May 2013)—S. Anna Torino, and
infants’ parents gave their written consent.
Criteria for enrollment were as follows:
Age: children from 10 days of life to 6 months and 15 days of life;
Gestational age: from 38 to 40 weeks;
Birth characteristics: birth weight from 2500 g to 4500 g, APGAR equal or above 7 and absence of
neonatal diseases;
Nutrition: infants were fed with breast milk and they had not been weaned;
Clinical condition: at the time of blood sampling, infants did not have acute diseases and
were afebrile.
At the time of sampling, infants were exclusively breastfed and they had not received any
complementary feeding.
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2.1.2. Mothers
Fifty-eight caucasian mothers belonging to a rural or urban setting were enrolled with their
children. Regarding delivery, 19 mothers underwent a Caesarian section, while 39 had a spontaneous
delivery. Criteria for enrollment were as follows:
Mothers who delivered infants at 38 to 40 weeks’ gestation;
Mothers who were planning to exclusively breastfeed;
Mothers who signed written informed consent. Eligibility criteria for mothers were no maternal
medical complications, non-smoking mothers, normal response to a glucose tolerance test, no mastitis,
no prescribed medication, no digestive disorders.
2.2. BMI Measurement
Anthropometric measures were collected by two trained medical doctors with high intra-observer
and inter-observer reliability.
Infants were weighed with an electronic integrating scale (SECA, model 757, Vogel & Halke,
Hamburg, Germany), were measured in length with a stat meter and BMI was calculated as the ratio
of body weight (kg) to the square of length (m2). Mothers were weighed with a scale (Wunder, Italy),
measured in height with a stat meter (Holtain Limited, Crymych, Dyfed, UK) and BMI was calculated
as above.
2.3. Blood Sampling and Hormone Analysis
For the evaluation of leptin in serum, infants underwent four hours fasting before blood testing
usually at 8.00 in the morning. The sample was stored in a refrigerator for 60 min and was then put
in the refrigerated centrifuge at 4 ˝C at 4000 revolutions/min for 10 min. The serum obtained was
divided into 2 test tubes and was stored in a freezer at ´30 ˝C. The same procedure was carried out
for mothers.
Hormone analysis was conducted with a commercially available radioimmunoassay (RIA) kit
(LEP R-40, Multispecie-Leptin-RIA-Sensitive, Mediagnost, Reutlingen, Germany) with a sensitivity of
0.04 ng/mL (0.01 ng/mL with the procedure for increased sensitivity). The intra-assay variation was
less than 5%, and the inter-assay variation did not exceed 7.6%.
2.4. Breast Milk Sampling and Hormone Analysis
About 5 mL of foremilk samples were collected from the lactating women by hand expression
between 07:00 and 09:00. All milk samples were collected in tubes containing protease inhibitors
(Sigma-Aldrich Company Ltd., Dorset, England) and immediately frozen at ´20 ˝C. Samples were
thawed at 4–6 ˝C overnight and centrifuged at 2500 revolutions at 4 for 20 min to separate the fat
milk. Like serum leptin, 2 mL of skimmed breast milk leptin was analyzed with a RIA kit (LEP R-40,
Multispecie-Leptin-RIA-Sensitive, Mediagnost, Reutlingen, Germany) with a sensitivity of 0.04 ng/mL
(0.01 ng/mL with the procedure for increased sensitivity).
2.5. Statistical Analysis
Statistical analyses were conducted using SPSS software (version 21.0, SPSS, Inc., Chicago, IL,
USA). First, we performed univariate descriptive analysis. The normal distribution of the variables
was tested by the Shapiro-Wilk test. Continuous variables were expressed as median and interquartile
range (IQR). Data that were not normally distributed were analysed with the Mann-Whitney U test
and the Kruskal-Wallis test. Correlations are expressed by the Spearman correlation coefficient. All
tests were done with two tails, with a fixed significance alpha =5%.
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3. Results
Median leptin concentration was 3.9 ng/mL (IQR: 2.75) in infant serum, 4.27 ng/mL (IQR: 5.62)
in maternal serum and 0.89 ng/mL (IQR: 1.32) in breast milk (Tables 1 and 2). Statistical significance
was set at p < 0.05 and correlations were assessed using Spearman’s rho.





Age (days) 61 (76.5)
Gestational Age (weeks) 39 (1.5)
Birth Weight (kg) 3.275 (0.622)
Birth Length (cm) 49.45 (2.2)
Birth Cranial Circumference (cm) 34.05 (1.5)
Weight (kg) 5.130 (1.269)
Height (cm) 55 (3.25)
Cranial Circumference (cm) 39 (3)
BMI (kg/m2) 15.80 (2.47)
Serum Leptin (ng/mL) 3.9 (2.75)





Age (years) 28.5 (8)
Weight (kg) 64 (12.59)
Height (cm) 164 (0.064)
BMI (kg/m2) 24 (4.52)
Serum Leptin (ng/mL) 4.27 (5.62)
Breast Milk Leptin (ng/mL) 0.89 (1.32)
We evaluated the impact of potential confounders on breast milk leptin values and maternal
and infant serum leptin values. Particularly, we analyzed the effect of infant age and gender on
leptin concentrations.
Regarding infant age, we divided our cohort into three age groups at enrollment. We obtained a
median (IQR) leptin concentration of 2.87 (2.53) ng/mL in infant serum, 3.27 (5.38) ng/mL in maternal
serum and 0.83 (1.17) ng/mL in breast milk in group 1 (<2 months; n = 30), of 4.54 (9.89) ng/mL in
infant serum, 2.46 (1.49) ng/mL in maternal serum and 1.18 (1.29) ng/mL in breast milk in group 2
(<4 months; n = 18) and of 4.85 (7.51) ng/mL in infant serum, 3.21 (2.25) ng/mL in maternal serum
and 0.87 (3.55) ng/mL in breast milk in group 3 (4–6 months; n = 10). No significant differences in
breast milk and infant and serum leptin values were detected among the three groups (p > 0.05).
We divided patients by gender into two groups: as concernes males (n = 26), the median (IQR)
leptin concentration was 2.83 (2.16) ng/mL in infant serum, 3.27 (5.13) ng/mL in maternal serum
and 0.83 (1.32) ng/mL in breast milk; in females (n = 32), the median (IQR) leptin concentration was
4.79 (8.46) ng/mL in infant serum, 2.84 (2.14) ng/mL in maternal serum and 0.93 (2.59) ng/mL in
breast milk. With reference to gender, we did not observe any statistical differences in breast milk
leptin values and maternal and infant serum leptin values (p > 0.05).
3.1. Infant Serum Leptin Values and Infant BMI
Serum leptin values positively correlated with infants’ weight (p = 0.002; r = 0.2) and BMI (p = 0.001;
r = 0.213), as shown in Figure 1.
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Figure 1. Correlation between infant serum leptin values and infant Body Mass Index (BMI) and
weight. (a) Association between serum leptin values and BMI; (b) Association between serum leptin
values and weight.
The positive correlation between infant serum leptin values and both infant BMI and weight
suggests that leptin concentrations are directly related to body fat stores. This hormone is primarily
released by adipocytes in adipose white tissue [15]. This is the reason why infants with higher BMI
have higher serum leptin values [20].
3.2. Maternal Serum Leptin Values, Maternal BMI and Breast Milk Leptin
Maternal BMI positively correlated with maternal serum leptin levels (p = 0.000; r = 0.449) and
breast milk leptin (p = 0.004; r = 0.368) as illustrated in Figure 2. We found a significant correlation
between breast milk leptin and maternal serum leptin values (p = 0.026; r = 0.322) as shown in Figure 3.
(a) (b)
Figure 2. Correlation between maternal BMI and maternal serum leptin and breast milk leptin.
(a) Association between maternal BMI and maternal serum leptin values; (b) Association between
maternal BMI and breast milk leptin.
Figure 3. Correlation between maternal serum leptin and breast milk leptin.
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We found a positive and significant correlation between BMI and serum leptin values. As
shown for infants, mothers with higher BMI have higher serum leptin values, suggesting that leptin
concentration is directly proportional to body fat mass percentage [20].
Regarding breast milk, it is interesting that a positive correlation exists between maternal BMI
and leptin levels in breast milk [21]. It could be that not only breast milk leptin depends on the amount
produced by mammary epithelial cells, but also on the amount released from maternal body fat stores.
A significant correlation was observed between maternal serum leptin values and breast milk
leptin [22]. Also Weyermann et al. [23] observed that leptin concentration in breast milk correlated
positively with leptin in maternal serum.
3.3. Infant Serum Leptin Values, Maternal Serum Leptin Values and Breast Milk Leptin
We did not find any significant correlation between maternal and infant serum leptin values
(p > 0.05), suggesting that further studies are required to investigate the possible role of maternal
leptin in the regulation of infant metabolism [24]. Regarding breast milk leptin and infant serum leptin
values, we obtained a positive correlation, as illustrated in Figure 4 (p = 0.03; r = 0.285).
Figure 4. Correlation between breast milk leptin and infant serum leptin values.
The higher the breast milk leptin concentration is, the higher infant serum leptin values are. These
findings suggest a possible association between breast milk components and infant adiposity [18].
4. Discussion
This study presents data of a positive correlation between breast milk leptin and infant serum
leptin values. Furthermore, our study is strengthened by the fact that we found that breast milk
leptin directly correlates with maternal serum leptin values. Actually, we did not obtain a significant
association between maternal and infant serum leptin values. Regarding maternal and infant BMI,
we showed that breast milk leptin and maternal serum leptin values directly correlate with materal
BMI. In addition, we demonstrated a positive association between infant BMI and infant serum leptin
values. We evaluated the possible impact of infant age and gender on infant and maternal serum leptin
values and breast milk leptin concentrations. We did not obtain any significant differences in leptin
values among the created groups.
4.1. Serum Leptin Values and BMI
Leptin is mainly produced by adipocytes; thus its levels are strictly associated to body fat mass
percentage. During fasting, this hormone decreases; on the other hand, in overeating, its levels
increase [25]. Both in infants and their mothers, we found that this hormone correlates with BMI
and weight. Higher BMI correlates with higher serum leptin levels. It is known that people with an
elevated BMI have high serum leptin levels not only because they have a larger amount of fat mass,
but also because their adipocytes are bigger. What is more, Dusserre et al. showed that leptin values
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vary according to the type of adipose tissue that releases them: omental adipocytes express leptin
mRNA less than subcutaneous adipocytes [26].
4.2. Breast Milk Leptin and Maternal Serum Leptin Values
Casabiell et al. showed that leptin is transferred from maternal bloodstream to breast milk in
mice [16]. We found a positive correlation between breast milk leptin values and maternal serum
leptin ones. It is thus possible that leptin in breast milk depends not only on the amount produced by
mammary epithelial cells, but also on the amount in maternal bloodstream. It would be interesting to
evaluate if maternal leptin values represent a predictor for infant obesity [27].
4.3. Breast Milk Leptin and Infant Serum Leptin Values
Leptin receptors have been found on gastrointestinal epithelial cells, suggesting that this hormone
could be absorbed from infant mucosa and then transferred to infant bloodstream. The significant
correlation that we found between breast milk leptin and infant serum leptin values could indicate
that leptin in children is influenced by both infant fat stores and breast milk leptin. In previous studies,
we demonstrated that formula fed infants have lower leptin levels than breast milk fed ones [28]. Data
on the presence of leptin in infant formula are still controversial [29], however more investigations
are needed to detect if hormones present in breast milk have a beneficial effect on obesity later in
life [30,31].
4.4. Study Limitations
This study has several limitations. We could not assess the influence of leptin circadian variations
since we do not have daily access to serum leptin samples, nor were we able to assess daily changes in
breast milk leptin.
Moreover, we did not measure serum leptin at the same age time in all subjects enrolled.
However, baseline characteristics were similar among the infants in the study group.
Further, we were unable to measure fat mass at the same time of leptin sampling in mothers
and infants.
Finally, since this study is observational it is important to interpret our correlations with caution.
Our findings are consistent with the possibility that breast milk leptin affects infant health
later in life and opens new implications for research such as the role of breastfeeding and infant
metabolic response.
Therefore, a follow-up of our patients, based on these results, will help us build a stronger overall
evidence base and fill the gap in knowledge.
It is known that early nutrition plays an important role in the development of metabolic diseases
in adolescence and adulthood. It has been shown that breastfed infants are at lower risk to become
obese than formula-fed ones [32]. The positive correlation observed between maternal serum leptin
concentration and maternal BMI is strictly linked to breast milk leptin values, suggesting that the
amount of leptin in breast milk is influenced not only by mammary gland, but also by leptin released
from maternal fat storages [33]. Interestingly, in a previous study, we demonstrated that infant serum
leptin values are correlated to maternal BMI, thus showing that infants breast-fed by mothers with
high BMI receive higher amounts of leptin [34]. Children with obese mothers seem to be at higher risk
to become obese themselves [35]. The protective effect of breastfeeding against early childhood obesity
may differ with race and ethnicity [36].
Many factors related to breastfeeding may influence childhood weight outcomes and obesity such
as breastfeeding duration [37]; however, it should be considered that, ingesting high amounts of leptin,
infants with obese mothers become leptin resistant and have alterations in appetite regulation [7,9,38].
In animal models it has been shown that obese phenotype can be transmitted by mothers to the
following generations [39]. Since recently it has been observed that higher perinatal leptin is associated
with lower adiposity at 3 years of life [40], leptin could be a key to understand the relationship between
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maternal BMI and infant growth and development. Intersting data showed that breast feeding affects
infant’s self-regulation of milk intake during late infancy [41].
5. Conclusions
Understanding the determinants of infant body mass index is relevant for the study of childhood
obesity and the related risk of obesity in adulthood.
The existing data of the effects of breast milk leptin on infant growth and adiposity are
controversial. Growing evidence suggests that human milk may reduce the transfer of obesity from
mother to progenies and leptin is one of the possible factors involved.
In this study we investigated the possible correlations between maternal and infant serum leptin
values, breast milk leptin concentrations and infant and maternal BMI. We demonstrated a positive
correlation between infants’ serum leptin concentrations and both maternal and infant BMI.
Regarding breast milk leptin values, we obtained a positive association not only with maternal
BMI but also with maternal and infant serum leptin values.
There was no association between infant and maternal serum leptin concentrations.
Leptin is a peptide hormone produced by both adipocytes and mammary gland and it could be
considered a marker that may signify excess fat accumulation.
Overall, our findings show that breast feeding and maternal BMI could influence infant serum
leptin values. Further studies are needed to better elucidate the role of genetics on infant leptin
production and risk of obesity later in life.
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Abstract: The association between elevated body mass index (BMI) and risk of death has been
reported in many studies. However, the association between BMI and all-cause mortality for
hypertensive Chinese adults remains unclear. We conducted a post-hoc analysis using data from the
China Stroke Primary Prevention Trial (CSPPT). Cox regression analysis was performed to determine
the significance of the association of BMI with all-cause mortality. During a mean follow-up duration
of 4.5 years, 622 deaths (3.0%) occurred among the 20,694 participants aged 45–75 years. A reversed
J-shaped relationship was observed between BMI and all-cause mortality. The hazard ratios (HRs)
for underweight (<18.5 kg/m2), overweight (24.0–27.9 kg/m2), and obesity (ě28.0 kg/m2) were
calculated relative to normal weight (18.5–23.9 kg/m2). The summary HRs were 1.56 (95% CI,
1.11–2.18) for underweight, 0.78 (95% CI 0.64–0.95) for overweight and 0.64 (95% CI, 0.48–0.85) for
obesity. In sex-age-specific analyses, participants over 60 years of age had optimal BMI in the obesity
classification and the results were consistent in both males and females. Relative to normal weight,
underweight was associated with significantly higher mortality. Excessive weight was not associated
with increased risk of mortality. Chinese hypertensive adults had the lowest mortality in grade
1 obesity.
Keywords: obesity; body mass index; mortality; hypertension; China
1. Introduction
Obesity is a global epidemic issue that is highly prevalent in both developed and developing
countries; it affects people of both sexes and all ages, has adverse health consequences, accrues large
economic costs, and has negative social implications [1]. Body mass index (BMI), defined as weight in
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kilograms divided by the square of the height in meters, is commonly used in clinical practice to screen
for overweight and obesity and to guide weight loss recommendations. In China, an increasingly
large proportion of the population has a BMI ě 25 kg/m2, the standard definition of overweight [2].
Although obesity has been demonstrated to be associated with multiple non-communicable diseases,
including hypertension, type 2 diabetes, coronary heart disease, stroke and several cancers [3], the
association between BMI and all-cause mortality remains controversial: a direct association, a J-shaped,
a U-shaped, or a reversed J-shaped relationship have all been recently reported [4–8].
The World Health Organization (WHO) defines the following six categories based on BMI values:
<18.5 kg/m2 = underweight; 18.5 to 24.9 kg/m2 = normal weight; 25.0 to 29.9 kg/m2 = overweight;
30.0 to 34.9 kg/m2 = grade 1 obesity; 35.0 to 39.9 kg/m2 = grade 2 obesity; and ě40 kg/m2 =
grade 3 obesity [9]. These definitions of overweight and obesity are mainly based on criteria
derived from studies that involved populations of European origin. It has been suggested that
the associations of BMI with body composition and health outcomes may differ between Asian and
European populations [10]. The BMI cut-off points for overweight and obesity should be lower for
Asian populations than they are for European populations (suggested cut-off points for Asians are
ě23.0 kg/m2 for overweight and ě27.5 kg/m2 for obesity) [10]. However, a consensus statement
from the WHO concluded that the available data were not sufficient to support Asian-specific cut-off
points [10]. The Ministry of Health of the People’s Republic of China determined a reclassification of
BMI for Chinese adults that differs from the WHO classification: underweight (<18.5 kg/m2), normal
weight (18.5–23.9 kg/m2), overweight (24.0–27.9 kg/m2) and obesity (ě28.0 kg/m2) [11].
For decades, the prevalence of hypertension has been increasing in China, and by the year 2010 it
reached 20% [12]. During the period of 2005–2009, about 42% of Chinese adults aged 35–70 years were
hypertensive [12]. Although obesity is clearly regarded as a risk factor for developing hypertension, the
optimal BMI for middle-aged or elderly hypertensive Chinese remains unclear. Therefore, the objective
of this study was to evaluate the relationship between BMI and all-cause mortality in hypertensive
Chinese adults.
2. Materials and Methods
2.1. Data Sources
This post-hoc analysis utilizes data from the China Stroke Primary Prevention Trial (CSPPT), which
enrolled 20,702 subjects with primary hypertension in a multi-community, randomized, double-blind,
controlled trial to assess whether enalapril maleate and folic acid supplementation was more effective
in reducing risk of stroke than enalapril maleate supplementation alone. This study was conducted in
accordance with the principles of the Declaration of Helsinki. The Human Subjects Committee at the
Biomedical Institute of Anhui Medical University approved the study protocol. All patients provided
written informed consent prior to data collection.
2.2. Participants and Treatment
The methods and primary results of the CSPPT trial have been reported elsewhere [13]. Briefly, the
CSPPT was conducted from 19 May 2008 to 24 August 2013 in 32 communities in Jiangsu and
Anhui Provinces in China. Eligible participants were men and women aged 45–75 years old who
had hypertension, defined as seated resting systolic blood pressure (SBP) ě140 mmHg or diastolic
blood pressure (DBP) ě90 mmHg at both the screening and recruitment visit, or who were on
anti-hypertensive medication. The major exclusion criteria included history of physician-diagnosed
stroke, myocardial infarction (MI), heart failure, post-coronary revascularization, or congenital
heart disease.
The current analysis was designed to investigate the relationship between BMI and all-cause
mortality in this cohort. All-cause mortality included death due to any reason. After excluding eight
subjects with missing information on weight and height, the final analysis included 20,694 subjects.
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Participants contributed person-years from the date of recruitment until date of death or end of
follow-up (24 August 2013). BMI classifications as set according to the guidelines from the Ministry of
Health of the People’s Republic of China were used and included: underweight (<18.5 kg/m2), normal
weight (18.5–23.9 kg/m2), overweight (24.0–27.9 kg/m2) and obesity (ě28.0 kg/m2). At the initial
study visit trained research staff measured and recorded height (to the nearest 0.1 cm) and weight (to
the nearest 0.1 kg) for each participant. In addition, trained staff collected baseline demographic data,
medical history, and medication use. Cigarette smoking was classified into never, former, and current
smoker (defined as smoke at least one cigarette per day for more than one year). Alcohol drinking was
stratified into never, former and current drinker (defined as drink alcohol at least twice weekly for
more than one year). Education was categorized into illiterate (0 years of education), primary school
(1–6 years), and secondary school (>6 years) or above. Stress was defined as mild, moderate or severe
according to the participant’s personal evaluation.
2.3. Follow-Up and Outcomes
Patients were evaluated every three months for an average of five years to assess blood pressure
(BP), adherence to medication, and adverse outcomes including stroke, composite major cardiovascular
(CV) events and resultant death, and all-cause death. The study outcomes were adjudicated according
to standard criteria by a clinical end points committee.
2.4. Statistical Analysis
All participants were divided into four groups according to the Chinese classification for BMI
(<18.5, 18.5–23.9, 24.0–27.9, ě28.0 kg/m2). Baseline characteristics of all participants were compared
using the analysis of variance (ANOVA) for continuous variables and the χ2 test for categorical
variables. All-cause mortality was first assessed using the Kalpan-Meier method and log-rank tests,
and then multivariable Cox proportional-hazards regression models were applied to calculate hazard
ratios (HR) and 95% confidence intervals (CI) for the risk of all-cause mortality in each of the BMI
groups. Potential confounders were adjusted including sex, age, center, baseline and on-treatment
BP, smoking status, alcohol drinking, education, stress, fasting blood glucose (FBG), total cholesterol
(TC), triglycerides (TG), serum creatinine (SCr), homocysteine (Hcy) and albumin. Further stratified
analyses by subgroups including sex, age, center, smoking and alcohol drinking status, education,
stress and albumin levels were also explored by Cox proportional-hazards regression models to test for
consistency of results. All tests were two-sided, and p-values less than 0.05 were considered statistically
significant. All analyses were performed by EmpowerStats [14] and the statistical package R [15].
3. Results
3.1. Patient Characteristics
Baseline characteristics of all patients are presented in Table 1. Of the 20,694 participants, 59.0%
were female, and the mean age was 60.0 years (SD, 7.5 years), with a range from 45 to 75 years.
The mean BMI was 25.0 kg/m2 (SD, 3.4 kg/m2). Men had a lower of BMI 24.2 kg/m2 (SD, 3.7 kg/m2)
than women, who had a BMI of 25.4 kg/m2 (SD, 3.4 kg/m2). The percentages of underweight, normal
weight, overweight and obese were 2.5%, 39.1%, 38.9% and 19.5%, respectively. Higher BMI categories
were associated with younger age, female gender, better education, and higher levels of FBG, TC, TG,
albumin, and baseline and on-treatment blood pressure measurements. Lower BMI categories were
associated with higher HDL-C levels and current smoking status.
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Table 1. Baseline characteristics of the study participants by BMI categories 1.
Variables
BMI Categories, kg/m2
All Subjects <18.5 18.5–23.9 24.0–27.9 ě28.0 p-Value
Number (%) 20,694 526(2.5) 8083 (39.1) 8043 (38.9) 4042 (19.5)
Age, mean (SD), years 60.0 (7.5) 64.6 (6.7) 61.3 (7.4) 59.3 (7.5) 58.2 (7.4) <0.001
BMI, mean (SD), kg/m2 25.0 (3.7) 17.5 (0.8) 21.8 (1.4) 25.8 (1.1) 30.4 (2.2) <0.001
Male, No. (%) 8491 (41.0) 271 (51.5) 3863 (47.8) 3137 (39.0) 1220 (30.2) <0.001
Center, No. (%) <0.001
Anqing 5211 (25.2) 350 (66.5) 3119 (38.6) 1406 (17.5) 336 ( 8.3)
Lianyungang 15,483 (74.8) 176 (33.5) 4964 (61.4) 6637 (82.5) 3706 (91.7)
SBP, mean (SD), mmHg
baseline 166.9 (20.4) 164.3 (17.9) 166.0 (20.0) 167.1 (20.4) 168.4 (21.4) <0.001
on-treatment 139.4 (10.9) 138.8 (10.8) 138.9 (11.0) 139.4 (10.8) 140.4 (11.0) <0.001
DBP, mean (SD),mmHg
baseline 94.1 (11.9) 88.0 (11.4) 91.8 (11.7) 95.0 (11.6) 97.7 (11.9) <0.001
on-treatment 82.9 (7.5) 78.9 (7.7) 81.5 (7.4) 83.5 (7.2) 85.3 (7.2) <0.001
Pulse, mean (SD),bpm 73.6 (10.1) 74.0 (11.0) 73.6 (10.2) 73.5 (10.1) 73.8 (9.9) 0.53
Smoking status (%) <0.001
never 14,252 (68.9) 293 (55.7) 5015 (62.1) 5791 (72.0) 3153 (78.0)
former 1567 (7.6) 35 (6.7) 604 (7.5) 649 (8.1) 279 (6.9)
current 4867 (23.5) 198 (37.6) 2459 (30.4) 1601 (19.9) 609 (15.1)
Alcohol drinking (%) <0.001
never 14,265 (69.0) 343 (65.2) 5155 (63.8) 5665 (70.5) 3102 (76.8)
former 1458 (7.0) 52 (9.9) 609 (7.5) 540 (6.7) 257 (6.4)
current 4960 (24.0) 131 (24.9) 2313 (28.6) 1836 (22.8) 680 (16.8)
Education (%) <0.001
illiterate 13,221 (63.9) 365 (69.4) 5261 (65.1) 4999 (62.2) 2596 (64.3)
primary 3446 (16.7) 103 (19.6) 1468 (18.2) 1296 (16.1) 579 (14.3)
secondary or above 4015 (19.4) 58 (11.0) 1347 (16.7) 1745 (21.7) 865 (21.4)
Stress (%) 0.035
mild 12,578 (60.8) 289 (54.90) 4846 (60.0) 4960 (61.7) 2479 (61.4)
moderate 6921 (33.4) 204 (38.8) 2765 (34.2) 2627 (32.7) 1323 (32.8)
severe 1189 (5.7) 33 (6.3) 464 (5.7) 454 (5.6) 237 (5.9)
FPG, mean (SD), mmol/L 5.8 (1.7) 5.3 (1.6) 5.6 (1.6) 5.9 (1.8) 6.1 (1.7) <0.001
TC, mean (SD), mmol/L 5.5 (1.2) 5.0 (1.2) 5.4 (1.2) 5.6 (1.2) 5.7 (1.2) <0.001
TG, mean (SD), mmol/L 1.7 (1.2) 1.2 (0.5) 1.4 (0.8) 1.8 (1.0) 2.0 (1.8) <0.001
HDL-C, mean (SD), mmol/L 1.3 (0.4) 1.6 (0.4) 1.5 (0.4) 1.3 (0.3) 1.2 (0.3) <0.001
SCr, mean (SD), umol/L 66.0 (19.3) 67.6 (16.7) 67.3 (19.6) 65.6 (20.5) 64.0 (16.3) <0.001
Hcy, mean (SD), umol/L 14.5(8.4) 14.3 (7.7) 14.5 (8.1) 14.5 (8.4) 14.3 (8.9) 0.534
Albumin, mean (SD), g/L 49.0 (5.9) 47.57 (6.6) 48.57 (6.0) 49.34 (5.7) 49.34 (5.6) <0.001
Treatment (%) 0.832
Enalapril 10,352 (50.0) 271 (51.5) 4053 (50.1) 4025 (50.0) 2003 (49.6)
Enalapril-Folic Acid 10,342 (50.0) 255 (48.5) 4030 (49.9) 4018 (50.0) 2039 (50.4)
1 For the determination of p-values, two-sample t-tests for continuous variables, chi-square tests for categorical
variables. SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total
cholesterol; TG, triglycerides; SCr, serum creatinine; Hcy, homocysteine.
3.2. BMI and Mortality
The relationship between BMI and overall mortality for all patients with hypertension is shown
in Table 2. During a median follow-up period of 4.5 years (88,466.64 person-years), 622 deaths
occurred. Specifically, with increasing BMI, the all-cause mortality rate in underweight, normal weight,
overweight and obese groups was 7.8%, 3.9%, 2.4% and 1.8%, respectively. According to the BMI
category, the all-cause mortality rate per 1000 person-years was 17.63, 8.93, 5.76 and 4.24, respectively.
In a crude Cox proportional-hazards regression model, the HRs were 1.97 (95% CI, 1.42–2.73) for
underweight, 0.64 (95% CI, 0.54–0.77) for overweight and 0.47 (95% CI, 0.37–0.61) for obesity compared
with normal weight. In model II, after adjusting for sex, age, center, baseline and on-treatment BP,
smoking status, alcohol drinking, education, stress and serum biochemical measurements, the HRs
were 1.56 (95% CI, 1.11–2.18) for underweight, 0.78 (95% CI, 0.64–0.95) for overweight and 0.64 (95%
CI, 0.48–0.85) for obesity compared with normal weight.
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Table 2. Hazard ratios for all-cause mortality according to BMI status 1.
BMI kg/m2 N Event (%) Curde Rate
All-Cause Mortality
Model 1 p-Value Model 2 p-Value
Continuous 20,694 622 (3.0%) 7.03 0.90 (0.88, 0.92) <0.001 0.94 (0.91, 0.96) <0.001
<18.5 526 41 (7.8%) 17.63 1.97 (1.42, 2.73) <0.001 1.56 (1.11, 2.18) 0.010
18.5–23.9 8083 312 (3.9%) 8.93 1 1
24.0–27.9 8043 197 (2.4%) 5.76 0.64 (0.54, 0.77) <0.001 0.78 (0.64, 0.95) 0.012
ě28 4042 72 (1.8%) 4.24 0.47 (0.37, 0.61) <0.001 0.64 (0.48, 0.85) 0.002
1 Multivariable Cox proportional-hazards regression models were applied to calculate hazard ratios (HR) and
95% confidence intervals (CI) for the risk of all-cause mortality in each of the BMI groups. A BMI (kg/m2)
of 18.5–23.9 was used as the reference to estimate all HRs. Crude rates are all-cause mortality per 1000
person-years. Model 1: crude; Model 2: adjustment for sex, age, center, baseline and on-treatment BP, smoking
status, alcohol drinking, education, stress, fasting blood glucose, total cholesterol, triglycerides, serum creatinine,
homocysteine, albumin.
Figure 1 shows the Kaplan-Meier curves of the cumulative hazards of all-cause mortality stratified
by BMI categories. All-cause mortality between each of the four BMI groups was significantly different
(log-rank test, p < 0.001). With increased BMI, the cumulative mortality risk gradually decreased,
rendering the underweight group with the maximum mortality risk.
Figure 1. Kaplan-Meier curves of cumulative hazards of all-cause mortality stratified by BMI
categories (underweight <18.5, normal weight 18.5–23.9, overweight 24.0–27.9, obesity ě28.0 kg/m2).
log-rank test, p < 0.001.
Further stratified analyses were performed by important covariables including gender, center,
smoking status, alcohol drinking status, education, stress and albumin levels (Table 3). There were
no significant interactions in any of the subgroups (p > 0.05 for all comparisons). The beneficial effect
appeared to be more pronounced in participants older than 60 years.
We subsequently repeated the analysis using narrower BMI categories (<18.5, 18.5–19.9, 20.0–21.9,
22.0–23.9, 24.0–25.9, 26.0–27.9, 28.0–29.9, 30–34.9, ě35 kg/m2) to delineate the relationship between
BMI and mortality with greater precision. Compared to patients with normal BMI (between 22.0
and 23.9 kg/m2), patients with grade 1 obesity (30–34.9 kg/m2) had the lowest risk of all-cause
mortality (Figure 2). However, all-cause mortality increased drastically for patients with severe obesity
(ě35 kg/m2).
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Figure 2. Hazard ratios for all-cause mortality according to narrower BMI categories. A BMI (in kg/m2)
of 22.0–23.9 was used as the reference to estimate all HRs. Adjustment for sex, age, center, baseline
and on-treatment BP, smoking status, alcohol drinking, education, stress, fasting blood glucose, total
cholesterol, triglycerides, serum creatinine, homocysteine, albumin.
4. Discussion
Our post-hoc analysis of this Chinese population with primary hypertension in the CSPPT showed
the association between BMI and all-cause mortality followed a reversed J-shaped curve with increased
risk at low and high BMI status. Even after adjusting for potential confounders, the results were similar.
Compared to normal weight, the HRs were 1.56 (95% CI, 1.11–2.18) for underweight, 0.78 (95% CI,
0.64–0.95) for overweight and 0.64 (95% CI, 0.48, 0.85) for obesity. In this population, the optimal BMI
was grade 1 obesity (30–34.9 kg/m2). Stratified analyses were consistent in all important covariables.
Moreover, overweight or obese patients older than 60 years showed the most benefit.
Many studies conducted on different populations showed a U-shaped or J-shaped association
between BMI and all-cause mortality, which is consistent with our results when applied to the
underweight participants only [4–8]. In these studies, the population age distribution and whether
subgroup analyses were performed by age group might be two major reasons for the controversial
results. Janssen et al. found that BMI was inversely associated with mortality risk in elderly Asians [16].
Compared to middle-aged adults, some previous studies found that the optimal BMI among the elderly
shifted upwards [17,18]. This finding is similar to what has been observed in other Asian regions such
as Taiwan [19], Hong Kong [20], India and Bangladesh [8], among others [4,5,7]. Many of the elderly
participants from these studies were residents of live-in care facilities, and/or were diagnosed with
a health ailment such as hypertension, or were from undeveloped communities compared with urban
residents. However, the optimal range of BMI proposed among the elderly varies among studies.
As the world’s population ages and the number of hypertensive adults rises, our findings are important
for health care professionals and policy-makers whose decisions affect elderly hypertensives.
Several potential explanations for the observed obesity paradox seen in our study exist.
Firstly, reverse causality is a major problem in observational studies. For example, weight loss
is classically experienced prior to death among the elderly who are ill. Secondly, socioeconomic status
could confound the association between BMI and the risk of death, as people from less well-developed
countries with a high BMI are more likely to have a higher socioeconomic status, allowing them
better access to health care than those with a lower BMI [8]. However, the participants in our study
are from rural communities, and a similar relation between BMI and socioeconomic status exists for
them. Thirdly, in a meta-analysis of patients with existing coronary artery disease, those classified as
121
Nutrients 2016, 8, 384
overweight and obese had longer survival rates, potentially because of the benefit from the body’s
reservation of nutrition within the population of elderly suffering from illness [21]. Fourthly, intensive
pharmacotherapy could play a large role in the reverse J-shaped relationship. It has been demonstrated
that patients with intensive pharmacotherapy are more likely to reach targets for secondary prevention.
In population studies conducted in the USA and Canada, obese patients are more likely to meet
targets for BP, lipids, and glycemic control than normal-weight patients [22]. In addition, hypertensive
participants are relatively less healthy compared to the general population, although in our study
we excluded patients with stroke and MI. Mary et al. found that among elderly Chinese with poor
health status, there was an inverse, dose-response relationship between BMI and mortality, and this
relationship was more pronounced in the group with the most morbidity compared to subjects of
normal weight [23]. Another interpretation is that BMI can be a marker of adiposity, fitness and
muscle mass, so that BMI maintenance in older people serves as an overall marker of health. Song et al.
accessed the sex-age-specific association between BMI and all-cause mortality in the general population,
and showed that the optimal BMI increased according to age and the trend was consistent in both
males and females [24]. Similarly, Woo et al. found that in older elderly (aged over 75 years), a higher
BMI was a protection from mortality [17].
Our study also has several limitations. Firstly, our participants were all middle-aged or
elderly hypertensives; therefore, the result of this study cannot be generalized to all populations.
Secondly, with the strict exclusion of the history of cardiovascular disease, cardiovascular cause of
death counted for only 14% of all-cause death, which is less than other studies conducted on Chinese
hypertensive adults. The association between BMI and a specific cause of death cannot be analyzed.
Thirdly, in the current study, relatively few elderly were ě30 kg/m2 (10% of total subjects) and
ě35 kg/m2 (1%); thus, the impact of obesity cannot be adequately assessed. Moreover, although we
have excluded subjects with a baseline diagnosis of coronary heart disease, stroke, cancer, or acquired
organic diseases, some preexisting illness may modify the association between BMI and mortality risk.
However, according to our investigation, after excluding those subjects with no history of disease at
baseline and who survived the first two years of follow-up, the BMI and all-cause mortality association
was consistent with all 4.5 years of this study.
5. Conclusions
In conclusion, this study revealed a reversed J-shaped association between BMI and all-cause
mortality in Chinese hypertensive adults. Relative to normal weight, underweight was associated with
significantly higher mortality. Excessive weight was not associated with increased risk of mortality.
A BMI classification of grade 1 obesity for Chinese hypertensive adults without stroke or MI showed
the lowest mortality. Additional large-scale prospective studies with well-controlled confounding
factors are needed to further address this important public health issue.
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Abstract: Adipose tissue (AT) expansion is the result of two processes: hyperplasia and hypertrophy;
and both, directly or indirectly, depend on the adipogenic potential of adipocyte precursor cells
(APCs). Glucocorticoids (GCs) have a potent stimulatory effect on terminal adipogenesis; while their
effects on early stages of adipogenesis are largely unknown. In the present work, we study, in a
model of high GC levels, the adipogenic potential of APCs from retroperitoneal AT (RPAT) and its
relationship with RPAT mass expansion. We employed a model of hyper-adiposity (30- and 60-day-old
rats) due to high endogenous GC levels induced by neonatal treatment with L-monosodium glutamate
(MSG). We found that the RPAT APCs from 30-day-old MSG rats showed an increased adipogenic
capacity, depending on the APCs’ competency, but not in their number. Analyses of RPAT adipocyte
diameter revealed an increase in cell size, regardless of the rat age, indicating the prevalence of a
hypertrophic process. Moreover, functional RPAT alterations worsened in 60-day-old rats, suggesting
that the hyperplastic AT expansion found in 30-day-old animals might have a protective role. We
conclude that GCs chronic excess affects APCs’ adipogenic capacity, modifying their competency. This
change would modulate the hyperplastic/hypertrophic balance determining healthy or unhealthy
RPAT expansion and, therefore, its functionality.
Keywords: retroperitoneal adipose tissue; adipogenesis; stromal vascular fraction cells; cell
determination; adipogenic competency
1. Introduction
Glucocorticoids (GCs) have several effects on adipose tissue (AT) biology: among others, they
regulate terminal adipocyte differentiation, AT endocrine function and lipogenic-lipolysis balance [1–3].
Some of these effects are more predominant on visceral (VAT) rather than on subcutaneous (SCAT)
AT function [4]. One clear example is the Cushing’s syndrome (CS) phenotype, mainly characterized
by high GC levels in blood and increased VAT rather than SCAT mass [5]. Other features of CS,
some of them shared by the human metabolic syndrome (MS) phenotype, are the presence of VAT
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hypertrophic adipocytes, altered lipid metabolism and impaired adipokine secretion [6]. The existence
of these alterations suggests that GCs have a pivotal role in the pathogenesis of central obesity and the
associated alterations seen in the CS phenotype.
Neonatal i.p. administration of the neurotoxin monosodium L-glutamate (MSG) in rodents
causes neuronal loss, mainly at the hypothalamic arcuate nucleus level [7], triggering a failure in
hypothalamus-pituitary-adrenal axis regulation, which results in high plasma GC levels [8]. Because
of this reason, the MSG treatment has been widely used to generate animal models resembling that of
the human CS phenotype. We have extensively used the MSG rat model, which is characterized by
increased VAT mass with hypertrophic adipocytes and an altered peripheral pattern of adipokines [8,9].
It is generally accepted that the ability of an AT depot to expand its mass depends on two
processes: the generation of new adipocytes (adipogenesis) and the hypertrophy of mature AT cells. It
has been proposed [10] that at the AT level, hyperplasia contributes to maintaining a pool of small
and functional adipocytes, thus preventing the development of metabolic alterations associated with
hypertrophic obesity [11]. Indeed, adipocyte hypertrophy is associated with cell dysfunction, such as
insulin resistance [12] and changes in the adipokine secretion pattern [13,14].
During the adipogenic process, adipose precursor cells (APCs) differentiate into mature adipocytes
in two sequential steps: commitment of mesenchymal stem cells (MSCs) to APCs, acquiring their
adipogenic potential and restricting them to the adipocyte linage, followed by terminal adipocyte
differentiation [15]. CD34 is a cell surface antigen that distinguishes between adipogenic and
non-adipogenic cell subpopulations in the stromal vascular fraction (SVF) of the AT [16]. This
CD34+ subpopulation expresses almost exclusively the transcriptional factor Zinc finger protein
423 (Zfp423) [17], which in turn activates the basal expression of cell peroxisome proliferator-activated
receptor (PPAR)-γ2, a key pro-adipogenic signal that assures APCs conversion into adipocytes [18].
The differential expression of both transcriptional factors determines the competency of APCs, that is,
the cell’s ability to differentiate into adipocytes after the addition of defined stimuli [15].
GCs are one of the most important cell differentiation inducers through their inhibitory effect on
Preadipocyte Factor 1 (Pref-1) and Wingless-type MMTV integration site family member 10b (Wnt-10b)
expression [19–21]. Both, Pref-1 and Wnt-10b, are highly expressed in preadipocytes and absent in
mature adipocytes [22,23]. In vitro experiments with the preadipocyte cell line 3T3-L1 have shown
that Pref-1 is an early target for dexamethasone (DXM) action and that its expression decreases with
high DXM concentrations, at the same time that adipocyte differentiation increases [19]. Similarly,
in vivo and in vitro studies demonstrated that the inhibition of the Wnt/b-catenin signaling pathway
by methylprednisolone or DXM, respectively, can promote adipocyte differentiation [21,24]. Several
studies show that GCs can affect adipogenesis through their binding to mineralocorticoid (MR) and/or
glucocorticoid (GR) receptors [25–27], although the contribution of MR and GR in mediating GCs’
adipogenic effect has not been fully understood.
While the activity of GCs on adipocyte terminal differentiation has been extensively studied, the
effect of chronic GC exposure of SVF cells remains almost unexplored. Using adult male MSG rats, it
has been previously demonstrated that adipogenesis is inhibited as a consequence of long-term GC
exposure of SVF cells, thus contributing to hypertrophic retroperitoneal AT (RPAT) mass expansion [28].
The present study focuses on the APCs’ adipogenic potential during in vivo RPAT mass expansion
under an earlier chronic GCs circulating excess.
2. Materials and Methods
2.1. Animals and Treatment
Sprague-Dawley newborn pups were i.p. injected with either 4 mg/g of body weight (BW) MSG
(Sigma Chemical CO., St. Louis, MO, USA) dissolved in sterile 0.9% NaCl or 10% NaCl (litter-mate
controls; CTR) on alternate days between 2 and 10 days of age [9]. CTR and MSG male rats were
used for experimentation at 30 days of age. Additional groups of rats at 60 days of age were used for
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a set of comparative experiments (SVF cell composition analysis by flow cytometry and adipocyte size
measurements, as described below). Animals under non-fasting (basal) conditions (between 08:00 a.m.
and 09:00 a.m.) were euthanized, and trunk blood was collected into Ethylenediaminetetraacetic
acid (EDTA)-coated tubes. After centrifugation (3000 rpm for 15 min at 4 ˝C), plasma samples
were kept frozen (´20 ˝C) until metabolite measurements. Retroperitoneal adipose tissue (RPAT)
pads were aseptically dissected, placed into sterile conic tubes containing 10 mL sterile Dulbecco’s
Modified Eagle’s Medium-Low Glucose (1 g/L) (DMEM) and immediately processed as describe
below (Section 2.3). Animals were euthanized according to protocols for animal use, in agreement
with the National Institutes of Health (NIH) Guidelines for the care and use of experimental animals.
All experiments were approved by our Institutional Animal Care Committee (ID 03-05-12).
2.2. Plasma Measurements
Circulating levels of leptin (LEP), insulin (INS) and corticosterone (CORT) were determined
by specific radioimmunoassays (RIAs) developed in our laboratory as previously validated and
described [8]. LEP (standard curve 0.05–25 ng/mL) coefficients of variation (CV) intra- and inter-assay
were 4%–7% and 9%–11%, respectively. INS (standard curve 0.08–10 ng/mL) CVs intra- and inter-assay
were 3%–7% and 8%–11%, respectively. CORT (standard curve 0.05–50 μg/dL) CVs intra- and
inter-assay were 4%–6% and 8%–10%, respectively. Peripheral glucose (Glu) and triglyceride (TG)
levels were measured using commercial kits (Wiener Laboratory, Rosario, Argentina).
2.3. RPAT SVF Cell and Adipocyte Isolation
Fresh RPAT pads were dissected, weighed and digested with collagenase as previously
reported [29]. Briefly, fat tissues were minced and digested using 1 mg/mL collagenase solution
in DMEM (at 37 ˝C, for 1 h). After centrifugation (at 1000 rpm for 15 min), floating mature
adipocytes were separated and reserved for adipocyte size analyses. The SVF cell-pellet was
collected, filtered (in a 50-μm mesh nylon cloth) and washed with DMEM (ˆ3). SVF cells
were then resuspended in DMEM supplemented with 10% (vol/vol) fetal bovine serum (FBS),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 20 nM), 100 IU/mL penicillin and
100 μg/mL streptomycin.
2.4. Adipocyte Size Analysis
The size of the isolated fat cells was measured as previously described [30], with minor changes.
Briefly, a 50–150-μL aliquot from the top layer obtained as previously described (Section 2.3) was
added to 450 μL DMEM. Five to ten microliters from the cell suspension were placed into the Neubauer
chamber and coverslipped. Five representative pictures from each sample were taken using a Nikon
Eclipse 50i microscope equipped with a camera (Nikon Digital Sight D5-U3, Melville, NY, USA). Cell
diameters were measured with image analysis software (Image ProPlus6.0, Rockville, MD, USA).
Values below 25 μm were discarded as they can be considered lipid droplets. The values were
recorded and assigned to groups differing by 10 μm in diameter, creating a histogram with 10-μm bins.
Histograms were used to determine whether the distribution of adipocyte diameters was normal or
binomial and to assess the presence of different sized adipocyte subpopulations. We measured an
average of 500–600 cells per site to calculate average adipocyte size.
2.5. SVF Cell Composition Analysis by Flow Cytometry
SVF cells from RPAT pads from CTR and MSG animals were isolated, and at least 2 ˆ 105 cells
(in 100 μL Phosphate-buffered saline (PBS)/0.5% Bovine Serum Albumin (BSA)) were incubated
with fluorescent antibodies or respective isotype controls (1/50 diluted, for 1 h at 4 ˝C). After
washing steps, flow cytometry was analyzed using a FACSCalibur flow cytometer (Becton Dickinson
Biosciences, San Jose, CA, USA). A combination of cell surface markers was used to identify
APCs as: CD34+/CD45´/CD31´ [31]. The conjugated monoclonal antibodies used were: anti-rat
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CD34:PE (PE: phycoerythrin), anti-rat CD45:FITC (FITC: fluorescein isothiocyanate) and anti-rat
CD31:FITC (1 μg/1 ˆ 106 cells, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Samples were
analyzed using CellQuest Pro (Becton-Dickinson, San Jose, CA, USA) and FlowJo software (TreeStar,
San Carlo, CA, USA).
2.6. RPAT SVF Cell Culture and Proliferation
RPAT SVF cells from CTR and MSG groups were seeded (2 ˆ 104 cells/cm2) in 24-well plates
(Greiner Bio-One, Kremsmünster, Austria) and cultured in DMEM supplemented with 10% (v/v) FBS
and antibiotics at 37 ˝C in a 5% CO2-atmosphere [29]. Cells were left in culture to proliferate for up to
9 days (proliferation day: Pd 9). Every 24 h, cells (4 wells per day) were washed (ˆ1) with PBS buffer,
and 0.25% (w/v) trypsin solution (dissolved in PBS-EDTA) was added for 2–3 min at 37 ˝C; the cell
suspension was then collected, and the cell number was determined in a Neubauer chamber.
2.7. Cell Differentiation Assay
Proliferating CTR and MSG SVF cells (having reached 70%–80% confluence after 5–6 days of
culture) were induced to differentiate by the addition of a differentiation mix containing 5 μg/mL
INS, 0.25 μM DXM, 0.5 mM 3-isobutyl-L-methylxanthine (IBMX) in DMEM-HEPES, supplemented
with 10% FBS and antibiotics [29]. After 48 h, media were removed and replaced with fresh media
containing 5 μg/mL INS, 10% FBS and antibiotics (DMEM + INS). Cell samples were harvested
on different differentiation days (Dd) and processed for several determinations, as described below.
Medium samples of Dd 10 were kept frozen at ´20 ˝C until the measurement of LEP concentrations
(Section 2.8.3).
2.8. Determinations
2.8.1. RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from cells of both groups by the TRIzol extraction method (Invitrogen,
Life Tech., Carlsbad, CA, USA). Total RNA was reverse-transcribed using random primers (250 ng) and
RevertAid Reverse Transcriptase (200 U/μL, Thermo Scientific, Vilnius, Lithuania). Two microliters of
cDNA were amplified with HOT FIRE Pol EvaGreen qPCR Mix Plus (Solis BioDyne, Tartu, Estonia)
containing 0.5 μM of each specific primer, using the LightCycler Detection System (MJ Mini Opticon,
Bio-Rad, CA, USA). PCR efficiency was near 1. Expression levels were analyzed for β-actin (ACTβ,
reporter gene), adiponectin (Adipoq), GR, Leptin (Ob), MR, PPAR-γ2, CCAAT/enhancer binding
protein alpha (C/EBPα), Pref-1, Wnt-10b and Zfp423 (the designed primers are shown in alphabetical
order in Table 1). Relative changes in the expression level of one specific gene (ΔΔCt) were calculated
by the ΔCt method.
2.8.2. Immunofluorescence Assay
CTR and MSG SVF cells were cultured in cover glasses and differentiated as mentioned before.
On Dd 4, when it was previously detected that PPARγ2 reaches its highest expression [28], cells were
fixed with 10% formalin (for 10–15 min), rinsed twice with PBS and treated with Triton 0.2% for 15 min.
Subsequently, cells were incubated overnight with primary antibody PPAR-γ (2 μg/0.1 mL, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). For visualization, we used secondary antibody Alexa-Fluor
594 labeled (Invitrogen Life Technologies, Carlsbad, CA, USA), and the nucleus staining was performed
with Vectashield (Vector Laboratories, Burlingame, CA, USA) with 41,6-diamidino-2-phenylindole
(DAPI). Immunostaining of the negative control was performed (elimination of primary antibody),
which did not show any antiserum immunolabeling. The percentage of PPAR-γ positive cells was
expressed in relation to the total number of cells (by counting DAPI stained nucleus, 300–400 total
cells per layer at 40ˆ magnification). Immunoreactivity was visualized using a Nikon Eclipse 50i
microscope equipped with a Nikon Digital Sight D5–U3 camera (Nikon Instruments Inc., Melville,
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NY, USA) and NIS-Elements software (Nikon Instruments Inc., Melville, NY, USA). An image editing
software program, Adobe Photoshop CS3 (Adobe Systems, San Jose, CA, USA) was used to adjust the
contrast and brightness of microphotographs.
Table 1. Primers used for real-time polymerase chain reaction (PCR) analysis.









Glucocorticoid Receptor (GR) se, TGCCCAGCATGCCGCTATCG NW_047512 170as, GGGGTGAGCTGTGGTAATGCTGC
Mineralocorticoid Receptor (MR) se, TCGCTCCGACCAAGGAGCCA NM_013131 193as, TTCGCTGCCAGGCGGTTGAG
Leptin (Ob) se, GAGACCTCCTCCATCTGCTG NM_013076 192as, CTCAGCATTCAGGGCTAAGG
Peroxisome proliferator-activated
receptor gamma 2 (PPAR-γ2)
se, AGGGGCCTGGACCTCTGCTG
NW_047696 185as, TCCGAAGTTGGTGGGCCAGA
Preadipocyte Factor 1 (Pref-1) se, TGCTCCTGCTGGCTTTCGGC NM_053744 113as, CCAGCCAGGCTCACACCTGC
Wingless-type MMTV integration
site family member 10b (Wnt-10b)
se, AGGGGCTGCACATCGCCGTTC
NW_047784 175as, ACTGCGTGCATGACACCAGCAG
Zinc finger protein 423 (Zfp423) se, CCGCGATCGGTGAAAGTTG NM_053583.2 121as, CACGGCTGGATTTCCGATCA
Rat-specific primers for real-time PCR are listed in alphabetical order. se: sense; as: anti-sense; GBAN: GenBank
Accession Number; amplicon length in bp.
2.8.3. Leptin Measurement
Medium LEP concentration was determined by specific RIA developed in our laboratory [32].
In this assay, the standard curve ranged between 0.05 and 25 ng/mL, with coefficients of intra- and
inter-assay variation of 4%–7% and 9%–11%, respectively.
2.8.4. Cellular Lipid Content
Cell on Dd 10 were washed with PBS and fixed with 10% formalin (for 10–15 min) in PBS. Then,
cells were quickly washed with PBS and stained for 1 h with Oil-Red O (ORO) solution (2:3 vol/vol
H2O:isopropanol, containing 0.5% ORO) [33]. After staining, cells were washed (ˆ3 with PBS), and
the dye from lipid droplets was extracted by adding 200 μL isopropanol (10 min). To quantify cell lipid
content, sample OD was obtained at 510 nm in a spectrophotometer. Remaining cells were digested
with 200 μL 0.25% trypsin solution in PBS-EDTA, at 37 ˝C for 24 h and centrifuged at 8000ˆ g for 15 s.
The OD of supernatants was read at 260 nm for DNA quantification, and cell lipid content (measured
by ORO and expressed in OD units) was then expressed by the corresponding cell DNA content.
2.8.5. Cell Differentiation and Maturation
On Dd 10, differentiated cells were fixed with 10% formalin solution for 1 h at room temperature
and then stained using the Papanicolaou technique. The percentage of differentiated cells was
calculated by counting the total number of cells and that of cells containing lipid droplets, when
visualized in a light microscope (after counting 200–250 total cells per layer, at 40ˆ magnification).
Lipid-containing cells were assigned to 3 graded stages of maturation according to the nucleus position:
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stage I (GI, central), stage II (GII, between central and peripheral) and stage III (GIII, completely
peripheral) [34]. The percentage of cells corresponding to different maturation stages was expressed in
relation to the total number of differentiated cells. Image analysis was assessed using a using a Nikon
Eclipse 50i microscope equipped with a camera Nikon Digital Sight D5–U3 (Nikon Instruments Inc.,
Melville, NY, USA) and image analysis software (Image ProPlus 6.0, Rockville, MD, USA).
2.9. Statistical Analysis
Results are expressed as mean values ˘ SEM. Data were analyzed by ANOVA (one-way) followed
by Fisher’s test. To determine the differential effect of the treatment according to age, ANOVA
(two-way) followed by the Bonferroni post-test were performed. For comparison of adipocyte size
populations between groups, the non-parametric Mann–Whitney test was used. The normal or
binomial distribution of adipocyte size data was determined by the Kruskal–Wallis test, followed
by the Mann–Whitney test. In all cases, p-values lower than 0.05 were considered statistically
significant. All statistical tests were performed using GraphPad Prism 6.0 (GraphPad Software Inc.,
San Diego, CA, USA).
3. Results
3.1. The MSG Rat Phenotype
Thirty-day-old MSG rats displayed lower BW (Table 2) and significantly higher LEP and CORT
levels, as well as increased RPAT adipocyte diameter and RPAT/100 g of BW (Figure 1). Glu, INS
and TG plasmatic levels remained similar to CTR litter-mate values (Table 2). As we have previously
shown [28], 60-day-old MSG rats showed the same altered parameters as 30-day-old MSG rats (Table 2
and Figure 1), but when we compared all of these parameters in both ages, we found that the circulating
levels of LEP and CORT, as well as RPAT/100 g of BW and RPAT adipocyte hypertrophy increased in
MSG rats during development (Figure 1).
Table 2. Metabolic parameters of control (CTR) and Monosodium L-glutamate (MSG) treated rats.
CTR 30-Day-Old MSG 30-Day-Old CTR 60-Day-Old MSG 60-Day-Old
Body Weight (BW, g) 78.84 ˘ 1.78 71.23 ˘ 1.56 * 312.34 ˘ 9.32 a,b,c 242.50 ˘ 5.47 *,a,b,c
Insulin (INS, ng/mL) 0.25 ˘ 0.02 0.31 ˘ 0.04 2.01 ˘ 0.05 a 2.42 ˘ 0.35 a
Glucose (Glu, g/L) 1.26 ˘ 0.03 1.27 ˘ 0.03 1.17 ˘ 0.03 1.14 ˘ 0.06
Triglyceride (TG, g/L) 0.82 ˘ 0.06 1.19 ˘ 0.11 1.16 ˘ 0.14 1.24 ˘ 0.22
BW and plasma levels of INS, Glu and TG in CTR and MSG rats at 30 (n = 20 rats per group) and 60 days of
age (n = 10 rats per group). Values are the means ˘ SEM. * p < 0.05 vs. CTR values of similar age. Two-way
ANOVA: a those parameters significantly affected by age; b those parameters significantly affected by treatment;
c a significant synergic effect of MSG treatment and age.
3.2. Proliferation Capacity of SVF Cells from MSG Rats at 30 Days of Age
After seeding, the proliferation capacity of RPAT SVF cells from both groups was assessed by
counting the cell number every 24 h and recording those numbers throughout the proliferation period
(Pd 1–Pd 9). Data indicated a significant (p < 0.05) decrease in the proliferation capacity of cells
from the MSG group, which was noticed at the end of the proliferation period (158,083 ˘ 13,086
and 103,312 ˘ 17,028 cells/well on Pd 8 and 177,020 ˘ 11,097 and 115,688 ˘ 15,433 cells/well on
Pd 9, in CTR and MSG groups, respectively). Moreover, the slopes of these curves were as follows:
21,722 ˘ 1457 and 16,628 ˘ 2055 cells per day, in CTR and MSG cell groups, respectively (p < 0.05).
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Figure 1. Comparison of hormone levels and retroperitoneal adipose tissue (RPAT) parameters from
CTR and MSG rats. Corticosterone (CORT) and leptin (LEP) plasma levels; RPAT/100 g of BW and
RPAT adipocyte size from rats at 30 and 60 days of age. Values are means ˘ SEM. * p < 0.05 vs. CTR
values for similar ages. Two-way ANOVA: a those parameters significantly affected by age; b those
significantly affected by treatment; c a significant synergic effect of MSG treatment and age.
3.3. Enhanced Terminal Differentiation of SVF Cells from MSG Rats at 30 Days of Age
On Dd 4, MSG cultured SVF cells showed a higher percentage of PPARγ positive cells (Figure 2A)
in addition to enhanced PPARγ2 expression on the same culture day (Figure 2B). Intracellular lipid
content and cell LEP release into the culture medium on Dd 10 were evaluated as parameters of
adipocyte differentiation. As shown in Figure 3, MSG adipocytes displayed significantly (p < 0.05 vs.
CTR values) higher lipid content (Figure 3A,B) and LEP release (Figure 3C). The expression of marker
genes of fully-differentiated cells (on Dd 10), such as Ob, Adipoq, C/EBP-α and PPAR-γ2 mRNAs,
were significantly (p < 0.05) higher in MSG than in CTR cells; conversely, no difference was noticed in
Adipoq mRNA concentration (Figure 3D). Additionally, we determined the extent of adipogenesis
in vitro by quantifying the percentage of differentiated cells at the end of the differentiation period
(Dd 10). Our results showed no differences among groups for this parameter (53.99% ˘ 1.90% and
50.29% ˘ 2.8% of differentiated cells in the CTR and MSG groups, respectively; n = 3 independent
experiments). However, differences in the percentage of cells at different maturation degrees were
found. Indeed, MSG specimens showed a higher percentage of cells at an advanced maturation degree
(GII and GIII; see Figure 3E,F), thus indicating that MSG cells maturate faster than CTR cells.
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Figure 2. MSG cells display higher expression of Peroxisome proliferator-activated receptor (PPAR)γ2
during in vitro differentiation. (A) Percentage of PPARγ positive cells related to the total cell number
counted by nucleus 41,6-diamidino-2-phenylindole (DAPI) staining; (B) mRNA cell expression levels
of PPARγ2 in CTR and MSG stromal vascular fraction (SVF) cells on Differentiation Day (Dd) 4 (AU:
arbitrary units). Values are the means ˘ SEM (n = 5/6 different experiments). * p < 0.05 vs. CTR
values; (C) Representative images of DAPI nucleus staining (blue), PPARγ positive cells (red) and
merged image of CTR and MSG cells on Dd 4 (40ˆ magnification, scale bar at 20 μm). The insert shows
cytoplasmatic or nuclear PPARγ localization.
3.4. Age-Dependent Effect of GCs on APCs’ Competency and Adipogenic Potential
Taking into account the differences found in the adipogenic capacity of MSG cells, the expression
levels of several pro- and anti-adipogenic factors expressed by SVF cells were analyzed. MSG RPAT
SVF cells expressed significantly (p < 0.05) lower levels of Pref-1 and Wnt-10b (Figure 4), whereas
the expression of MR and GR genes remained the same. These results are different from those
previously found for SVF cells from MSG rats at 60 days of age, where anti-adipogenic factors
showed higher expression and the MR mRNA level was lower [28]. Similarly, the expression levels of
Zfp423 and PPARγ2 were higher in SVF cells from MSG rats at 30 days of age (Figure 4), in contrast
with the corresponding values previously found for SVF cells from MSG rats at 60 days of age [28].
Taken together, these data clearly indicate that high GC plasmatic levels induce a different effect
on APCs’ adipogenic competency, a fact probably dependent on the differential cell pattern of MR
gene expression.
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Figure 3. MSG cells exhibit increased in vitro adipocyte differentiation. (A) Macroscopic (left panel)
and microscopic (right panel, magnification 10ˆ, scale bars at 200 μm) views of the Oil Red O-stained
dishes; (B) Quantification of intracellular lipid accumulation; (C) cell leptin secretion (n = 5/6 different
experiments with 10/12 wells per day per experiment) and (D) cell mRNA expression levels of
PPAR-γ2, CCAAT/enhancer binding protein (C/EBP)α, Leptin (Ob) and Adiponectin (Adipoq) on
Differentiation day (Dd) 10 of SVF cells isolated from RPAT pads of 30 day-old CTR and MSG male rats
(n = 5/6 different experiments) (AU: arbitrary units); (E) Percentages of cells according to their stages
of maturation; (F) Representative fields containing in vitro differentiated CTR and MSG adipocytes
(stained on Dd 10, magnification 40ˆ, scale bars at 20 μm), displaying different degrees of maturation
depending on the nucleus position: GI, central (red arrow); GII, displaced from the center (green
arrow); and GIII: fully peripheral (blue arrow) (n = 4/5 different experiments; data from 200/250 cells
were recorded in each experiment). Values are means ˘ SEM *, p < 0.05 vs. CTR values.
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Figure 4. MSG SVF cells displayed higher competency, but lower anti-adipogenic factors
expression. RPAT-SVF cell mRNA levels of anti-adipogenic (Pref-1 and Wnt-10b), glucocorticoid
and mineralocorticoid receptors (GR and MR) and competency markers (PPAR-γ2 and Zfp423) from
CTR and MSG male rats (AU: arbitrary units).Values are means ˘ SEM (n = 5/6 different experiments).
* p < 0.05 vs. CTR values.
3.5. High Peripheral GC Levels Do Not Modify APC Number over Development
The adipogenic population (CD34+/CD31´/CD45´) contained in the RPAT SVF from 30- and
60-day-old rats from both groups was evaluated in order to assess a possible GC effect on APC number.
Interestingly, GCs exposure did not change the APC number at any age studied (Figure 5). These
data strongly suggest that the main GC effect on SFV cells is on APCs’ competency rather than on
cell number.
Figure 5. High GC exposure does not change adipocyte precursor cells (APCs) number. (A) Number
of APCs in SVF from CTR and MSG animals at both ages. Adipocyte progenitors were identified
by flow cytometry analysis using the CD34+/CD31´/CD45´ profile; (B) Characteristic forward
versus side scatter dot plot of freshly-isolated SVF cells from RPAT. Fluorescence profiles obtained for
(C) IgG isotype control FITC conjugated combined with CD34 PE staining; (D) IgG1 isotype control PE
conjugated combined with CD45/CD31 FITC staining and (E) APC subset (upper left quadrant). FITC:
fluorescein isothiocyanate; PE: phycoerythrin. Values are means ˘ SEM (n = 3/4 different experiments).
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3.6. Relationship between APCs’ Competency and Adipogenic Capacity in MSG Rats
As described above, APCs from MSG rats at 30 days of age displayed an increased competency
and differentiated rapidly when compared to CTR cells. Therefore, in order to establish any possible
relationship between these data and the characteristic of in vivo RPAT mass expansion, the size
distribution of mature adipocytes contained in RPAT pads from CTR and MSG rats of both age groups
(Figure 6) was determined. Our data indicate that adipocytes from 30-day-old MSG animals were
hypertrophic vs. age-matched CTR cells (Figure 6, upper panel). However, the smaller size of all
adipocytes from 30-day-old rats compared to those from 60-day-old rats suggests that newly-generated
adipocytes appeared at 30 days of age, regardless of the group examined. Interestingly, the profile
of adipocyte size found in RPAT pads from 60-day-old MSG rats was conspicuous. In fact, while
two adipocyte populations were found in the MSG group, one smaller and the other larger, a unique
adipocyte size (intermediate) population characterizes CTR RPAT pads (Figure 6, lower panel). These
data reveal that the in vivo activation of the adipogenic process could be dependent on a higher APCs
competency in the 30-day-old MSG rat.
Figure 6. In vivo adipogenesis occurs in MSG animals. Adipocyte size distribution in RPAT depot
from CTR and MSG rats at 30 (upper panel) and 60 days of age (lower panel). Purple and blue lines
represent MSG (MSG SP: MSG small population; MSG LP: MSG large population) and CTR adipocyte
populations, respectively. Representative images of mature adipocytes in cell suspension are shown
for each group (magnification 10ˆ, scale bars at 200 μm). Values are the means ˘ SEM (n = 3 animals
per group).
4. Discussion
Enhanced VAT is associated with an increased risk of the development of several pathologies,
such as diabetes mellitus type 2 and cardiovascular disease. Conversely, SCAT function is considered
as protective against them [35,36]. This difference has been attributed, at least in part, to a higher
adipogenic capacity of SCAT [37]. However, a system has been recently developed for the inducible
and permanent labelling of mature adipocytes in vivo, which indicates that hyperplastic expansion of
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the AT occurs mainly at the epididymal, but not at the SCAT depot [38]. The present work showed
that high chronic GC plasma levels are associated with early activation of adipogenesis (30-day-old
MSG rats), supporting the concept that RPAT could expand through the generation of new adipocytes.
In contrast, our previous studies revealed the inhibition of the RPAT adipogenic process at advanced
age (60 day-old MSG rats) [28]. This age-/time-dependent shift in the adipogenic potential could be a
consequence of changes in the expression levels of APCs’ competency factors.
GCs have diverse effects on both AT functions [39,40] and distribution [41,42], favoring an increase
in VAT, but not in SCAT mass. MSG rats share several features of the human CS phenotype, which is
characterized by chronic high circulating levels of GC, enhanced AT mass and adipocyte size and an
altered pattern of adipokine secretion, among others. In the MSG rat phenotype, restoring to normal
the peripheral levels of GC reverses most of such dysfunctions [43]. Our present data indicate that the
MSG animal phenotype is already established at 30 days of age, and some characteristic alterations get
differentially worse over time.
Regarding the terminal stage of adipogenesis, an increase in all differentiation parameters
was observed in MSG cells from 30-day-old rats. According to these findings, the expression of
anti-adipogenic factors, such as Pref-1 and Wnt-10b decreased in undifferentiated MSG cells. In fact,
the pro-adipogenic action of GCs is due to its inhibitory effect on Pref-1 and Wnt/b-catenin signaling
pathway expression [21]. As mentioned above, these results show evidence of a dual behavior of the
adipogenic process by itself in a GC-rich endogenous environment, characterized by adipogenesis
activation at an initial step and the subsequent inhibition of the process, as shown before [28].
Cristancho et al. [15] distinguished between two functional terms: cell competency and cell
commitment, where adipogenic competency refers to the cell’s ability to differentiate into adipocyte
upon the addition of defined stimuli, and adipogenic commitment indicates the multipotent cell type
fate to undergo its conversion into adipocyte. Within this context, the adipogenic potential of an AT
pad depends, besides any adipogenic stimulus environment, on the number and competency of APCs
present in the local SVF. GCs are known to inhibit the proliferation capacity of APCs and to play an
important role driving APCs to differentiate into adipocytes.
Over the last few years, great effort has been made to find cell surface markers that unequivocally
identify APCs applying diverse criteria. Most of them agree that the CD34 antigen can distinguish
between cells that are able or not to differentiate into mature adipocytes [44–46]. Interestingly, the
expansion of different AT pads, both in mouse and human obese phenotypes, has been proposed
to depend on changes in progenitor cell number [10,37,47]. To our knowledge, the effect of chronic
exposure to high GC levels on APCs number in VAT pad has not been yet explored. In fact, our study
is the first to show that APCs number in the SVF of RPAT from MSG rats is not altered at 30 or 60 days
of age, and consequently, this parameter does not seem to be responsible for the changes observed in
their adipogenic potential.
Zfp423 has been described as a marker of APCs competency, because it regulates PPARγ2
expression throughout the amplification of SMAD protein activity [17]. Thus, since PPARγ2 plays a
key role within the overall adipogenic process, we are persuaded that PPARγ2 should be considered
as a competency factor by itself. In SVF cells from 30 day-old MSG rats, the levels of PPARγ2 and
Zfp423 mRNA were higher than in CTR SVF cells, which indicates high APC competency. These data
are opposite to those found in 60 day-old MSG rat cells where both PPARγ2 and Zfp423 mRNA levels
were low. Our results demonstrate that changes in APCs competency are responsible for the different
adipogenic capacities of SVF cells from MSG rats of 30 and 60 days of age.
In obese phenotypes, a recruitment of immune cells occurs in VAT, including macrophages,
lymphocytes and neutrophils, thus contributing to the development of a chronic inflammatory
state [48–51]. Furthermore, there is a macrophage polarization toward the M1 type, which secretes
pro-inflammatory cytokines (e.g., TNFα, IL1β and MCP-1) to the detriment of the anti-inflammatory
M2 type (IL-10) [52,53]. These pro-inflammatory macrophage-secreted factors have been involved in
an antiadipogenic activity, by decreasing the expression levels of adipogenic markers, such as aP2 and
136
Nutrients 2016, 8, 410
PPARγ2 in human and 3T3-L1 preadipocytes [54,55]. The role of GCs mediating the inflammatory
response in AT depends on the MR or GR activation, which will determine a pro- or anti-inflammatory
response, respectively, due to the decrease or increase of pro-inflammatory cytokines’ secretion [26].
Nevertheless, CS patients display increased adiposity, but the establishment of a chronic inflammatory
state is controversial [56,57]. We have previously shown that RPAT expression of TNFα, IL-6, MCP-1
and F4/80 does not increase in 60-day-old MSG rats, probably due to the anti-inflammatory effect of
GCs exerted through GR activation [28]. In this regard, further studies are needed to evaluate the AT
inflammatory response in MSG rats at 30 days of age.
Pro-adipogenic activity of GCs has been clearly recognized; then, the co-existence of high GC
levels and a reduced adipogenic cell capacity could be indicative of changes in the RPAT sensitivity
to GCs. This could explain why high levels of a potent adipogenic factor do not stimulate the
process continuously, preventing hypertrophy of VAT. It is known that aldosterone is able to promote
differentiation of APCs in both 3T3-L1 [58] and human preadipocytes. Notably, expression silencing
or activity blocking of MR in both cell types prevent adipogenesis, but this is not the same for GR
inactivation [25,26]. We found that MR mRNA levels did not change in 30-day-old MSG rats, though
they decreased in 60-day-old rats, coinciding with the low adipogenic capacity found in them [28].
This could suggest that MR is involved in the development of a GC-resistant state, although the
participation of MR or GR in the biological actions of GCs upon the AT is still being debated [25–27].
However, the contribution of GR to the lack of GC effect cannot be ruled out, despite not finding any
change in cell GR expression.
The distribution of adipocyte size has been previously used to determine the presence of AT
hypertrophy and/or hyperplasia [10]. Analysis of the adipocyte size distribution in RPAT from MSG
animals at both ages showed interesting data. Indeed, MSG rats at 30 days of age displayed one
hypertrophic adipocyte population, while MSG rats at 60 days of age presented two adipocyte size
populations, one smaller and another larger than the only adipocyte size population found in CTR
pads. The additional presence of small adipocytes in 60-day-old MSG rats suggests that increased APC
competency (seen in 30-day-old MSG rats) leads to adipogenesis stimulation between Days 30 and
60 of age.
5. Conclusions
The present study shows that changes in competency and/or number of APCs are two
independent mechanisms that can modulate the adipogenic potential of an AT depot. In particular, long
term in vivo cell exposure to high GC levels induces an early stimulation and subsequent inhibition of
RPAT adipogenesis, a dual age-dependent process, mainly due to changes in APCs’ competency, but
not in number. Metabolic dysfunctions associated with obesity are dependent on the development of
adipocyte hypertrophy; hence, the possibility of increased APC competency and/or number could
result in the activation of the adipogenic process by activating hyperplastic VAT expansion, with
consequent benefits for health.
Acknowledgments: This work was supported by grants from CONICET (PIP-2013-2015-0198), Fondo para la
Investigación Científica y Tecnológica (FONCYT, PICT-2012-1415 and PICT-2013-0930) and Fondation pour la
Recherche en Endocrinologie, Diabetologie et Metabolisme (FPREDM 062013). The authors are grateful to Rebecca
Doyle for careful manuscript edition/correction. A.A., G.M., E.S. and A.G. are researchers from the National
Research Council of Argentina (CONICET).
Author Contributions: A.G., M.G.Z. and E.S. conceived of and designed the experiments. M.G.Z. performed the
research. A.A., D.C. and A.P. participated in the cell culture and qPCR assays and analyses. G.M. participated in
the flow cytometry experiments and analyses. A.G. and M.G.Z. analyzed all of the data and wrote the manuscript.
E.S. participated in the critical revision and correction of the final manuscript. All authors read and approved the
final manuscript.
Conflicts of Interest: The authors declare no conflicts of interest.
137
Nutrients 2016, 8, 410
References
1. Peckett, A.J.; Wright, D.C.; Riddell, M.C. The effects of glucocorticoids on adipose tissue lipid metabolism.
Metabolism 2011, 60, 1500–1510. [CrossRef] [PubMed]
2. Lee, M.J.; Fried, S.K. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion.
Am. J. Physiol. Endocrinol. Metab. 2009, 296, E1230–E1238. [CrossRef] [PubMed]
3. Lee, M.J.; Pramyothin, P.; Karastergiou, K.; Fried, S.K. Deconstructing the roles of glucocorticoids in adipose
tissue biology and the development of central obesity. Biochim. Biophys. Acta 2014, 1842, 473–481. [CrossRef]
[PubMed]
4. Rebuffé-Scrive, M.; Krotkiewski, M.; Elfverson, J.; Björntorp, P. Muscle and adipose tissue morphology and
metabolism in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 1988, 67, 1122–1128. [CrossRef] [PubMed]
5. Mayo-Smith, W.; Hayes, C.W.; Biller, B.M.; Klibanski, A.; Rosenthal, H.; Rosenthal, D.I. Body fat distribution
measured with CT: Correlations in healthy subjects, patients with anorexia nervosa, and patients with
Cushing syndrome. Radiology 1989, 170, 515–518. [CrossRef] [PubMed]
6. Chanson, P.; Salenave, S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology 2010, 92 (Suppl. 1),
96–101. [CrossRef] [PubMed]
7. Nemeroff, C.B.; Grant, L.D.; Bissette, G.; Ervin, G.N.; Harrell, L.E.; Prange, A.J. Growth, endocrinological
and behavioral deficits after monosodium L-glutamate in the neonatal rat: Possible involvement of arcuate
dopamine neuron damage. Psychoneuroendocrinology 1977, 2, 179–196. [CrossRef]
8. Perelló, M.; Gaillard, R.C.; Chisari, A.; Spinedi, E. Adrenal enucleation in MSG-damaged hyperleptinemic
male rats transiently restores adrenal sensitivity to leptin. Neuroendocrinology 2003, 78, 176–184. [CrossRef]
[PubMed]
9. Moreno, G.; Perelló, M.; Camihort, G.; Luna, G.; Console, G.; Gaillard, R.C.; Spinedi, E. Impact of
transient correction of increased adrenocortical activity in hypothalamo-damaged, hyperadipose female rats.
Int. J. Obes. 2006, 30, 73–82. [CrossRef] [PubMed]
10. Joe, A.W.B.; Yi, L.; Even, Y.; Vogl, A.W.; Rossi, F.M.V. Depot-specific differences in adipogenic progenitor
abundance and proliferative response to high-fat diet. Stem Cells 2009, 27, 2563–2570. [CrossRef] [PubMed]
11. Wang, M.Y.; Grayburn, P.; Chen, S.; Ravazzola, M.; Orci, L.; Unger, R.H. Adipogenic capacity and the
susceptibility to type 2 diabetes and metabolic syndrome. Proc. Natl. Acad. Sci. USA 2008, 105, 6139–6144.
[CrossRef] [PubMed]
12. Franck, N.; Stenkula, K.G.; Ost, A.; Lindström, T.; Strålfors, P.; Nystrom, F.H. Insulin-induced GLUT4
translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated
from the same individual. Diabetologia 2007, 50, 1716–1722. [CrossRef] [PubMed]
13. Skurk, T.; Alberti-Huber, C.; Herder, C.; Hauner, H. Relationship between adipocyte size and adipokine
expression and secretion. J. Clin. Endocrinol. Metab. 2007, 92, 1023–1033. [CrossRef] [PubMed]
14. Wåhlen, K.; Sjölin, E.; Löfgren, P. Role of fat cell size for plasma leptin in a large population based sample.
Exp. Clin. Endocrinol. Diabetes 2011, 119, 291–294. [CrossRef] [PubMed]
15. Cristancho, A.G.; Lazar, M.A. Forming functional fat: a growing understanding of adipocyte differentiation.
Nat. Rev. Mol. Cell Biol. 2011, 12, 722–734. [CrossRef] [PubMed]
16. Sengenès, C.; Lolmède, K.; Zakaroff-Girard, A.; Busse, R.; Bouloumié, A. Preadipocytes in the human
subcutaneous adipose tissue display distinct features from the adult mesenchymal and hematopoietic stem
cells. J. Cell. Physiol. 2005, 205, 114–122. [CrossRef] [PubMed]
17. Gupta, R.K.; Arany, Z.; Seale, P.; Mepani, R.J.; Ye, L.; Conroe, H.M.; Roby, Y.A.; Kulaga, H.; Reed, R.R.;
Spiegelman, B.M. Transcriptional control of preadipocyte determination by Zfp423. Nature 2010, 464, 619–623.
[CrossRef] [PubMed]
18. Tontonoz, P.; Spiegelman, B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem.
2008, 77, 289–312. [CrossRef] [PubMed]
19. Smas, C.M.; Chen, L.; Zhao, L.; Latasa, M.J.; Sul, H.S. Transcriptional repression of pref-1 by glucocorticoids
promotes 3T3-L1 adipocyte differentiation. J. Biol. Chem. 1999, 274, 12632–12641. [CrossRef] [PubMed]
20. Mulholland, D.J.; Dedhar, S.; Coetzee, G.A.; Nelson, C.C. Interaction of nuclear receptors with the
Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev. 2005, 26, 898–915. [CrossRef]
[PubMed]
138
Nutrients 2016, 8, 410
21. Xiao, X.; Li, H.; Yang, J.; Qi, X.; Zu, X.; Yang, J.; Zhong, J.; Cao, R.; Liu, J.; Wen, G. Wnt/β-catenin signaling
pathway and lipolysis enzymes participate in methylprednisolone induced fat differential distribution
between subcutaneous and visceral adipose tissue. Steroids 2014, 84, 30–35. [CrossRef] [PubMed]
22. Christodoulides, C.; Lagathu, C.; Sethi, J.K.; Vidal-Puig, A. Adipogenesis and WNT signalling.
Trends Endocrinol. Metab. TEM 2009, 20, 16–24. [CrossRef] [PubMed]
23. Wang, Y.; Hudak, C.; Sul, H.S. Role of preadipocyte factor 1 in adipocyte differentiation. Clin. Lipidol. 2010, 5,
109–115. [CrossRef] [PubMed]
24. Pantoja, C.; Huff, J.T.; Yamamoto, K.R. Glucocorticoid signaling defines a novel commitment state during
adipogenesis in vitro. Mol. Biol. Cell 2008, 19, 4032–4041. [CrossRef] [PubMed]
25. Caprio, M.; Fève, B.; Claës, A.; Viengchareun, S.; Lombès, M.; Zennaro, M.C. Pivotal role of the
mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007, 21, 2185–2194. [CrossRef]
[PubMed]
26. Hoppmann, J.; Perwitz, N.; Meier, B.; Fasshauer, M.; Hadaschik, D.; Lehnert, H.; Klein, J. The balance between
gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J. Endocrinol.
2010, 204, 153–164. [CrossRef] [PubMed]
27. Lee, M.J.; Fried, S.K. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role
in adipogenesis and adipokine production in human adipocytes. Int. J. Obes. 2014, 38, 1228–1233. [CrossRef]
[PubMed]
28. Zubiría, M.G.; Vidal-Bravo, J.; Spinedi, E.; Giovambattista, A. Relationship between impaired adipogenesis
of retroperitoneal adipose tissue and hypertrophic obesity: Role of endogenous glucocorticoid excess. J. Cell.
Mol. Med. 2014, 18, 1549–1561. [CrossRef] [PubMed]
29. Giovambattista, A.; Gaillard, R.C.; Spinedi, E. Ghrelin gene-related peptides modulate rat white adiposity.
Vitam. Horm. 2008, 77, 171–205. [PubMed]
30. Tchoukalova, Y.D.; Harteneck, D.A.; Karwoski, R.A.; Tarara, J.; Jensen, M.D. A quick, reliable, and automated
method for fat cell sizing. J. Lipid Res. 2003, 44, 1795–1801. [CrossRef] [PubMed]
31. Maumus, M.; Sengenès, C.; Decaunes, P.; Zakaroff-Girard, A.; Bourlier, V.; Lafontan, M.; Galitzky, J.;
Bouloumié, A. Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: Influence of
fat mass microenvironment and growth. J. Clin. Endocrinol. Metab. 2008, 93, 4098–4106. [CrossRef] [PubMed]
32. Giovambattista, A.; Piermaría, J.; Suescun, M.O.; Calandra, R.S.; Gaillard, R.C.; Spinedi, E. Direct effect
of ghrelin on leptin production by cultured rat white adipocytes. Obesity (Silver Spring) 2006, 14, 19–27.
[CrossRef] [PubMed]
33. Chen, J.; Dodson, M.V.; Jiang, Z. Cellular and molecular comparison of redifferentiation of intramuscular-
and visceral-adipocyte derived progeny cells. Int. J. Biol. Sci. 2010, 6, 80–88. [CrossRef] [PubMed]
34. Grégoire, F.; Todoroff, G.; Hauser, N.; Remacle, C. The stroma-vascular fraction of rat inguinal and epididymal
adipose tissue and the adipoconversion of fat cell precursors in primary culture. Biol. Cell 1990, 69, 215–222.
[CrossRef]
35. Wang, Y.; Rimm, E.B.; Stampfer, M.J.; Willett, W.C.; Hu, F.B. Comparison of abdominal adiposity and overall
obesity in predicting risk of type 2 diabetes among men. Am. J. Clin. Nutr. 2005, 81, 555–563. [PubMed]
36. Tankó, L.B.; Bagger, Y.Z.; Alexandersen, P.; Larsen, P.J.; Christiansen, C. Peripheral adiposity exhibits an
independent dominant antiatherogenic effect in elderly women. Circulation 2003, 107, 1626–1631. [CrossRef]
[PubMed]
37. Macotela, Y.; Emanuelli, B.; Mori, M.A.; Gesta, S.; Schulz, T.J.; Tseng, Y.H.; Kahn, C.R. Intrinsic differences in
adipocyte precursor cells from different white fat depots. Diabetes 2012, 61, 1691–1699. [CrossRef] [PubMed]
38. Wang, Q.A.; Tao, C.; Gupta, R.K.; Scherer, P.E. Tracking adipogenesis during white adipose tissue
development, expansion and regeneration. Nat. Med. 2013, 19, 1338–1344. [CrossRef] [PubMed]
39. Hauner, H.; Schmid, P.; Pfeiffer, E.F. Glucocorticoids and insulin promote the differentiation of human
adipocyte precursor cells into fat cells. J. Clin. Endocrinol. Metab. 1987, 64, 832–835. [CrossRef] [PubMed]
40. Lee, M.J.; Gong, D.W.; Burkey, B.F.; Fried, S.K. Pathways regulated by glucocorticoids in omental and
subcutaneous human adipose tissues: A microarray study. Am. J. Physiol. Endocrinol. Metab. 2011, 300,
E571–E580. [CrossRef] [PubMed]
41. Geer, E.B.; Shen, W.; Gallagher, D.; Punyanitya, M.; Looker, H.C.; Post, K.D.; Freda, P.U. MRI assessment of
lean and adipose tissue distribution in female patients with Cushing’s disease. Clin. Endocrinol. (Oxf.) 2010,
73, 469–475. [CrossRef] [PubMed]
139
Nutrients 2016, 8, 410
42. Rockall, A.G.; Sohaib, S.A.; Evans, D.; Kaltsas, G.; Isidori, A.M.; Monson, J.P.; Besser, G.M.; Grossman, A.B.;
Reznek, R.H. Computed tomography assessment of fat distribution in male and female patients with
Cushing’s syndrome. Eur. J. Endocrinol. 2003, 149, 561–567. [CrossRef] [PubMed]
43. Perelló, M.; Moreno, G.; Gaillard, R.C.; Spinedi, E. Glucocorticoid-dependency of increased adiposity in
a model of hypothalamic obesity. Neuro Endocrinol. Lett. 2004, 25, 119–126. [PubMed]
44. Miranville, A.; Heeschen, C.; Sengenès, C.; Curat, C.A.; Busse, R.; Bouloumié, A. Improvement of postnatal
neovascularization by human adipose tissue-derived stem cells. Circulation 2004, 110, 349–355. [CrossRef]
[PubMed]
45. Rodeheffer, M.S.; Birsoy, K.; Friedman, J.M. Identification of white adipocyte progenitor cells in vivo. Cell
2008, 135, 240–249. [CrossRef] [PubMed]
46. Maumus, M.; Peyrafitte, J.; D’Angelo, R.; Fournier-Wirth, C.; Bouloumié, A.; Casteilla, L.; Sengenès, C.;
Bourin, P. Native human adipose stromal cells: Localization, morphology and phenotype. Int. J. Obes. 2011,
35, 1141–1153. [CrossRef] [PubMed]
47. Tchoukalova, Y.; Koutsari, C.; Jensen, M. Committed subcutaneous preadipocytes are reduced in human
obesity. Diabetologia 2007, 50, 151–157. [CrossRef] [PubMed]
48. Elgazar-Carmon, V.; Rudich, A.; Hadad, N.; Levy, R. Neutrophils transiently infiltrate intra-abdominal fat
early in the course of high-fat feeding. J. Lipid Res. 2008, 49, 1894–1903. [CrossRef] [PubMed]
49. Talukdar, S.; Oh, D.Y.; Bandyopadhyay, G.; Li, D.; Xu, J.; McNelis, J.; Lu, M.; Li, P.; Yan, Q.; Zhu, Y.; et al.
Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 2012,
18, 1407–1412. [CrossRef] [PubMed]
50. Nishimura, S.; Manabe, I.; Nagasaki, M.; Eto, K.; Yamashita, H.; Ohsugi, M.; Otsu, M.; Hara, K.; Ueki, K.;
Sugiura, S.; et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation
in obesity. Nat. Med. 2009, 15, 914–920. [CrossRef] [PubMed]
51. Choe, S.S.; Huh, J.Y.; Hwang, I.J.; Kim, J.I.; Kim, J.B. Adipose tissue remodeling: Its role in energy metabolism
and metabolic disorders. Front. Endocrinol. (Lausanne) 2016, 7, 30. [CrossRef] [PubMed]
52. Chawla, A.; Nguyen, K.D.; Goh, Y.P.S. Macrophage-mediated inflammation in metabolic disease.
Nat. Rev. Immunol. 2011, 11, 738–749. [CrossRef] [PubMed]
53. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage
polarization. J. Clin. Invest. 2007, 117, 175–184. [CrossRef] [PubMed]
54. Lacasa, D.; Taleb, S.; Keophiphath, M.; Miranville, A.; Clement, K. Macrophage-secreted factors impair
human adipogenesis: Involvement of proinflammatory state in preadipocytes. Endocrinology 2007, 148,
868–877. [CrossRef] [PubMed]
55. Lu, C.; Kumar, P.A.; Fan, Y.; Sperling, M.A.; Menon, R.K. A novel effect of growth hormone on macrophage
modulates macrophage-dependent adipocyte differentiation. Endocrinology 2010, 151, 2189–2199. [CrossRef]
[PubMed]
56. Barahona, M.J.; Sucunza, N.; Resmini, E.; Fernández-Real, J.M.; Ricart, W.; Moreno-Navarrete, J.M.; Puig, T.;
Farrerons, J.; Webb, S.M. Persistent body fat mass and inflammatory marker increases after long-term cure of
Cushing’s syndrome. J. Clin. Endocrinol. Metab. 2009, 94, 3365–3371. [CrossRef] [PubMed]
57. Setola, E.; Losa, M.; Lanzi, R.; Lucotti, P.; Monti, L.D.; Castrignanò, T.; Galluccio, E.; Giovanelli, M.; Piatti, P.
Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing’s
disease from metabolic syndrome. Clin. Endocrinol. 2007, 66, 586–592. [CrossRef] [PubMed]
58. Rondinone, C.M.; Rodbard, D.; Baker, M.E. Aldosterone stimulated differentiation of mouse 3T3-L1 cells
into adipocytes. Endocrinology 1993, 132, 2421–2426. [PubMed]
© 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Natural Course of Metabolically Healthy
Overweight/Obese Subjects and the Impact
of Weight Change
Ruizhi Zheng 1,†, Chengguo Liu 2,†, Chunmei Wang 3,†, Biao Zhou 4, Yi Liu 1, Feixia Pan 1,
Ronghua Zhang 4,* and Yimin Zhu 1,*
1 Department of Epidemiology & Biostatistics, School of Public Health, Zhejiang University, Hangzhou 310058,
Zhejiang, China; canprezrz@126.com (R.Z.); lyzju_2012@163.com (Y.L.); pfx19911119@163.com (F.P.)
2 Department of Endocrinology and Institute of Cardiovascular Diseases, Zhejiang Putuo Hospital,
Zhoushan 316100, Zhejiang, China; Prylcg@mail.zsptt.zj.cn
3 Tongxiang Center for Disease Control and Prevention, Tongxiang 314500, Zhejiang, China;
chunmei328@sina.com
4 Institute of Nutrition and Food Safety, Zhejiang Center for Disease Control and Prevention,
Hangzhou 310000, Zhejiang, China; bzhou@cdc.zj.cn
* Correspondence: rhzhang@cdc.zj.cn (R.Z.); zhuym@zju.edu.cn (Y.Z.); Tel.: +86-571-8711-5111 (R.Z.);
+86-571-8820-8138 (Y.Z.); Fax: +86-571-8711-5111 (R.Z.); +86-571-8820-8198 (Y.Z.)
† These authors contributed equally to this work.
Received: 19 May 2016; Accepted: 11 July 2016; Published: 15 July 2016
Abstract: Few studies have described the characteristics of metabolically healthy individuals with
excess fat in the Chinese population. This study aimed to prospectively investigate the natural
course of metabolically healthy overweight/obese (MH-OW/OB) adults, and to assess the impact
of weight change on developing metabolic abnormalities. During 2009–2010, 525 subjects without
any metabolic abnormalities or other obesity-related diseases were evaluated and reevaluated after
5 years. The subjects were categorized into two groups of overweight/obese and normal weight
based on the criteria of BMI by 24.0 at baseline. At follow-up, the MH-OW/OB subjects had
a significantly increased risk of developing metabolically abnormalities compared with metabolically
healthy normal-weight (MH-NW) individuals (risk ratio: 1.35, 95% confidence interval: 1.17–1.49,
p value < 0.001). In the groups of weight gain and weight maintenance, the MH-OW/OB subjects was
associated with a larger increase in fasting glucose, triglycerides, systolic blood pressure, diastolic
blood pressure and decrease in high-density lipoprotein cholesterol comparing with MH-NW subjects.
In the weight loss group, no significant difference of changes of metabolic parameters was observed
between MH-OW/OB and MH-NW adults. This study verifies that MH-OW/OB are different
from MH-NW subjects. Weight management is needed for all individuals since weight change has
a significant effect on metabolic health without considering the impact of weight change according to
weight status.
Keywords: metabolically healthy; overweight and obese; weight change
1. Introduction
Obesity is a key risk factor for various diseases, including type 2 diabetes, cardiovascular disease
(CVD), certain cancers, and musculoskeletal diseases [1]. However, it has been appreciated for many
years that about 20% to 30% of obese adults exhibit fewer of these complications and do not meet all
the criteria for metabolic syndrome [2]. Intense interest surrounds the “healthy” obese phenotype,
which is defined as being obesity in the absence of metabolic syndrome (MetS), termed as metabolically
healthy obesity (MHO) [3]. Despite the fact that there is no consensus on which criteria is preferable
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for defining MHO phenotype, longitudinal studies have suggested that this subtype of obesity are
still at increased risk of diabetes and cardiovascular diseases [4–7]. Additionally, several studies have
reported that MHO is not a permanent state and almost 30% to 50% of these individuals will convert
to metabolically unhealthy status, with resultant increased cardiovascular risk [8,9]. Therefore, it has
been speculated that the MHO subjects are not protected, but simply require additional time to develop
adverse metabolic outcomes.
Weight change has a strong impact on metabolic status; however, several studies investigating the
effects of weight loss by lifestyle intervention on metabolic status in the MHO subjects have yielded
inconsistent results [10–12]. Most of these studies find that the MHO individuals obtain smaller
improvements in MetS components from weight loss, compared with the metabolically abnormal
obese (MAO) patients. Furthermore, it has been suggested that weight loss in postmenopausal MHO
women may be unnecessary and paradoxically harmful given their favorable metabolic profiles [12].
Fabbrini et al. have evaluated the effect of a high-calorie diet on the metabolic status between the MHO
and the MAO subjects [13]. The results demonstrate distinct differences in the response to weight gain.
The MAO patients are predisposed to adverse metabolic effects of moderate weight gain, but not in
the MHO subjects [13]. According to their conclusion, it can be speculated that the MHO subjects may
maintain a healthy status in weight maintenance or even a little weight gain.
China has been experiencing an epidemic of obesity and metabolic disease in the last few decades;
it has been estimated that almost 70% of Chinese adults are in the overweight and obesity category [14].
Furthermore, the Chinese population tend to accumulate fat intra-abdominally, and thus even lean
subjects may have ectopic fat deposition and intra-abdominal obesity, accompanied with increasing
cardiometabolic problems in overweight and obese subjects [15]. Our previous study found that
27.9% of obese participants are in metabolic health in the Chinese population [16]. However, little
is known regarding the impact of weight changes on the metabolic profile for metabolically healthy
overweight/obese subjects in Chinese population. Given this background, the aim of this study was to
assess the metabolic response to 5-year weight change for metabolically healthy overweight/obese
(MH-OW/OB) adults.
2. Materials and Methods
2.1. Subjects
During 2009–2010, the population aged over 30 and residing in the city of Tongxiang and
Zhoushan in the Zhejiang province, China, were invited to participate in a health survey aimed
at identifying risk factors for non-communicable diseases. A total of 3603 subjects participated in the
prospective study, and data collected in 2009–2010 were used as the baseline for the present study.
A clinical assessment was repeated 5 years later. This study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all procedures involving human subjects were approved
by the Institutional Review Board of School of Medicine, Zhejiang University, Zhejiang, China (ethic
approval code: ZGL201304-3). Written informed consents were obtained from all participants.
According to the objective for the current study, those with a history of chronic diseases
were excluded (e.g., diabetes, cardiovascular disease, dyslipidemia, cancer, hypertension) (n = 719).
After exclusion of those with body mass index (BMI) < 18.5 kg/m2 (n = 150), and those who had missing
anthropometric, metabolic detection data and questionnaire information (n = 30), 2704 participants
were remained. Of these subjects, we selected those who had healthy metabolic status at baseline.
Namely, all of the selected subjects had no metabolic abnormality of MetS definition of the International
Diabetes Federation (IDF) criteria (waist circumference was not included in the definition of metabolic
health because of collinearity with BMI), including elevated triglycerides (TG) (ě1.7 mmol/L), low
high-density lipoprotein cholesterol (HDL-C) (men < 1.03 mmol/L, women < 1.29 mmol/L), elevated
systolic blood pressure (SBP) (ě130 mm¨ Hg) or diastolic blood pressure (DBP) (ě85 mm¨ Hg), elevated
fasting plasma glucose (FPG) (ě5.6 mmol/L) [17]. The selection yielded 630 subjects in metabolic
142
Nutrients 2016, 8, 430
health. After starting the study, 105 subjects (16.7%) were excluded for not attending a follow-up visit.
Ultimately, 525 subjects were included in the analysis (Figure 1). General obesity was defined by BMI,
which was recommended by the Working Group on Obesity in China (WGOC) [18]. There were
392 subjects in the normal weight category (BMI < 24.0 kg/m2), 98 in the overweight category
(BMI 24 textasciitilde 28 kg/m2) and 35 in the obesity category (BMI ě 28 kg/m2).
3603 subjects recruited from ZhejiangMetabolic Syndrome cohort in 2009 2010
Exclusions (n = 2973)
With history of diabetes, CVD, dyslipidemia, cancer,
hypertension (n = 719)
Missing data on anthropometric measures or covariates (n = 30)
Body mass index < 18.5 kg/m2 (n = 150)
Presenting at least one abnormal metabolic component (n = 2074)
630 eligible subjects for the study
Missed in follow up n = 105
525 metabolically healthy participants with complete data for final analysis
Figure 1. The flowchart of including subjects in the analysis.
2.2. Clinical Measurements at Baseline and Follow-up
Follow-up measurements took place 5 years after baseline examination. Both at baseline and
follow-up investigation, the same measurements were conducted. Nurses collected anthropometric
data (weight, height) and blood pressure using standard protocols. Height and weight were measured
on a scale, with the subjects wearing light clothing and without shoes. Waist circumference was
measured twice after a normal expiration halfway between the lowest rib and the top of the pelvis.
The mean of the two measurements was calculated. Blood pressure was measured in a sitting position
with a mercury sphygmomanometer. SBP and DBP were reported as the average of three repeat
measurements with 30-s intervals.
After a 12-h overnight fast, whole blood and serum samples were collected for each subject. All of
the laboratory tests were conducted on fresh samples in an ISO-9002 quality-assured, core facility
laboratory. Glucose was analyzed with a glucose oxidase method with the Beckman Glucose Analyzer
(Beckman Instruments, Irvine, CA, USA). Biochemical variables including, TG, total cholesterol
(TC), HDL-C and low density lipoprotein cholesterol (LDL-C) were determined using biochemical
auto-analyzers (Hitachi 7060, Tokyo, Japan).
2.3. Covariates
At baseline, each participant had completed a self-reported questionnaire to determine ethnicity
and lifestyle factors such as smoking behavior, alcohol intake, history of disease and medication use.
Smoking and alcohol consumption status were regarded as positive when the participant was currently
smoking and drinking; in the case of former or never, it was regarded as negative. International
Physical Activity Questionnaire (IPAQ) (short vision) was used for the assessment of the average
amount of time per week engaged in exercise activities [19]. The energy expended for each activity in
metabolic equivalent (MET) minutes per week (MET-m/week) was calculated and summed.
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2.4. Outcome Measurement
Follow-up measurements were conducted 5 years later. To determine the incident of metabolic
abnormalities, the same threshold levels previously mentioned according to MetS definition of IDF
criteria was used, including elevated TG, low HDL-C, elevated FPG and elevated SBP or DBP.
Participants who used medication for either high blood pressure or high fasting glucose or a reduced
HDL cholesterol or elevated triglycerides were defined as having the corresponding metabolic
abnormalities. The occurrence of metabolically abnormal status was defined as presenting one or more
metabolic abnormalities. Changes in these components were calculated as the values at follow-up
minus the values at baseline. For each observation, weight change was calculated as the percent
change between follow-up relative to the baseline ((weight at follow-up—weight at baseline)/weight
at baseline ˆ 100%). Weight change groups included weight loss, weight maintenance and weight
gain, which were defined as percent change of <´3%, ě´3% to ď3% and >3%, respectively [20].
2.5. Statistical Analysis
We firstly classified the subjects into three groups by the BMI status at baseline (normal-weight,
overweight and obesity). The software of Power Analysis and Sample Size (PASS) version 11 was
used to calculate the statistical power for comparing the change of metabolic parameters (FPG, SBP,
DBP, TG and HDL-C) among the groups of baseline BMI status. The results showed that statistical
power ranged from 43% to 56%. Therefore, we combined the subjects in overweight and obesity.
The subjects were classified as metabolically healthy normal weight (MH-NW) and metabolically
healthy overweight/obese (MH-OW/OB). The statistical power increased to over 85%, which is
enough to detect reasonable departures from the null hypothesis.
Continuous variables were checked for normality using the Kolmogorov-Smirnov test and the
skewed variable (alanine aminotransferase) was log transformed. Categorical variables are presented
as percentages. Chi-square tests were used for categorical variables. The comparisons of baseline
clinical and anthropometry parameters between the groups were assessed using a 2-by-2 (body
size-by-metabolic status at follow-up) ANCOVA, and Bonferroni correction was used to control for the
inflation of type I error due to multiple comparisons.
Relationships between incident metabolic abnormalities were investigated with multivariable
logistic regression analyses, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were
calculated with MH-NW subjects as the reference to assess the risk of developing metabolic
abnormalities for MH-OW/OB. The OR and 95% CI were then used to compute risk ratio (RR)
and 95% CI [21]. Models were adjusted for age, sex, smoking status, alcohol drinking status, physical
activity, absolute weight change and the correspondingly metabolic parameters at baseline. Changes of
metabolic parameters from baseline to follow-up were assessed by using mixed effects models
with compound symmetry accounting for within-subjects correlation (multiple observation from
a participant) with adjusting for the covariates previously mentioned.
We did not conduct sex-specific analyses because there were too few events in some subgroups to
calculate stable risk estimates. A p-value < 0.05 was considered significant. All the statistical analysis
was conducted using SAS software package (version 9.3; SAS institute, Cary, NC, USA).
3. Results
At baseline, the sample consisted of 630 individuals although loss to follow up resulted in
a final analytic sample of 525 individuals. We checked for withdrawal bias by testing for differences
in baseline variables between the participants who participated in follow-up measurements and
those who did not participated in follow-up examinations. There were no differences in age, gender,
metabolic parameters, BMI, smoking status, alcohol drinking status, and education level between the
participated and non-participated individuals (Table S1).
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At baseline, 392 participants were classified as MH-NW and 133 as MH-OW/OB. Baseline
characteristics of the participants are presented in Table 1. The subjects in MH-OW/OB had larger
values of baseline BMI and waist, and slightly higher DBP compared with MH-NW individuals.
Table 1. Characteristics of the metabolically healthy normal-weight (MH-NW) and metabolically
healthy overweight/obese (MH-OW/OB) subjects at baseline and the incidences of the metabolic
abnormalities at follow-up.
Variables MH-NW (n = 392) MH-OW/OB (n = 133) p-Value
Female (n (%)) 203 (51.8) 87 (65.4) 0.006
Age (years) 55.0 ˘ 9.0 55.6 ˘ 7.2 0.513
BMI (kg/m2) 21.15 ˘ 1.77 25.95 ˘ 1.84 <0.001
Waist circumference (cm) 77.52 ˘ 5.60 87.58 ˘ 5.81 <0.001
SBP (mm¨ Hg) 115.0 ˘ 8.6 116.8 ˘ 8.1 0.066
DBP (mm¨ Hg) 73.5 ˘ 6.4 76.2 ˘ 6.3 <0.001
FPG (mmol/L) 4.85 ˘ 0.37 4.88 ˘ 0.38 0.555
TC (mmol/L) 4.95 ˘ 0.88 5.05 ˘ 0.91 0.121
TG (mmol/L) 0.93 ˘ 0.32 0.98 ˘ 0.34 0.059
HDL-C (mmol/L) 1.54 ˘ 0.33 1.50 ˘ 0.28 0.196
ALT (U/L) * 1.31 ˘ 0.17 1.33 ˘ 0.19 0.266
Current smoking (n (%)) 135 (34.4) 37 (27.7) 0.121
Current drinking (n (%)) 105 (26.8) 25 (18.8) 0.065
Percent in weight change (n (%))
Weight loss 84 (21.4) 42 (31.6) 0.054
Weight maintenance 167 (42.6) 52 (39.1)
Weight gain 141 (36.0) 39 (29.3)
Changes in measurement
Body weight (kg) 0.75 ˘ 3.93 ´0.47 ˘ 6.07 0.007
BMI (kg/m2) 0.24 ˘ 1.53 ´0.24 ˘ 2.26 0.005
Waist circumference (cm) 2.48 ˘ 6.15 0.49 ˘ 5.42 0.026
FPG (mmol/L) 0.42 ˘ 0.59 0.55 ˘ 0.49 0.018
TG (mmol/L) 0.18 ˘ 0.55 0.29 ˘ 0.57 0.037
SBP (mm¨ Hg) 7.7 ˘ 13.6 12.1 ˘ 13.2 0.004
DBP (mm¨ Hg) 2.4 ˘ 8.3 4.1 ˘ 8.4 0.042
HDL-C (mmol/L) ´0.11 ˘ 0.32 ´0.20 ˘ 0.31 0.016
Developing metabolic abnormalities at follow-up (n (%))
Pre-diabetes 82 (20.9) 52 (39.1) <0.001
Hypertriglyceridemia 51 (13.0) 28 (21.1) 0.026
High SBP 115 (29.3) 57 (42.9) 0.004
High DBP 51 (13.0) 31 (23.3) 0.005
Low HDL-C 77 (19.6) 49 (36.8) <0.001
Developing one or more 218 (55.6) 100 (75.2) <0.001
Abbreviations: MH-NW, metabolically healthy normal-weight; MH-OW/OB, metabolically healthy
overweight/obese. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG,
fasting plasma glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; ALT, alanine aminotransferase. * Data were log transformed.
Data are expressed as means ˘ standard deviation and number (percentage).
After 5 years, the proportion of individuals in each weight change category was not significantly
different between MH-NW and MH-OW/OB participants. The MH-NW subjects had greater increase
in body weight, BMI and waist circumference than that of MH-OW/OB subjects. However, the
MH-OW/OB subjects had more detrimental changes in all the metabolic parameters compared with
the MH-NW counterparts (Table 1). Correspondingly, higher incidents of metabolic abnormalities
were observed in the MH-OW/OB than MH-NW subjects. Compared with the MH-NW subjects,
MH-OW/OB group was at a significantly elevated risk for developing pre-diabetes (RR = 2.01,
95% CI = 1.42–2.57, p < 0.001), high SBP (RR = 1.50, 95% CI = 1.11–1.91, p < 0.001), low HDL-C
(RR = 1.69, 95% CI = 1.18–2.29, p < 0.001) and one or more metabolic abnormalities (RR = 1.35,
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95% CI = 1.17–1.49, p < 0.001) with adjusting for age, gender, smoking status, alcohol drinking status,
physical activity, weight change and correspondingly baseline metabolic parameters.
Both baseline BMI status and weight change contributed to the changes of metabolic parameters
over time (both p < 0.01). No interaction of baseline BMI status by weight change category (p > 0.05) was
noted for the changes of metabolic parameters. Table 2 presents the comparison of the paired-difference
of the metabolic parameters between the MH-NW and MH-OW/OB subjects within each weight
change category. In the weight loss group, there was no significant difference in the changes of these
metabolic parameters between the MH-NW and MH-OW/OB adults. In the weight maintenance
category, the MH-OW/OB subjects had significantly larger increase in TG (0.34 vs. 0.16 mmol/L,
p = 0.040), SBP (12.4 vs. 7.4 mm¨ Hg, p = 0.020), DBP (5.6 vs. 1.9 mm¨ Hg, p = 0.001) and decrease
in HDL-C (´0.21 vs. ´0.08 mmol/L, p = 0.014) compared with MH-NW peers. In weight gain
category, significantly more deleterious changes in FPG, SBP, DBP and HDL-C were observed in the
MH-OW/OB subjects.
The MH-NW subjects with weight maintenance and weight gain had larger increase in SBP
compared with the subjects in weight loss. Among the MH-OW/OB adults, weight maintainers had
larger increase in DBP (5.6 vs. 1.1 mm¨ Hg, p = 0.003) and decrease in HDL-C (´0.21 vs. ´0.11 mmol/L,
p = 0.029) than that of the subjects in weight loss. Both the MH-NW and the MH-OW/OB subjects in
the weight gain group lead to worse changes in metabolic parameters compared with the subjects in
the weight loss group.
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4. Discussion
This is, to the best of our knowledge, the first prospective study describing the characteristics of
developing metabolic abnormalities in MH-OW/OB subjects in the Chinese population. In this
prospective study, we found that the MH-OW/OB subjects had higher incidences of metabolic
derangements compared with MH-NW counterparts as time passed. Our findings relating to stability
in healthy individuals with excess fat over time were consistent with recently reported studies. Another
prospective study in Spanish had shown that 30%–40% of healthy obese subjects had converted to the
unhealthy status after 6 years of follow-up. Bobbioni et al. also examined the change of the metabolic
status in the metabolically healthy overweight/obese individuals. At 3 years follow-up, the incidence
of one or more cardiometabolic risk factors was 57.2% in the overweight/obese adults compared with
31.7% in the normal-weight subjects [22]. In the present study, the subjects in the overweight and
obesity groups were positively correlated with higher incidences of metabolic abnormalities over time
compared with the MH-NW subjects. This suggested that the MH-OW/OB individuals underwent
more deterioration in metabolic change associated with excess fat. Our findings might explain the
reason that the MH-OW/OB individuals had a higher risk for incident diabetes and cardiovascular
events compared with that of MH-NW individuals [23]. Further longitudinal investigation of the
sustainability and other predictors of the metabolic health subjects might better stratify the sub-type of
obese individuals and provide potential intervention targets.
The beneficial effects of weight loss for the overweight and obese subjects have been well
documented. However, intervention studies investigating the effect of weight loss on the metabolic
status in MHO individuals had yielded contradictory results. Karelis et al. had carried out
an intervention study in MHO subjects [12]. After 6-month energy-restricted diet, the MHO
individuals exhibited significant reduction in body weight, accompanied with deterioration in insulin
sensitivity [12]. Two similar studies observed no measureable effect of weight loss on inflammation
levels in the MHO individuals [24,25]. Another two intervention studies also observed no significant
improvements of the metabolic profiles in the MHO subjects [10,26]. However, a longer-term intensive
lifestyle intervention including Mediterranean diet nutritional counselling and high-intensity interval
training improved body composition and metabolic parameters in the MHO patients [27]. Similarly,
three intervention studies found that energy-restricted diet and exercise intervention induced weight
loss among the MHO subjects was associated with improvement in metabolic health status [28–30].
It was also suggested that the laparoscopic adjustable gastric banding was suitable for the morbidly
obese individuals in metabolic health [31]. In the present study, under the natural conditions, the
MH-NW and MH-OW/OB subjects in the weight loss group had similar changes in the metabolic
parameters. They also presented better metabolic profiles than the subjects who gained weight.
Although weight maintenance literally implies no change in body weight, in free-living
individuals, weight varies over time. The research by Forbes et al. showed that even with weight
maintenance, adults lost about 1.5 kg of fat-free mass per decade [32]. In the present study, by using
the definition of within ˘3.0 percent change of baseline weight as weight maintenance, it showed
that fasting plasma glucose, triglycerides, systolic blood pressure and diastolic blood pressure were
significantly increased, while HDL-cholesterol decreased in weight maintainers. Naturally, long-term
trends were superimposed upon the effects of aging in the longitudinal study. Truesdale et al. and
Cui et al. compared the changes of the metabolic profiles between normal weight and obese subjects
who maintained their weight based on the data from the Atherosclerosis Risk in Communities (ARIC)
study [33,34]. However, they obtained opposite conclusions. The research of Truesdale et al. observed
more favorable changes of metabolic parameters in the obese maintainers compared with the normal
weight individuals, while Cui et al. reported reverse results. In the present study, the overweight and
obese weight maintainers had more deleterious changes in the metabolic profiles than that of the normal
weight maintainers. It suggested that the notion of metabolically healthy overweight/obese subjects
should be used in caution, since weight maintenance and weight gain was associated with much more
deleterious changes of metabolic conditions in MH-OW/OB adults compared with MH-NW.
148
Nutrients 2016, 8, 430
Theoretically, MHO subjects were protected from the adverse metabolic effects of weight gain
and increased adiposity, which had been proved by Fabbrini et al. [13]. They compared the metabolic
response to a high-calorie diet intervention between the MHO and metabolically unhealthy obese
subjects. Their results suggested that MHO phenotypes were protected against the adverse metabolic
effects of weight gain by increased adipose tissue capacity for lipogenesis. However, plenty of
studies have challenged the existence of a healthy obese phenotype by demonstrating that such
subjects had higher risk of incident hypertension, type 2 diabetes, cardiovascular diseases than that
of MH-NW individuals [24]. In line with these studies, our findings indicated that both the MH-NW
and MH-OW/OB subjects had higher risk of advancing to metabolic abnormal status as a result of
weight gain. A recent Mendelian randomization study concluded that increased adiposity had causal
adverse effects on numerous risk markers for cardiovascular disease and type 2 diabetes in non-obese
young adults [35]. Therefore, guidelines advising health care professionals to treat, monitor and
prevent weight gain covered the population in all BMI would benefit from interventions on developing
cardiometabolic risk factors.
Since the MHO phenotype was first described, many investigators have explored the
characteristics that might distinguish these individuals from those with unfavorable metabolic
status [36]. However, there was still lack of consensus on the definition of metabolic health. One study
summarized that, up to now, there were at least 30 different definitions had been used to define
a metabolically healthy phenotype in the literature [2]. Without specific and precise definition of
metabolic health, we might not obtain an accurate risk estimate of metabolic diseases for MHO subjects.
However, even if there would be a gold standard to accurately differentiate healthy and unhealthy
subjects, it might still be invalid in the research of metabolic diseases. Since it has been generally
accepted that overweight-to-moderately-obese individuals can be either metabolically healthy or
unhealthy, it is not clear to what degree an individual could switch “categories” [37]. It might be
efficient and convenient to operationally dichotomizing a continuous metabolic parameter above or
below a certain threshold of interest so as to target persons who were at risk, but it would ignore
the variability of metabolic status and other influencing factors during the follow up. Data from the
present study showed that weight change had a strong impact on the developing cardiometabolic risk
factors. Dozens of longitudinal studies had assessed the risk of developing type 2 diabetes, fatty liver
and cardiovascular disease for MHO subjects [38,39]. However, few of these studies had taken account
of the effects of weight change after stratifying by body size and metabolic status category [40].
There were several limitations to this study. The relatively small sample size made it impossible
to stratify the subjects into three categories by BMI categories (normal weight, overweight and obese).
Secondly, it has been demonstrated that inflammation was secondary to obesity in humans. However,
we did not have the information of inflammation markers, such as C-reactive protein. The inclusion of
inflammation as a criterion might modify the identification of metabolically healthy and abnormal
individuals at baseline. We were aware that the results from this study could be varied if we used
a different definition of weight change. Yet owning to the relatively small sample size in the present
study, when using the cut-off of 5.0% for weight change classification, the sample size became much
less concentrated in weight loss and weight gain categories, but the results were similar to our
primary analyses.
5. Conclusions
MH-OW/OB is a relatively unstable condition and a considerable portion of these individuals
will transition into unhealthy status at follow-up. Therefore, the potential benefits of differentiating
the MHO and metabolically unhealthy obese phenotypes in clinical practice in the Chinese population
appear limited. Our results suggest that weight gain and weight maintenance are strong indicators for
advancing to metabolic abnormalities. With regards to BMI, there is plentiful evidence that, for the
same category of BMI, Chinese subjects have higher percentage of total body fat and higher risk of
cardiometabolic disease compared with white subjects. Therefore, even though obesity management
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consumes considerable labor and expense, weight management is needed for all individuals since
weight change has a significant effect on metabolic health without considering the effect of weight
change according to weight status.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/7/430/s1,
Table S1: The comparison of the baseline characteristics of the people participated in follow-up examinations and
lost to follow up.
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Abstract: This study aimed to examine the proportion and socio-demographic correlates of
Metabolically Healthy Overweight and Obesity (MHOv/O) among Lebanese adults and to investigate
the independent effect of previously identified dietary patterns on odds of MHOv/O. Data were
drawn from the National Nutrition and Non-Communicable Disease Risk Factor Survey (Lebanon
2008–2009). Out of the 337 adult participants who had complete socio-demographic, lifestyle, dietary
as well as anthropometric and biochemical data, 196 had a BMI ě 25 kg/m2 and their data were
included in this study. MHOv/O was identified using the Adult Treatment Panel criteria. Dietary
patterns previously derived in this study population were: Fast Food/Dessert, Traditional-Lebanese
and High-Protein. The proportion of MHOv/O in the study sample was 37.2%. Females, higher
education and high level of physical activity were positively associated with odds of MHOv/O.
Subjects with higher adherence to the Traditional-Lebanese pattern had higher odds of MHOv/O (OR:
1.83, 95% CI: 1.09–3.91). No significant associations were observed between the Fast Food/Dessert
and the high-protein patterns with MHOv/O. Follow-up studies are needed to confirm those findings
and understand the mechanisms by which the Traditional-Lebanese pattern may exert a protective
effect in this subgroup of overweight and obese adults.
Keywords: metabolically healthy obesity; Lebanese dietary pattern; traditional dietary pattern
1. Introduction
Obesity is generally associated with numerous metabolic disorders such as insulin resistance
(IR) and type 2 diabetes [1], hypertension [2–4], dyslipidemia, and some forms of cancer [5–7].
However, studies have shown that a subset of overweight and obese individuals does not display
such cardio-metabolic abnormalities and were identified under a phenotype termed ‘Metabolically
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Healthy Obese: MHO’. Those individuals present with favorable metabolic profiles such as insulin
sensitivity, normal blood pressure and lipids profiles [8]. Additional protective factors identified
among individuals with MHO include lower levels of circulating C-reactive protein (CRP) [9] and a
possible elevation of adiponectin [10]. It has been suggested that this subset of overweight and obese
subjects may also have a lower risk of mortality and a better prognosis than their non-metabolically
healthy obese counterparts [11,12].
The prevalence of MHO varies according to the definitions used to characterize this phenotype
and could reach up to 40% among obese adults [13,14]. Given the possible protective effects of MHO on
morbidity and its considerable prevalence, the identification of underlying characteristics that may be
associated with it may help provide a better understanding of the factors that may protect overweight
and obese individuals from developing metabolic disturbances [12,15]. Some studies have shown
that the prevalence of MHO is higher among younger vs. older individuals and among women vs.
men [16,17]. Physical activity has been suggested as one of the lifestyle factors that may be associated
with a metabolically healthy profile among overweight and obese subjects [16,17]. Similarly, it was
suggested that specific dietary factors may be associated with the MHO phenotype, even though
the number of studies in this field is still limited [18]. For instance, a study conducted among adult
overweight and obese women showed that the MHO phenotype was positively associated with higher
daily intakes of fiber and a higher number of daily servings of vegetables [18]. However, subsequent
studies failed to confirm similar associations [19,20]. Results from a recent investigation of food groups,
macro- and micronutrients’ intakes in a multi-ethnic group of 775 obese Americans did not support the
hypothesis that dietary intake is associated with MHO [21]. This controversy may partly result from
the use of traditional methods in nutritional epidemiology which focuses on the intake of individual
nutrients, foods or food groups when investigating the association between diet and MHO. Such a
conventional approach has several limitations mainly the interaction between nutrients, confounding
by foods/nutrients not eaten and the problem of collinearity [22]. In this context, and to overcome the
limitations of the traditional methods of examining single foods or nutrients, dietary pattern analysis
was proposed as an approach that allows the examination of the holistic effect of diet on disease [23].
In fact, the dietary pattern approach looks beyond single nutrients or foods and attempts to capture
the broader picture of diet that is hypothesized to be linked to health. In addition, results stemming
from dietary patterns analyses are more helpful in disseminating diet-related messages to consumers
who seem more likely to adhere to these messages rather than those stemming related to single foods
or nutrients [22].
In Lebanon, similarly to other Eastern Mediterranean countries, the rate of overweight and
obesity among adults is reported to follow an escalating secular trend, with its prevalence estimates
increasing from 54.4% to 65.0% over the past decade [24]. Such an alarming trend coupled with the
potential protective effect of MHO on disease risk, underscores the need to examine the proportions
of overweight and obese individuals who are metabolically healthy and to investigate associated
dietary and lifestyle factors. This study aims to (1) examine the proportion of Metabolically Healthy
Overweight and Obesity (MHOv/O) among Lebanese adults (2) evaluate the socio-demographic and
lifestyle correlates of MHOv/O; and (3) investigate the independent effect of previously identified
dietary patterns on odds of MHOv/O in the study population.
2. Materials and Methods
2.1. Study Design and Participants
Data for this study were drawn from the cross-sectional National Nutrition and
Non-Communicable Disease Risk Factor Survey (2008–2009) described elsewhere [25]. In brief,
households, the primary sampling units, were drawn using a stratified cluster random sampling
frame. The strata were the six administrative Lebanese governorates, while the clusters were further
selected at the level of districts. Using the household roster, one adult from each household was
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selected. The distribution of the study sample by sex and 5-year age group was similar to that of the
Lebanese population as estimated by the Central Administration for Statistics in Lebanon (2004) [26].
Out of 2202 visited households, 1982 accepted to participate in the study (response rate 90%) [27].
Of those, participants who had no chronic diseases and were not taking blood pressure, sugar or
lipid lowering medications were contacted to give blood samples (n = 1331). From these participants,
337 subjects provided written consent and gave a blood sample. Comparison of subjects who gave
blood and those who did not showed that both groups were comparable across the sociodemographic
characteristics except for marital status (62% of respondents vs. 50% of non-respondents are married).
In addition, significantly higher proportions of overweight and obesity were found among those who
gave blood as compared to those who did not (Overweight 36%, Obesity: 22% vs. Overweight 33%,
Obesity 16% respectively, p < 0.05). (Unpublished data). Of these 337 subjects, 196 were overweight and
obese individuals (BMI ě 25 kg/m2), and their data are included in this study (overweight: n = 119;
obese: n = 77).
2.2. Data Collection
At the participants’ homes, data collection was conducted by trained field workers, phlebotomists
and dietitians. Data collection procedures followed the WHO STEP wise approach to Surveillance
(STEPS) [26] and included socio-demographic and lifestyle questionnaires, anthropometric
measurements, biochemical assessment, as well as a food frequency questionnaire (FFQ) for the
evaluation of dietary intake. The study protocol was reviewed and approved by the Institutional
Review Board of the American University of Beirut, and informed consent was obtained from all
participants in the study.
Socio-demographic characteristics were age, sex, marital status, education level, crowding index,
and family history of obesity. Crowding index was defined as the average number of people per room,
excluding the kitchen and bathroom. Previous studies have shown that a higher crowding index
was correlated with a lower socioeconomic status [28–30]. This finding was further validated in
the Lebanese context [31]. A positive family history of obesity was defined as either one of the
two parents (mother or father) identified as obese. Lifestyle factors included smoking, physical
activity, weekly frequency of breakfast, snack consumption as well as frequency of eating at TV and
eating out. Snacking was defined as an intake occasion that was not considered a main meal, light
meal/breakfast or drink-only [32]. ‘Eating out’ and ‘Eating at TV’ were examined in terms of number of
occasions per week. Physical activity was assessed using the short version of the International Physical
Activity Questionnaire, and three levels of physical activity were determined based on metabolic
equivalents-min per week (low, moderate, high) [33].
Anthropometric measurements obtained included weight, height and waist circumference, all
of which were obtained using standardized protocols. The percent body fat was computed using
skinfold thickness measurements according to the Durnin and Womersley formula [34]. Blood pressure
was measured using a standard mercury sphygmomanometer. Two readings were obtained for both
systolic and diastolic blood pressure, at 5-min intervals, and their average was used in this study.
Metabolic and biochemical assessments were measured after an overnight fast and included
serum triglycerides, HDL and LDL-cholesterol, fasting blood glucose, fasting blood insulin, and CRP.
Details regarding blood collection and analysis were described elsewhere [25].
Dietary patterns in the study population: Previous work by our research group derived dietary
patterns among survey participants who had complete socio-demographic, lifestyle, dietary as well as
anthropometric and biochemical data [25]. The FFQ used to assess dietary intake had 61 items and
measured food intake over the past year. For each food item listed in the FFQ, a standard portion
size was indicated and five frequency choices were given. This FFQ was designed by a panel of
nutritionists and included culture specific dishes and recipes. It was tested on a convenient sample to
check for clarity and cultural sensitivity. For the derivation of the dietary patterns, food items were
grouped into 25 food groups based on similarities in ingredients, nutrient profile, and/or culinary
usage [25]. Food items having a unique composition (e.g., eggs, olives, and mayonnaise) were classified
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individually. The total consumption for each group was determined by summing the daily gram
intake of each item within the group. Using the dietary intake of these 25 food groups, dietary
patterns were identified by factor analysis. The latter is a data-driven technique which identifies
foods that are frequently consumed together by grouping food items based on the degree to which the
amounts eaten are correlated together [35]. The number of factors/patterns to be retained was based
on three criteria: (1) the Kaiser criterion (eigenvalues > 1); (2) inflection point of the scree plot; and
(3) the interpretability of factors. The rotated factor loadings matrix was extracted (Varimax rotation).
The derived dietary patterns were labeled based on food groups having a rotated factor loading greater
than 0.4. Factor scores were calculated by multiple regressions; a higher factor score indicated a greater
adherence to the respective factor or pattern [36].
Accordingly, three dietary patterns were identified: Fast Food/Dessert, Traditional-Lebanese, and
High Protein. The Fast Food/Dessert pattern consisted mainly of hamburger, shawarma, pizza and
pies, falafel sandwiches, desserts, as well as carbonated beverages and juices. The Traditional-Lebanese
pattern was identified as a variant of the Mediterranean diet [37] and included foods such as dairy
products, olives, fruits, legumes, grains, eggs, vegetable oil, dried fruits, and traditional sweets.
The High Protein pattern was characterized by high intakes of fish, chicken, meat, and low fat dairy
products. Further details about the patterns and the loadings of each food items are presented in
Appendix. The patterns’ scores for Fast Food/Dessert, Traditional-Lebanese, and High Protein of
overweight and obese participants (BMI ě 25kg/m2) were included in the analyses of this study.
2.3. MHOv/O Classification
To date, there is no consensus on the MHO phenotype’s definition. A commonly used definition is
The Adult Treatment Panel criteria for the metabolic syndrome (ATP-III) criterion, which was used in
this study. Accordingly, an overweight or obese subject was classified as MHOv/O if he/she had one or
none of the following: triglycerides ě1.7 mmol/L; systolic blood pressure (BP) ě130 mm¨ Hg; diastolic
blood pressure ě85 mm¨ Hg; fasting blood glucose ě5.6 mmol/L; and HDL- cholesterol <1.04 mmol/L
for men and <1.29 mmol/L for women. Overweight and obese subjects with more than one of these
conditions were classified as Metabolically Unhealthy Overweight and Obese (MUHOv/O).
2.4. Statistical Analyses
Descriptive statistics for socio-demographic, lifestyle, anthropometric, and biochemical
characteristics of study participants were presented as means ˘ SD and proportions for continuous and
categorical variables, respectively. Chi-square and independent t-tests were used to compare MHO and
MUHOv/O groups. The association of each of the characteristics of study participants with MHOv/O
was assessed using simple logistic regression analysis. In order to evaluate the determinants of
MHOv/O, a multiple logistic regression model was used. In this model, variables were included if they
were significantly associated with the outcome in the univariate analysis. Simple and multiple logistic
regression models were also used to evaluate the associations between the dietary patterns of the study
population and the odds of the MHOv/O phenotype. In these models, scores of the dietary pattern
were the independent variable (grouped as low adherence-1st tertile- and high adherence-2nd and 3rd
tertile), and MHOv/O phenotype as dependent variable (MHOv/O vs. MUHOv/O). These models
were adjusted for variables found to be significantly associated with MHOv/O. Tests for linearity
(Tolerance > 0.4) of the covariates included in the regression models were performed. Normality of the
residuals was assessed by the histogram of standardized residuals and normal probability plot in all
regression models. All analyses were undertaken using SPPS software version 22 (IBM Corp. Released
2013. IBM SPSS Statistics for Windows, Version 22.0. IBM Corp: Armonk, NY, USA).
3. Results
The proportion of MHOv/O in the study population was 37.24%, 95% CI (30.78–44.19).
Descriptive characteristics of the study population and their association with MHOv/O, as derived
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by simple logistic regression, are shown in Table 1. Of socio-demographic characteristics, sex, and
education level were associated with MHOv/O status. Females and participants with a higher
education level had higher odds of MHOv/O. Belonging to the ‘High Physical Activity’ category was
also associated with a higher odd of MHOv/O. While BMI and percent body fat were not associated
with MHOv/O, a one unit increase in waist circumference led to significantly lower odds of MHOv/O
in the study population.
Table 1. Descriptive characteristics of the study population and their association with Metabolically






† OR (95% CI)
Age (years) 42.7 ˘ 15.7 39.2 ˘ 13.0 0.12 0.98 (0.96–1.00)
Sex 0.00
Males 81 (66) 29 (40) Ref
Females 42 (34) 44 (60) 2.93 (1.61–5.33)
Marital status 0.93
Single 38 (31) 23 (32) Ref
Married 85 (69) 50 (68) 0.97 (0.52–1.81)
Education 0.06
Middle school 60 (49) 23 (31) Ref
High school 32 (26) 27 (37) 1.93 (0.94–3.99)
University & Higher
education 31 (25) 23 (32) 2.20 (1.09–4.44)
Family history of obesity 0.84
No 69 (56) 42 (57) Ref
Yes 54 (44) 31 (43) 0.94 (0.523–1.69)
Crowding index 1.0 ˘ 0.5 1.2 ˘ 0.5 0.10 1.56 (0.91–2.66)
<1person per room 52 (43) 22 (31) Ref
ě1 person per room 70 (57) 50 (69) 1.69 (0.91–3.13)
Breakfast per week 5.0 ˘ 2.8 5.3 ˘ 2.5 0.40 1.05 (0.94–1.17)
Breakfast Skippers (ď5
times/week) 44 (36) 24 (33) Ref
Breakfast consumers (>5
times/week) 79 (64) 49 (67) 1.14 (0.62–2.10)
Smoking 0.24
No 83 (67) 55 (75) Ref
Yes 40 (33) 18 (25) 0.68 (0.35–1.30)
Physical activity level 0.00
Low 49 (40) 18 (25) Ref
Moderate 29 (24) 9 (12) 0.85 (0.34–2.13)
High 45 (36) 46 (63) 2.78 (1.41–5.49)
Snack per day 1.5 ˘ 1.2 1.5 ˘ 0.9 0.60 0.93 (0.71–1.23)
Eating at TV per week 2.6 ˘ 3.1 2.4 ˘ 3.2 0.57 0.97 (0.89–1.07)
Eating out per week 1.5 ˘ 2.2 0.8 ˘ 1.4 0.03 0.84 (0.70–1.01)
BMI (Kg/m2) 30.2 ˘ 4.1 29.3 ˘ 3.7 0.13 0.94 (0.87–1.02)
Waist circumference (cm) 97.4 ˘ 11.1 92.6 ˘ 10.4 <0.01 0.95 (0.93–0.98)
Insulin (μU/mL) 29.5 ˘ 22.6 21.2 ˘ 8.3 <0.01 0.95 (0.91–0.98)
CRP (mg/dl) 6.9 ˘ 9.2 5.6 ˘ 5.6 0.29 0.985 (0.93–1.02)
Percent body fat 32.0 ˘ 7.6 32.7 ˘ 6.9 0.56 1.01 (0.97–1.06)
Numbers in this table represent mean ˘ SD for continuous variables and n (%) for categorical variables.
† p-values were derived from chi square test for categorical variables and from independent samples t-test for
continuous variables.
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Correlates of the MHOv/O status were examined by multiple logistic regression, and the resulting
OR and their corresponding 95% CI are presented in Table 2. After adjustment, female sex, higher
education, and physical activity levels were associated with a higher odd of MHOv/O among
study participants.
The OR and 95% CI for the association of adherence to these dietary patterns with the odds
of MHOv/O are presented in Table 3. These odds were derived from multiple logistic regression
adjusted for sex, education, and physical activity. Results indicated that a high adherence to the
Traditional-Lebanese pattern was associated with 83% increase in the odds of MHOv/O (OR: 1.83,
95% CI: 1.09–3.91). No significant association was noted between the Fast Food/Dessert and the High
Protein patterns and the odds of MHOv/O in the study population.
Table 2. Multiple logistic regression for the association between socio-demographic and lifestyle
characteristics with MHOv/O in the study population (n = 196).
Demographic and Lifestyle Variables OR (95% CI)
Age (years) 0.99 (0.97–1.02)
Sex
Males Ref
Females 3.81 (1.95–7.40) **
Education
Middle school Ref
High school 2.66 (1.19–5.96) *




High 2.35 (1.13–4.92) *
* p-value ď 0.05. ** p-value ď 0.001.
Table 3. Crude and adjusted logistic regression models describing the association between the various
dietary patterns and MHOv/O in the study population, as derived by logistic regression (n = 196) *,†.
Crude Model OR; 95% CI Adjusted Model OR; 95% CI
Fast Food/Dessert
Low adherence Ref Ref
High adherence 0.79 (0.43–1.45) 1.38 (0.66–2.92)
Traditional-Lebanese Pattern
Low adherence Ref Ref
High adherence 1.29 (0.69–2.40) 1.83 (1.09–3.91)
High Protein Pattern
Low adherence Ref Ref
High adherence 1.17(0.63–2.17) 1.36 (0.69–2.70)
* Low adherence was defined as belonging to the 1st tertile of the pattern score, while high adherence was defined
as belonging to the 2nd and 3rd tertiles. † The adjusted model included sex, education, and physical activity.
4. Discussion
This study is the first in Lebanon and the region to assess the proportion and correlates of
MHOv/O and investigate its association with dietary patterns among overweight and obese adults.
The results showed that the proportion of MHOv/O in the current study sample is 38.2%, implying
that approximately one out of three overweight/obese individuals is considered metabolically healthy.
This proportion is higher than a recent estimate from a prospective cohort of 4397 adults in Spain,
where prevalence of MHOv/O was found to be 28.7% [38]. Such a difference could be attributed to
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the fact that overweight and obese participants with medical complications were not included in the
denominator for calculating the proportion of MHOv/O in the study sample, given that subjects were
excluded if they had a known history of chronic diseases and/or were taking blood pressure, sugar, or
lipid lowering medications. Such an exclusion criterion was chosen to avoid reverse causality in the
association between MHOv/O and dietary patterns.
The findings of this study showed that, even though BMI and percent body fat were not associated
with MHOv/O, a negative association between waist circumference and MHOv/O was observed.
Recognizing waist circumference as a proxy measure of visceral adiposity [39], these findings implicate
a possible role for visceral fat in modulating the metabolic profile in overweight and obese subjects.
In fact, it has been proposed that metabolically healthy individuals have lower amounts of visceral
fats [40,41]. Abdominal obesity, with its characteristic increase in visceral fat, is associated with an
increase in the levels of free fatty acids (FFA) and abnormal adipokine profiles, which can result
in the development of insulin resistance and other metabolic abnormalities including dyslipidemia,
hyperglycemia, and elevated blood pressure.
In this study, investigation of the correlates of MHOv/O showed that female gender, higher
education levels, and higher physical activity are significantly associated with higher odds of this
phenotype. The fact that MHOv/O status was positively associated with female gender is in
line with what has been reported in other investigations on MHO [40] and may be a reflection
of the lower visceral fat deposition in women compared to men, when matched for BMI [42,43].
The positive association between female gender and MHOv/O is also in agreement with studies
reporting women as being more health-conscious and followers of dietary recommendations than
men [44,45]. Higher education may also be a driving factor towards healthier diets and lifestyles,
and therefore higher odds of being metabolically healthy [46]. Our findings regarding the positive
association between physical activity and MHOv/O are in accordance with what has been previously
reported [13] and may be explained by several mechanisms including stimulation of fatty acid uptake
and oxidation and increasing insulin sensitivity [47].
In the present study, we have opted to use the dietary pattern approach in investigating the
association between diet and the MHOv/O phenotype. Previous studies conducted by our group
on a national sample of Lebanese adults, which included normal weight, overweight and obese
subjects, documented a positive association between metabolic syndrome and adherence to the Fast
Food/Dessert pattern, a pattern that contains most of the food groups characteristic of the “Western
Pattern” [25,48] and which was found to be associated with higher intakes of fat, saturated fat, sugar,
and sodium coupled with lower intakes of dietary fiber and calcium, when compared to traditional
Lebanese dietary pattern [25]. However, in the present study, which focuses on overweight and obese
subjects only, we did not observe an association between the MHOv/O status and adherence to the Fast
Food/Desert pattern. These results suggest that the negative effects of the Fast Food/Desert pattern on
cardio-metabolic risk and the metabolic syndrome could be mediated mainly by its effects on increasing
adiposity and obesity itself. In addition, even though previous studies conducted by our group did not
document an association between the Traditional-Lebanese pattern and obesity risk [48], the results of
this study showed that higher adherence to the Lebanese pattern was associated with higher odds
of MHOv/O in overweight and obese adults. Taken together, these findings suggest that, although
the Traditional-Lebanese dietary pattern may not be protective against obesity, it may offset or buffer
adiposity-related metabolic abnormalities in overweight and obese subjects. The Traditional-Lebanese
dietary pattern, a variant of the Mediterranean diet [37], is in fact a pattern that is rich in fruits,
vegetables, legumes, olives, olive oil, and dairy products. This dietary pattern was also found to be
associated with higher intakes of monounsaturated fats, polyunsaturated fats, fiber, and calcium while
being characterized by lower intakes of protein, cholesterol, saturated fat, and sugars [25]. Dietary fiber,
through its colonic, intrinsic and hormonal effects, and mono- and polyunsaturated fats, through their
ability to buffer lipid and insulin fluctuations and peaks, may work in concert to increase insulin
sensitivity, enhance fat oxidation, and decrease cardio-metabolic risk [49–52]. In addition, the beneficial
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combinations of phytochemicals, antioxidants, and fiber brought by a diet rich in legumes, fruits, and
vegetables may decrease oxidative stress, temper the inflammatory response, and therefore enhance
insulin sensitivity [53]. Dairy products, which also characterize the Lebanese dietary pattern, have
been associated with decreased visceral fat, an effect that is likely to be mediated by independent or
synergistic effects of calcium and dairy protein, on lipolysis, lipogenesis, and thermogenesis [54,55].
Our findings related to the positive association between the Lebanese dietary pattern and the MHOv/O
phenotype are similar to those reported by Phillips et al. [20], whereby in a cross-sectional study among
adults aged 45–74 years, greater compliance with the food pyramid recommendations and higher
dietary quality were positively associated with metabolic health in obese subjects.
The findings of this study ought to be considered within the context of its limitations. First, we
have included in our sample both overweight and obese individuals and not only obese. Descriptive
statistics, however, have demonstrated that there was no significant difference in BMI between
MHOv/O and MUHOv/O, indicating that overweight individuals did not have higher odds
of belonging to the MHOv/O phenotype over obese participants. Second, the MHOv/O state
may not be a stable phenotype, and there remain open questions related to whether MHOv/O
represents a transient phenotype changing with aging and behavioral and environmental factors [56].
Third, the percentage of survey participants who agreed to give blood (respondents) was low (24.3%).
Comparison of respondents and non-respondents showed that both groups were comparable across
the sociodemographic characteristics except for marital status and proportions of overweight and
obesity (as indicated in the Methods section). Lastly, the cross-sectional design of this study does not
allow for causality inference. Longitudinal studies are needed to further confirm the role of dietary
patterns in modulating metabolic profiles in high risk individuals.
5. Conclusions
In conclusion, the study showed that overweight and obese subjects with higher adherence to the
Traditional-Lebanese dietary pattern had higher odds of belonging to the MHOv/O phenotype,
independent of other socio-demographic, lifestyle characteristics. These findings suggest that
the Traditional-Lebanese dietary pattern, a variant of the Mediterranean diet, may be associated
with offset or delayed development of adiposity-related metabolic abnormalities. In this context,
interventions and strategies aiming at preserving and promoting the traditional diet could be proposed
in Lebanon. It is important to note that, even though this study has identified factors that modulate
the odds of MHOv/O, maintaining a healthy body weight remains the most impactful public health
recommendation to decrease metabolic abnormalities and associated diseases.
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Appendix A
Table A1. Food items/groups constituting the dietary patterns prevalent in the study population *,†.
Dietary Patterns
Fast Food/Dessert Traditional-Lebanese High protein
Hamburger (0.76) Dairy products-full fat (0.58) Fish (0.70)
160
Nutrients 2016, 8, 432
Table A1. Cont
Dietary Patterns
Shawarma (0.72) Olives (0.56) Chicken (0.69)
Pizza and pies (0.70) Fruits and vegetables (0.49) Meat (0.60)
Falafel Sandwiches (0.61) Legumes (0.47) Dairy products-low fat (0.54)
Desserts (0.41) Grains (0.47) Breakfast cereals (0.23)
Carbonated beverages and juices
(0.4) Eggs (0.45) -
Mayonnaise (0.35) Vegetable oil (0.43) -
Butter (0.22) Nuts and dried fruits (0.40) -
Alcoholic beverages (0.2) Traditional sweets (0.37) -
* Factor loading of the various food groups/items are presented in (). † The dietary patterns and the food
items-and their factor loading-making up these patterns were taken from Naja et al. (2013) [29].
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Abstract: The aim of this systematic review was to assess the effect of diet on changes in parameters
describing the body size phenotype of metabolically healthy obese subjects. The databases Medline,
Scopus, Web of Knowledge and Embase were searched for clinical studies carried out between 1958
and June 2016 that reported the effect of dietary intervention on BMI, blood pressure, concentration
of fasting triglyceride (TG), high density lipoprotein cholesterol (HDL-C), fasting glucose level,
the homoeostatic model assessment of insulin resistance (HOMA-IR) and high sensitivity C-Reactive
Protein (hsCRP) in metabolically healthy, obese subjects. Twelve clinical studies met inclusion
criteria. The combined analyzed population consists of 1827 subjects aged 34.4 to 61.1 with a
BMI > 30 kg/m2. Time of intervention ranged from eight to 104 weeks. The baseline characteristics
related to lipid profile were more favorable for metabolically healthy obese than for metabolically
unhealthy obese. The meta-analyses revealed a significant associations between restricted energy
diet and BMI (95% confidence interval (CI): ´0.88, ´0.19), blood pressure (systolic blood pressure
(SBP): ´4.73 mmHg; 95% CI: ´7.12, ´2.33; and diastolic blood pressure (DBP): ´2.75 mmHg; 95% CI:
´4.30, ´1.21) and TG (´0.11 mmol/l; 95% CI: ´0.16, ´0.06). Changes in fasting glucose, HOMA-IR
and hsCRP did not show significant changes. Sufficient evidence was not found to support the use
of specific diets in metabolically healthy obese subjects. This analysis suggests that the effect of
caloric restriction exerts its effects through a reduction in BMI, blood pressure and triglycerides in
metabolically healthy obese (MHO) patients.
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1. Introduction
The prevalence of obesity is increasing worldwide with prognoses expected to affect more than
one billion people by 2030 [1]. An association between obesity and increased risk of co-morbidities, i.e.,
metabolic syndrome (MetS) and cardiovascular disease (CVD) leading to significantly higher all-causes
of mortality, has been observed [2]. However, the metabolically healthy obese (MHO) phenotype was
described in the early 1980s [3], and, to date, there is no single consistent definition that covers “the
metabolic health” approach in relation to differentiated dietary habits in obese subjects [4–6].
So far, the direct mechanism, which contributes to the different effects of weight loss in MHO
and metabolically unhealthy obese (MUHO) subjects is not known, though it seems that it may vary
as a function of different baseline metabolic profiles in MHO and MUHO groups. Only limited data
are available with regards to dietary behaviors in MHO [7]. The prevalence of MHO is predicted
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to be 30%–40% of the obese population, with higher rates in younger subjects and in females [4,8].
Nevertheless, it should be taken under consideration that MHO subjects can shift to the metabolically
unhealthy phenotype, a change confirmed by Schröder et al. [9] in a 10 years follow-up study.
Due to the fact that the effectiveness of dietary interventions in MHO is not very well known, we
aimed to describe the influence of applied diet from intervention studies on changes in parameters
describing the body size phenotype (body mass index—BMI, blood pressure—BP and concentration of
selected biomarkers) of MHO.
2. Experimental Section
2.1. Search Strategy
The databases Medline, Scopus, Web of Knowledge and Embase were searched for clinical studies
carried out between 1958 and June 2016 that reported the effect of dietary intervention on BMI and
selected cardio-metabolic parameters (blood pressure and concentration of selected biomarkers) as
primary or secondary outcomes in MHO. Search strategy was restricted to humans, English language
and full length, original articles. The search based upon the listed below following index terms
and title: #1 “Benign Obesity, Metabolically” OR “Metabolically Healthy Obesity” OR “Healthy
Obesity, Metabolically” OR “Obesity, Metabolically Healthy” OR “Metabolically Benign Obesity” OR
“Metabolically normal” OR “Metabolic syndrome” AND #2 ”Diet” OR “Diet, carbohydrate-restricted”
OR “Diet, fat-restricted” OR “Diet, protein-restricted” OR “Ketogenic diet” OR “Diet, high-fat” OR
“Diet, reducing” OR “Weight reduction programs” OR “Caloric restriction” OR “Lifestyle intervention”
NOT “Animals”. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Statement was followed [10].
2.2. Metabolically Healthy Obese—Definition
The criteria for MHO used in the studies include: absence of abdominal obesity on the basis of
waist circumference, absence of metabolic syndrome components, e.g., normal blood pressure, normal
lipid values, normal fasting glucose concentrations (at times also including normal C-reactive protein
concentrations), insulin sensitivity determined on the basis of the homoeostatic model assessment
of insulin resistance (HOMA-IR) and a high level of cardiorespiratory fitness [11]. All features were
also used in the long-term prognosis of cardiovascular disease and all-cause mortality for MHO by
Bo et al. [12], Calori et al., [13] and Hammer et al. [14].
Specifically, the criteria for the body size phenotype of MHO subjects include: a BMI ě 30 kg/m2
and <2 cardio-metabolic abnormalities (systolic/diastolic blood pressure (SBP/DBP) ě 130/85 mmHg
or antihypertensive medication use; fasting triglyceride (TG) level ě 150 mg/dL (1.693 mmol/L));
decreased high density lipoprotein cholesterol (HDL-C) level < 40 mg/dL (1.0344 mmol/L) in men
and <50 mg/dL (1.293 mmol/L) in women or lipid-lowering medication use; fasting glucose (Glc)
level ě 100 mg/dL (5.55 mmol/L) or antidiabetic medication use; insulin resistance: HOMA-IR > 5.13,
i.e., the 90th percentile; systemic inflammation: high sensitivity C-Reactive Protein (hsCRP)
level > 0.1 mg/L, i.e., the 90th percentile) [6]. Similar criteria were proposed by Meigs et al. [5]
including the addition of waist circumference (WC) (>102 cm in men and >88 cm in women) and
expanding the definition to include up to <3 cardio-metabolic abnormalities.
2.3. Inclusion and Exclusion Criteria
Only studies conducted with subjects described as metabolically healthy obese subjects, indicating
the changes in BMI, blood pressure and selected blood parameters after various dietary interventions,
were included. The intervention studies (randomized controlled trial and non-randomized trial) were
taken into consideration. The articles that did not meet inclusion criteria (animal studies, other than
the type of documents mentioned above, articles in any other language than English) were excluded.
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2.4. Data Extraction and Analysis
Relevant articles were identified by screening the abstracts, titles and full-texts. The study selection
process was performed by two independent researchers (M.S.-M. and J.W.) in parallel for each database.
In every step of assessment, all disagreements between researchers were resolved after consultation.
In the case of disagreement during the title assessment process, the paper was included in the next
step. The process outline and workflow is presented in Figure 1.
Figure 1. Process flow sheet.
Eligible studies were evaluated according to: the number of participants, study design, type
of dietary intervention, changes in BMI (defined as body mass divided by the square of the height),
and criteria for body size phenotype of MHO defined according to Third Report of the National
Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) [6]. To assess the study quality,
a nine-point scoring system according to the Newcastle-Ottawa Scale was used. The maximum score
was nine, with a high-quality study defined by a threshold of ě7 points [15].
The recorded biomarkers concentrations were converted to mmol/L (fasting glucose,
Triglycerides, HDL-Cholesterol) and mg/L (hsCRP) in order to standardize results. A meta-analysis
was performed to combine the results of individual studies. Data were analyzed using a random-effects
model. The effect size of a study was investigated by calculating the standardized mean difference with
a 95% confidence interval (CI). The heterogeneity of the sum of studies was tested for significance. As a
measure for quantifying inconsistency, I2 was selected [16]. Although included studies in our analysis
were heterogeneous, careful inclusion of the suited arms (MHO group) in different interventions
allowed us to combine the collected papers and run our analyses. The results of the meta-analysis were
visualized using a forest plot which illustrates the results of the individual studies and the summary
effect. The analysis was performed with Review Manager (RevMan, V5.3, The Nordic Cochrane Centre,
the Cochrane Collaboration, Copenhagen, Denmark, 2014).
3. Results
3.1. Search Results
Using wide terms to describe the metabolically healthy obese patients, we end up with more than
14,000 articles that were screened. After initial exclusion criteria, 135 papers were assigned for full-text
review with 12 articles included for data extraction and analysis [17–28] (Figure 2).
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Figure 2. Process of literature search on the association between diet and selected cardio-metabolic
parameters in metabolically healthy obese.
3.2. Studies and Populations Characteristics
The characteristics of clinical studies (randomized and non-randomized) and populations are
presented in Table 1. The population consists of 1827 subjects and was characterized by a baseline
BMI > 30 kg/m2, a mean age from 34.4 [18] to 61.1 [20], and representing Caucasian and Asian
ethnicities. Time of interventions ranged from 12 to 104 weeks and were based on diet only [18,21–27]
or diet with combination of light to moderate physical activity (PA) [19,20,28] that supported the daily
energy deficit.
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3.3. Changes in Body Mass Index and Selected Cardio-Metabolic Outcomes during Dietary Interventions
The changes in BMI and selected cardio-metabolic outcomes during dietary interventions are
presented in Table 2. Reduction in BMI, from baseline to the final day of intervention, ranged from 1.1 to
2.9 kg/m2 in MHO, and were statistically significant in seven of twelve studies [18,20,22,23,25,27,28]
within the study group. Kantartizis et al. [19], Haro et al. [24], and Foster et al. [26] failed to report exact
values of baseline BMIs. The quantitative meta-analysis revealed a significant association between
the restricted energy diets (p < 0.0001, I2 = 99%) and change in BMI (´2.70 kg/m2; 95% CI: ´4.01,
´1.39) (Figure 3). The changes in systolic and diastolic blood pressure during the dietary interventions
were measured only in six studies [20,22,25–28]. However, the meta-analysis showed statistically
significant reduction in SBP (´4.73 mmHg; 95% CI: ´7.12, ´2.33; p = 0.0001, I2 = 87%) and DBP
(´2.75 mmHg; 95% CI: ´4.30, ´1.21; p = 0.0005, I2 = 86%) within MHO group after applied dietary
interventions, clinical relevance cannot be considered (Figure 4). The concentrations of TG and HDL-C
were reported in all selected studies, where the baseline characteristic with regards to blood lipids
was mostly more favorable for MHO than for metabolically unhealthy obese (MUHO) [19,21,23].
Nevertheless, the statistically significant association was observed only between energy restricted diets
and the reduction in TG concentration (´0.11 mmol/L; 95% CI: ´0.16, ´0.06; p < 0.0001, I2 = 59%)
(Figure 5). Fasting glucose was assessed in ten studies [15–18,20–23,25,26] with no significant decrease
(´0.05 mmol/L; 95% CI: ´0.14, 0.03; p = 0.21, I2 = 81%). Additionally, in the meta-analysis of
studies reporting changes in HOMA-IR [17–19,21,25,27,28] in relation to dietary intervention, no
significant reduction was observed within MHO group (´0.08; 95% CI: ´0.31, 0.14; p = 0.47, I2 = 85%)
(Figure 6). The reduction in hsCRP concentration were reported in only four studies [17,18,21,27] with
no significant association with dietary intervention found (´0.19 mg/L; 95% CI: ´1.35, 0.97; p = 0.75,
I2 = 98%) (Figure 7). The funnel plot did not reveal asymmetry despite selected studies being outliers,
suggesting no real evidence of a publication bias (Figure S1).
Figure 3. Forest plot of the random-effects meta-analysis of changes in BMI according to reduction in
energy intake shown as polled standard differences in the means with 95% Cis and in randomized and
non-randomized trials. * For each study, the square represents the point estimate of the intervention
effect. Horizontal lines join the lower and upper limits of the 95% CI of this effect. The area of shaded
squares reflects the relative weight of the study in the meta-analysis. Diamonds represent the subgroup
mean difference and pooled mean differences. CI indicates confidence interval.
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Figure 4. Forest plot of the random-effects meta-analysis of changes in Systolic and Diastolic Blood
Pressure according to reduction in energy intake shown as polled standard differences in the means
with 95% Cis and in randomized and non-randomized trials. * For each study, the square represents
the point estimate of the intervention effect. Horizontal lines join the lower and upper limits of
the 95% CI of this effect. The area of shaded squares reflects the relative weight of the study in
the meta-analysis. Diamonds represent the subgroup mean difference and pooled mean differences.
CI indicates confidence interval.
Figure 5. Forest plot of the random-effects meta-analysis of changes in Triglycerides and
HDL-cholesterol according to reduction in energy intake shown as polled standard differences in
the means with 95% Cis and in randomized and non-randomized trials. * For each study, the square
represents the point estimate of the intervention effect. Horizontal lines join the lower and upper limits
of the 95% CI of this effect. The area of shaded squares reflects the relative weight of the study in
the meta-analysis. Diamonds represent the subgroup mean difference and pooled mean differences.
CI indicates confidence interval.
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Figure 6. Forest plot of the random-effects meta-analysis of changes in Fasting Glucose and HOMA-IR
according to reduction in energy intake shown as polled standard differences in the means with
95% Cis and in randomized and non-randomized trials. * For each study, the square represents
the point estimate of the intervention effect. Horizontal lines join the lower and upper limits of
the 95% CI of this effect. The area of shaded squares reflects the relative weight of the study in
the meta-analysis. Diamonds represent the subgroup mean difference and pooled mean differences.
CI indicates confidence interval.
Figure 7. Forest plot of the random-effects meta-analysis of changes in high sensitivity C-Reactive
Protein according to reduction in energy intake shown as polled standard differences in the means
with 95% Cis and in randomized and non-randomized trials. * For each study, the square represents
the point estimate of the intervention effect. Horizontal lines join the lower and upper limits of
the 95% CI of this effect. The area of shaded squares reflects the relative weight of the study in
the meta-analysis. Diamonds represent the subgroup mean difference and pooled mean differences.
CI indicates confidence interval.
4. Discussion
Here, we present the first review summarizing the results from clinical studies performed in
MHO with a primary interest in changes in BMI and selected cardio-metabolic outcomes. The findings
of the conducted systematic review with meta-analysis did not find sufficient evidence to support
174
Nutrients 2016, 8, 455
the use of some specific diet in metabolically healthy obese subjects. However, it seems that effect
of caloric restriction is related to reduction in BMI, blood pressure and triglycerides in the group of
MHO patients.
It was imperative for the conducted review to show that the MHO subjects should be recognized
as the core group with a primary interest in a changing lifestyle being the determinant of “metabolic
health”. Other longitudinal studies [29,30] with shorter follow-up (6–8.2 years) have indicated that
only approximately half of MHO subjects maintained their “metabolic health” status. It was also
suggested that initially MHO subjects undergo adverse metabolic changes associated with obesity over
time [31]. Nevertheless, there is no clear data regarding the most beneficial dietary interventions, nor
the effectiveness, of energy restricted diets in MHO patients taking into account clinical significance.
As previously demonstrated [32,33], obesity can be associated with a higher relative risk for CVD
and cancer mortality compared to non-obese subjects. Therefore, the decrease in BMI can reflect the
improvement in body composition, and consequently, reduce the mortality [34]. We have observed a
significant association between the applications of energy restricted diets and BMI reduction in MHO
individuals. Recently, Phillips and Perry [35] has also indicated that greater low density lipoprotein
cholesterol (LDL-C) and HDL-C and less very low density lipoprotein cholesterol (VLDL-C) particles
increase the likelihood of MHO. However, the results of our meta-analysis, through the applied dietary
interventions, indicated only significantly beneficial association with the TG concentration within the
MHO group. However, the inflammatory status in MHO can be reduced [36], partially stemming
from more favorable fatty acid profiles [37] compared to MUHO, a significant decrease in hsCRP
concentration was not observed in our analysis. As has been highlighted by Karelis et al. [38] health
status may strongly influence the response to diet. For example, it was indicated in the MHO sedentary
obese postmenopausal women without type 2 diabetes that the response to an energy-restricted
diet may be different compared to at-risk individuals who achieve a similar weight loss, in that
insulin sensitivity significantly improved in at-risk participants, but significantly deteriorated in
MHO individuals in response to long-term diet. In our study, we did not find significant relation
between energy restricted diets and biomarkers related to carbohydrates metabolism, i.e., fasting
glucose and HOMA-IR within the MHO group of individuals. As shown in previously published
studies [31,33], the baseline characteristic of metabolic profile can be more favorable in MHO compared
to MUHO, which stay in line with some data selected for this systematic review [19,21]. As reported
in Karelis et al. [39], MHO may have higher insulin sensitivity and a more favorable lipid profile.
It has also been confirmed by Badoud et al. [40] that MHO individuals may show preserved insulin
sensitivity and a greater ability to adapt to a caloric challenge compared to MUHO individuals.
The postprandial response (i.e., area under the curve, AUC) for serum glucose and insulin were
similar between MHO and lean healthy individuals and significantly lower than MUHO individuals
(p < 0.05) [32]. However, a healthy metabolic profile and the absence of diabetic risk factors did not
protect young adults from incident diabetes associated with overweight and obesity [40]. The intake
of contraceptive pills by premenopausal women studied by Ruiz et al. [18] suggested that obtained
results might be applied only for this sex and age group. Interestingly, the potential differences in
body composition between MHO and MUHO were assessed in adults from the Pennington Center
Longitudinal Study showing differences consistent between genders in both analyzed groups [34].
In clinical practice, as a goal for reducing CVD risk, the importance of body weight loss contributing
to the maintenance of body weight loss is highlighted [4,41,42]. Camhi et al. [43] indicated that
MHO young women demonstrate healthier lifestyle habits with less sedentary behavior, more time
doing light physical activity, and healthier dietary quality for fat type and fiber in comparison to
MUHO. Therefore, MUHO subjects are characterized by a higher risk of diabetes compared to MHO,
which has been previously observed in Korean populations [44]. Indeed, metabolic health status,
obesity and weight change were all independently associated with increased incidences of diabetes
over five years of follow-up [44]. Nevertheless, we focused in our analysis on the MHO group of
individuals only looking at the consequence of the applied dietary interventions. The data from the
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International Population Study on Macro/Micronutrients and Blood Pressure (INTERMAP) cohort
study did not support the hypothesis that diet composition accounts for the absence of cardio-metabolic
abnormalities in MHO [45]. Furthermore, it has also been confirmed by Kimokoti et al. [46] in the
cross-sectional analysis from the REasons for Geographic And Racial Differences in Stroke (REGARDS)
study. Although HOMA-IR index can be slightly higher in MHO subjects than in subjects characterized
by normal weight, it may also be lower compared to MUHO [21]. It has been also shown that
a long-term intensive lifestyle program, including Mediterranean diet nutritional counselling and
high-intensity interval training, may be an appropriate intervention in MHO and MUHO subjects with
similar potential clinical health benefits including an improved body composition, blood pressure,
fasting glucose levels, insulin sensitivity, peak oxygen uptake, and muscle endurance [47]. Therefore,
it could be beneficial that the results obtained in intervention studies with regards to analyzed
cardio-metabolic outcomes may have yielded stronger and more consistent support from the results of
observational studies. More broadened interventional studies are needed to assess different dietary
approaches in MHO subjects.
5. Limitations
The present findings are based on limited ethnicity (Caucasian, Asian), and, therefore,
results could vary as a function of ethnic background. Although the duration of interventions
in analyzed studies was relatively long, we could not analyze long-term follow-up changes of
analyzed cardio-metabolic parameters (no data available in the literature). Although the applied
dietary interventions were very different and heterogeneous in nature, all of them were based on
energy restriction.
6. Conclusions
Based on the limited body of extracted data, we did not find sufficient evidence to support the
use of some specific diet in metabolically healthy obese subjects. In general, it seems that the effect of
caloric restriction is related to reduction in BMI, blood pressure and triglycerides in MHO individuals.
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Abstract: Low-grade chronic inflammatory conditions such as ageing, obesity and related metabolic
disorders are associated with deterioration of skeletal muscle (SkM). Human studies have shown that
marine fatty acids influence SkM function, though the underlying mechanisms of action are unknown.
As a model of diet-induced obesity, we fed C57BL/6J mice either a high fat diet (HFD) with purified
marine fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (HFD-ED), a HFD
with corn oil, or normal mouse chow for 8 weeks; and used transcriptomics to identify the molecular
effects of EPA and DHA on SkM. Consumption of ED-enriched HFD modulated SkM metabolism
through increased gene expression of mitochondrial β-oxidation and slow-fiber type genes compared
with HFD-corn oil fed mice. Furthermore, HFD-ED intake increased nuclear localization of nuclear
factor of activated T-cells (Nfatc4) protein, which controls fiber-type composition. This data suggests
a role for EPA and DHA in mitigating some of the molecular responses due to a HFD in SkM. Overall,
the results suggest that increased consumption of the marine fatty acids EPA and DHA may aid in
the prevention of molecular processes that lead to muscle deterioration commonly associated with
obesity-induced low-grade inflammation.
Keywords: eicosapentaenoic acid (EPA)/Docosahexaenoic acid (DHA); obesity; skeletal-muscle
metabolism; mitochondrial β-oxidation; transcriptome
1. Introduction
The World Health Organization (WHO) estimates that chronic inflammatory conditions accounts
for more than 17 million deaths every year [1]. Obesity is considered one of the main underlying
factors for chronic inflammation and has almost doubled since 1980 and now over 1.4 billion adults
worldwide are obese. Obesity, once considered a problem only in developed countries, is now also
a major problem in low- and middle-income countries. Parallel to the increase in obesity, diseases
associated with chronic inflammation such as cardiovascular diseases and type 2 diabetes are also
rising [1]. One of the major concerns associated with low-grade inflammation is sarcopenia—loss of
muscle mass. Generally, after the age of 50 the muscle mass reduces at a rate of up to 1%–2% annually,
while fat mass increases [2,3]. At the same time, muscle strength drops at the rate of 1.5% annually
between the age of 50 and 60 years and at the rate of 3% thereafter [4]. Obesity accelerates age-related
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muscle deterioration [5] exacerbating the risk for type 2 diabetes (T2D) by approximately 30% [6].
The negative feedback loop defined as the combination of excess weight-gain and reduced muscle
mass, strength and performance is known as sarcopenic obesity [7]. Further suggestions of a role
for inflammation in sarcopenia includes an association between increased TNF-α [8] and Il-6 [9] and
decreased muscle mass and strength.
Skeletal muscle (SkM) constitutes about 40% of total body mass in adult lean men and is an
adaptable tissue in response to changes in lifestyle such as diet and physical training [10,11]. SkM is one
of the major sites of glucose metabolism, accounting for about 30% of postprandial glucose disposal [12].
This makes SkM a crucial organ for maintaining healthy glucose concentrations in the body, with
loss of muscle mass also associated with increased type 2 diabetes risk. Changes to diet may impact
on SkM and use of fish oil rich in the fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) have been proposed to improve SkM metabolism [13]. An intervention with marine fatty
acids improved muscle mass and function in older adults [13] and animal studies suggest a role for
marine fatty acids in SkM anabolism and increased protein synthesis [14,15]. In addition, marine
fatty acids have anti-inflammatory activity in animals and humans [16], which may reduce the loss
of inflammation-mediated SkM mass in older adults. Supplementation with EPA and DHA, the two
main marine fatty acids, could be the basis for a simple, safe and low-cost solution for preventing
and mitigating negative changes to SkM metabolism. For such a strategy to be credible, it is crucial to
understand the underlying signaling mechanisms mediated by EPA and DHA on SkM.
Our previous intervention studies showed that mice fed high fat diets (HFDs) supplemented with
herring improve muscle mass compared with mice fed HFD supplemented with beef [17,18]. In several
randomized control trials in humans, marine fatty acids improve muscle volume, a surrogate marker
for improved muscle performance [13,19,20]. In order to build on these results and determine if EPA
and DHA, or other components in fatty fish, are responsible for improving muscle metabolism and to
determine what the underlying mechanisms could be, we conducted a follow-up trial on earlier work
with fatty fish [17,18]. Here we have used transcriptomics to explore how replacing a commonly used
source of dietary fat, corn oil with purified EPA and DHA interacts with gastrocnemicus skeletal muscle
(gSkM) gene expression, in order to investigate how EPA and DHA can affect muscle deterioration.
2. Materials and Methods
2.1. Animal Experiment
Six-week old male C57BL/6 J mice (Harlan BV, The Netherlands) were grouped 5–6 mice/cage,
and were housed in a temperature and humidity-controlled environment with 12 h light/dark cycle
for three weeks to acclimatize to the facility. At nine weeks of age, mice were switched from a normal
mouse chow to one of three intervention diets: high fat diet with EPA and DHA (HFD-ED), a high fat
diet with corn oil (HFD-corn oil) or the same mouse chow as during the acclimatization period (control
group). Mice were maintained on these diets for 8-weeks (see Diets for details). After 8-weeks the
animals were anesthetized by intraperitoneal injection of sodium pentobarbital (>60 mg/kg) and blood
was collected from the heart followed by cervical dislocation. Plasma was obtained by centrifugation
at 4 ◦C of EDTA whole blood (10 min; 10,000× g). The tissues were weighed and snap-frozen in liquid
nitrogen immediately after dissection. Both, tissues and plasma were stored at −80 ◦C until further
analysis. The animal experiments were approved by the Animal Ethics Committee at the University of
Gothenburg (Dnr: 253-2009) [21].
2.2. Diets
The mice were fed a standard control chow during the 3-weeks acclimatization period. The mice
did not differ in body weight at the start of the study (Table 1) and the body weights were measured
weekly during the study. We removed two mice from the control group due to unsocial behavior, thus
there were n = 9 mice in control and n = 12 mice in either HFD group. HFD were used to induce obesity
in the mice. The two HFD used in the study differed only in their fatty acid composition. The reference
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HFD was prepared with 5 weight/weight (w/w)% corn oil, while the treatment HFD was prepared
with 2 w/w% purified EPA and DHA (EPAX AS Lysaker, Norway) plus 3 w/w% corn oil. The control
diet provided 24 energy% (E%) as protein, 12 E% as fat and 65 E% as carbohydrates, whereas the two
HFD contained 25 E% as protein, 32 E% as fat and 44 E% as carbohydrates (Table 2). The diets were
prepared by Lantmännen AB (Kimstad, Sweden). Access to water and diet was ad libitum and the
diets were changed three times per week throughout the study.
Table 1. Changes in Body Weight Composition and Plasma Lipid Composition.
Parameter Control HFD-ED HFD-Corn oil
Total number of animals; n 9 12 12
Initial body weight (g) 27.5 ± 0.8 28.6 ± 0.8 24.3 ± 0.5
Final body weight (g) 31.4 ± 1 33.8 ± 0.8 36.2 ± 0.9
Change in body weight (g) 3.9 ± 0.5 a 5.2 ± 0.3 a 8.6 ± 0.5 b
plasma cholesterol (mmol/L) 5.6 ± 0.4 5.5 ± 0.4 5.2 ± 0.6
plasma triglyceride (mmol/L) 0.9 ± 0.1 a,b 1.1 ± 0.1 a 0.7 ± 0.1 b
The data are shown as mean ± SEM; different letters show significant different tested by ANOVA followed by
Tukey’s multiple comparison test. To calculate the changes in body weight (g), initial body weight values from
individual animals was subtracted from the final body weight measurement.
Table 2. Diet Compositions Namely Control, HFD-ED and HFD-Corn Oil (CO) [21].
Ingredient (g/100 g Diet) Control HFD-ED HFD-CO
Protein Casein 22.2 25.6 25.6
Carbohydrates
Sucrose 5.0 10.0 10.0
Corn starch 56.0 34.8 34.8
Cellulose 5.0 5.8 5.8
Fat
Total 5.0 15.0 15.0
Corn oil 2.5 3.0 5.0
Coconut oil 2.5 10.0 10.0
EPAX oils a 0 2.0 0
Minerals b 2.0 2.5 2.5
Miconutrients c 3.0 3.0 3.0
Choline bitartrate 1.6 2.0 2.0
Cholesterol 0 1.0 1.0
Methionine 0.2 0.3 0.3
Energy content (kJ/100 g) 1599 1752 1752
Protein E% 24 25 25
Carbohydrate E% 65 44 44




C10:0 0.20 1.47 1.33
C12:0 2.37 7.58 7.72
C14:0 1.54 4.58 4.78
C16:0 1.90 3.44 3.59
C18:0 0.68 2.26 2.49
SFA 6.70 19.33 19.91
C18:1n9 2.82 4.80 5.26
MUFA 2.82 4.80 5.26
C18:2n6 3.62 5.03 7.36
C18:3n6 0.12 0.22 0.26
n-6 PUFA 3.74 5.26 7.62
C20:5n3 (EPA) 0.00 2.03 0.01
C22:6n3 (DHA) 0.00 4.58 0.01
n-3 PUFA 0.00 6.61 0.02
a EPAX 1050. EPAX 6015. b CaCO3 (57.7%); KCl (19.9%); KH2PO4 (11.9%); MgSO4 (10.4%). c Corn starch
(98.22%); Ca(IO3)2 (0.0007%); CoCO3 (0.064%); CuO (0.02%); FeSO4 (0.5%); MnO2 (0.035%); Na2MoO4
(0.001%); NaSeO3 (0.0007%); ZnO (0.1%); Vitamin A (0.013%); B2 (Riboflavin-5-phosphate sodium; 0.027%);
B3 (0.1%); B5 (Ca Pantothenate; 0.057%); B6 (0.023%); B7 (0.0007%); B9 (0.007%); B12 (0.00008%); D3 (0.007%);
E (0.25%); K (0.003%). d Analyses were performed in triplicate and data was obtained by Gas chromatography
mass spectroscopy.
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2.3. Muscle Composition
Gastrocnemicus skeletal muscles were dissected and weighed directly after sacrifice. Plasma total
triglyceride and cholesterol was measured enzymatically with Konelab Autoanalyser version 2.0 at the
Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden. Clinical
chemistry procedures have been previously described in detail [21].
2.4. RNA Isolation and Quality Assurance
Four mice, representative from each diet group on the basis of body weight, plasma triglyceride
and plasma cholesterol levels were selected for RNA isolation and microarray analysis (Supplemental
Table S1). Total RNA from gSkM was purified using the RNeasy® Plus Universal Mini kit (Qiagen
Nordic, Sollentuna, Sweden). RNA samples were quantified spectrophotometrically (NanoDrop 2000c
UV-Vis Spectrophotometer, Thermo Scientific, Wilmington, NC, USA) and the quality of the RNA was
controlled by the ratio of 28S and 18S rRNA (RNA 6000 Nano LabChip for Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).
2.5. Western Blot Analysis
Nuclear and cytosolic extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction
Reagents kit (78833, Thermo Fisher Scientific). Western blot analysis was performed as described
earlier [22]. Briefly, the protein concentration was measured in duplicate using the Pierce BCA
Protein Assay kit (Thermo Fisher Scientific) for equal protein loading to the SDS-PAGE. After transfer
of the proteins to the membranes, the membranes were stained with 0.5% Ponceau S (Merck
Chemicals, Darmstadt, Germany) to visualize the protein transfer. For the detection of specific proteins,
the following primary antibodies were used: Rb-anti-m acetyl-CoA carboxylase (Acc; 3662; Cell
Signaling Technology), Rb-anti-m phospho-acetyl-CoA carboxylase (P-Acc; Ser79, 3661; Cell Signaling
Technology), Rb-anti-m troponin c1 (Tnnc1; sc-20642, Santa Cruz Biotechnology), Rb-anti-m Nuclear
factor of activated T-cells (Nfatc4; sc-13036, Santa Cruz Biotechnology). The secondary antibodies
were: HRP-conjugated Horse-anti-m IgG (7076; Cell Signaling Technology), Goat-anti-m IgG (sc-2020;
Santa Cruz Biotechnology) and Rb-anti-m IgG (7074; Cell Signaling Technology). As loading control
for each western blot, either glyceraldehyde 3-phosphate dehydrogenase (anti-Gapdh; sc-47724;
Santa Cruz Biotechnology), or lamin (anti-lamin A/C, sc-6215; Santa Cruz Biotechnology) was used.
Western blots for the protein Acc, P-Acc and Tnnc1 are in supplemental Figure S1.
2.6. Microarray—Data Acquisition and Analysis
RNA was labeled and hybridized to MouseWG-6_V2.0 Expression BeadChip (R3_11278593_A;
Illumina, CA, USA) that contains 45,281 transcripts, at the SCIBLU Genomics core facility (Swegene
Centre for Integrative Biology at Lund University, Sweden). The content of this BeadChip is derived
from the National Center for Biotechnology Information Reference Sequence (NCBI RefSeq) database
(Build 36, Release 22) [23], supplemented with probes from the Mouse Exonic Evidence Based
Oligonucleotide (MEEBO) [24] set, as well as example protein-coding sequences from RIKEN
FANTOM2 database [25]. The raw and normalized data is available in SOFT format at the Gene
Expression Omnibus database under Accession Number GSE76361.
The Illumina bead array files were imported to GenomeStudio Gene Expression (GSGX) software
1.9.0. The un-normalized expression data (fluorescence intensities) were extracted for the mean
intensity of arrays. R Studio software (Version 3.2.3, © 2015 RStudio, Inc., Boston, MA, USA) was used
for microarray data analysis. The data was quantile normalized and variance-stabilizing transformation
(VST) was performed using the default setting of lumiExpresso function from the lumi package [26].
The top 100 differentially expressed genes regulated by HFD-ED compared with HFD-corn oil are
provided in supplemental Table S2. The Empirical Bayes method from the limma package was then
applied to the signals to calculate moderated t- and F-statistics, log odds and differential expression
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for comparisons between the diets from skeletal muscle tissue [27]. The Generally Applicable
Gene-Set/Pathway Analysis (GAGE) Bioconductor package was used for gene-set enrichment analysis
(GSEA) for functional inference [28]. Before implementing the gage function, canonical signaling and
metabolic pathways from the KEGG mouse database was prepared for better-defined results. For the
microarray data, false discovery rate (FDR) adjusted p-values were calculated and FDR adjusted
p-value < 0.05 was considered significant. The Pathview package was used to visualize the data,
where the pathview function downloads KEGG graph data and renders a pathway map, based on
experimental results [29].
2.7. Fatty Acid Analysis
Approximately 100 mg gSkM tissue was weighed, freeze-dried and extracted using the Folch total
lipid extraction method [30]. Briefly, 5 mL chloroform–methanol (2:1 v/v) was added to the samples
followed by sonication at 40 Hz for 30 min at RT (Branson 8510, Branson Ultrasonics Corp, CT, USA).
One mL of physiological saline (0.9% NaCl) was mixed with the samples followed by brief vortexing
and centrifugation for 5 min at 3000 rpm (1700× g), to separate the two phases. The organic lower phase
was collected and the remaining aqueous phase was re-extracted with 1.5 mL chloroform. The two
extracted phases were combined and evaporated under N2 and re-dissolved in 1 mL isopropanol.
All solvents were from Sigma-Aldrich, Sweden.
Solid phase extraction (SPE) method was used to separate lipid classes [31]. Internal phospholipid
(C17:0) and triglyceride (C19:0) standards (Nu-Chek prep, Inc., Elysian, MN, USA) were added to the
samples. Hexane conditioned aminopropyl SPE columns were loaded with 1 mL of extracted SkM lipid
samples. Neutral lipids, free fatty acid and phospholipids were eluted with chloroform–isopropanol
(2:1), diethylether-2% acetone and methanol, respectively and evaporated under N2. Dried SPE
fractions were methylated by overnight incubation with 1 mL 10% acetyl chloride in methanol and
1 mL toluene. After methylation, 0.3 mL water and 4 mL petroleum ether was added to the samples
and the resulting two phases were separated by 3 min centrifugation at 3000× g. The upper phase was
then removed, evaporated under N2 and re-dissolved in 250 μL isooctane [32].
The fatty acid methyl esters (FAMEs) were analyzed by gas chromatography mass spectrometry
(Focus GC, ISQ, Thermo Fischer Scientific, USA) using a ZB-WAX column (30 × 0.25 mm I.D., 0.25 μm)
(Phenomenex, UK). One μl of sample was injected in splitless mode. The injector temperature was 240
and helium was used as the carrier gas with the flow of 1 mL/min. Oven temperature was as follows:
50 ◦C 1.5 min, ramped to 180 ◦C at 25 ◦C/min where held for 1 min, ramped to 220 ◦C at 10 ◦C/min,
held for 1 min and ramped to 250 ◦C at 15 ◦C/min and held for 3 min. The transfer line was kept at
250 ◦C and ion source at 200 ◦C. Electron impact ionization (70 eV) was used and the FAMEs were
detected by scanning a mass range from 50 to 650 m/z. An external FAME standard mix GLC 463
(Nu-Chek prep, Inc., Elysian, MN, USA) was used for identification of peaks in gSkM samples. Fatty
acids were quantified against internal standards, summed and expressed as mg/g dry gSkM biomass
and as a percentage of total lipid fractions.
2.8. Statistical Analysis of Western Blot and Fatty Acid Analyses
Differences in SkM western blot and fatty acid analyses were tested using ANOVA with Tukey’s
honest significant difference (Tukey-HSD) post-hoc test. Statistical significance between the protein
groups was calculated with an unpaired 2-tailed Student’s t-test. A p-value < 0.05 was considered
statistically significant. Statistical calculations were performed using Microsoft® Excel® for Mac 2011
version 14.5.8 and R software (Version 3.2.3) under RStudio interface. All data are presented as
mean ± SEM.
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3. Results
3.1. Effect of EPA and DHA vs Corn Oil on gSkM Weight and Transcriptome
Delayed weight gain was observed in HFD-ED compared with HFD-corn oil fed animals (Table 1).
Moreover, relative adiposity was lower in HFD-ED compared with HFD-corn oil fed mice [21].
Principle component analysis of the gSkM transcriptome did not detect any outliers in the data
(Supplemental Figure S2a) indicating good analytical reproducibility. To visualize the global effects
of different diets on gSkM, differential expression of the genes was performed on the following
comparisons: HFD-ED versus control diet, HFD-corn oil versus control diet and HFD-ED versus
HFD-corn oil. Venn diagrams show the number of differentially expressed genes (DEGs) corrected for
multiple testing by Benjamini and Hochberg at p-value < 0.001 (supplemental Figure S2b). The total
number of DEGs was 365, 129 and 383 for the comparison HFD-ED versus control diet, HFD-corn
oil versus control diet and HFD-ED versus HFD-corn oil, respectively. Differential gene expression
analysis found that the different fat composition of the two HFDs affected gene expression in gSkM
differently when compared to the control group (Supplemental Figure S3).
3.2. gSkM Fatty Acid Composition
Neutral lipids: The total amount of neutral lipids was significantly higher in the mice fed
HFD-corn oil compared to mice fed the other two study diets (Table 3). The concentration of fatty
acid C12:0 was higher in HFD-corn oil fed animals compared with both HFD-ED and control diets
(Table 3). C14:0 was higher in HFD-corn oil fed animals compared with control diet but there was no
difference compared with HFD-ED fed animals. Fatty acids C16:0, C18:1 and C18:2 n-6 (linoleic acid)
were higher in HFD-corn oil fed animals compared with mice fed HFD-ED or control diets, whereas no
difference was observed between the control and HFD-ED fed animals. C22:6 n-3 (DHA) was higher
in the HFD-ED fed animals compared to the control diet.
Free fatty acids: Free fatty acids (FFA) mainly comprised of saturated and monounsaturated
fatty acids including C16:0, C19:0, C16:1 and C18:1 (Table 3). Apart from C12:0, which was higher in
HFD-ED fed animals, the remaining FFAs were higher in HFD-corn oil fed animals compared with the
other two diets. The concentration of C20:3 n-3 was higher in the HFD-corn oil fed animals compared
with HFD-ED and the concentration did not differ compared with control diet. As expected, C22:6
n-3 concentrations were higher in the HFD-ED fed animals compared with HFD-corn oil. The total
amount of FFAs in gSkM did not differ between the different groups.
Phospholipids: The concentration of C14:0 was significantly higher in the HFD-ED fed animals
compared with the other two diets (Table 3). The amount of C18:1 was significantly lower in the
HFD-ED fed animals compared with HFD-corn oil fed animals. The amount of C20:4 n-6 (arachidonic
acid) was lower in HFD-ED fed animals compared with either HFD-corn oil or control diet fed animals.
The amount of n-3 PUFA C20:5 n-3 (EPA) did not differ for any of the diets, with only very low
concentrations measured, whereas the concentrations of C22:5 n-3 (DPA) and C22:6 n-3 (DHA) were
significantly higher in the animals fed HFD-ED compared with animals fed HFD-corn oil but the
expected increase in EPA was not found. The total phospholipid content was significantly lower in the
HFD-ED fed animals compared with control diet fed animals but did not differ from that found in
gSkM from the animals fed HFD-corn oil.
Table 3. The Fatty Acid Profiles of Different Lipid Fractions in Gastrocnemicus Skeletal Muscle.
Lipid Fraction mg/g mg/g mg/g % value % value % value
Neutral lipids Control HFD-ED HFD-Corn oil Control HFD-ED HFD-Corn oil
C12:0 0.12 ± 0.06 a 1.51 ± 0.42 b 2.87 ± 0.41 c 0.44 ± 0.18 a 3.93 ± 0.21 b 4.02 ± 0.33 b
C14:0 1.18 ± 0.24 a 3.15 ± 0.76 4.81 ± 0.49 b 4.35 ± 0.48 a 8.19 ± 0.52 b 6.74 ± 0.23 c
C16:0 8.11 ± 2.31 a 9.75 ± 2.28 a 19.01 ± 2.11 b 29.93 ± 1.78 25.35 ± 1.51 26.63 ± 2.34
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Table 3. Cont.
Lipid Fraction mg/g mg/g mg/g % value % value % value
Neutral lipids Control HFD-ED HFD-Corn oil Control HFD-ED HFD-Corn oil
C18:0 0.55 ± 0.05 0.65 ± 0.05 0.68 ± 0.04 2.03 ± 0.48 a 1.69 ± 0.4 a 0.95 ± 0.09 b
C18:1 13.11 ± 3.05 a 14.86 ± 3.45 a 29.2 ± 2.19 b 48.38 ± 0.81 a 38.64 ± 1.06 b 40.91 ± 1.6 b
C18:2 n6 3.75 ± 0.78 a 7.29 ± 1.89 a 14.55 ± 1.25 b 13.84 ± 0.67 a 18.95 ± 0.9 b 20.38 ± 0.73 b
C18:3 n3 0.07 ± 0.04 0.07 ± 0.03 0.09 ± 0.02 0.26 ± 0.08 0.18 ± 0.04 0.13 ± 0.03
C20:3 n6 0.02 ± 0.01 0.01 ± 0 a 0.03 ± 0 b 0.07 ± 0.06 0.03 ± 0 0.04 ± 0
C22:5 n3 0.03 ± 0.01 0.06 ± 0.01 0 ± 0 0.11 ± 0.09 0.16 ± 0.01 a 0 ± 0 b
C22:6 n3 0.14 ± 0.02 a 1.1 ± 0.09 b 0.14 ± 0.02 a 0.52 ± 0.25 a 2.86 ± 0.68 b 0.2 ± 0.04 a
Total neutral lipids 27.1 ± 6.48 a 38.46 ± 8.89 a 71.38 ± 6.13 b
Free fatty acids Control HFD-ED HFD-Corn oil Control HFD-ED HFD-Corn oil
C12:0 0.13 ± 0.04 0.16 ± 0.04 a 0.04 ± 0.01 b 6.6 ± 2.11 8.21 ± 2.26 a 1.61 ± 0.43 b
C16:0 0.52 ± 0.07 a 0.64 ± 0.02 0.78 ± 0.04 b 26.4 ± 3.14 a 32.82 ± 1.34 b 31.33 ± 2.03 b
C16:1 0.12 ± 0.03 0.09 ± 0.03 0.15 ± 0.05 6.09 ± 1.17 4.62 ± 1.3 6.02 ± 1.58
C18:1 1.07 ± 0.09 0.89 ± 0.07 a 1.29 ± 0.12 b 54.31 ± 4.03 a 45.64 ± 1.96 b 51.81 ± 1.68
C18:2 n6 0 ± 0 a 0 ± 0 a 0.11 ± 0.02 b 0 ± 0 a 0 ± 0 a 4.42 ± 0.46 b
C18:3 n3 0.09 ± 0 0.07 ± 0.01 0.07 ± 0.01 4.57 ± 0.64 a 3.59 ± 0.51 2.81 ± 0.27 b
C20:3 n3 0.04 ± 0 a 0 ± 0 b 0.04 ± 0.01 a 2.03 ± 0.27 a 0 ± 0 b 1.61 ± 0.24 c
C22:6 n3 0 ± 0 a 0.09 ± 0.03 b 0 ± 0 a 0 ± 0 a 4.62 ± 1.25 b 0 ± 0.14 a
Total free fatty acids 1.97 ± 0.17 1.95 ± 0.12 2.49 ± 0.21
Phospholipids Control HFD-ED HFD-Corn oil Control HFD-ED HFD-Corn oil
C14:0 0.33 ± 0.02 a 0.83 ± 0.04 b 0.64 ± 0.07 2.17 ± 0.14 a 6.14 ± 0.28 b 4.7 ± 0.49 c
C16:0 5.06 ± 0.06 a 4.93 ± 0.09 4.73 ± 0.06 b 33.29 ± 0.76 a 36.49 ± 0.55 b 34.75 ± 1.37
C18:0 1.97 ± 0.33 2.65 ± 0.18 2.01 ± 0.26 12.96 ± 2.38 19.62 ± 1.41 14.77 ± 2.02
C18:1 3.67 ± 0.68 a 0.39 ± 0.26 b 2.07 ± 0.44 a 24.14 ± 3.71 a 2.89 ± 1.81 b 15.21 ± 3.12 a
C18:2 n6 1.73 ± 0.06 a 0.58 ± 0.09 b 2.13 ± 0.05 c 11.38 ± 0.28 a 4.29 ± 0.61 b 15.65 ± 0.6 c
C20:3 n6 0.05 ± 0 a 0 ± 0 b 0.06 ± 0.01 a 0.33 ± 0 a 0 ± 0 b 0.44 ± 0.04 a
C20:4 n6 0.57 ± 0.01 a 0.1 ± 0 b 0.55 ± 0.01 a 3.75 ± 0.12 a 0.74 ± 0.01 b 4.04 ± 0.28a
C20:5 n3 0 ± 0 0.04 ± 0 0.02 ± 0.02 0 ± 0 0.3 ± 0.01 0.15 ± 0.15
C22:3 n6 0.54 ± 0.02 a 0.07 ± 0 b 0.26 ± 0.03 c 3.55 ± 0.18 a 0.52 ± 0.01 b 1.91 ± 0.23 c
C22:5 n3 0.05 ± 0 a 0.11 ± 0 b 0.06 ± 0.01 a 0.33 ± 0.02 a 0.81 ± 0.02 b 0.44 ± 0.05 c
C22:6 n3 1.23 ± 0.03 a 3.45 ± 0.06 b 1.07 ± 0.1 a 8.09 ± 0.3 a 25.54 ± 0.53 b 7.86 ± 0.73 a
Total phospholipids 15.2 ± 0.47 a 13.15 ± 0.34 b 13.61 ± 0.45 b
Total Fat content 44.26 ± 6.99 53.56 ± 9 87.47 ± 6.45
The fatty acid profiles from the mice fed, either control, HFD-corn oil or HFD-ED are shown as mean ± SEM
and as a proportion of total fatty acid fraction; different letters show statistical difference tested by ANOVA
followed by Tukey’s multiple comparison test. For details see methods section.
3.3. Increased Mitochondrial B—Oxidation and Oxidative Phosphorylation in the Gskm of Mice Fed HFD-ED
Energy metabolism is a biochemical process to generate energy from nutrients via aerobic
or anaerobic pathways. KEGG pathway analysis suggested that HFD-ED intake led to an
increased regulation of energy metabolism relating to lipid metabolism, Krebs cycle and oxidative
phosphorylation, leading to increased capacity for ATP production in gSkM compared with HFD-corn
oil fed animals.
Eight gene transcripts were upregulated by HFD-ED compared with the HFD-corn oil fed mice
(Figure 1a). Functionally, the enzymes in the β-oxidation pathway facilitate the breakdown of fatty
acids to form acetyl-CoA, which enters the Krebs cycle. The upregulated gene products, which are
responsible for transporting fatty acids into the mitochondria, were two carnitine palmitoyltransferases
(Cpt1a and Cpt2). In addition, RNA transcription of genes responsible for the subsequent degradation
of fatty acids within the mitochondrial matrix producing acetyl-CoA including short/medium chain
acyl-CoA dehydrogenase (Acadm), long chain acyl-CoA dehydrogenase (Acadl), very long chain
acyl-CoA dehydrogenase (Acadvl), acetyl-CoA acyl transferase 2 (Acaa2), enoyl-CoA delta isomerase 1
(Eci1) and aldehyde dehydrogenese (Aldh2), were upregulated by the HFD-ED diet.
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Figure 1. Pathway analysis of the gSkM transcriptome for the comparison of HFD-ED and HFD-corn
oil fed mice. The illustration is based on the Kegg pathway database (http://www.genome.jp/kegg/
pathway.html). (a) Fatty acid β-oxidation: Genes highlighted in red are upregulated in gSkM of
mice fed HFD-ED compared with HFD-corn oil; (b) Electron transport chain: Genes highlighted in
red are upregulated in gSkM of mice fed HFD-ED compared with HFD-corn oil; (c) Krebs Cycle:
Genes highlighted in red are upregulated in gSkM of mice fed HFD-ED compared with HFD-corn
oil; (d) Relative Acc protein levels in HFD-ED (white bars) fed mice was lower than HFD-corn oil
(black bars) and there was no difference in the phosphorylation of Acc (p-Acc) protein after 8-weeks
diet intervention. * Different at p < 0.05.
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Pathway analyses showed a significant increase in the oxidative phosphorylation pathway in
gSkM from the HFD-ED fed mice compared with HFD-corn oil animals (Figure 1b). Several genes
involved in electron transport complex I-V were upregulated by HFD-ED fed mice compared with
HFD-corn oil. Genes from the NADH dehydrogenase family that constitutes complex I (Ndufa11,
Ndufb3, Ndufb5, Ndufb7, Ndufb10 and Ndufs6); two succinate dehydrogenases (Sdhb and Sdhc) from
complex II; ubiquinol-cytochrome c reductase core protein 1, cytochrome c oxidase subunit VIIb-Muscle
and ATP synthase H+ transporting mitochondrial F0 complex subunit B1 (Uqcrc1, Cox7b and Atp5f1)
constituting complex-III, IV and complex-V respectively, were upregulated.
HFD-ED upregulated the Krebs cycle in mice gSkM compared with HFD-corn oil (Figure 1c).
The mitochondrial event consumes Acetyl-CoA producing NADH, FADH2, GTP and the by-product
CO2. NADH and FADH2 are in turn used by oxidative phosphorylation to generate ATP. Genes for
key proteins in this metabolic pathway that were upregulated by EPA and DHA include pyruvate
dehydrogenase E1 alpha 1 (Pdha1) and dihydrolipoamide S-acetyl transferase (Dlat), which converts
pyruvate to Acetyl-CoA. HFD-ED upregulated several Krebs cycle genes including two kinds of
isocitrate dehydrogenases (Idh1 and Idh3g), oxoglutarate dehydrogenase (Ogdh), Succinate-CoA
ligase GDP forming alpha subunit 2 (Sucla2), succinate dehydrogenase subunit a (Sdha) and malate
dehydrogenase 2 (Mdh2), when compared with HFD-corn oil. There was no difference in the gene
expression of Acacb (Acetyl-CoA carboxylase beta) but the total protein content of total acetyl-CoA
carboxylase (Acc) was markedly lower in the gSkM of HFD-ED fed mice (Figure 1d). However, the
phosphorylation levels of Acc did not differ in between the two HFDs (Figure 1d). This suggests
increased internalization of fatty acids in mitochondria for potential β-oxidation in gSkM of HFD-ED
fed mice rather than synthesis of fatty acids, as seems to be ongoing in HFD-corn oil animals.
3.4. Increased Expression of Muscle Contraction Pathway Genes in the Gskm of Mice Fed HFD-ED
Skeletal muscle fibers require stimulation from the neuromuscular junctions acting on the
cholinergic nicotine receptor on the muscle cells to initiate contraction. These efferent cholinergic
nerves are crucial for voluntary control of skeletal muscles. Gene expression of the cholinergic receptor
nicotinic α polypeptide 1 (Chrna1), insulin growth factor receptor (Igfr) and two L-type voltage
dependent Ca-channel genes (Cacna1s and Cacnb2), two calcium ATPases (Atp1a1 and Atp2a2, a.k.a







































Figure 2. Pathway analysis of the gSkM transcriptome for the comparison HFD-ED versus HFD-corn
oil fed mice. The illustration is based on the Kegg pathway database (http://www.genome.jp/kegg/
pathway.html). (a) Nerve-Muscle contraction: Genes highlighted in red are upregulated in gSkM of
mice fed HFD-ED compared with HFD-corn oil; (b) Relative Troponin C1 protein level in HFD-corn oil
(black bars) fed mice was lower than HFD-ED (white bars). * Different at p < 0.05.
188
Nutrients 2016, 8, 543
3.5. Increased Slow-Fiber-Specific Gene Expression Program in the Gskm of Mice Fed HFD-ED
The calcium mediated calcineurin-Nfat signaling cascade has been suggested to upregulate
slow-fiber type gene expression. Differential gene expression of gSkM from the mice fed HFD-ED
compared with HFD-corn oil suggested upregulation of several Nfat (Nfatc1; Nfatc2; Nfatc4) isoforms.
The slow-fiber type genes troponin C1, cardiac/slow skeletal (Tnnc1), tropomyosin 1 alpha (Tpm1)
and actin alpha 1 (Actc1) complex genes and crossbridge myosin heavy polypeptide isoforms (Myh1,
Myh2, Myh3, Myh6, Myh7, Myh8) were upregulated in gSkM of HFD-ED fed mice compared with
HFD-corn oil animals. Protein levels of Tnnc1, a biomarker for slow muscle fiber type, were higher
in gSkM of HFD-ED fed mice compared with HFD-corn oil animals (Figure 2b). Furthermore, the
gene product forming complex with Nfatc2 and Nfact4, namely myogenin (Myog) and GATA Binding
Protein 5 (Gata5) regulating the transcription of slow-fiber type gene expression was upregulated in
the HFD-ED gSkM compared with HFD-corn oil. Nuclear localization of Nfat protein is essential for
regulation of the slow-fiber-type gene expression. In the gSkM of HFD-ED fed mice, nuclear protein
Nfat levels were significantly higher than HFD-corn oil fed animals (Figure 3). The master regulator of
the calcineurin-Nfat signaling cascade, the regulator of calcineurin-2, Rcan2, was upregulated and its
inhibitor glycogen synthase kinase 3β (Gsk3β) was downregulated in mice fed HFD-ED, compared
with HFD-corn oil animals. Another transcriptional activator, suggested to be a direct target of marine
fatty acids, peroxisome proliferator-activated receptor-γ coactivator 1α (Ppargc1α) was upregulated in
gSkM of HFD-ED compared with HFD-corn oil fed mice.


























Figure 3. Representative Western blot is shown with LaminA/C loading control. Nuclear (black bars)
and cytosolic (white bars) protein extract from the gSkM of HFD-ED (left-panel) and HFD-corn oil
(right-panel) were analyzed by Western blot using antibodies for total anti-Nfatc4 antibody and the
cytosolic protein levels in the HFD-ED was kept to 1. Different at ** p < 0.05 and # p < 0.01.
4. Discussion
In this study, we have shown that HFD-ED improves muscle metabolism and promotes a switch
to slow-fiber type compared to HFD-corn oil. HFD-ED improves metabolism of fatty acids in gSkM
by upregulating expression of genes coding for proteins involved in fatty acid β-oxidation, the Krebs
cycle and oxidative phosphorylation. Lipid analysis shows that the HFD-ED fed animals had lower
total fatty acid content compared to HFD-corn oil and control diet fed animals. Reduced ectopic fat
accumulation in HFD-ED compared with HFD-corn oil fed animals suggests a physiological effect
of EPA and DHA on muscle metabolic health. Higher expression of the genes involved in muscle
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contraction was found in gSkM of HFD-ED fed animals compared with HFD-corn oil fed animals.
Western blot analysis showed reduced Acc protein levels in gSkM of HFD-ED fed animals compared
with HFD-corn oil, confirming gene expression results. Acc is an inhibitor of fatty acid β-oxidation in
mitochondria and the lower levels shows increase in mitochondrial fatty acid β-oxidation. In addition,
increased Tnnc1 levels suggest increased muscle contraction in gSkM of HFD-ED fed animals compared
with HFD-corn oil. Moreover, increased nuclear protein levels of the Nfatc4 isoform strongly suggests
up-regulation of slow-fiber-type gene expression in gSkM of HFD-ED fed animals compared with





















Figure 4. Schematic representation of the role of ED—enriched HFD on the gSkM transcriptome and
modulation of ageing and/or obesity-induced sarcopenia in C57Bl/6J mice. Briefly, ED enriched
HFD downregulates glucose synthase kinase 3 beta (Gsk3β) that phosphorylates nuclear factor of
activated T cells (Nfatc4) and excludes it from entering into the nucleus. It also increases cytosolic
calcium concentrations that in turn regulate calcineurin that then dephosphorylates Nfat allowing
its localization in the nucleus. Upon localization, Nfat forms complex with myogenin (Myog) to turn
on slow-fiber-type specific gene-program for e.g., Troponin C1. Pgc1α, a known master regulator
of mitochondrial biogenesis was also seen upregulated by ED enriched HFD that could act upon
multiple targets, one of which regulating dephosphorylation of Nfatc4 isoforms and its further
nuclear localization.
The gSkM neutral lipid and free fatty acid profiles reflect the higher amount of DHA in the
feed of HFD-ED fed mice, though EPA was not detected in either fraction, in line with our previous
findings in liver; that EPA was present in very low amounts, not in proportion to EPA in the diet [21].
There was no substantial proportional difference in gSkM fatty acid composition between the two
HFD groups, even though HFD-corn oil fed mice had nearly twice the amount of total neutral lipids.
This suggests that ED does not specifically upregulate any of the reactions related to β-oxidation
and rather, leads to stimulation of β-oxidation in general, resulting in reduced total neutral lipids
in SkM. Although there were several differences in the amount and proportion of free fatty acids
and phospholipids, these differences were not quantitatively important aside from the increase DPA
and DHA in mice fed HFD-ED but lower EPA in phospholipids fractions [33]. Notably C18:1 was
substantially higher in HFD-corn oil fed mice compared with HFD-ED fed mice and this result was
reversed for DHA. This could have implications for membrane fluidity within SkM and this may play
a role in the observed transcriptome changes.
Previously we found that HFD-ED induced β-oxidation reduced liver fat compared to HFD-corn
oil [21], similarly, reduced SkM fat can be due to the increase in β-oxidation and the lower amount
of neutral lipids in HFD-ED fed mice. Reduced SkM mitochondrial fatty acid β-oxidation has been
proposed as a key feature leading to insulin resistance [34,35] and high fat diets led to downregulation
of the group of genes involved in oxidative phosphorylation in human SkM biopsies [36–38]. In the
gSkM of the HFD-ED fed mice, the expression of rate limiting enzymes in fatty acid β-oxidation
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in mitochondria, Cpt1 and Cpt2 were upregulated compared with HFD-corn oil fed mice. Notably,
the protein level of Acc was significantly reduced in gSkM of HFD-ED fed mice compared with
HFD-corn oil. Acc regulates fatty acid metabolism by synthesizing malonyl-CoA (building blocks
for new fatty acids) but suppresses mitochondrial β-oxidation by inhibiting fatty acid transporter
Cpt1. Therefore, lower protein levels of Acc suggests entry of fatty acid into mitochondria via Cpt1
transporter for mitochondrial β-oxidation in gSkM of HFD-ED fed mice compared with HFD-corn oil.
A SkM specific isoform of Acc (Acc2) knockout mice were protected against fat-induced peripheral
insulin resistance [39] whereas overexpression of Cpt1 is sufficient to reduce insulin resistance [40].
Impairments in mitochondrial oxidative capacity in skeletal muscle have been seen in relation to a
decrease in energy expenditure [35,41,42]. Thus, increased mitochondrial oxidative capacity in the
gSkM of HFD-ED fed animals, supported by increased levels by Cpt1 and decreased total protein
levels of Acc may contribute to increased energy expenditure. Further work on a possible stimulation
of energy expenditure by EPA and DHA, possibly via diet-induced thermogenesis is required.
Ageing and obesity may contribute to the decrease in the contractibility of skeletal muscle. Muscle
contraction is regulated by intracellular calcium concentration via the thin filament regulatory proteins
troponin and tropomyosin. In the absence of calcium, actin-myosin interaction and subsequently
muscle contraction is inhibited. In the gSkM of HFD-ED, two ATPases, namely Na+/K+-ATPase
transporting α2 polypeptide (Atp1a2; sodium pump) and ATPase Ca+2 transporting skeletal muscle
slow switch 2 (Atp2a2; Serca2a) were upregulated compared with HFD-corn oil. A tissue specific
knockout study shows that the sodium pump (Atp1a2) is required to prevent fatigue, and systematic
analysis of Serca isoforms in calcium transport showed their importance for restoring muscle
contractibility [43,44]. Protein levels of the oxidative fiber biomarker Troponin C1 were higher in
gSkM of HFD-ED fed mice compared with HFD-corn oil, indicative of increased muscle contraction
via control of intracellular calcium in mice fed HFD-ED. Together, these results suggest that HFD-ED
contributes to increased calcium release into the sarcoplasm, compared with HFD-corn oil fed mice.
Calcineurin has been proposed to play a major role in the upregulation of slow-fiber-specific gene
expression [45–47]. Earlier, it was found that inhibition of calcineurin by cyclosporin-A could result
in an increased number of fast fibers in rat skeletal muscle [45]. Activated calcineurin phosphatase
capacity is required for dephosphorylation of Nfat proteins, which then localize to the nucleus to initiate
slow-fiber-specific gene expression [45,47]. Our data shows that the gSkM of HFD-ED fed animals
has markedly higher nuclear levels of Nfat (Nfatc4 isoform) compared with HFD-corn oil, which
could contribute to upregulation of the slow-fiber-specific gene expression upon nuclear localization.
An earlier study showed abundant myogenin mRNA in slow oxidative muscles and this relationship
followed phenotype transition caused by cross-innervation [48]. In HFD-ED fed mice, myogenin
(Padj-value = 0.06) tends to be higher compared with HFD-corn oil fed animals suggesting upregulation
of genes for the slower muscle fiber phenotype. We also found that EPA and DHA increased gene
expression of Ppargc1α, a master regulator of mitochondrial biogenesis leading to red type I fiber, also
suggests genetic programing towards stimulating slower muscle fiber [49–52]. It is known that the
products of peroxisomal β-oxidation are also targeted towards mitochondria for oxidation in skeletal
muscle and therefore assist in complete lipid disposal [53]. Further support for an effect on muscle
fiber type comes from stimulation of insulin growth factor 1 (Igf -1), which regulates the Akt pathway.
Activation of Akt phosphorylates Gsk3β thereby inactivating it. Gsk3β phosphorylates Nfat and
excluding its entry into the nucleus and subsequent DNA binding [54], which would down-regulate
slow-fiber gene expression. In our study, Gsk3β was downregulated in the gSkM of HFD-ED compared
with HFD-corn oil animals, indicating little Nfat phosphorylation and thus, conditions that would
favor production of slow-fiber type. Resistance training, testosterone treatment, growth hormone, or
dehydroepiandrosterone interventions have shown favorable effects in retaining muscle mass and
function [19,55–58]. However, long-term use of growth hormone treatment can be harmful due to
associated side effects, making this a poor choice for intervention against muscle loss. Our findings
suggest a mechanistic basis for the human results and supports the case for further research on either
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ED or fish oil supplements as potential molecules for the long-term prevention of sarcopenia. In this
study we were unable to determine if muscle fiber type regulation is due to the effects of increased
β-oxidation, or a direct effect of EPA or DHA on gene transcription.
Although the effects of EPA and DHA on gSkM gene expression are conclusive, due to the limited
sample amount we have been unable to validate many of the possible physiological effects found
from transcriptome analysis. Ideally, future work should study these effects across a wider range of
SkM and perform histology to confirm the hypothesis on fiber-type regulation. Similarly, our results
suggest an effect on many parameters related to energy metabolism, supported in part by finding a
lower fat content in the gSkM of HFD-ED fed mice compared with HFD-corn oil. Future work will
need to see if this effect extends to improved glucose disposal which could extend the findings to
possible relevance for T2D. A role for regulation of calcium concentrations for signaling should also be
tested using muscle cell models. Future work will also need to test if these pathways are still relatively
upregulated with lower proportions of n-3 fatty acids and at lower amounts, to test if they are relevant
at normal amounts of dietary fat.
These results clearly demonstrate the wide-ranging impact a difference in dietary fatty acid
composition can have on SkM gene-transcription. It is unclear if ED regulates all of these gene targets
simultaneously, or if some are a result of downstream interactions with initial ED targets. Given the
clear sequential effects on energy metabolism from β-oxidation to oxidative phosphorylation, it appears
likely that the observed upregulation of these processes is directly related to increased circulating EPA
and DHA. Further studies on cell and rodent models of ageing and functional analysis of SkM are
required to confirm these effects and the likely regulatory nodes for these mechanisms.
5. Conclusions
The skeletal muscle transcriptome from mice fed HFDs differing in fat composition for 8 weeks,
showed marked differences in expression of genes coding for metabolic proteins. Our results suggest
muscle-protective effects of EPA and DHA against catabolic degradation, possibly via stimulation of
pathways that increase mitochondrial β-oxidation capacity and control calcium release for muscle
contraction. These shifts in gene expression, even against a background of HFD are clearly favorable
for hindering molecular progression towards muscle loss. With the limited availability of clinical
treatments for preventing muscle loss, increased intake of fatty fish that are abundant in EPA and
DHA, or supplementation with marine fatty acids could provide a safe and economic alternative to
pharmaceutical interventions.
Supplementary Materials: The following are available online at www.mdpi.com/link, Figure S1: Protein lysate
from the gSkM of HFD-ED and HFD-corn oil were analyzed by Western blot using antibodies for total Acc,
p-Acc (Ser79) and total anti-Troponin C1. Gapdh was used as a loading control for the Western blot, Figure S2:
(a) Principle Component Analysis (PCA) plot based on the normalized gene expression from the gSkM tissue
fed control, HFD-ED and HFD-corn oil is plotted for assessing the quality of the datasets. No animals or any
related data was excluded from further assessment. (b) Venn diagrams showing the number of differentially
expressed genes (FDR adjusted p-value < 0.001) in each diet-comparison for gSkM tissue. HFD-ED compared
with control diet and HFD-corn oil fed mice shows most transcriptional response to the diet. Key: ED = HFD-ED;
CO = HFD-corn oil and CD = control diet, Figure S3: (a) Fatty acid β-oxidation pathway rendered by the
pathview function from the Kegg pathway database. Genes highlighted in red are upregulated for the comparison
HFD-ED vs. HFD-corn oil. (b) Krebs cycle pathway rendered by the pathview function from the Kegg pathway
database. Genes highlighted in red are upregulated for the comparison HFD-ED vs. HFD-corn oil. (c) Oxidative
phosphorylation pathway rendered by the pathview function from the Kegg pathway database. Genes highlighted
in red are upregulated for the comparison HFD-ED vs. HFD-corn oil, Table S1: Table for the selection criteria
for animals for microarray analysis. Animals marked in green were selected for microarray analysis, Table S2:
The top 100 differentially regulated genes regulated by HFD-ED compared to HFD-corn oil fed mice, based on
adjusted p-value.
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